{"docstore/data": {"4972ee75-c737-4c62-adc6-975003ebb7d2": {"__data__": {"id_": "4972ee75-c737-4c62-adc6-975003ebb7d2", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.   (MCK ) \nQ2 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f43cc1d0-0218-4941-a2a2-4b921ef536d8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa4d7cad335497093a5025b1b9196aec73c5efabffd8c950b765f360c19a1d82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd0e9e2e-5fb9-40c2-adbe-54c6853b322b", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.   (MCK ) \nQ2 2022 Earnings Call    ", "original_text": "(MCK ) \nQ2 2022 Earnings Call    "}, "hash": "2f295b018d423a8f49a0a5a1aa8a2b9d1061881487e601098261f164b8d1b418", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd0e9e2e-5fb9-40c2-adbe-54c6853b322b": {"__data__": {"id_": "fd0e9e2e-5fb9-40c2-adbe-54c6853b322b", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.   (MCK ) \nQ2 2022 Earnings Call    ", "original_text": "(MCK ) \nQ2 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f43cc1d0-0218-4941-a2a2-4b921ef536d8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa4d7cad335497093a5025b1b9196aec73c5efabffd8c950b765f360c19a1d82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4972ee75-c737-4c62-adc6-975003ebb7d2", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.   (MCK ) \nQ2 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c77f72b8625015abe345b93d1b8dfd4c1250ca1f7c078d867736030374da32e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c03e914f-f60c-4e7f-aa8f-b29dd6e865d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "5033c168a9ad384258789f23c326980849ee4ecc291a5038c4301f86c7c715bf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c03e914f-f60c-4e7f-aa8f-b29dd6e865d8": {"__data__": {"id_": "c03e914f-f60c-4e7f-aa8f-b29dd6e865d8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd0e9e2e-5fb9-40c2-adbe-54c6853b322b", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.   (MCK ) \nQ2 2022 Earnings Call    ", "original_text": "(MCK ) \nQ2 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c631750e7d0859cc3ec99d519dae692cecfab039069f1001e7b0332d7c522bd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9698887a-5846-49bf-b947-5f85bd0d096f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n"}, "hash": "e092f09dab34b392a380c2725c0a3d6872dede99fa1607c41761a1213a21c2cc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9698887a-5846-49bf-b947-5f85bd0d096f": {"__data__": {"id_": "9698887a-5846-49bf-b947-5f85bd0d096f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c03e914f-f60c-4e7f-aa8f-b29dd6e865d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ebd48c6a4184d4d32cd359d546b7f7efbcbbcfad497ed6aa0787b658eb0b7b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f438986e-ed83-4a47-9861-e24f7e799d83", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "d7d45329460e1c14ae96177d254c1e6f63ffd34ecbaa5a28a16f4a5083206049", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f438986e-ed83-4a47-9861-e24f7e799d83": {"__data__": {"id_": "f438986e-ed83-4a47-9861-e24f7e799d83", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9698887a-5846-49bf-b947-5f85bd0d096f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d49c35979ff3a0ad1257b1c6522e334687a6c10e064e94ba0efaf4e6fbb238c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfb49db0-67d7-45b9-8ab4-117b853430a0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "110a25486fecdf32461391e3e1d37aee5195aa440016af5d26f89703016cacf6", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 282, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfb49db0-67d7-45b9-8ab4-117b853430a0": {"__data__": {"id_": "bfb49db0-67d7-45b9-8ab4-117b853430a0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f438986e-ed83-4a47-9861-e24f7e799d83", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81bfbf964d4397b6d9b047ff891a5624c631861b5a08cef9740d170ce2bbeeb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77677100-623b-4db3-9022-1b26e28830e7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "ee33a1e1e215c3585ecea016d1a9a6606c4f587043fe7957fb83ff4bc43aabbe", "class_name": "RelatedNodeInfo"}}, "text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 354, "end_char_idx": 441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77677100-623b-4db3-9022-1b26e28830e7": {"__data__": {"id_": "77677100-623b-4db3-9022-1b26e28830e7", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfb49db0-67d7-45b9-8ab4-117b853430a0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb132e47ee1e9e69010338be990e51067f2ef2e4f547dec56be60a4957698256", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fdb68c1-027d-4a01-a262-6eddb01bb8b2", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "6d1f50c271da71459944c9e0b68454475c011f55fab89e02e9a75d9f52d0f7de", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 441, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fdb68c1-027d-4a01-a262-6eddb01bb8b2": {"__data__": {"id_": "5fdb68c1-027d-4a01-a262-6eddb01bb8b2", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77677100-623b-4db3-9022-1b26e28830e7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b46845c51da1b4b1909d2b2f9f86307c63cb48cc4ad7b44e0d87d272e9a91ffa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1653a396-7214-4f45-8ffe-efb60e19fee0", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n"}, "hash": "c9f1db436b8b11910ca0b7dad919e973933cda0e15d15c32aba2d35d82f3464a", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 823, "end_char_idx": 860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1653a396-7214-4f45-8ffe-efb60e19fee0": {"__data__": {"id_": "1653a396-7214-4f45-8ffe-efb60e19fee0", "embedding": null, "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fdb68c1-027d-4a01-a262-6eddb01bb8b2", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65ca60a35e29cef670a7aa1cd4d8bca82782e7abed3dc36f97f1c8fa992fe5a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8faf3715-f1dd-488f-93fa-2f9ff63fc449", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n"}, "hash": "2f7114545c32e253b54c83971349e0ef0ef9e2a3aa11e73cbea77f0d5fe953b8", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n", "start_char_idx": 860, "end_char_idx": 1015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8faf3715-f1dd-488f-93fa-2f9ff63fc449": {"__data__": {"id_": "8faf3715-f1dd-488f-93fa-2f9ff63fc449", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1653a396-7214-4f45-8ffe-efb60e19fee0", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "542523e75c7f69cc7b522446c1169abbe5fc9b0cd48ff0661667008be6b7d612", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03890988-ea69-4f7a-815a-ddbf3631867d", "node_type": "1", "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded. ", "original_text": "Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n"}, "hash": "96d4181e0629469aa8ba64018c94244b3c0984278073f73aa9f8f8cef83f4e8d", "class_name": "RelatedNodeInfo"}}, "text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "start_char_idx": 1015, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03890988-ea69-4f7a-815a-ddbf3631867d": {"__data__": {"id_": "03890988-ea69-4f7a-815a-ddbf3631867d", "embedding": null, "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded. ", "original_text": "Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8faf3715-f1dd-488f-93fa-2f9ff63fc449", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call. ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0c439f095db7f8df579c147417257c1714ae4470d3e3c5593409e3147405cc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8719cd4c-754a-418f-99e6-b4e380ae59f4", "node_type": "1", "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez. ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "7c1cceab2b80251f594049d079b8c289096e17ad687da0b85b980fdd57d3a04d", "class_name": "RelatedNodeInfo"}}, "text": "Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "start_char_idx": 1071, "end_char_idx": 1128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8719cd4c-754a-418f-99e6-b4e380ae59f4": {"__data__": {"id_": "8719cd4c-754a-418f-99e6-b4e380ae59f4", "embedding": null, "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez. ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03890988-ea69-4f7a-815a-ddbf3631867d", "node_type": "1", "metadata": {"window": "Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded. ", "original_text": "Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "879d26a977cbbe8440aca764cb1e55eac3a3eb3b71248bb22affa87ca1ae2af1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7294be3f-2c4b-4c17-8bc1-f7840a1d25e0", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n ", "original_text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call. "}, "hash": "6e93e42269c594f300af476efe7b3837febf58032a1faa86ad35c5a5a8adb781", "class_name": "RelatedNodeInfo"}}, "text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1128, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7294be3f-2c4b-4c17-8bc1-f7840a1d25e0": {"__data__": {"id_": "7294be3f-2c4b-4c17-8bc1-f7840a1d25e0", "embedding": null, "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n ", "original_text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8719cd4c-754a-418f-99e6-b4e380ae59f4", "node_type": "1", "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric Percher  \nAnalyst , Nephron Research LLC  Brian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez. ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6bbd9a88f2b02269618398a1e587c4706ad332e55b0bd1c77fbf49e4fa211a5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f81b5f3d-df62-4633-93f1-c0954b0f3cd3", "node_type": "1", "metadata": {"window": "Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. "}, "hash": "0c9e358f236dd460a1730fbac01e92b39f11c4652fb23edc748eec5e60b932bb", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call. ", "start_char_idx": 1180, "end_char_idx": 1611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f81b5f3d-df62-4633-93f1-c0954b0f3cd3": {"__data__": {"id_": "f81b5f3d-df62-4633-93f1-c0954b0f3cd3", "embedding": null, "metadata": {"window": "Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7294be3f-2c4b-4c17-8bc1-f7840a1d25e0", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n ", "original_text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd6ef472e587685f891ff5faf70ef1f3b70f44ad4225386a406fb34bd873e7cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d277702-4ea3-4c50-ba12-02899cfcb02d", "node_type": "1", "metadata": {"window": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah. ", "original_text": "At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez. "}, "hash": "cb1addd510a77f49b71aef2edb8cf17e87979e213938129bdb9484186ed0ba38", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 1611, "end_char_idx": 1649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d277702-4ea3-4c50-ba12-02899cfcb02d": {"__data__": {"id_": "1d277702-4ea3-4c50-ba12-02899cfcb02d", "embedding": null, "metadata": {"window": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah. ", "original_text": "At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f81b5f3d-df62-4633-93f1-c0954b0f3cd3", "node_type": "1", "metadata": {"window": "Steven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57f8dba5174a263edc03588b3e399f3c900309448334dc841cddaf87377789f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19ee4baf-1c35-4491-b34c-ea993670210c", "node_type": "1", "metadata": {"window": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall. ", "original_text": "Please go ahead.  \n "}, "hash": "493d9f6ce75a77327d85bb4efa06e271f72673d3edd70cc8af822a7d290fc0c7", "class_name": "RelatedNodeInfo"}}, "text": "At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez. ", "start_char_idx": 1649, "end_char_idx": 1727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19ee4baf-1c35-4491-b34c-ea993670210c": {"__data__": {"id_": "19ee4baf-1c35-4491-b34c-ea993670210c", "embedding": null, "metadata": {"window": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d277702-4ea3-4c50-ba12-02899cfcb02d", "node_type": "1", "metadata": {"window": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah. ", "original_text": "At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "120b3f573f24a2ab5495033e879a4853bc20049e33f7dac221e4750d4aa9792d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90676184-35fa-46f6-826f-6334d51adc5a", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n"}, "hash": "69e3e85b8ba99c180c3522093df5c5dba73085e14be73bba5a4e66e3a884ac27", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1727, "end_char_idx": 1747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90676184-35fa-46f6-826f-6334d51adc5a": {"__data__": {"id_": "90676184-35fa-46f6-826f-6334d51adc5a", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19ee4baf-1c35-4491-b34c-ea993670210c", "node_type": "1", "metadata": {"window": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q2 Fiscal 2022 Earnings Call.  Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "479b1b92a0006f1b508cc64163c20e8fc227e1869be70e1dbf504c1abe21eb87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05cf3aea-0273-429d-b6e6-59dda3ce6212", "node_type": "1", "metadata": {"window": "At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Sarah. "}, "hash": "45c2c51e4dc827d58aba4832bd3b5adbfaec1829b47b0336efc45b7d954f9a4e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "start_char_idx": 1747, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05cf3aea-0273-429d-b6e6-59dda3ce6212": {"__data__": {"id_": "05cf3aea-0273-429d-b6e6-59dda3ce6212", "embedding": null, "metadata": {"window": "At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Sarah. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90676184-35fa-46f6-826f-6334d51adc5a", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "328cea2308a54d093f9a4bd420afa1d59ff33ec8cfcf4260997e2389e218b204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91745cef-186d-4347-9f12-aaf8b08cc44d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall. "}, "hash": "25ba220375b6fcea9a8e563518153f1d6795cbe284b3f0b5e6c9bf10f478ec46", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Sarah. ", "start_char_idx": 2077, "end_char_idx": 2095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91745cef-186d-4347-9f12-aaf8b08cc44d": {"__data__": {"id_": "91745cef-186d-4347-9f12-aaf8b08cc44d", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05cf3aea-0273-429d-b6e6-59dda3ce6212", "node_type": "1", "metadata": {"window": "At \nthis time, I would like to turn the conference ove r to Rachel Rodriguez.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Sarah. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61a81cee383f7b07b436bd2e1d71076e71625a2c4ac8e5b8eabd780ee6df2096", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "386ecae3-bd0c-49fd-9c57-6c65b14f9c9e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "c303cd389914e3a3136836c70c887a02a57bb180f141a55be9b90a8b8765f04d", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall. ", "start_char_idx": 2095, "end_char_idx": 2188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "386ecae3-bd0c-49fd-9c57-6c65b14f9c9e": {"__data__": {"id_": "386ecae3-bd0c-49fd-9c57-6c65b14f9c9e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91745cef-186d-4347-9f12-aaf8b08cc44d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f1c4aa3c657de06af103fbfac10836bac7e4f580dfabc71512cba5500c065d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a76bc05-343f-4f56-8972-c8008458898a", "node_type": "1", "metadata": {"window": "Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "0a1f5bb3576f68e2d56500a1c87a24f4493dd963e419238d080834f9b67a5eb2", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 2188, "end_char_idx": 2301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a76bc05-343f-4f56-8972-c8008458898a": {"__data__": {"id_": "1a76bc05-343f-4f56-8972-c8008458898a", "embedding": null, "metadata": {"window": "Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "386ecae3-bd0c-49fd-9c57-6c65b14f9c9e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f22888fa681f06aee495935ef4753ce21010628c5eecc5e1be4a1ce20dc630ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcc3b48a-ab1d-4bbf-a5a2-c705cfa29d96", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results. "}, "hash": "efb0fa3d3dc6f1b7b315e557675f8d1dcb40f90c0d6280ccaade9478f85dbe2a", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 2301, "end_char_idx": 2402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcc3b48a-ab1d-4bbf-a5a2-c705cfa29d96": {"__data__": {"id_": "dcc3b48a-ab1d-4bbf-a5a2-c705cfa29d96", "embedding": null, "metadata": {"window": "Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a76bc05-343f-4f56-8972-c8008458898a", "node_type": "1", "metadata": {"window": "Thank you, Sarah.  Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21d4aedcdea7493f921177969af609f8728377a51a28bd01a65f4c222e1d94a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ace85974-01eb-4186-a6e6-7b8684524612", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n"}, "hash": "50e21cb8b08dd099783daca54afc058065585501b1600d7bf0bc4ff586c53b90", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results. ", "start_char_idx": 2402, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ace85974-01eb-4186-a6e6-7b8684524612": {"__data__": {"id_": "ace85974-01eb-4186-a6e6-7b8684524612", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcc3b48a-ab1d-4bbf-a5a2-c705cfa29d96", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's second quarter fiscal 2022 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3140a785d2bb5ca755ad0fa7c9ac32242ccd482a65e4136ef5f0d1942d1c3291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05085222-e830-462b-9baa-f700c0475121", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "0b9f87c0c93acead1e9c5c78045a0b38c6aa542fa5b861335a433f9095113f73", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 2531, "end_char_idx": 2847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05085222-e830-462b-9baa-f700c0475121": {"__data__": {"id_": "05085222-e830-462b-9baa-f700c0475121", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ace85974-01eb-4186-a6e6-7b8684524612", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1491cdfd1a43fb5b2ce65addda5fcf3c19158898d916f00f2769e3b185d87b3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f89ca5a-7484-4d43-b424-ae05308686a3", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n"}, "hash": "df609ccd205c7a2035a0fe8d4e7c916b363a598ac979df515add86a392bfdd8f", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 2847, "end_char_idx": 2911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f89ca5a-7484-4d43-b424-ae05308686a3": {"__data__": {"id_": "0f89ca5a-7484-4d43-b424-ae05308686a3", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05085222-e830-462b-9baa-f700c0475121", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476439e578ebf1b45412679e696f25efa7c33f137c79d2d53d6023311064f7ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0b5ed14-cb7d-4294-b0a5-67a489b8276f", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "With that, let me turn it over to Brian.  "}, "hash": "be56468c4b3d947defdbea93fa01552f032c9d178683919c6c6238264e1fc8a7", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "start_char_idx": 2911, "end_char_idx": 3165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0b5ed14-cb7d-4294-b0a5-67a489b8276f": {"__data__": {"id_": "c0b5ed14-cb7d-4294-b0a5-67a489b8276f", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "With that, let me turn it over to Brian.  ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a16dced-c81a-4c27-b101-6755155f7b96", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648ece674fc052dde87000b17dc03ae8bf64982eb226b22e8ecd64b2f1a56e74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f89ca5a-7484-4d43-b424-ae05308686a3", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts abo ut McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a99e3485eb46018b165707e5be3e0b82edb18010120c92732370b8ec5aa8ad6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34a304f7-d91e-4536-8ddd-f3cc6e2b6c74", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today. ", "original_text": "McKesson Corp.  "}, "hash": "a5676e4c3f4ef05fb82ab6dc57eff95aa02d1e09028ed453a1a3e46f69c33a53", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  ", "start_char_idx": 3165, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34a304f7-d91e-4536-8ddd-f3cc6e2b6c74": {"__data__": {"id_": "34a304f7-d91e-4536-8ddd-f3cc6e2b6c74", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0b5ed14-cb7d-4294-b0a5-67a489b8276f", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that c ould \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of tho se measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  ", "original_text": "With that, let me turn it over to Brian.  ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb23bf392c12ce569107452d8bba894b9c6dc0d05999c432fbcb8912b2e4c041", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d35235ab-9c1e-4111-afea-8365b511e7a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "74d29a0fbf6e112fd0cd66614831090aff72078cecac5fbfa92c001e3e31ba93", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d35235ab-9c1e-4111-afea-8365b511e7a7": {"__data__": {"id_": "d35235ab-9c1e-4111-afea-8365b511e7a7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34a304f7-d91e-4536-8ddd-f3cc6e2b6c74", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a42db290cf5ba87b403f00e32ff8b4a26bab69742b1b38d7b529bf87408d910e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45dc345e-9d05-4ba1-88fe-cc25ef3d158a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everyone. "}, "hash": "79c1854571581db742db1c47dce34142dccbe98cacacac8d141b8e7319fe6852", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45dc345e-9d05-4ba1-88fe-cc25ef3d158a": {"__data__": {"id_": "45dc345e-9d05-4ba1-88fe-cc25ef3d158a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everyone. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d35235ab-9c1e-4111-afea-8365b511e7a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e343ed7dacc8feac221bf5f49fb2170b008d472c1038ace523a9cdac820e533f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1fab1de-4322-40a5-b6cf-7c65ee04a996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n", "original_text": "Thank you for joining us on our second quarter call today. "}, "hash": "691671af13bb3f9a5c5fbb0b6684c3798aa14156c416daafe6a3074080a29897", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and good afternoon, everyone. ", "start_char_idx": 253, "end_char_idx": 302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1fab1de-4322-40a5-b6cf-7c65ee04a996": {"__data__": {"id_": "a1fab1de-4322-40a5-b6cf-7c65ee04a996", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n", "original_text": "Thank you for joining us on our second quarter call today. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45dc345e-9d05-4ba1-88fe-cc25ef3d158a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n", "original_text": "Thank you, Rachel, and good afternoon, everyone. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e477e7a753486817b5ebae98bdc5e4bb082615d38dcbc86e82978ca2b861d934", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4a98fcd-a082-4d17-9962-65d001ccdc92", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year. ", "original_text": "We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses. "}, "hash": "bb8a0b8adfbb13978eedabbf1ed2724eb21a70dba7ec05b798e7f113dec91920", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for joining us on our second quarter call today. ", "start_char_idx": 302, "end_char_idx": 361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4a98fcd-a082-4d17-9962-65d001ccdc92": {"__data__": {"id_": "c4a98fcd-a082-4d17-9962-65d001ccdc92", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year. ", "original_text": "We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1fab1de-4322-40a5-b6cf-7c65ee04a996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n", "original_text": "Thank you for joining us on our second quarter call today. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "609bef1773f70c20dd3a6c28502e858261d9cfcf733cd2c0f5e95413947bdec1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86a1ec01-4c90-4e4e-bc6d-761bbc8426cf", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes. ", "original_text": "We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n"}, "hash": "fdd0a1735467e39d223f553b46353d39c81f06479b5960feb9a91314e7bccd3f", "class_name": "RelatedNodeInfo"}}, "text": "We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses. ", "start_char_idx": 361, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86a1ec01-4c90-4e4e-bc6d-761bbc8426cf": {"__data__": {"id_": "86a1ec01-4c90-4e4e-bc6d-761bbc8426cf", "embedding": null, "metadata": {"window": "Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes. ", "original_text": "We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4a98fcd-a082-4d17-9962-65d001ccdc92", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year. ", "original_text": "We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f795af394a05fecd825851f22df3dcbd3efa865b10d49b32ea21117819889ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cfc8f6c-4ec9-4c02-bb0f-0cd91cca5186", "node_type": "1", "metadata": {"window": "Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n", "original_text": "As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n"}, "hash": "27816d6bd55707284cbc41dc92a454bf34d8f213c9c2f1d394ce084d0b344d87", "class_name": "RelatedNodeInfo"}}, "text": "We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n", "start_char_idx": 510, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cfc8f6c-4ec9-4c02-bb0f-0cd91cca5186": {"__data__": {"id_": "0cfc8f6c-4ec9-4c02-bb0f-0cd91cca5186", "embedding": null, "metadata": {"window": "Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n", "original_text": "As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86a1ec01-4c90-4e4e-bc6d-761bbc8426cf", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes. ", "original_text": "We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbd1dfe090ec1ac13edecac0a99f2287398aa40aade199c3da5fa2c10f797eb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddba9857-0301-4b02-9dee-07348904aebb", "node_type": "1", "metadata": {"window": "We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth. ", "original_text": "We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year. "}, "hash": "50a066289e8f6f1bb1b4b67d5cccebd343cc452e90006b78680b8095d70e57f7", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n", "start_char_idx": 673, "end_char_idx": 989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddba9857-0301-4b02-9dee-07348904aebb": {"__data__": {"id_": "ddba9857-0301-4b02-9dee-07348904aebb", "embedding": null, "metadata": {"window": "We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth. ", "original_text": "We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cfc8f6c-4ec9-4c02-bb0f-0cd91cca5186", "node_type": "1", "metadata": {"window": "Thank you for joining us on our second quarter call today.  We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n", "original_text": "As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "387f0ba09a06999d9cab25a1515d58392bdb14477084a6226580f1d09990d489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfe20a8e-80ca-45bf-b1f7-475b19ef3a90", "node_type": "1", "metadata": {"window": "We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n", "original_text": "We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes. "}, "hash": "7403185c5fdc855b67e3b773c937b6ec27a6adc98554c843416affeaf3f284c1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year. ", "start_char_idx": 989, "end_char_idx": 1154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfe20a8e-80ca-45bf-b1f7-475b19ef3a90": {"__data__": {"id_": "dfe20a8e-80ca-45bf-b1f7-475b19ef3a90", "embedding": null, "metadata": {"window": "We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n", "original_text": "We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddba9857-0301-4b02-9dee-07348904aebb", "node_type": "1", "metadata": {"window": "We \nare happy to report another strong quarter for McKesson, driven by continued market improvements in underlying \nfundamentals of our busines ses.  We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth. ", "original_text": "We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6542e3e208499a6c39f8d75702456c329c982d99357e99ed3e8248c526a0e0af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fdc5ac4-f23d-4391-b6e7-016649d4ffcb", "node_type": "1", "metadata": {"window": "As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values. ", "original_text": "We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n"}, "hash": "0ff33feb7dd465d0cbf762371ac02546c9bb18f87b1a3209f2c69dd3692ad9cd", "class_name": "RelatedNodeInfo"}}, "text": "We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes. ", "start_char_idx": 1154, "end_char_idx": 1310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fdc5ac4-f23d-4391-b6e7-016649d4ffcb": {"__data__": {"id_": "6fdc5ac4-f23d-4391-b6e7-016649d4ffcb", "embedding": null, "metadata": {"window": "As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values. ", "original_text": "We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfe20a8e-80ca-45bf-b1f7-475b19ef3a90", "node_type": "1", "metadata": {"window": "We achieved double -digit adjusted operating profit growth in all four segments, \nbased on a strong operating performance and alignment across the enterprise.  \n \n As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n", "original_text": "We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9dfc77bce9dc28c2f3533a185b5e13182b64d1aae695a2edc2736b5b1c4f060", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28ca8238-c13a-46c4-bc62-8594df734550", "node_type": "1", "metadata": {"window": "We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n", "original_text": "Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth. "}, "hash": "2d5625dafe944f57ac50c9e32f588e236abd9026b134964c724e42c2fe1477b4", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n", "start_char_idx": 1310, "end_char_idx": 1404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28ca8238-c13a-46c4-bc62-8594df734550": {"__data__": {"id_": "28ca8238-c13a-46c4-bc62-8594df734550", "embedding": null, "metadata": {"window": "We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n", "original_text": "Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fdc5ac4-f23d-4391-b6e7-016649d4ffcb", "node_type": "1", "metadata": {"window": "As a result of our second quarter performance, our confidence in the second half of the fisca l year and \nMcKesson's continued role in the COVID -19 response efforts, we are raising our guidance range for fiscal 2022 \nadjusted earnings per diluted share from $19.80 to $20.40 to a new range of $21.95 to $22.55.  \n \n We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values. ", "original_text": "We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b82478955df1a9df596400210d8100d31d5cd659ebf6f0c70fb72dbff710820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dc4af81-13d0-4945-9672-15324fc2a1c5", "node_type": "1", "metadata": {"window": "We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work. ", "original_text": "I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n"}, "hash": "331d4d8d8ce2e08e5b5af82593f26a26513755ae4981fecb159b1d6ae6a699a2", "class_name": "RelatedNodeInfo"}}, "text": "Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth. ", "start_char_idx": 1404, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dc4af81-13d0-4945-9672-15324fc2a1c5": {"__data__": {"id_": "8dc4af81-13d0-4945-9672-15324fc2a1c5", "embedding": null, "metadata": {"window": "We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work. ", "original_text": "I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28ca8238-c13a-46c4-bc62-8594df734550", "node_type": "1", "metadata": {"window": "We continue to believe we will see a ret urn to pre -COVID pharmaceutical prescription and patient engagement \nlevels in the second half of our current fiscal year.  We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n", "original_text": "Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03658739f3666cad0279fd9a801608d215bf4bc68e78445d07c2e7216f97dba6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "759ca668-b276-45dd-a551-a356f04f4add", "node_type": "1", "metadata": {"window": "We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion. ", "original_text": "First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values. "}, "hash": "9967d9ec707da09d6cb99190f501f4232bf43baeab47ed2942439b16e30ba9ed", "class_name": "RelatedNodeInfo"}}, "text": "I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n", "start_char_idx": 1548, "end_char_idx": 1638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "759ca668-b276-45dd-a551-a356f04f4add": {"__data__": {"id_": "759ca668-b276-45dd-a551-a356f04f4add", "embedding": null, "metadata": {"window": "We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion. ", "original_text": "First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dc4af81-13d0-4945-9672-15324fc2a1c5", "node_type": "1", "metadata": {"window": "We're encouraged by the trends we continue to see across \nprimary care, specialty and oncology patient visits in addition to overall pr escription volumes.  We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work. ", "original_text": "I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f32499b772db78b487f3bc3fe59187df6c3a8be54ed735030587c18492d329ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dce0e43-0058-45fa-a356-0456e6209d68", "node_type": "1", "metadata": {"window": "Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n", "original_text": "These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n"}, "hash": "04c8e5e0c6051eea4b40a1772cbd1c8230ec1602c91c9a486ddb41bb18104e2b", "class_name": "RelatedNodeInfo"}}, "text": "First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values. ", "start_char_idx": 1638, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dce0e43-0058-45fa-a356-0456e6209d68": {"__data__": {"id_": "8dce0e43-0058-45fa-a356-0456e6209d68", "embedding": null, "metadata": {"window": "Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n", "original_text": "These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "759ca668-b276-45dd-a551-a356f04f4add", "node_type": "1", "metadata": {"window": "We are pleased to \nsee our markets are recovering in line with our original expectations.  \n \n Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion. ", "original_text": "First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cf9df94fab8536a54f9756655a92a43d0bc76ea8e7719e592d395d079885f19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe15e061-c9d4-45ad-a0a7-b8d9f3e0533d", "node_type": "1", "metadata": {"window": "I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way. ", "original_text": "Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work. "}, "hash": "341d64dfcf4c9b6734b3563325e616baa03d7f10363837be57d2f32382a000ca", "class_name": "RelatedNodeInfo"}}, "text": "These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n", "start_char_idx": 1739, "end_char_idx": 1983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe15e061-c9d4-45ad-a0a7-b8d9f3e0533d": {"__data__": {"id_": "fe15e061-c9d4-45ad-a0a7-b8d9f3e0533d", "embedding": null, "metadata": {"window": "I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way. ", "original_text": "Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dce0e43-0058-45fa-a356-0456e6209d68", "node_type": "1", "metadata": {"window": "Our enterprise -wide focus on our company priorities is driving operating performance and furthering the \nadvancement of our long -term growth.  I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n", "original_text": "These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fec1b4dd1c67a856a4a28e3954a3b26843723c40ee168511c1466786038fb6d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9716f33f-eca4-413e-80e9-34037095cb4b", "node_type": "1", "metadata": {"window": "First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5. ", "original_text": "As an organization, we continue to be committed to \ndiversity, equity, and inclusion. "}, "hash": "f04c7b8c6aed3b4695f2802a17adfff1b8f300c144506c160c374d15945443a1", "class_name": "RelatedNodeInfo"}}, "text": "Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work. ", "start_char_idx": 1983, "end_char_idx": 2152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9716f33f-eca4-413e-80e9-34037095cb4b": {"__data__": {"id_": "9716f33f-eca4-413e-80e9-34037095cb4b", "embedding": null, "metadata": {"window": "First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5. ", "original_text": "As an organization, we continue to be committed to \ndiversity, equity, and inclusion. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe15e061-c9d4-45ad-a0a7-b8d9f3e0533d", "node_type": "1", "metadata": {"window": "I wou ld like to take the time today to talk about each of our company's \npriorities.  \n \n First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way. ", "original_text": "Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc6a9c10ea18016b80a20fccd9b8eaa69bf4ac17f0849542851a0e86c07cc684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11e0890f-261b-468e-8c27-c2e612f3fac5", "node_type": "1", "metadata": {"window": "These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam. ", "original_text": "Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n"}, "hash": "73863aa0af94d9b26858635b471ecc7607acceea6d5d884d78a9daa886430d72", "class_name": "RelatedNodeInfo"}}, "text": "As an organization, we continue to be committed to \ndiversity, equity, and inclusion. ", "start_char_idx": 2152, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11e0890f-261b-468e-8c27-c2e612f3fac5": {"__data__": {"id_": "11e0890f-261b-468e-8c27-c2e612f3fac5", "embedding": null, "metadata": {"window": "These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam. ", "original_text": "Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9716f33f-eca4-413e-80e9-34037095cb4b", "node_type": "1", "metadata": {"window": "First, we have a focus on our people and the culture, which is guided by our ICARE and ILEAD values.  These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5. ", "original_text": "As an organization, we continue to be committed to \ndiversity, equity, and inclusion. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dfb4e21346f7fa0f62255da3db4316e9877ae8598882d32050d06ba4bfb238d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3b5f654-ebdd-4d14-a143-8a3a59a60e16", "node_type": "1", "metadata": {"window": "Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves. ", "original_text": "At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way. "}, "hash": "cbeb7e45cdfd6e690dbd35ecc851a8c1d8002fb632c6c282f08810cce5bb83a5", "class_name": "RelatedNodeInfo"}}, "text": "Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n", "start_char_idx": 2238, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3b5f654-ebdd-4d14-a143-8a3a59a60e16": {"__data__": {"id_": "e3b5f654-ebdd-4d14-a143-8a3a59a60e16", "embedding": null, "metadata": {"window": "Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves. ", "original_text": "At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11e0890f-261b-468e-8c27-c2e612f3fac5", "node_type": "1", "metadata": {"window": "These \nvalues include a commitment to both our local and global communities,  our customers and the healthcare industry \nto innovate and deliver opportunities that make our customers more successful, all for the better health of \npatients.  \n \n Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam. ", "original_text": "Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d824b2635f68769a5618046fca44f69527c2942367a1475619611d591e77a295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdaf1edc-00df-472c-aa19-292a9feb015c", "node_type": "1", "metadata": {"window": "As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n", "original_text": "This will take place this Friday, \nNovember 5. "}, "hash": "c16295b97bfc78df131976c02442bb0a9a6cba7a404460a9a65ae0a16eeb65d5", "class_name": "RelatedNodeInfo"}}, "text": "At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way. ", "start_char_idx": 2354, "end_char_idx": 2640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdaf1edc-00df-472c-aa19-292a9feb015c": {"__data__": {"id_": "fdaf1edc-00df-472c-aa19-292a9feb015c", "embedding": null, "metadata": {"window": "As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n", "original_text": "This will take place this Friday, \nNovember 5. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3b5f654-ebdd-4d14-a143-8a3a59a60e16", "node_type": "1", "metadata": {"window": "Along with these values, we're committed to fostering an inclusive workplace that celebrates o ur differences and \nrespects the diverse world in which we live and work.  As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves. ", "original_text": "At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9deb97e46a6d6cf6a8ded1fc1bf59d2b719f98124d181af3973e12db9450d231", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99b51cae-eac2-4f7a-9b6d-61362092aa7a", "node_type": "1", "metadata": {"window": "Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n", "original_text": "We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam. "}, "hash": "1dc6197a41bf9c2488d1f1c5b0248180ef53913582dcc34c25288a7a9ee7929a", "class_name": "RelatedNodeInfo"}}, "text": "This will take place this Friday, \nNovember 5. ", "start_char_idx": 2640, "end_char_idx": 2687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99b51cae-eac2-4f7a-9b6d-61362092aa7a": {"__data__": {"id_": "99b51cae-eac2-4f7a-9b6d-61362092aa7a", "embedding": null, "metadata": {"window": "Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n", "original_text": "We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdaf1edc-00df-472c-aa19-292a9feb015c", "node_type": "1", "metadata": {"window": "As an organization, we continue to be committed to \ndiversity, equity, and inclusion.  Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n", "original_text": "This will take place this Friday, \nNovember 5. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae30cdbce804a11de32fac44a2c14ff7054b2cdf7268b5e627feba82701c0c7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be0aed15-29b5-4b33-b82f-7eabbcf05600", "node_type": "1", "metadata": {"window": "At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses. ", "original_text": "So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves. "}, "hash": "90ae2a343effa91df2318953641969ffa69921a012a5977dae25ca1529c9b087", "class_name": "RelatedNodeInfo"}}, "text": "We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam. ", "start_char_idx": 2687, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be0aed15-29b5-4b33-b82f-7eabbcf05600": {"__data__": {"id_": "be0aed15-29b5-4b33-b82f-7eabbcf05600", "embedding": null, "metadata": {"window": "At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses. ", "original_text": "So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99b51cae-eac2-4f7a-9b6d-61362092aa7a", "node_type": "1", "metadata": {"window": "Through a more diverse and inclusive workplace, we're a stronger, a more \ncreative and a more produ ctive team.  \n \n At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n", "original_text": "We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a74dcc75f1ae6d5afdcf86cefc905c7adc273c3ea96978aa82cc3c3c6764e7eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d94f93b-552f-47b0-b015-19b0503d4570", "node_type": "1", "metadata": {"window": "This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain. ", "original_text": "We're so grateful for all the contributions from the team over the last 19 months. \n"}, "hash": "e178a4cc63bf97608408d2c879a6849abaa0e53fef1ea64c8acec2ee8fe0810b", "class_name": "RelatedNodeInfo"}}, "text": "So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves. ", "start_char_idx": 2790, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d94f93b-552f-47b0-b015-19b0503d4570": {"__data__": {"id_": "5d94f93b-552f-47b0-b015-19b0503d4570", "embedding": null, "metadata": {"window": "This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain. ", "original_text": "We're so grateful for all the contributions from the team over the last 19 months. \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be0aed15-29b5-4b33-b82f-7eabbcf05600", "node_type": "1", "metadata": {"window": "At McKesson, our priority has been the health and safety of our employees and we're deeply committed to \nsupporting our team members across the organization, which why I am incredibly pleased to have announced \nMcKesson's first -ever day of welln ess, which we call Your Day, Your Way.  This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses. ", "original_text": "So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e8d87b848ec78aa249aa5074c8d91d63353ab40877be3d1c7ce7d60adade26b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9050348-8720-4ea8-b78a-ba2604a77d98", "node_type": "1", "metadata": {"window": "We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day. ", "original_text": "McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n"}, "hash": "1f9032365735f807eacb10a53af2a49de390f26f87ec510f838ea5afa44225c7", "class_name": "RelatedNodeInfo"}}, "text": "We're so grateful for all the contributions from the team over the last 19 months. \n", "start_char_idx": 2921, "end_char_idx": 3005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9050348-8720-4ea8-b78a-ba2604a77d98": {"__data__": {"id_": "e9050348-8720-4ea8-b78a-ba2604a77d98", "embedding": null, "metadata": {"window": "We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day. ", "original_text": "McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d94f93b-552f-47b0-b015-19b0503d4570", "node_type": "1", "metadata": {"window": "This will take place this Friday, \nNovember 5.  We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain. ", "original_text": "We're so grateful for all the contributions from the team over the last 19 months. \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87dc384fceeea489aa419081fcc4ca05d9dfcaa4b15a9aad71afeeb30b7be313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be9ec31e-5326-4717-ab59-c9eeeb953e51", "node_type": "1", "metadata": {"window": "So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n", "original_text": "Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses. "}, "hash": "06329d01ce6cd73e42287e0bc847a67f5b1b36e362902e83057bfaafa2f9f800", "class_name": "RelatedNodeInfo"}}, "text": "McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n", "start_char_idx": 3005, "end_char_idx": 3170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be9ec31e-5326-4717-ab59-c9eeeb953e51": {"__data__": {"id_": "be9ec31e-5326-4717-ab59-c9eeeb953e51", "embedding": null, "metadata": {"window": "So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n", "original_text": "Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9050348-8720-4ea8-b78a-ba2604a77d98", "node_type": "1", "metadata": {"window": "We understand that mental, physical and emotional wellbeing are of the utmost importance to our \nteam.  So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day. ", "original_text": "McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a42ec0793c23b05acafd56eddcfcf17d7227e1c023734d3ee17456a91ae238d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "408350a7-0960-4395-9b54-0e470131bf56", "node_type": "1", "metadata": {"window": "We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners. ", "original_text": "Across North \nAmerica, we have a best -in-class pharmaceutical supply chain. "}, "hash": "b466aa3311ed417bf63f00ac35c6234e36b4b2ef27ed3fe609aad5d0f0a58f4b", "class_name": "RelatedNodeInfo"}}, "text": "Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses. ", "start_char_idx": 3170, "end_char_idx": 3268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "408350a7-0960-4395-9b54-0e470131bf56": {"__data__": {"id_": "408350a7-0960-4395-9b54-0e470131bf56", "embedding": null, "metadata": {"window": "We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners. ", "original_text": "Across North \nAmerica, we have a best -in-class pharmaceutical supply chain. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be9ec31e-5326-4717-ab59-c9eeeb953e51", "node_type": "1", "metadata": {"window": "So we made the decision to set aside a special day to help ensure our  employees can rest, recharge and \ntake time for themselves.  We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n", "original_text": "Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e71dd36fc7441bc073802971f7b2f4902645c5600a86215f3601b7ce0780bda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e41fc4e2-8e86-40d3-8ccf-25832310a5ab", "node_type": "1", "metadata": {"window": "McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently. ", "original_text": "As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day. "}, "hash": "d78d43a47998e30b53e3e4abd4c250273e79bbd42563e90ec088794a2839b146", "class_name": "RelatedNodeInfo"}}, "text": "Across North \nAmerica, we have a best -in-class pharmaceutical supply chain. ", "start_char_idx": 3268, "end_char_idx": 3345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e41fc4e2-8e86-40d3-8ccf-25832310a5ab": {"__data__": {"id_": "e41fc4e2-8e86-40d3-8ccf-25832310a5ab", "embedding": null, "metadata": {"window": "McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently. ", "original_text": "As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "408350a7-0960-4395-9b54-0e470131bf56", "node_type": "1", "metadata": {"window": "We're so grateful for all the contributions from the team over the last 19 months. \n McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners. ", "original_text": "Across North \nAmerica, we have a best -in-class pharmaceutical supply chain. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32abb697842c2a916ac657d65e5b27c45cce06bf5bf97bc3cd412b82b3fed769", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d463d52-7e93-47c6-8e63-9891e3381c17", "node_type": "1", "metadata": {"window": "Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n"}, "hash": "062dfe215718adef65f44d89dd4749793d258836bd7e17847dadf62ea199e2b6", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day. ", "start_char_idx": 3345, "end_char_idx": 3480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d463d52-7e93-47c6-8e63-9891e3381c17": {"__data__": {"id_": "3d463d52-7e93-47c6-8e63-9891e3381c17", "embedding": null, "metadata": {"window": "Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e41fc4e2-8e86-40d3-8ccf-25832310a5ab", "node_type": "1", "metadata": {"window": "McKesson employees continue to be in the center of the fight against COVID -19, and we want to make sure \neveryone gets a chance to take a well -deserved break.  \n \n Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently. ", "original_text": "As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a9676ac26b6a31bbc2a4eacf06c1be4e414fe9cdc48da8c37f85a166da9e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a62fa0f-c731-4a15-854d-0ba670913d70", "node_type": "1", "metadata": {"window": "Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "We strengthen our business when we strengthen our customers and partners. "}, "hash": "e9de9b539896e4a46fc7f320d53024a27dd1befe3f6f546d92d25579175a8c70", "class_name": "RelatedNodeInfo"}}, "text": "Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n", "start_char_idx": 3480, "end_char_idx": 3711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a62fa0f-c731-4a15-854d-0ba670913d70": {"__data__": {"id_": "6a62fa0f-c731-4a15-854d-0ba670913d70", "embedding": null, "metadata": {"window": "Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "We strengthen our business when we strengthen our customers and partners. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d463d52-7e93-47c6-8e63-9891e3381c17", "node_type": "1", "metadata": {"window": "Our second priority is to strengthen our core pharmaceutical and medical supply chain businesses.  Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9523d5eb38a7424d7146b1f670de834a7e016c1a131d6df006b3442d1c004c58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ee20a0e-5f18-4e5a-95b2-16a63e40ee1f", "node_type": "1", "metadata": {"window": "As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently. "}, "hash": "d42062e1ad6d6dd96fd41b5f7e088d39233a90d80e354fd577b552b61d410f93", "class_name": "RelatedNodeInfo"}}, "text": "We strengthen our business when we strengthen our customers and partners. ", "start_char_idx": 3711, "end_char_idx": 3785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ee20a0e-5f18-4e5a-95b2-16a63e40ee1f": {"__data__": {"id_": "5ee20a0e-5f18-4e5a-95b2-16a63e40ee1f", "embedding": null, "metadata": {"window": "As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a62fa0f-c731-4a15-854d-0ba670913d70", "node_type": "1", "metadata": {"window": "Across North \nAmerica, we have a best -in-class pharmaceutical supply chain.  As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "We strengthen our business when we strengthen our customers and partners. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3bff449c71ce437e2a671555e51e75ead23017b264144404c5bef6bfa03cb5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb2b5651-1c00-4849-bdce-69512600964c", "node_type": "1", "metadata": {"window": "Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "The virtual experience helped "}, "hash": "4dceb4275a4acd84128e1f5b2c855c5789c0533f891cfc86071a4caf2f27b10e", "class_name": "RelatedNodeInfo"}}, "text": "This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently. ", "start_char_idx": 3785, "end_char_idx": 4007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb2b5651-1c00-4849-bdce-69512600964c": {"__data__": {"id_": "eb2b5651-1c00-4849-bdce-69512600964c", "embedding": null, "metadata": {"window": "Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "The virtual experience helped ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "250e85a797486fe41a0a7d21afabfc4a0850bcf6fc5f601f845ed5b680b2a11a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ee20a0e-5f18-4e5a-95b2-16a63e40ee1f", "node_type": "1", "metadata": {"window": "As a reminder, in the US, we have a s cale \ndistribution presence that delivers roughly one -third of prescription medicines each day.  Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently. ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a03d7acd6ddf93b8e86b9b1416b1eaf7cf5e9b6bf5db5df3002385344447859", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4761bf74-8559-4b55-9b99-5459610a6bd9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. ", "original_text": "McKesson Corp.  "}, "hash": "2c64e7e758769bc98477c2be3b490598f721980553693cb51561436f597108c4", "class_name": "RelatedNodeInfo"}}, "text": "The virtual experience helped ", "start_char_idx": 4007, "end_char_idx": 4037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4761bf74-8559-4b55-9b99-5459610a6bd9": {"__data__": {"id_": "4761bf74-8559-4b55-9b99-5459610a6bd9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb2b5651-1c00-4849-bdce-69512600964c", "node_type": "1", "metadata": {"window": "Our operational \nexcellence and our ability to leverage our scale with global suppliers is one of the many reasons why McKesson \ncontinues to be the partner of cho ice for hospitals, health systems, and pharmacies of all size.  \n \n We strengthen our business when we strengthen our customers and partners.  This past quarter, we held our \nannual McKesson ideaShare educational event, which brought together independent pharmac y operators to help \nthem learn new skills, how to grow strategically and how to operate efficiently.  The virtual experience helped ", "original_text": "The virtual experience helped ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9da7deca079e57f409ecdb4b628a22daa49c8ccd95985698252b1eb62868be4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "816be645-f31f-4f1b-8628-ec3e050e6baa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n"}, "hash": "e674da5f329e7b1682395e681771fa25147d4cc71bb9f7ac72ecf7c0e1d047ad", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "816be645-f31f-4f1b-8628-ec3e050e6baa": {"__data__": {"id_": "816be645-f31f-4f1b-8628-ec3e050e6baa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4761bf74-8559-4b55-9b99-5459610a6bd9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e8902bb4b4bf1ca3e39cd8d7852f31a326b9d9e2d530225ac59dcaca64a3f85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f6a59cb-481e-4680-b482-54413aad6a48", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n", "original_text": "In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble. "}, "hash": "352ce1624d1438b662753dafdcc9d53369c68cd9c79225679d1cf2a32f5fda74", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n", "start_char_idx": 16, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f6a59cb-481e-4680-b482-54413aad6a48": {"__data__": {"id_": "2f6a59cb-481e-4680-b482-54413aad6a48", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n", "original_text": "In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "816be645-f31f-4f1b-8628-ec3e050e6baa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92eef5997733baad6f58b1c6aaf9d0b1f500910f3937f1d5e3a2b07023c589a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81653593-7634-4284-b844-1771f1ac6b6c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n", "original_text": "We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. "}, "hash": "e3f58ab790bd7536d1e61c63d92c0f703298c4bf267b2bd37c14b16ed288da5e", "class_name": "RelatedNodeInfo"}}, "text": "In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble. ", "start_char_idx": 369, "end_char_idx": 573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81653593-7634-4284-b844-1771f1ac6b6c": {"__data__": {"id_": "81653593-7634-4284-b844-1771f1ac6b6c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n", "original_text": "We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f6a59cb-481e-4680-b482-54413aad6a48", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n", "original_text": "In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f48217a68a90a5c06fea93c2dfcba1019b09c3bd74902b8097c84e7080dbd2c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38173c01-8fcd-466d-b375-d14568b53900", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business. ", "original_text": "We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n"}, "hash": "151301280a043501a47dcb536ba4034effc66a52a6e12973264c278319087243", "class_name": "RelatedNodeInfo"}}, "text": "We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. ", "start_char_idx": 573, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38173c01-8fcd-466d-b375-d14568b53900": {"__data__": {"id_": "38173c01-8fcd-466d-b375-d14568b53900", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business. ", "original_text": "We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81653593-7634-4284-b844-1771f1ac6b6c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n", "original_text": "We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32f5ce16fc9e498cbc4d891b84e3f95914621703f88fba67e569acbe5db06b18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21a66825-0a99-41c5-86d9-67192e06fad0", "node_type": "1", "metadata": {"window": "In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market. ", "original_text": "Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n"}, "hash": "2fb8b0c650a5dc9cb9de6dd89e1fe324897f404a7d353c6ac7640c759d598b94", "class_name": "RelatedNodeInfo"}}, "text": "We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n", "start_char_idx": 749, "end_char_idx": 835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21a66825-0a99-41c5-86d9-67192e06fad0": {"__data__": {"id_": "21a66825-0a99-41c5-86d9-67192e06fad0", "embedding": null, "metadata": {"window": "In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market. ", "original_text": "Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38173c01-8fcd-466d-b375-d14568b53900", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business. ", "original_text": "We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d49730b58102cf12bd22b26d74e31fec2c2fd9aa1296fb71cfa476fefc592f3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed2f864-8456-4446-8fa3-28de33a17456", "node_type": "1", "metadata": {"window": "We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region. ", "original_text": "I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n"}, "hash": "202d5be424f80ccfc16bac207f441898c32b5a2e1b0a11a4e886a851125f52fa", "class_name": "RelatedNodeInfo"}}, "text": "Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n", "start_char_idx": 835, "end_char_idx": 1128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed2f864-8456-4446-8fa3-28de33a17456": {"__data__": {"id_": "fed2f864-8456-4446-8fa3-28de33a17456", "embedding": null, "metadata": {"window": "We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region. ", "original_text": "I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21a66825-0a99-41c5-86d9-67192e06fad0", "node_type": "1", "metadata": {"window": "In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market. ", "original_text": "Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c5d0dc8070f2b2cd659c8de34dbfdaaedd0545a92ffc6d86ed18024b2d22a08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "667067c6-a91f-4f54-8ff7-c5376f129b8b", "node_type": "1", "metadata": {"window": "We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n", "original_text": "Our third company priority is to simplify and streamline the business. "}, "hash": "271fc3f1d155dc024a4372d857d49b90145153190f095f9f14b5643b521b7d9d", "class_name": "RelatedNodeInfo"}}, "text": "I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n", "start_char_idx": 1128, "end_char_idx": 1353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "667067c6-a91f-4f54-8ff7-c5376f129b8b": {"__data__": {"id_": "667067c6-a91f-4f54-8ff7-c5376f129b8b", "embedding": null, "metadata": {"window": "We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n", "original_text": "Our third company priority is to simplify and streamline the business. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed2f864-8456-4446-8fa3-28de33a17456", "node_type": "1", "metadata": {"window": "We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities.  We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region. ", "original_text": "I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd7421a1382377ec3b3e0d48b811edb06aacf2857bffb9d2e5fffc8a48459879", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea308ee1-d756-4e0e-bbbe-84bc3ae780ac", "node_type": "1", "metadata": {"window": "Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole. ", "original_text": "We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market. "}, "hash": "c1ed5563205e9c5e50080cff69860696c62277b96c07230e2b691fd437ec8e5a", "class_name": "RelatedNodeInfo"}}, "text": "Our third company priority is to simplify and streamline the business. ", "start_char_idx": 1353, "end_char_idx": 1424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea308ee1-d756-4e0e-bbbe-84bc3ae780ac": {"__data__": {"id_": "ea308ee1-d756-4e0e-bbbe-84bc3ae780ac", "embedding": null, "metadata": {"window": "Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole. ", "original_text": "We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "667067c6-a91f-4f54-8ff7-c5376f129b8b", "node_type": "1", "metadata": {"window": "We deliver medical and surgical supplies and services to over 250,000 \ncustome rs. \n \n Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n", "original_text": "Our third company priority is to simplify and streamline the business. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "075595c68890387faa469935fc5adc332119477a41e9d73a05a3edd3e26df7ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55a06f22-c320-4273-9ba1-04fec8db0bde", "node_type": "1", "metadata": {"window": "I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals. ", "original_text": "As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region. "}, "hash": "609748e87f332b4743eaace55d3ead6e9b7740f21c6a2766aafac20b7e851696", "class_name": "RelatedNodeInfo"}}, "text": "We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market. ", "start_char_idx": 1424, "end_char_idx": 1578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55a06f22-c320-4273-9ba1-04fec8db0bde": {"__data__": {"id_": "55a06f22-c320-4273-9ba1-04fec8db0bde", "embedding": null, "metadata": {"window": "I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals. ", "original_text": "As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea308ee1-d756-4e0e-bbbe-84bc3ae780ac", "node_type": "1", "metadata": {"window": "Our pharmaceutical and medical distribution businesses continue to play an integral role in the pandemic \nresponse efforts, and our capabilities have been highlighted through our evolving partnership with the US \ngovernment's COVID -19 vaccine distributi on, kitting and storage programs.  \n \n I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole. ", "original_text": "We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "921837844e658e7483f87f853688973f038a987143de90c6d49c2a2960e21779", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76f68b29-596a-4c4a-ba46-3f903cf8a9ca", "node_type": "1", "metadata": {"window": "Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n", "original_text": "In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n"}, "hash": "b5c41153d1d2bb0e921ff569058006c323321917ad004a041e6e105768418fc7", "class_name": "RelatedNodeInfo"}}, "text": "As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region. ", "start_char_idx": 1578, "end_char_idx": 1674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76f68b29-596a-4c4a-ba46-3f903cf8a9ca": {"__data__": {"id_": "76f68b29-596a-4c4a-ba46-3f903cf8a9ca", "embedding": null, "metadata": {"window": "Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n", "original_text": "In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55a06f22-c320-4273-9ba1-04fec8db0bde", "node_type": "1", "metadata": {"window": "I'm glad to say that the fundamentals in our core business remain solid, and our execution has continued to \nimprove as we accelerate our growth and work to deliver high quality, resilient supply chains to our customers.  \n \n Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals. ", "original_text": "As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d0ab07d67060ed046ac46ce89d215cc471600e03e0b3870c4c7c2ddfc129f4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0918f91-e83d-4eca-a27a-615767f1329e", "node_type": "1", "metadata": {"window": "We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars. ", "original_text": "Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole. "}, "hash": "187d7d98dc95a8c46df19f348905166fd195797e958b196804888ca82dd188cb", "class_name": "RelatedNodeInfo"}}, "text": "In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n", "start_char_idx": 1674, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0918f91-e83d-4eca-a27a-615767f1329e": {"__data__": {"id_": "a0918f91-e83d-4eca-a27a-615767f1329e", "embedding": null, "metadata": {"window": "We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars. ", "original_text": "Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76f68b29-596a-4c4a-ba46-3f903cf8a9ca", "node_type": "1", "metadata": {"window": "Our third company priority is to simplify and streamline the business.  We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n", "original_text": "In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef244051d426944ce04dfa5a5b320ba84d44ffe598425f63a38c7f9dccaa9b12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c99776e-0eb7-47ed-9f1d-6bb7654102fb", "node_type": "1", "metadata": {"window": "As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n", "original_text": "The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals. "}, "hash": "e772d807c7f85c6c1c3979460f33dcb03908c88f06503a51112507d613fc8e73", "class_name": "RelatedNodeInfo"}}, "text": "Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole. ", "start_char_idx": 1853, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c99776e-0eb7-47ed-9f1d-6bb7654102fb": {"__data__": {"id_": "6c99776e-0eb7-47ed-9f1d-6bb7654102fb", "embedding": null, "metadata": {"window": "As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n", "original_text": "The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0918f91-e83d-4eca-a27a-615767f1329e", "node_type": "1", "metadata": {"window": "We're prioritizing the areas where we have \ndeep expertise and are central to our long -term growth strategies, largely within the North American market.  As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars. ", "original_text": "Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "013879dcc2ae075caf06fbdbb5f9cbfd50c3bb351404b50c6032896505daddeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f00e5e36-bc0d-4266-a586-7d2cc93e4aa5", "node_type": "1", "metadata": {"window": "In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space. ", "original_text": "We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n"}, "hash": "ad5a6bda6c212a3fe25b68c32a2d6b89fae53f23cc53c85fa950a0bd8951d3d0", "class_name": "RelatedNodeInfo"}}, "text": "The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals. ", "start_char_idx": 1977, "end_char_idx": 2130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f00e5e36-bc0d-4266-a586-7d2cc93e4aa5": {"__data__": {"id_": "f00e5e36-bc0d-4266-a586-7d2cc93e4aa5", "embedding": null, "metadata": {"window": "In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space. ", "original_text": "We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c99776e-0eb7-47ed-9f1d-6bb7654102fb", "node_type": "1", "metadata": {"window": "As a \nresult, we made the decision  to fully exit McKesson's businesses in the European region.  In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n", "original_text": "The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03a809d801005565af026655c7d451ae4a20afd241cebad10a5281eca4448f1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2050ef4d-d9d5-487b-b83b-28ddaf0ec0d4", "node_type": "1", "metadata": {"window": "Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n", "original_text": "Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars. "}, "hash": "c7815d05d5e4b7bd41b48cd8b711504727273a8499faf2fc9863de05b80dd664", "class_name": "RelatedNodeInfo"}}, "text": "We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n", "start_char_idx": 2130, "end_char_idx": 2293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2050ef4d-d9d5-487b-b83b-28ddaf0ec0d4": {"__data__": {"id_": "2050ef4d-d9d5-487b-b83b-28ddaf0ec0d4", "embedding": null, "metadata": {"window": "Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n", "original_text": "Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f00e5e36-bc0d-4266-a586-7d2cc93e4aa5", "node_type": "1", "metadata": {"window": "In July, we announced \nthat we have entered into an agreement to sell our European businesses in France, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  \n \n Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space. ", "original_text": "We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b26ee8f970bc1e30948d8c98f160454c2bc26c6562bc457d88fcbcf017d1d01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2e452cd-cdfb-42aa-b859-fa514ffc9888", "node_type": "1", "metadata": {"window": "The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n", "original_text": "We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n"}, "hash": "98d57c418085872de569227695259d53e7de8368aceb21ce19bea0cad976966b", "class_name": "RelatedNodeInfo"}}, "text": "Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars. ", "start_char_idx": 2293, "end_char_idx": 2447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2e452cd-cdfb-42aa-b859-fa514ffc9888": {"__data__": {"id_": "d2e452cd-cdfb-42aa-b859-fa514ffc9888", "embedding": null, "metadata": {"window": "The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n", "original_text": "We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2050ef4d-d9d5-487b-b83b-28ddaf0ec0d4", "node_type": "1", "metadata": {"window": "Today, we're announci ng that McKesson has made the decision to sell our UK retail and distribution businesses \nas a whole.  The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n", "original_text": "Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de0c61ad6b409ef944902948df6bd2c11517d94d753c20ad8c88c08a7e02856a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4179669b-dc20-48a3-adf2-6f02936d0ebe", "node_type": "1", "metadata": {"window": "We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes. ", "original_text": "McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space. "}, "hash": "12148f484b83e43e9ebcd35518c3d40a615d2f957af78c01d02993f3493c4ca7", "class_name": "RelatedNodeInfo"}}, "text": "We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n", "start_char_idx": 2447, "end_char_idx": 2744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4179669b-dc20-48a3-adf2-6f02936d0ebe": {"__data__": {"id_": "4179669b-dc20-48a3-adf2-6f02936d0ebe", "embedding": null, "metadata": {"window": "We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes. ", "original_text": "McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2e452cd-cdfb-42aa-b859-fa514ffc9888", "node_type": "1", "metadata": {"window": "The transaction is expected to close in Q4 of fiscal 2022, subject to customary closing conditions, \nincluding receipt of required regulatory approvals.  We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n", "original_text": "We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2fbee7937c90031424f378945fc7b6e0caf4f97b40c98439f763ddf5a14758d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e7db23e-4a92-486a-9f5c-07b6e5772b40", "node_type": "1", "metadata": {"window": "Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n", "original_text": "We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n"}, "hash": "9d5835a74124be0ca3f410eb0380e202170dd37136cb947f80d742cfd62d2cc4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space. ", "start_char_idx": 2744, "end_char_idx": 2925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e7db23e-4a92-486a-9f5c-07b6e5772b40": {"__data__": {"id_": "4e7db23e-4a92-486a-9f5c-07b6e5772b40", "embedding": null, "metadata": {"window": "Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n", "original_text": "We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4179669b-dc20-48a3-adf2-6f02936d0ebe", "node_type": "1", "metadata": {"window": "We believe this step toward a full exit of our European business \nis an important milestone in our strategy as a streamlined, efficient, focused organization.  \n \n Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes. ", "original_text": "McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aeb2bfd8f9b2172fccf09f783b4bdd1885edfd237947d5ecb0b8410ed5e414ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f97ffe18-3a54-4e76-b799-4231335188f1", "node_type": "1", "metadata": {"window": "We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients. ", "original_text": "Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n"}, "hash": "d00725d6f4c68d23b400a5fb2713339021393aca8554cb97d8a2cdbc9e468271", "class_name": "RelatedNodeInfo"}}, "text": "We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n", "start_char_idx": 2925, "end_char_idx": 3042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f97ffe18-3a54-4e76-b799-4231335188f1": {"__data__": {"id_": "f97ffe18-3a54-4e76-b799-4231335188f1", "embedding": null, "metadata": {"window": "We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients. ", "original_text": "Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e7db23e-4a92-486a-9f5c-07b6e5772b40", "node_type": "1", "metadata": {"window": "Building upon the foundation of a strong company culture and a stable business, the last company pri ority \nencompasses our two strategic growth pillars.  We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n", "original_text": "We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0c530eee26303fbf4ece020bdff223a3e5699709e693e6d50c5c7e4493e8fb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19fab122-5c53-489e-bb1a-62601c60f5d6", "node_type": "1", "metadata": {"window": "McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes. "}, "hash": "ddade551755dc08b03c191db0538aa8ba3ef1b64b994085344a5ddc6a244e119", "class_name": "RelatedNodeInfo"}}, "text": "Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n", "start_char_idx": 3042, "end_char_idx": 3316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19fab122-5c53-489e-bb1a-62601c60f5d6": {"__data__": {"id_": "19fab122-5c53-489e-bb1a-62601c60f5d6", "embedding": null, "metadata": {"window": "McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f97ffe18-3a54-4e76-b799-4231335188f1", "node_type": "1", "metadata": {"window": "We are investing to advance our oncology and biopharma services, \nwhich includes building integrated ecosystems that leverage our differentiated assets and capabilities and our \nstrategic focus on these two  pillars is important as both of these areas have good inherent growth opportunities.  \n \n McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients. ", "original_text": "Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "156d86d417631ac53aec6966a16c4256e68bae8c4d401b92473e546946663a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3097d65-a296-4f76-a187-b3b3ef300e54", "node_type": "1", "metadata": {"window": "We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n"}, "hash": "c72a113007da0c7a9dc097849417bb9d37ea9c3fc1ce5c47025c338ba70f1ae0", "class_name": "RelatedNodeInfo"}}, "text": "The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes. ", "start_char_idx": 3316, "end_char_idx": 3528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3097d65-a296-4f76-a187-b3b3ef300e54": {"__data__": {"id_": "c3097d65-a296-4f76-a187-b3b3ef300e54", "embedding": null, "metadata": {"window": "We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19fab122-5c53-489e-bb1a-62601c60f5d6", "node_type": "1", "metadata": {"window": "McKesson's oncology ecosystem supports over 14,000 specialty physicians through distribution and GPO \nservices, and we are the leading distributor in the community oncolo gy space.  We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1625a8ae66408a74c20db6dd48334546ea34209f5dfcd1ad151ad427a4d3074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3159a24f-25e7-45c0-aad0-0023f5a8dac0", "node_type": "1", "metadata": {"window": "Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients. "}, "hash": "c0a715da347e92ebbc05288c42a1404843963a4bb3c38d3a8bdb15455167c760", "class_name": "RelatedNodeInfo"}}, "text": "We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n", "start_char_idx": 3528, "end_char_idx": 3739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3159a24f-25e7-45c0-aad0-0023f5a8dac0": {"__data__": {"id_": "3159a24f-25e7-45c0-aad0-0023f5a8dac0", "embedding": null, "metadata": {"window": "Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3097d65-a296-4f76-a187-b3b3ef300e54", "node_type": "1", "metadata": {"window": "We have over 1,400 physicians in \nthe US oncology network spread over approximately 600 sites of care in the US.  \n \n Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc11a00a20be38af2cceec5208ab99ec623d17bf1f4feb125ca938d4b8804f4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1ec5762-0224-4517-9b05-cf43c46ee4b4", "node_type": "1", "metadata": {"window": "The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and "}, "hash": "fbc5e6b9a8188159133989b048ff2d06aef0e0a39d35d7b9dff8eec1e9988de8", "class_name": "RelatedNodeInfo"}}, "text": "Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients. ", "start_char_idx": 3739, "end_char_idx": 3943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1ec5762-0224-4517-9b05-cf43c46ee4b4": {"__data__": {"id_": "d1ec5762-0224-4517-9b05-cf43c46ee4b4", "embedding": null, "metadata": {"window": "The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a7b410ddd3873cb430c7fb4e62d06674fd90e3adcd58f9761ebce65325111a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3159a24f-25e7-45c0-aad0-0023f5a8dac0", "node_type": "1", "metadata": {"window": "Within our oncology ecosystem, Ontada generates insights at the intersection of technology and data and \nsupports community providers with precise cancer care by improving patient outcomes and delivering evidence \nand insights to help accelerate life sciences research.  \n \n The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients. ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "061b8dce72eecb8ee3a3ef9215f76e909be013f27e0d252a70098a515b0f9d84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b5e6dd4-e7a9-43db-b311-8e1c0d70c3ae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. ", "original_text": "McKesson Corp.  "}, "hash": "32140b279d1f2983a6a133a6a4de4bb71581436de7446ac672b3f7dbdcd92c05", "class_name": "RelatedNodeInfo"}}, "text": "We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "start_char_idx": 3943, "end_char_idx": 4056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b5e6dd4-e7a9-43db-b311-8e1c0d70c3ae": {"__data__": {"id_": "1b5e6dd4-e7a9-43db-b311-8e1c0d70c3ae", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1ec5762-0224-4517-9b05-cf43c46ee4b4", "node_type": "1", "metadata": {"window": "The ecosystem helps the clinicians to provide better care in an increasingly complicated oncology care landscape \nby help ing them grow their businesses, attract more patients and produce better health outcomes.  We can then \nleverage interconnected technology and real -world insights to feed data back upstream to manufacturers, which \ncan help them think about identifying new pr oducts, innovations and new markets.  \n \n Within the biopharma ecosystem, the Prescription Technology Solutions businesses leverage technology \nnetworks and access to provider workflows to serve biopharma and life sciences partners and patients.  We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "original_text": "We have \nbuilt this ecosystem over many years as it in cludes assets like RelayHealth Pharmacy, CoverMyMeds, and ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29e34729ede6225e82c17094710079c23d9c8e87d677006a5eae3b0dfe5adf33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48ddf2ae-b7db-4571-b411-a91c22b72739", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads. "}, "hash": "9c0888508c6116657d79cb45406ab97d2132c8d1b7fc0adb47ddfbc122ff8768", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48ddf2ae-b7db-4571-b411-a91c22b72739": {"__data__": {"id_": "48ddf2ae-b7db-4571-b411-a91c22b72739", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b5e6dd4-e7a9-43db-b311-8e1c0d70c3ae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d02bb1b0e086b6fcdac0b1b65e9bfa50b00909b77010d3902c16e1f7528ac39a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c91c3fa-43be-4fc6-8529-d9ed31f3cd63", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n", "original_text": "It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n"}, "hash": "800a6e636a683c4738531da4d7818a9030331f7f027b4a95e052a9a1f7fed489", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads. ", "start_char_idx": 16, "end_char_idx": 194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c91c3fa-43be-4fc6-8529-d9ed31f3cd63": {"__data__": {"id_": "5c91c3fa-43be-4fc6-8529-d9ed31f3cd63", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n", "original_text": "It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48ddf2ae-b7db-4571-b411-a91c22b72739", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36fcf6704ebf3202018ca4950300b4331a302a5aba9793ae13c7788f185236c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8180407-fa32-46e2-a182-5d62cc9743fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors. ", "original_text": "Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. "}, "hash": "d84505c1fc82a73d6c126f9a14f80caa4545e11cdc80a05710d7ff0b4a89de43", "class_name": "RelatedNodeInfo"}}, "text": "It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n", "start_char_idx": 194, "end_char_idx": 322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8180407-fa32-46e2-a182-5d62cc9743fb": {"__data__": {"id_": "a8180407-fa32-46e2-a182-5d62cc9743fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors. ", "original_text": "Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c91c3fa-43be-4fc6-8529-d9ed31f3cd63", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n", "original_text": "It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c014e5bff1b963c596205ea81cfa216ccaf0af000b9716324a2f137b7285007f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbeb1214-53db-4c3f-a9ed-989c2eeac47b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr. ", "original_text": "We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson. "}, "hash": "adf86a41499200ed498243569ca0ef9a22fd66920a1af98ea347ef3fb7e3c982", "class_name": "RelatedNodeInfo"}}, "text": "Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. ", "start_char_idx": 322, "end_char_idx": 552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbeb1214-53db-4c3f-a9ed-989c2eeac47b": {"__data__": {"id_": "cbeb1214-53db-4c3f-a9ed-989c2eeac47b", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr. ", "original_text": "We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8180407-fa32-46e2-a182-5d62cc9743fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors. ", "original_text": "Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79ed37cff5be53cc0b308ff6834aac153fde164f3507e02a5af4a80372f10e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b20a446c-a639-4374-8472-24843ec119d7", "node_type": "1", "metadata": {"window": "It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director. ", "original_text": "I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n"}, "hash": "74b29e2c6df2c31f57147b92e7f853daa49b334f7699ed3ec72ffb7343d67c3c", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson. ", "start_char_idx": 552, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b20a446c-a639-4374-8472-24843ec119d7": {"__data__": {"id_": "b20a446c-a639-4374-8472-24843ec119d7", "embedding": null, "metadata": {"window": "It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director. ", "original_text": "I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbeb1214-53db-4c3f-a9ed-989c2eeac47b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr. ", "original_text": "We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20a3ab8d1f864435b8f4fb12265a338aaf08508fba6b56f7b57941fa66ab8b67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec4ab925-28a4-443f-b8cf-091faf765a30", "node_type": "1", "metadata": {"window": "Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr. ", "original_text": "Before I turn to our second quarter results, just a brief update on our Board of Directors. "}, "hash": "4c36fe1ab79bf552b1dcc9f9a23e703c22edb832e8ba34df3f1cf9dd5b948aa0", "class_name": "RelatedNodeInfo"}}, "text": "I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n", "start_char_idx": 685, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec4ab925-28a4-443f-b8cf-091faf765a30": {"__data__": {"id_": "ec4ab925-28a4-443f-b8cf-091faf765a30", "embedding": null, "metadata": {"window": "Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr. ", "original_text": "Before I turn to our second quarter results, just a brief update on our Board of Directors. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b20a446c-a639-4374-8472-24843ec119d7", "node_type": "1", "metadata": {"window": "It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director. ", "original_text": "I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0c1375bd20623e9fbaf9723a2d8b611872753486d20ae64224650a93a680a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c525ebd-e59d-4b7f-86a6-6bf1cc568516", "node_type": "1", "metadata": {"window": "We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006. ", "original_text": "In Sep tember, our Board \nof Directors welcomed Dr. "}, "hash": "bfbdecc4cf14d933e83cc9895c688c63022b863876da2416034cab6749c2960a", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn to our second quarter results, just a brief update on our Board of Directors. ", "start_char_idx": 806, "end_char_idx": 898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c525ebd-e59d-4b7f-86a6-6bf1cc568516": {"__data__": {"id_": "9c525ebd-e59d-4b7f-86a6-6bf1cc568516", "embedding": null, "metadata": {"window": "We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006. ", "original_text": "In Sep tember, our Board \nof Directors welcomed Dr. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec4ab925-28a4-443f-b8cf-091faf765a30", "node_type": "1", "metadata": {"window": "Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency.  We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr. ", "original_text": "Before I turn to our second quarter results, just a brief update on our Board of Directors. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b02c1ee7402d56bbfc06c387b9a81c949c79d277bb152a78e923bff1e664fdb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dae4129c-b121-4efe-805a-a0cc00a249ff", "node_type": "1", "metadata": {"window": "I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr. ", "original_text": "Richard Carmona as a new independent director. "}, "hash": "0cd9f36cd8ffd06f1599f7f571c4f6934b9b918c3a1f0a739aae4d957137c558", "class_name": "RelatedNodeInfo"}}, "text": "In Sep tember, our Board \nof Directors welcomed Dr. ", "start_char_idx": 898, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dae4129c-b121-4efe-805a-a0cc00a249ff": {"__data__": {"id_": "dae4129c-b121-4efe-805a-a0cc00a249ff", "embedding": null, "metadata": {"window": "I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr. ", "original_text": "Richard Carmona as a new independent director. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c525ebd-e59d-4b7f-86a6-6bf1cc568516", "node_type": "1", "metadata": {"window": "We will continue to invest and accelerate the execution against those strategies, which su pport the \nlong-term growth for McKesson.  I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006. ", "original_text": "In Sep tember, our Board \nof Directors welcomed Dr. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10a2529364d45daf118a743f2458c39110df513316ea9e47a6b71be045343a95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a17f6c9d-72aa-49b5-9fed-2bbeb8195a9f", "node_type": "1", "metadata": {"window": "Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na. ", "original_text": "Dr. "}, "hash": "910891d4c58e1493023aad53449abfe0fe369c7db5a4e67f2ecee055b989ac0a", "class_name": "RelatedNodeInfo"}}, "text": "Richard Carmona as a new independent director. ", "start_char_idx": 950, "end_char_idx": 997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a17f6c9d-72aa-49b5-9fed-2bbeb8195a9f": {"__data__": {"id_": "a17f6c9d-72aa-49b5-9fed-2bbeb8195a9f", "embedding": null, "metadata": {"window": "Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na. ", "original_text": "Dr. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dae4129c-b121-4efe-805a-a0cc00a249ff", "node_type": "1", "metadata": {"window": "I'm confident in the progress against our company's priorities that they will enable \nthe advancement of our growth.  \n \n Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr. ", "original_text": "Richard Carmona as a new independent director. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "459549507e00414b8db0be44c51fb3e63615bc4958761cee48f7a92cf895c8bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e183fb6f-6416-4e14-8aab-dfb1f90be615", "node_type": "1", "metadata": {"window": "In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n", "original_text": "Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006. "}, "hash": "7336b0e6d4a96f59b83db33e85dc55a87b355432e4edc0ea104f377ecb8d8393", "class_name": "RelatedNodeInfo"}}, "text": "Dr. ", "start_char_idx": 946, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e183fb6f-6416-4e14-8aab-dfb1f90be615": {"__data__": {"id_": "e183fb6f-6416-4e14-8aab-dfb1f90be615", "embedding": null, "metadata": {"window": "In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n", "original_text": "Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a17f6c9d-72aa-49b5-9fed-2bbeb8195a9f", "node_type": "1", "metadata": {"window": "Before I turn to our second quarter results, just a brief update on our Board of Directors.  In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na. ", "original_text": "Dr. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26eeb707cff314a4887ac898d000b8dda7e85a37de918a855f0096ed1d5366ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6362c647-3296-4d01-af20-a85406979720", "node_type": "1", "metadata": {"window": "Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter. ", "original_text": "Currently, Dr. "}, "hash": "36f06a9799e284856fce1af1c4bf283a1b40df7adb9ab7d6fa625deda7cabacd", "class_name": "RelatedNodeInfo"}}, "text": "Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006. ", "start_char_idx": 1001, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6362c647-3296-4d01-af20-a85406979720": {"__data__": {"id_": "6362c647-3296-4d01-af20-a85406979720", "embedding": null, "metadata": {"window": "Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter. ", "original_text": "Currently, Dr. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e183fb6f-6416-4e14-8aab-dfb1f90be615", "node_type": "1", "metadata": {"window": "In Sep tember, our Board \nof Directors welcomed Dr.  Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n", "original_text": "Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecc2b152bb1fb27ab7c8aecb517638c45eaa34f3955f9fa9c962058aff5c9f67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f29e39b3-4b96-491c-be24-4a9c8106df29", "node_type": "1", "metadata": {"window": "Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business. ", "original_text": "Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na. "}, "hash": "693c3647e7405cc6afbd04343207e13bf597e1abd0806d0cfbf6962474be1db3", "class_name": "RelatedNodeInfo"}}, "text": "Currently, Dr. ", "start_char_idx": 1292, "end_char_idx": 1307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f29e39b3-4b96-491c-be24-4a9c8106df29": {"__data__": {"id_": "f29e39b3-4b96-491c-be24-4a9c8106df29", "embedding": null, "metadata": {"window": "Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business. ", "original_text": "Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6362c647-3296-4d01-af20-a85406979720", "node_type": "1", "metadata": {"window": "Richard Carmona as a new independent director.  Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter. ", "original_text": "Currently, Dr. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7e49e633cf3b00cf2b237bd9fec90ee57388078076955e90b6ae5d363a57765", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb55197d-adbe-4d8b-b3b8-d0a6a2012c4e", "node_type": "1", "metadata": {"window": "Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations. ", "original_text": "His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n"}, "hash": "c80b146e07f75ed9d23edeceb83cf57f83eb199fea230169fca2477a4a659659", "class_name": "RelatedNodeInfo"}}, "text": "Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na. ", "start_char_idx": 1307, "end_char_idx": 1427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb55197d-adbe-4d8b-b3b8-d0a6a2012c4e": {"__data__": {"id_": "bb55197d-adbe-4d8b-b3b8-d0a6a2012c4e", "embedding": null, "metadata": {"window": "Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations. ", "original_text": "His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f29e39b3-4b96-491c-be24-4a9c8106df29", "node_type": "1", "metadata": {"window": "Dr.  Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business. ", "original_text": "Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b78a6b70b4a2b209e457e9f09daf2a17bead13912fec217ffde9e52ea4014774", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e54576d6-4eeb-4ad1-ad9a-7d7402c831c0", "node_type": "1", "metadata": {"window": "Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n", "original_text": "Now I want to turn to the business performance within the second quarter. "}, "hash": "61b400fe72ff57112392bec292527cc45b43bc2a25bf8e2c751b0d18c1435e83", "class_name": "RelatedNodeInfo"}}, "text": "His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n", "start_char_idx": 1427, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e54576d6-4eeb-4ad1-ad9a-7d7402c831c0": {"__data__": {"id_": "e54576d6-4eeb-4ad1-ad9a-7d7402c831c0", "embedding": null, "metadata": {"window": "Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n", "original_text": "Now I want to turn to the business performance within the second quarter. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb55197d-adbe-4d8b-b3b8-d0a6a2012c4e", "node_type": "1", "metadata": {"window": "Carmona has a strong focus on \nimproving public healthcare and extensive experience in clinical sciences, healthcare management and \nemergency preparedness, which led to his nomination and unanimous Senate confirmation as the 17th Surgeon \nGeneral of the United States from 2002 until 2006.  Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations. ", "original_text": "His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8bc5dc8da741fe97b9bb8d551607601089306b8a1825485cb8767a794c78989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6d14a09-d91f-4889-b09d-7ec6e843e08b", "node_type": "1", "metadata": {"window": "Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations. ", "original_text": "We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business. "}, "hash": "4b49ab51adcd588bad329540652667847d57de792e4db9aaed52018f3778d838", "class_name": "RelatedNodeInfo"}}, "text": "Now I want to turn to the business performance within the second quarter. ", "start_char_idx": 1522, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d14a09-d91f-4889-b09d-7ec6e843e08b": {"__data__": {"id_": "c6d14a09-d91f-4889-b09d-7ec6e843e08b", "embedding": null, "metadata": {"window": "Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations. ", "original_text": "We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e54576d6-4eeb-4ad1-ad9a-7d7402c831c0", "node_type": "1", "metadata": {"window": "Currently, Dr.  Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n", "original_text": "Now I want to turn to the business performance within the second quarter. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0df15f0570b344029b0785762b973b85df235474094358d699f833e3fefd9b9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54e9552e-a613-4060-8402-95a909543f05", "node_type": "1", "metadata": {"window": "His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n", "original_text": "Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations. "}, "hash": "ff4208b3a77f23efe11501de1c7476fd1d8156ce30a50d9c8f381d857d5df38a", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business. ", "start_char_idx": 1596, "end_char_idx": 1730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54e9552e-a613-4060-8402-95a909543f05": {"__data__": {"id_": "54e9552e-a613-4060-8402-95a909543f05", "embedding": null, "metadata": {"window": "His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n", "original_text": "Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6d14a09-d91f-4889-b09d-7ec6e843e08b", "node_type": "1", "metadata": {"window": "Carmona is Chief of Health Innovations at \nCanyon Ranch and a Professor of Public Health at the University of Arizo na.  His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations. ", "original_text": "We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a205a72eadad11b204c60357f3af47a167895d2937279cfdc04c215d401e54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1045f4a-c4b1-45aa-94e8-e55fc9a79fad", "node_type": "1", "metadata": {"window": "Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n", "original_text": "Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n"}, "hash": "b1e37632ffc5591e38508f37281c211acbc8f7f3eb07337744dcda209e13d99f", "class_name": "RelatedNodeInfo"}}, "text": "Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations. ", "start_char_idx": 1730, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1045f4a-c4b1-45aa-94e8-e55fc9a79fad": {"__data__": {"id_": "a1045f4a-c4b1-45aa-94e8-e55fc9a79fad", "embedding": null, "metadata": {"window": "Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n", "original_text": "Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54e9552e-a613-4060-8402-95a909543f05", "node_type": "1", "metadata": {"window": "His hands -on healthcare experience \nwill be invaluable for McKesson's Board of Directors.  \n \n Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n", "original_text": "Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dae9c34c4ddf3e59163bb8cbefd2a8fadee5f31dc96f4f587b5b0ff6204dfde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e937c734-40be-4fac-bc9d-c070eaddfd3a", "node_type": "1", "metadata": {"window": "We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms. ", "original_text": "The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations. "}, "hash": "e223477d628a255aa6d5d2c14b8753eb9f44b9faf370d2d431c09cd6047b2f2a", "class_name": "RelatedNodeInfo"}}, "text": "Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n", "start_char_idx": 1914, "end_char_idx": 2044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e937c734-40be-4fac-bc9d-c070eaddfd3a": {"__data__": {"id_": "e937c734-40be-4fac-bc9d-c070eaddfd3a", "embedding": null, "metadata": {"window": "We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms. ", "original_text": "The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1045f4a-c4b1-45aa-94e8-e55fc9a79fad", "node_type": "1", "metadata": {"window": "Now I want to turn to the business performance within the second quarter.  We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n", "original_text": "Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "433e3c7d567a301f34460fb19d82444bdb31110e07ca3d32027b0ff2222234c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "006ff6a7-f48b-4945-8787-07db49735a73", "node_type": "1", "metadata": {"window": "Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n", "original_text": "We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n"}, "hash": "9c6a4109bf371737f40418571ea831509cd807681c7518d75b3b98657bc18589", "class_name": "RelatedNodeInfo"}}, "text": "The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations. ", "start_char_idx": 2044, "end_char_idx": 2300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "006ff6a7-f48b-4945-8787-07db49735a73": {"__data__": {"id_": "006ff6a7-f48b-4945-8787-07db49735a73", "embedding": null, "metadata": {"window": "Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n", "original_text": "We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e937c734-40be-4fac-bc9d-c070eaddfd3a", "node_type": "1", "metadata": {"window": "We are pleased with our strong second \nquarter performance, and we remain encouraged by t he underlying fundamentals in our business.  Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms. ", "original_text": "The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22df7a307a18b1e045d58c42dbaeb459a7a6dabe69e1e13c488f02edc6856e4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "640382c3-307a-4538-9feb-f75e8d5cd909", "node_type": "1", "metadata": {"window": "Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n", "original_text": "Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n"}, "hash": "026d7b2a1c042cf90383d8dddc78111f65ed1fabd14e1da164fdf51b47bf4330", "class_name": "RelatedNodeInfo"}}, "text": "We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n", "start_char_idx": 2300, "end_char_idx": 2566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "640382c3-307a-4538-9feb-f75e8d5cd909": {"__data__": {"id_": "640382c3-307a-4538-9feb-f75e8d5cd909", "embedding": null, "metadata": {"window": "Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n", "original_text": "Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "006ff6a7-f48b-4945-8787-07db49735a73", "node_type": "1", "metadata": {"window": "Let me start \nwith US Pharmaceutical, where our solid results for the second quarter reflected continued improvement of \nprescription trends, which were in line with our expectations.  Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n", "original_text": "We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c364db4d8debf63162b45cad53a481c0589ecb245b274ee907a4fba02346875", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4578289b-774d-4860-965a-894454c1c4cb", "node_type": "1", "metadata": {"window": "The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract. ", "original_text": "In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms. "}, "hash": "fad507d25b144e2405fb0dd3b8774452d67fd1ca31701a80a33f4a5f16a36910", "class_name": "RelatedNodeInfo"}}, "text": "Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n", "start_char_idx": 2566, "end_char_idx": 2835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4578289b-774d-4860-965a-894454c1c4cb": {"__data__": {"id_": "4578289b-774d-4860-965a-894454c1c4cb", "embedding": null, "metadata": {"window": "The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract. ", "original_text": "In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "640382c3-307a-4538-9feb-f75e8d5cd909", "node_type": "1", "metadata": {"window": "Within specialty oncology visi ts we saw an exit rate \nof pre -COVID levels, which, again, was in line with our expectations.  \n \n The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n", "original_text": "Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00698f7d5790a6510ad6510b444a7940a186d9558fc0a7cc3c636bab710a1fd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db0ed7b4-863e-4bab-ae88-14bf365e731b", "node_type": "1", "metadata": {"window": "We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n", "original_text": "The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n"}, "hash": "1a09bba9fd6b0a0df045bc449c8d683e92576398d36c51db6bb145d683e45f0e", "class_name": "RelatedNodeInfo"}}, "text": "In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms. ", "start_char_idx": 2835, "end_char_idx": 3101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db0ed7b4-863e-4bab-ae88-14bf365e731b": {"__data__": {"id_": "db0ed7b4-863e-4bab-ae88-14bf365e731b", "embedding": null, "metadata": {"window": "We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n", "original_text": "The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4578289b-774d-4860-965a-894454c1c4cb", "node_type": "1", "metadata": {"window": "The US Pharmaceutical segment saw a 12% adjusted operating profit growth, which was underpinned by the \ndistribution of specialty products to providers and health systems and the contribution from our successful \nCOVID -19 vaccine distribution operations.  We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract. ", "original_text": "In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7783c0df92e9f43ae2be60894e7e6946523a36d0cdeef2092737ae70b5910b83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ba5d83c-f41c-470a-9c70-bf1bc6025d92", "node_type": "1", "metadata": {"window": "Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement. ", "original_text": "In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n"}, "hash": "84db29b8f76768cebca017b326f2ea3476488af99309a61afc220eea8fecdd2d", "class_name": "RelatedNodeInfo"}}, "text": "The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n", "start_char_idx": 3101, "end_char_idx": 3233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ba5d83c-f41c-470a-9c70-bf1bc6025d92": {"__data__": {"id_": "3ba5d83c-f41c-470a-9c70-bf1bc6025d92", "embedding": null, "metadata": {"window": "Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement. ", "original_text": "In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db0ed7b4-863e-4bab-ae88-14bf365e731b", "node_type": "1", "metadata": {"window": "We are in a strong position to continue to support the government and \nprivate enterprise in the future for distributing COVID and flu vaccines, and our investments i n the distribution \nbusiness continue to be showcased through our successful vaccine response.  \n \n Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n", "original_text": "The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55085da383b9f27ccd589dee8ce0f5ea9e859c84bf4c6783273df5466efc819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2607f03-ec67-4701-979a-c6dc3de98f89", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers. ", "original_text": "In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract. "}, "hash": "7a43adc6f6fb8e343b2b47f74cf14803694e51e0092414a7a17b7e07e5b5e0cd", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n", "start_char_idx": 3233, "end_char_idx": 3420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2607f03-ec67-4701-979a-c6dc3de98f89": {"__data__": {"id_": "f2607f03-ec67-4701-979a-c6dc3de98f89", "embedding": null, "metadata": {"window": "In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers. ", "original_text": "In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ba5d83c-f41c-470a-9c70-bf1bc6025d92", "node_type": "1", "metadata": {"window": "Through October 28, our US Pharmaceutical business has successfully distributed over 311 million Moderna and \nJohnson & Johnson COVID -19 vaccines to administratio n sites across the United States and to support the US \ngovernment's international donation mission.  \n \n In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement. ", "original_text": "In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5703714af4dc0700d8540479497babd540ada4d58b94c1b2f6c63d59d3e3e5bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e570ae5b-5833-4baf-9adc-b915f740a55e", "node_type": "1", "metadata": {"window": "The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n"}, "hash": "8982d516e87ab6f66fc9d635386d6f0a44929c9f152d02fce9f99e6e338b6e67", "class_name": "RelatedNodeInfo"}}, "text": "In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract. ", "start_char_idx": 3420, "end_char_idx": 3632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e570ae5b-5833-4baf-9adc-b915f740a55e": {"__data__": {"id_": "e570ae5b-5833-4baf-9adc-b915f740a55e", "embedding": null, "metadata": {"window": "The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2607f03-ec67-4701-979a-c6dc3de98f89", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, the business continued to perform well this quarter as our technology and \nservice offerings have accelerated the supp ort and growth of our biopharma customers, and we've been \nsuccessful in adding new brands to our platforms.  The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers. ", "original_text": "In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f122f952191b6463560eae7ce7e7c5ee1767918e787a97f530aecbf8f1ba0fb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b551c54-9f86-4c7b-99b3-f0ab8c433fb6", "node_type": "1", "metadata": {"window": "In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement. "}, "hash": "d494c60d7a0d3ae17ea0115d8b59bb712a74ffa754a1bcc260a0629260ef667f", "class_name": "RelatedNodeInfo"}}, "text": "Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n", "start_char_idx": 3632, "end_char_idx": 3742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b551c54-9f86-4c7b-99b3-f0ab8c433fb6": {"__data__": {"id_": "3b551c54-9f86-4c7b-99b3-f0ab8c433fb6", "embedding": null, "metadata": {"window": "In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e570ae5b-5833-4baf-9adc-b915f740a55e", "node_type": "1", "metadata": {"window": "The segment had excellent momentum and delivered a 38% \nincrease to adjusted operating profit growth during the second quarter.  \n \n In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a2de5ccf8f7cd26f710f5c8ac62b8de4107b5494ef98567327c59ae40aaada7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f56cf395-bde0-4a0e-91df-0061fc11e176", "node_type": "1", "metadata": {"window": "In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers. "}, "hash": "2de658c248164b8b2abcd01e4059a445985b0be6599adb7a2b7d9d6a6ec16e3b", "class_name": "RelatedNodeInfo"}}, "text": "The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement. ", "start_char_idx": 3742, "end_char_idx": 3870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f56cf395-bde0-4a0e-91df-0061fc11e176": {"__data__": {"id_": "f56cf395-bde0-4a0e-91df-0061fc11e176", "embedding": null, "metadata": {"window": "In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b551c54-9f86-4c7b-99b3-f0ab8c433fb6", "node_type": "1", "metadata": {"window": "In addition to the o perational strength, I'm proud to say that we are helping patients get access to the therapies \nthrough our market -leading technology offerings in this segment.  \n \n In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9965199a481c81c95521fa464ef35c4ed7da0e77ab3123dff7a87b727c5bb85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43756234-b8ae-46d2-9713-5668919e560c", "node_type": "1", "metadata": {"window": "Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "We are partnering with "}, "hash": "c7847c18ee6766164545feb06d2490e78693202db7bac1d52da80afcfdf080d3", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers. ", "start_char_idx": 3870, "end_char_idx": 4064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43756234-b8ae-46d2-9713-5668919e560c": {"__data__": {"id_": "43756234-b8ae-46d2-9713-5668919e560c", "embedding": null, "metadata": {"window": "Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "We are partnering with ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54941f87-b696-42fe-b719-ddf222a3bf03", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727ed65d80f5001a44eaf6693639e1e87a4ba2848af974563317f0a4b0fd19f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f56cf395-bde0-4a0e-91df-0061fc11e176", "node_type": "1", "metadata": {"window": "In Medical -Surgical, we saw an increase in COVID -19 tests, an improvement in patient care visit s, and we \nannounced we are expanding our work with the US government through a new kitting and storage contract.  Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers. ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "635f51fa41a5f3305e25767bb48fb6d4e3b5d78ac840eabbd0d2d67d07883dba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f04e1ea7-114b-451a-aeca-ebda1a43cae9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. ", "original_text": "McKesson Corp.  "}, "hash": "6e82b13c0792fc370a033bd5a3cbd31104b20ca04cda2d2d5ab5d674a9bc152f", "class_name": "RelatedNodeInfo"}}, "text": "We are partnering with ", "start_char_idx": 4064, "end_char_idx": 4087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f04e1ea7-114b-451a-aeca-ebda1a43cae9": {"__data__": {"id_": "f04e1ea7-114b-451a-aeca-ebda1a43cae9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43756234-b8ae-46d2-9713-5668919e560c", "node_type": "1", "metadata": {"window": "Our \nMedical -Surgical business remains well -positioned to continue to support the government as needed.  \n \n The growth in our Medical -Surgical segm ent is reflective of strong top line performance and underlying business \nimprovement.  As it relates to international, the segment had solid adjusted operating profit growth, benefiting from \nboth local COVID programs and a new partnership with one of Canada 's largest retailers.  We are partnering with ", "original_text": "We are partnering with ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee40b744388a84aff792a0516690668307d52509c7ac9f1bb1ecbbdf4c056c79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1b08697-f73b-4213-94c7-9bb42e0e4725", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines. "}, "hash": "e1eed77f84f6e5da07c254cb5c31e4279df8180747e11b0088b4d2445321bb62", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1b08697-f73b-4213-94c7-9bb42e0e4725": {"__data__": {"id_": "f1b08697-f73b-4213-94c7-9bb42e0e4725", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f04e1ea7-114b-451a-aeca-ebda1a43cae9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63ed3e2807ba48742a3fc0e666889aa908b698fbe13c1db42434e0d807f401f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7741f89-0c3a-4fb7-9511-652023a7b072", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement. ", "original_text": "And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n"}, "hash": "7388d9701641921df5133022ddbe201bf63e2fba9a08f8f27f9aa5d0c4b0a47c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines. ", "start_char_idx": 16, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7741f89-0c3a-4fb7-9511-652023a7b072": {"__data__": {"id_": "c7741f89-0c3a-4fb7-9511-652023a7b072", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement. ", "original_text": "And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1b08697-f73b-4213-94c7-9bb42e0e4725", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e2f5c4b25f93206c566231d794366bc100addd0ebc9538da919af67d077301a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9364745-9987-4132-bd11-8460daa6a7ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n", "original_text": "As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. "}, "hash": "713bca088ddfd793e93ec407aa841e9218ae95c7dd02322858126987bd55061d", "class_name": "RelatedNodeInfo"}}, "text": "And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n", "start_char_idx": 247, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9364745-9987-4132-bd11-8460daa6a7ad": {"__data__": {"id_": "b9364745-9987-4132-bd11-8460daa6a7ad", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n", "original_text": "As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7741f89-0c3a-4fb7-9511-652023a7b072", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement. ", "original_text": "And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8af823fa0b25e21a16bfa034ad471fd0b8745b510b59afbb91c9d2ba6c734e30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c93f4a12-5f2e-4691-afcd-55aa44f80c81", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022. ", "original_text": "For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n"}, "hash": "8d2ce1b90621eaecdfdcbb91f5d8f83faee343909959cd6adc86d7552d71bec8", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. ", "start_char_idx": 398, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c93f4a12-5f2e-4691-afcd-55aa44f80c81": {"__data__": {"id_": "c93f4a12-5f2e-4691-afcd-55aa44f80c81", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022. ", "original_text": "For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9364745-9987-4132-bd11-8460daa6a7ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n", "original_text": "As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc4db788d64fdc5f0acd976e0a39b681031cc40bc9437c4d112821b31113e059", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0e8b8ff-cc50-4112-978a-5ceee1a2771a", "node_type": "1", "metadata": {"window": "And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n", "original_text": "Before I close, I'd like to update you on the status of the proposed opioid settlement. "}, "hash": "daa46528ae66d8cc123ec98025fe75e7092e599bb61480fd226c4747df78077f", "class_name": "RelatedNodeInfo"}}, "text": "For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n", "start_char_idx": 548, "end_char_idx": 690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0e8b8ff-cc50-4112-978a-5ceee1a2771a": {"__data__": {"id_": "e0e8b8ff-cc50-4112-978a-5ceee1a2771a", "embedding": null, "metadata": {"window": "And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n", "original_text": "Before I close, I'd like to update you on the status of the proposed opioid settlement. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c93f4a12-5f2e-4691-afcd-55aa44f80c81", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022. ", "original_text": "For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "317fa78d2384267498a595c5c0b21367753a391dcda68d904f2fe14b5463ef71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc3db8b5-665e-49a1-8e0d-af5bcdbcc2b0", "node_type": "1", "metadata": {"window": "As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities. ", "original_text": "Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n"}, "hash": "ca37f20995954ec6ac040473eae0deaacad5c8e754d2530bf3d9f779d903ff5a", "class_name": "RelatedNodeInfo"}}, "text": "Before I close, I'd like to update you on the status of the proposed opioid settlement. ", "start_char_idx": 690, "end_char_idx": 778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc3db8b5-665e-49a1-8e0d-af5bcdbcc2b0": {"__data__": {"id_": "bc3db8b5-665e-49a1-8e0d-af5bcdbcc2b0", "embedding": null, "metadata": {"window": "As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities. ", "original_text": "Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0e8b8ff-cc50-4112-978a-5ceee1a2771a", "node_type": "1", "metadata": {"window": "And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n", "original_text": "Before I close, I'd like to update you on the status of the proposed opioid settlement. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2e03d40392c9bc5e84e744f376c0606b28725a19c33dff722af465ac01d180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a08d0d2-9bc5-45a6-aff5-b046e008a4b4", "node_type": "1", "metadata": {"window": "For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n", "original_text": "During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022. "}, "hash": "7701cca5974f1c075a4f84a79ababc632ef4c5e11eec5b6def80d51253cc45af", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n", "start_char_idx": 778, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a08d0d2-9bc5-45a6-aff5-b046e008a4b4": {"__data__": {"id_": "6a08d0d2-9bc5-45a6-aff5-b046e008a4b4", "embedding": null, "metadata": {"window": "For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n", "original_text": "During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc3db8b5-665e-49a1-8e0d-af5bcdbcc2b0", "node_type": "1", "metadata": {"window": "As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment.  For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities. ", "original_text": "Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a891e1adf5705b363571831f95c8fc64ec67540366a10f96a6314d3f249156d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "190b4988-d2bc-430c-9d93-c641a55ed89b", "node_type": "1", "metadata": {"window": "Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n", "original_text": "We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n"}, "hash": "ff3f39e7ebff0e4e9dbeee118bbb6e258305f5b2a75cf371e70df237f0c3f539", "class_name": "RelatedNodeInfo"}}, "text": "During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022. ", "start_char_idx": 919, "end_char_idx": 1151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "190b4988-d2bc-430c-9d93-c641a55ed89b": {"__data__": {"id_": "190b4988-d2bc-430c-9d93-c641a55ed89b", "embedding": null, "metadata": {"window": "Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n", "original_text": "We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a08d0d2-9bc5-45a6-aff5-b046e008a4b4", "node_type": "1", "metadata": {"window": "For our remaining European businesses, we are exploring strategic \nalternatives as we align future investm ents to our growth strategies.  \n \n Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n", "original_text": "During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d28662201660f71d45560d9e4e465c2ddc2e69d56c32ea818a6dfa639cbaf874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7acb295a-23d4-4685-805c-d1767645f086", "node_type": "1", "metadata": {"window": "Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time. ", "original_text": "In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities. "}, "hash": "de3ee06e77abe47d62df7963423582e819d3609353f824593341e72bcd707d3b", "class_name": "RelatedNodeInfo"}}, "text": "We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n", "start_char_idx": 1151, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7acb295a-23d4-4685-805c-d1767645f086": {"__data__": {"id_": "7acb295a-23d4-4685-805c-d1767645f086", "embedding": null, "metadata": {"window": "Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time. ", "original_text": "In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "190b4988-d2bc-430c-9d93-c641a55ed89b", "node_type": "1", "metadata": {"window": "Before I close, I'd like to update you on the status of the proposed opioid settlement.  Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n", "original_text": "We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16d724c2a28a95330a38b6539325145ee2b5fd826d75db0586e915df1a61ed36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df731444-ac1c-413c-a43e-ab8ca0306d24", "node_type": "1", "metadata": {"window": "During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n ", "original_text": "Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n"}, "hash": "2c39e87b9e2f5ef724b7b32bb26a4881c7a2e8970a5f9d9f752ebda2147332b7", "class_name": "RelatedNodeInfo"}}, "text": "In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities. ", "start_char_idx": 1433, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df731444-ac1c-413c-a43e-ab8ca0306d24": {"__data__": {"id_": "df731444-ac1c-413c-a43e-ab8ca0306d24", "embedding": null, "metadata": {"window": "During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n ", "original_text": "Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7acb295a-23d4-4685-805c-d1767645f086", "node_type": "1", "metadata": {"window": "Recently, we announced that \nenough states have agreed to settle to proceed to the next phase, which is the subdivision sign -on period.  \n \n During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time. ", "original_text": "In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "069ebecb84ce0bde5c67ce1f875277548803c097e6f1875d94d6e9d75e4db883", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "696874bb-c18d-43b5-a653-328295a098a6", "node_type": "1", "metadata": {"window": "We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n"}, "hash": "e11cb7b6c09a30628c0951c0e5ee6c436987025bb736f1b5223f5ccf19b53d5f", "class_name": "RelatedNodeInfo"}}, "text": "Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n", "start_char_idx": 1554, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "696874bb-c18d-43b5-a653-328295a098a6": {"__data__": {"id_": "696874bb-c18d-43b5-a653-328295a098a6", "embedding": null, "metadata": {"window": "We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df731444-ac1c-413c-a43e-ab8ca0306d24", "node_type": "1", "metadata": {"window": "During this phase, each participating state will offer its political subdivisions, including those that have not sued, \nthe opportunity to participate in the settlement for an additional 120 -day period, which ends January 2, 2022.  We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n ", "original_text": "Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e76b680b754f8ad24ac1d693b79940d84d6beea0da64624bb7b0143a1d027309", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca34b33f-f66e-4f78-a92e-c4c45f2ce263", "node_type": "1", "metadata": {"window": "In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time. "}, "hash": "3b5478fed3544355ea8fe65fdcf30d38fc4abba414e1b4ea06c195cc429e7d5b", "class_name": "RelatedNodeInfo"}}, "text": "We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n", "start_char_idx": 1653, "end_char_idx": 1876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca34b33f-f66e-4f78-a92e-c4c45f2ce263": {"__data__": {"id_": "ca34b33f-f66e-4f78-a92e-c4c45f2ce263", "embedding": null, "metadata": {"window": "In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "696874bb-c18d-43b5-a653-328295a098a6", "node_type": "1", "metadata": {"window": "We \nare pleased with this i mportant step, and we believe the settlement framework will allow us to focus our attention \nand resources on the safe and secure delivery of medications and therapies, while expediting the delivery of \nmeaningful relief to the affected communities.  \n \n In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64ddda81a17b101add7d8fd788e6184e8006cabdc32ce2aa1c38c39a5a550f83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a28f04a-eb47-48a1-8ed4-da47866e5dd5", "node_type": "1", "metadata": {"window": "Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies. ", "original_text": "And with that, I'm going to turn it over to Britt for a few  additional comments.  \n "}, "hash": "993d1fce54e00e83e29e2c35065e6886a87872fff51614ca95309d0f961aa257", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your time. ", "start_char_idx": 1876, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a28f04a-eb47-48a1-8ed4-da47866e5dd5": {"__data__": {"id_": "4a28f04a-eb47-48a1-8ed4-da47866e5dd5", "embedding": null, "metadata": {"window": "Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies. ", "original_text": "And with that, I'm going to turn it over to Britt for a few  additional comments.  \n ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca34b33f-f66e-4f78-a92e-c4c45f2ce263", "node_type": "1", "metadata": {"window": "In clos ing, I'm encouraged as we continue to make progress and accelerate growth as we advance our company \npriorities.  Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff847d9019efe8b6b00c828a0cfec28621ed83d88ae40d1cabc49fe3cbac3f4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75cb6151-ab7e-40bc-8e46-2ae6bd673dfe", "node_type": "1", "metadata": {"window": "We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "b8d98732296a274d18f3f1c732fc721bab43d4c828e2def834271f0c90f865f2", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'm going to turn it over to Britt for a few  additional comments.  \n ", "start_char_idx": 1901, "end_char_idx": 1986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75cb6151-ab7e-40bc-8e46-2ae6bd673dfe": {"__data__": {"id_": "75cb6151-ab7e-40bc-8e46-2ae6bd673dfe", "embedding": null, "metadata": {"window": "We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a28f04a-eb47-48a1-8ed4-da47866e5dd5", "node_type": "1", "metadata": {"window": "Our underlying distribution business have stable fundamentals, great teams, and strong execution. \n We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies. ", "original_text": "And with that, I'm going to turn it over to Britt for a few  additional comments.  \n ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f12cabda4b9fbe95186e539ece3f8ab14c309afdd3b81bb67e67cb13de536fdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b536aa8-b5a4-4bbb-8972-12d5ebee2c7c", "node_type": "1", "metadata": {"window": "Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n", "original_text": "Thank you, Brian, and good afternoon, everyone. "}, "hash": "d93292b317be7f1d8376a6a982a3744ad46e0e7598454cd84501e6187bcdb40a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 1986, "end_char_idx": 2329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b536aa8-b5a4-4bbb-8972-12d5ebee2c7c": {"__data__": {"id_": "1b536aa8-b5a4-4bbb-8972-12d5ebee2c7c", "embedding": null, "metadata": {"window": "Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n", "original_text": "Thank you, Brian, and good afternoon, everyone. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75cb6151-ab7e-40bc-8e46-2ae6bd673dfe", "node_type": "1", "metadata": {"window": "We're investing in what we believe are two goo d growth markets where we have differentiated capabilities, and \nwe look forward to sharing more of those successes and proof points with you at our upcoming Investor Day.  \n \n Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eadaefa87f90b2d6e15da9cd6be523a262c030f81a855818c7f3b1f0c61a5113", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73df242d-7750-428e-98c6-dfb31eda065a", "node_type": "1", "metadata": {"window": "And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe. ", "original_text": "I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies. "}, "hash": "924adfbeb24c7a412f7f1e19b828d5a8a6455ebd0aa477228e5097abcaae6ce2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian, and good afternoon, everyone. ", "start_char_idx": 2329, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73df242d-7750-428e-98c6-dfb31eda065a": {"__data__": {"id_": "73df242d-7750-428e-98c6-dfb31eda065a", "embedding": null, "metadata": {"window": "And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe. ", "original_text": "I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b536aa8-b5a4-4bbb-8972-12d5ebee2c7c", "node_type": "1", "metadata": {"window": "Thank you for your time.  And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n", "original_text": "Thank you, Brian, and good afternoon, everyone. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5a08ffdf78218cc9f00140c4671e538b14fe9508a9ebeb9c642b3fa1c22bb59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d437dce9-f9e4-48da-97ce-b90896c84805", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n", "original_text": "This momentum could be seen in each of our segments.  \n \n"}, "hash": "6e76f10cb089813c4f178727114eef95bdf87af5b2226fec8819a3731f78f667", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies. ", "start_char_idx": 2377, "end_char_idx": 2600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d437dce9-f9e4-48da-97ce-b90896c84805": {"__data__": {"id_": "d437dce9-f9e4-48da-97ce-b90896c84805", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n", "original_text": "This momentum could be seen in each of our segments.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73df242d-7750-428e-98c6-dfb31eda065a", "node_type": "1", "metadata": {"window": "And with that, I'm going to turn it over to Britt for a few  additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe. ", "original_text": "I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "678a0e60e96077d1d1c16d0e8c5c2475efde501b7cb2c9292f1adea27a86cc8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1c2a1ef-5474-4467-9dfd-009a19cf9e81", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement. ", "original_text": "A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n"}, "hash": "41e3c1871e095332cb2670a8b7e2d2a59c2b435551bc0726b42856f4c5749664", "class_name": "RelatedNodeInfo"}}, "text": "This momentum could be seen in each of our segments.  \n \n", "start_char_idx": 2600, "end_char_idx": 2657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1c2a1ef-5474-4467-9dfd-009a19cf9e81": {"__data__": {"id_": "e1c2a1ef-5474-4467-9dfd-009a19cf9e81", "embedding": null, "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement. ", "original_text": "A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d437dce9-f9e4-48da-97ce-b90896c84805", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n", "original_text": "This momentum could be seen in each of our segments.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13133915ccadf6129c5345345e670bb85c174d1d3c17413bd59c9027c483a99c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b3196f6-78c7-4ad3-b918-3ef366f46ba3", "node_type": "1", "metadata": {"window": "I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price. ", "original_text": "Let me start with an update on Europe. "}, "hash": "e86f23dbf0a08ae0838a9fbe02c6dd70d048914a29b2e303f2d15ff95800128c", "class_name": "RelatedNodeInfo"}}, "text": "A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n", "start_char_idx": 2657, "end_char_idx": 2842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b3196f6-78c7-4ad3-b918-3ef366f46ba3": {"__data__": {"id_": "4b3196f6-78c7-4ad3-b918-3ef366f46ba3", "embedding": null, "metadata": {"window": "I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price. ", "original_text": "Let me start with an update on Europe. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1c2a1ef-5474-4467-9dfd-009a19cf9e81", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement. ", "original_text": "A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d904f33c51540038f1df48509f305d1317538833223e9725f63b73dbc3700b29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0698ac6-7cda-4562-a9de-3ab802bb7bdd", "node_type": "1", "metadata": {"window": "This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n", "original_text": "This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n"}, "hash": "48a5f896572dd5fa9e39e9901c60cb4ff15d46c7e6167bf7480cf2fda6772d14", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with an update on Europe. ", "start_char_idx": 2842, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0698ac6-7cda-4562-a9de-3ab802bb7bdd": {"__data__": {"id_": "b0698ac6-7cda-4562-a9de-3ab802bb7bdd", "embedding": null, "metadata": {"window": "This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n", "original_text": "This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b3196f6-78c7-4ad3-b918-3ef366f46ba3", "node_type": "1", "metadata": {"window": "I'm pleased to be here today to discuss our fiscal second \nquarter results, which reflects strong performance and momentum across the business, driven by operational \nexcellence and execution against our growth strategies.  This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price. ", "original_text": "Let me start with an update on Europe. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "721c8353534a3f93c282f5034a7a80d90eebff888ead333cc2a454f195a9ebbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4645d28-f102-4ea1-a5cb-48c0ab361bab", "node_type": "1", "metadata": {"window": "A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021. ", "original_text": "The ultimate proceeds from this transaction are subject to certain adjustments under the agreement. "}, "hash": "b19b6fe7b6631c5e9e60b96ba317200607c41a9a925b797cd66d0ef48b962352", "class_name": "RelatedNodeInfo"}}, "text": "This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n", "start_char_idx": 2881, "end_char_idx": 3064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4645d28-f102-4ea1-a5cb-48c0ab361bab": {"__data__": {"id_": "d4645d28-f102-4ea1-a5cb-48c0ab361bab", "embedding": null, "metadata": {"window": "A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021. ", "original_text": "The ultimate proceeds from this transaction are subject to certain adjustments under the agreement. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0698ac6-7cda-4562-a9de-3ab802bb7bdd", "node_type": "1", "metadata": {"window": "This momentum could be seen in each of our segments.  \n \n A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n", "original_text": "This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "829357f35c0fdf15d89b93b1f4a9cdbc23b6f3d2b3eab3e5470952b1b044b584", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3b9c012-562b-4051-b019-b4a97851c4b0", "node_type": "1", "metadata": {"window": "Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale. ", "original_text": "Therefore, \nthe proceeds may differ from the announced purchase price. "}, "hash": "85ce1bb20252350124a4ed24695aef06330c83c55bc715b85c83960af5d3b3ba", "class_name": "RelatedNodeInfo"}}, "text": "The ultimate proceeds from this transaction are subject to certain adjustments under the agreement. ", "start_char_idx": 3064, "end_char_idx": 3164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3b9c012-562b-4051-b019-b4a97851c4b0": {"__data__": {"id_": "a3b9c012-562b-4051-b019-b4a97851c4b0", "embedding": null, "metadata": {"window": "Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale. ", "original_text": "Therefore, \nthe proceeds may differ from the announced purchase price. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4645d28-f102-4ea1-a5cb-48c0ab361bab", "node_type": "1", "metadata": {"window": "A summary of our second quarter results and updated guidance assumptions can b e found in our earnings slide \npresentation, which is posted on the Investors section of our website.  \n \n Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021. ", "original_text": "The ultimate proceeds from this transaction are subject to certain adjustments under the agreement. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ae3d20230adbb6444b13d35adbd4573f73e5aaf505517ca66e6f69470917b7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "702dd0b2-b802-4d5d-914b-1538a22ad145", "node_type": "1", "metadata": {"window": "This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter. ", "original_text": "McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n"}, "hash": "276bad1667a29f9782895ad778140ee3e3ae39030a67c239455607328e98d19b", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, \nthe proceeds may differ from the announced purchase price. ", "start_char_idx": 3164, "end_char_idx": 3235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "702dd0b2-b802-4d5d-914b-1538a22ad145": {"__data__": {"id_": "702dd0b2-b802-4d5d-914b-1538a22ad145", "embedding": null, "metadata": {"window": "This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter. ", "original_text": "McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3b9c012-562b-4051-b019-b4a97851c4b0", "node_type": "1", "metadata": {"window": "Let me start with an update on Europe.  This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale. ", "original_text": "Therefore, \nthe proceeds may differ from the announced purchase price. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a11553f46f107975949ecd0ad80cc156f84d1ca042189bfbbb9e904ecc12ae6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e67b1856-8196-48d2-bcd9-6360b887953a", "node_type": "1", "metadata": {"window": "The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell. ", "original_text": "The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021. "}, "hash": "dd89dfd0af4ed60452cd401e10d089d43028161b99e4d86708f7758bace4e47c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n", "start_char_idx": 3235, "end_char_idx": 3525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e67b1856-8196-48d2-bcd9-6360b887953a": {"__data__": {"id_": "e67b1856-8196-48d2-bcd9-6360b887953a", "embedding": null, "metadata": {"window": "The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell. ", "original_text": "The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "702dd0b2-b802-4d5d-914b-1538a22ad145", "node_type": "1", "metadata": {"window": "This morning, we announced that we've entered into a definitive \nagreement to divest our retail and distribution bus inesses in the UK to Aurelius for approximately $438 million.  \n \n The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter. ", "original_text": "McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bb1ea6ab8c21c41737c5936250c2ec4dd70ba2e80e76dc916b092b633e1154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8d94c48-57bd-4e2e-a5b7-c64a8af8ae35", "node_type": "1", "metadata": {"window": "Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n", "original_text": "The net assets included in the transaction will be classified as held for \nsale. "}, "hash": "1b77ae0756166a0cb4eb2a4e9da15b6fcfa6830646d25ddadc94abb0ad15a409", "class_name": "RelatedNodeInfo"}}, "text": "The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021. ", "start_char_idx": 3525, "end_char_idx": 3677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8d94c48-57bd-4e2e-a5b7-c64a8af8ae35": {"__data__": {"id_": "e8d94c48-57bd-4e2e-a5b7-c64a8af8ae35", "embedding": null, "metadata": {"window": "Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n", "original_text": "The net assets included in the transaction will be classified as held for \nsale. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e67b1856-8196-48d2-bcd9-6360b887953a", "node_type": "1", "metadata": {"window": "The ultimate proceeds from this transaction are subject to certain adjustments under the agreement.  Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell. ", "original_text": "The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1471335284ee361e1a50a0c87633927cff2b3f408862a576807471c903eb8a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00a36027-2045-40ca-b18b-70e4b6ac9059", "node_type": "1", "metadata": {"window": "McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction. ", "original_text": "The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter. "}, "hash": "c6f299abf08917559af76d4911aee1f61d5875371129015b740acc5c029c88f1", "class_name": "RelatedNodeInfo"}}, "text": "The net assets included in the transaction will be classified as held for \nsale. ", "start_char_idx": 3677, "end_char_idx": 3758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00a36027-2045-40ca-b18b-70e4b6ac9059": {"__data__": {"id_": "00a36027-2045-40ca-b18b-70e4b6ac9059", "embedding": null, "metadata": {"window": "McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction. ", "original_text": "The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8d94c48-57bd-4e2e-a5b7-c64a8af8ae35", "node_type": "1", "metadata": {"window": "Therefore, \nthe proceeds may differ from the announced purchase price.  McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n", "original_text": "The net assets included in the transaction will be classified as held for \nsale. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d39600e693829a15df0a868ed9edc5f5d0bc97d9ebe89c0b66570c0850e63b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7d48126-42ab-4845-9f85-0ef54daacfc8", "node_type": "1", "metadata": {"window": "The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today. ", "original_text": "We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell. "}, "hash": "4df62e7e3b542cd1763cbeb13562bfd16297c183811eaace1f26d8f9e71f621e", "class_name": "RelatedNodeInfo"}}, "text": "The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter. ", "start_char_idx": 3758, "end_char_idx": 3852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7d48126-42ab-4845-9f85-0ef54daacfc8": {"__data__": {"id_": "f7d48126-42ab-4845-9f85-0ef54daacfc8", "embedding": null, "metadata": {"window": "The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today. ", "original_text": "We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00a36027-2045-40ca-b18b-70e4b6ac9059", "node_type": "1", "metadata": {"window": "McKesson will continue to operate these businesses \nand record revenue and income until the transaction is closed, which is expected to occur in our fourth quarter of \nfiscal 2022, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approv als. \n \n The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction. ", "original_text": "The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c58ed77b519bd43abc86e8eeabc02bf09ed80c1c99981b4c6689ddb4cf88b217", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b5163d3-28b9-4e31-9142-c83b9dfe31fb", "node_type": "1", "metadata": {"window": "The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n"}, "hash": "2b0e2d03207407f1cea4af5a534082e02d7b5093160ec5040f43557c96bb0533", "class_name": "RelatedNodeInfo"}}, "text": "We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell. ", "start_char_idx": 3852, "end_char_idx": 3952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b5163d3-28b9-4e31-9142-c83b9dfe31fb": {"__data__": {"id_": "9b5163d3-28b9-4e31-9142-c83b9dfe31fb", "embedding": null, "metadata": {"window": "The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7d48126-42ab-4845-9f85-0ef54daacfc8", "node_type": "1", "metadata": {"window": "The assets involved in this transaction contributed approximately $7.8 billion in revenue and $64 million in \nadjusted operating profit in fiscal 2021.  The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today. ", "original_text": "We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e9984b755c14c81e1d3791fc9b61d8a0cdc02dc237e575518bc94cfdc7164c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e02f7078-3bdf-4f47-af63-75030f04dbe6", "node_type": "1", "metadata": {"window": "The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction. "}, "hash": "6e04a0692e3feb19a5b476dd16cee91207968367ec0288617ac6d548f6cfc154", "class_name": "RelatedNodeInfo"}}, "text": "And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n", "start_char_idx": 3952, "end_char_idx": 4096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e02f7078-3bdf-4f47-af63-75030f04dbe6": {"__data__": {"id_": "e02f7078-3bdf-4f47-af63-75030f04dbe6", "embedding": null, "metadata": {"window": "The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b5163d3-28b9-4e31-9142-c83b9dfe31fb", "node_type": "1", "metadata": {"window": "The net assets included in the transaction will be classified as held for \nsale.  The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "052ecc1b346c88f34e3d1ccbc3f2245472cc9366f740ef8838c590ba71bc2c47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f615acc2-7089-4860-81e0-6feea9f2f591", "node_type": "1", "metadata": {"window": "We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "This impact is not included in the fiscal 2022 outlook provided today. "}, "hash": "aa78564a60f5313f09361ce1421ed7d04a2a8d53e2497fb671996eb68d8e7c1a", "class_name": "RelatedNodeInfo"}}, "text": "Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction. ", "start_char_idx": 4096, "end_char_idx": 4243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f615acc2-7089-4860-81e0-6feea9f2f591": {"__data__": {"id_": "f615acc2-7089-4860-81e0-6feea9f2f591", "embedding": null, "metadata": {"window": "We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "This impact is not included in the fiscal 2022 outlook provided today. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e02f7078-3bdf-4f47-af63-75030f04dbe6", "node_type": "1", "metadata": {"window": "The held for sale a ccounting will be effective beginning with our fiscal 2022 third quarter.  We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11a96d56fa5981a6045c53bb875f3fb9b085190dbd2f39f956ed6a4c63e813de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33c67cec-d842-4989-8d3a-564bb6a2da79", "node_type": "1", "metadata": {"window": "And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "This "}, "hash": "bd9202041119e13e41cd0af4bcc9c0b3bd400ac9b452060d9d6e4c8021c5373d", "class_name": "RelatedNodeInfo"}}, "text": "This impact is not included in the fiscal 2022 outlook provided today. ", "start_char_idx": 4243, "end_char_idx": 4314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33c67cec-d842-4989-8d3a-564bb6a2da79": {"__data__": {"id_": "33c67cec-d842-4989-8d3a-564bb6a2da79", "embedding": null, "metadata": {"window": "And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "This ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b19e11b4ce62be137eb2341963dd74c6f294c3899653ee02e6f799818891449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f615acc2-7089-4860-81e0-6feea9f2f591", "node_type": "1", "metadata": {"window": "We will remeasure \nthe net assets to the lower of carrying amount or fair value, less cost to sell.  And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "This impact is not included in the fiscal 2022 outlook provided today. ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "616babf90803a2aa9e404902b857dca0846e405a1f26170c721a97bfa954991b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ae9a421-4389-4ed3-ab23-3e580a9dedb7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results. ", "original_text": "McKesson Corp.  "}, "hash": "07be286e7c4d7381f000d7031bab666ca9d07c57cd2049e29c277ffe9f3ebd53", "class_name": "RelatedNodeInfo"}}, "text": "This ", "start_char_idx": 2600, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ae9a421-4389-4ed3-ab23-3e580a9dedb7": {"__data__": {"id_": "3ae9a421-4389-4ed3-ab23-3e580a9dedb7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33c67cec-d842-4989-8d3a-564bb6a2da79", "node_type": "1", "metadata": {"window": "And we estimate that this will result in \na GAAP -only charge of between $700 million  to $900 million in our third quarter of fiscal 2022.  \n \n Due to held for sale accounting treatment, we will discontinue recording depreciation and amortization on the \nassets involved in the transaction.  This impact is not included in the fiscal 2022 outlook provided today.  This ", "original_text": "This ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72f0ef80f60a5de0b6eb0533ae2823d7e630ed2bb002f288148437960fe9a273", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66981b51-07b6-4250-b274-c38ba2655b14", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America. "}, "hash": "1101e8730c00d39648b8dfb2ddb7b38ba94d69635e7f16d8aa9425485809ee13", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66981b51-07b6-4250-b274-c38ba2655b14": {"__data__": {"id_": "66981b51-07b6-4250-b274-c38ba2655b14", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ae9a421-4389-4ed3-ab23-3e580a9dedb7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba65e4db38360d58a0ced17125caaf0b833e24d3a34e78d0407acc9fb373ff14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "247ca319-2a9e-434c-b808-b2d64f7192bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell. ", "original_text": "And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n"}, "hash": "21bcf630c20346f2c8ea906ef6e1111aaf29be0a5e8e74db0d6e53a042576372", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America. ", "start_char_idx": 16, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "247ca319-2a9e-434c-b808-b2d64f7192bd": {"__data__": {"id_": "247ca319-2a9e-434c-b808-b2d64f7192bd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell. ", "original_text": "And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66981b51-07b6-4250-b274-c38ba2655b14", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e608a39a71c24201d775774d20fb9b87f25073504d6668c8080f4e6323cd29f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1f61059-c08d-4f0f-8e84-7cde9144ce9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months. ", "original_text": "Let me now turn to our second quarter results. "}, "hash": "bdd21f255de4bef99cc3763489aaa689796ce063d66df408b2bb59c5cc3c471d", "class_name": "RelatedNodeInfo"}}, "text": "And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n", "start_char_idx": 308, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1f61059-c08d-4f0f-8e84-7cde9144ce9e": {"__data__": {"id_": "d1f61059-c08d-4f0f-8e84-7cde9144ce9e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months. ", "original_text": "Let me now turn to our second quarter results. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "247ca319-2a9e-434c-b808-b2d64f7192bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell. ", "original_text": "And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8283d58705d5bbfd13f03d9cad80c87d402cb7edb2b57e6f112b3a2ab87f2c95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3914ccf1-15ab-4fb7-86c5-6a2731febc7f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n", "original_text": "Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter. "}, "hash": "43ef28cf0f12bec2ee9fb5f27cb9bda932324ec0a87c411676736e3d2428bff6", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to our second quarter results. ", "start_char_idx": 544, "end_char_idx": 591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3914ccf1-15ab-4fb7-86c5-6a2731febc7f": {"__data__": {"id_": "3914ccf1-15ab-4fb7-86c5-6a2731febc7f", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n", "original_text": "Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1f61059-c08d-4f0f-8e84-7cde9144ce9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months. ", "original_text": "Let me now turn to our second quarter results. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f3c1807df556222bf89c67a5cef10500866ed288b03eae932d37c0c034d0f34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb257384-d078-433b-b271-89ffbf8ca6ee", "node_type": "1", "metadata": {"window": "And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "original_text": "First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell. "}, "hash": "10b10975aad5a4e3dac44eee79064f239b8010ad9a11dc70ef6c83e6184a5709", "class_name": "RelatedNodeInfo"}}, "text": "Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter. ", "start_char_idx": 591, "end_char_idx": 756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb257384-d078-433b-b271-89ffbf8ca6ee": {"__data__": {"id_": "bb257384-d078-433b-b271-89ffbf8ca6ee", "embedding": null, "metadata": {"window": "And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "original_text": "First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3914ccf1-15ab-4fb7-86c5-6a2731febc7f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n", "original_text": "Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f9ca2976d1c755d0b143e37b021bd01d7954af4328fdb9316d52e0bb51c1c89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a4a71ac-fa5d-43f0-becb-bed7601a3c55", "node_type": "1", "metadata": {"window": "Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments. ", "original_text": "This transaction is expected to close within the next 12 months. "}, "hash": "680341b39255dcd3d48c67aa8795ebf7314d3fed4245ce80c3c8f224c1001b80", "class_name": "RelatedNodeInfo"}}, "text": "First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell. ", "start_char_idx": 756, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a4a71ac-fa5d-43f0-becb-bed7601a3c55": {"__data__": {"id_": "2a4a71ac-fa5d-43f0-becb-bed7601a3c55", "embedding": null, "metadata": {"window": "Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments. ", "original_text": "This transaction is expected to close within the next 12 months. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb257384-d078-433b-b271-89ffbf8ca6ee", "node_type": "1", "metadata": {"window": "And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "original_text": "First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94447e49b0e60b0261a5e95f3fe07866688aa22466789b4da3ec996ef84680a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c39ffa58-444d-4364-97b4-8dc557756bf0", "node_type": "1", "metadata": {"window": "Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter. ", "original_text": "Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n"}, "hash": "ad9ffb89186aa987d3ddc3978a0c858821d50794da3e0efddac1ef16a3a41f77", "class_name": "RelatedNodeInfo"}}, "text": "This transaction is expected to close within the next 12 months. ", "start_char_idx": 1019, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c39ffa58-444d-4364-97b4-8dc557756bf0": {"__data__": {"id_": "c39ffa58-444d-4364-97b4-8dc557756bf0", "embedding": null, "metadata": {"window": "Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter. ", "original_text": "Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a4a71ac-fa5d-43f0-becb-bed7601a3c55", "node_type": "1", "metadata": {"window": "Let me now turn to our second quarter results.  Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments. ", "original_text": "This transaction is expected to close within the next 12 months. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2364a4452eb96633ef2cc779fdacb67cd086de4cd80c9f8801dc63fa063d7d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c95b6270-63d6-4b19-b7df-824b86730d13", "node_type": "1", "metadata": {"window": "First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n", "original_text": "Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7. "}, "hash": "d6f927fdaf3d33b4490cb8736c032d8c56360a34cb8d3ceaff607ae76c08168f", "class_name": "RelatedNodeInfo"}}, "text": "Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n", "start_char_idx": 1084, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c95b6270-63d6-4b19-b7df-824b86730d13": {"__data__": {"id_": "c95b6270-63d6-4b19-b7df-824b86730d13", "embedding": null, "metadata": {"window": "First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n", "original_text": "Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c39ffa58-444d-4364-97b4-8dc557756bf0", "node_type": "1", "metadata": {"window": "Before I provide more details on our second quarter adjusted \nresults, I want to point out two additional items that impacted our GAAP -only results in the quarter.  First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter. ", "original_text": "Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a365b422f80bd19d1a783d51b8213a97685fceb7547f666649f37fd364fd9567", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b6bc8a4-ea7b-454c-ad9d-7acd628e7431", "node_type": "1", "metadata": {"window": "This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business. ", "original_text": "Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments. "}, "hash": "9b3de46f9e4090ff7ee5495ff7787142ad004f32973afefa5541dc00f8d53ecc", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "start_char_idx": 1247, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b6bc8a4-ea7b-454c-ad9d-7acd628e7431": {"__data__": {"id_": "1b6bc8a4-ea7b-454c-ad9d-7acd628e7431", "embedding": null, "metadata": {"window": "This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business. ", "original_text": "Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c95b6270-63d6-4b19-b7df-824b86730d13", "node_type": "1", "metadata": {"window": "First, we \nrecorded a GAAP -only after -tax charge of $472 million related to our agreement to sell certain European \nbusinesses to the Phoenix Group to account for the remeasurement of the net assets to lower of carrying amount \nof fair value less cost to sell.  This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n", "original_text": "Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2f54308d425dc3cfa8ee24e2570788b28c6c16792fa920956bfcc6d21b06c48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "872fff90-26b0-4f87-ad74-fcbac058bd31", "node_type": "1", "metadata": {"window": "Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year. ", "original_text": "We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter. "}, "hash": "10c98ebf825cb8db1320a16c3026d53153369eefdf8467ae597c2b44f0fc58c1", "class_name": "RelatedNodeInfo"}}, "text": "Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments. ", "start_char_idx": 1379, "end_char_idx": 1559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "872fff90-26b0-4f87-ad74-fcbac058bd31": {"__data__": {"id_": "872fff90-26b0-4f87-ad74-fcbac058bd31", "embedding": null, "metadata": {"window": "Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year. ", "original_text": "We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b6bc8a4-ea7b-454c-ad9d-7acd628e7431", "node_type": "1", "metadata": {"window": "This transaction is expected to close within the next 12 months.  Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business. ", "original_text": "Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40fc4a814031789a9955096f2c8417cb7a7fc54d0da1ef260f50a1a7aa0cbe49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d099e347-6402-4346-9151-2a810f43c1da", "node_type": "1", "metadata": {"window": "Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n", "original_text": "These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n"}, "hash": "ec55f7792c0dce39d7eff53b65b5648d053f141f55d7b6674f0c60cd28afae4c", "class_name": "RelatedNodeInfo"}}, "text": "We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter. ", "start_char_idx": 1559, "end_char_idx": 1703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d099e347-6402-4346-9151-2a810f43c1da": {"__data__": {"id_": "d099e347-6402-4346-9151-2a810f43c1da", "embedding": null, "metadata": {"window": "Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n", "original_text": "These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "872fff90-26b0-4f87-ad74-fcbac058bd31", "node_type": "1", "metadata": {"window": "Also during the \nquarter, we recorded an after -tax loss of $141 million on debt extinguishment related to the suc cessful completion \nof a bond tender offer.  \n \n Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year. ", "original_text": "We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0c95844015e7a204c3b87d7f11f3311642b30fca1723fcee7e72c3605ca6f03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07cd82b7-6d58-46df-a679-f7eb38781b95", "node_type": "1", "metadata": {"window": "Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n", "original_text": "In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business. "}, "hash": "817967674f069f9c8ca1be0f9cff901af9bf2bfc7ba69cd86801e093a2f4cbaa", "class_name": "RelatedNodeInfo"}}, "text": "These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n", "start_char_idx": 1703, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07cd82b7-6d58-46df-a679-f7eb38781b95": {"__data__": {"id_": "07cd82b7-6d58-46df-a679-f7eb38781b95", "embedding": null, "metadata": {"window": "Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n", "original_text": "In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d099e347-6402-4346-9151-2a810f43c1da", "node_type": "1", "metadata": {"window": "Moving now to our adjusted results for the second quarter, beginning with our consolidated results, which can be \nfound on slide 7.  Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n", "original_text": "These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b3a77df4c07881b8c23aec070679becf757e855b6fbe0f8bcc5ee513f537249", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d15266d6-3b21-4c9a-bcba-e77e7a3dd795", "node_type": "1", "metadata": {"window": "We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n", "original_text": "Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year. "}, "hash": "f8eea835d70c1a5ff586f591bfb5a5d4bf3a004dd181afc5b8dabf1f60d5a697", "class_name": "RelatedNodeInfo"}}, "text": "In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business. ", "start_char_idx": 1810, "end_char_idx": 2010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d15266d6-3b21-4c9a-bcba-e77e7a3dd795": {"__data__": {"id_": "d15266d6-3b21-4c9a-bcba-e77e7a3dd795", "embedding": null, "metadata": {"window": "We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n", "original_text": "Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07cd82b7-6d58-46df-a679-f7eb38781b95", "node_type": "1", "metadata": {"window": "Our second quarter results were highlighted by strong operating performance, which included \nrecord revenue and double -digit adjusted operating profit growth across all segments.  We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n", "original_text": "In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32327af230658bb788382fbc6e04c656988cdeabb409d3de16b023721af4b226", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f2a3782-fc19-421d-bd9d-5a5181716c65", "node_type": "1", "metadata": {"window": "These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year. ", "original_text": "This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n"}, "hash": "65950609f5d115238d6b3d3ed3c5f195eab7a7344078e5fe2feab75d641e7dae", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year. ", "start_char_idx": 2010, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f2a3782-fc19-421d-bd9d-5a5181716c65": {"__data__": {"id_": "6f2a3782-fc19-421d-bd9d-5a5181716c65", "embedding": null, "metadata": {"window": "These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year. ", "original_text": "This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d15266d6-3b21-4c9a-bcba-e77e7a3dd795", "node_type": "1", "metadata": {"window": "We are encouraged by the \nongoing market improvement in both prescription volumes and patient visits, which we observed in our second \nquarter.  These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n", "original_text": "Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e3ce4382bfd5d34df3e0823a3a18399a4571a94c2912bd9a8bfc280d965ae3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de8937de-c087-40cc-be25-dd6144df57f7", "node_type": "1", "metadata": {"window": "In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year. ", "original_text": "Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n"}, "hash": "b96004361f4c8c8c310e5a5c7a09bd12160e455254d6d5c5cc671731c341a98a", "class_name": "RelatedNodeInfo"}}, "text": "This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n", "start_char_idx": 2120, "end_char_idx": 2307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de8937de-c087-40cc-be25-dd6144df57f7": {"__data__": {"id_": "de8937de-c087-40cc-be25-dd6144df57f7", "embedding": null, "metadata": {"window": "In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year. ", "original_text": "Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f2a3782-fc19-421d-bd9d-5a5181716c65", "node_type": "1", "metadata": {"window": "These improve ments are supported by our strategic agenda, setting us on a path of disciplined growth.  \n \n In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year. ", "original_text": "This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18811a91817fd96d049343fbcfa02fd6c352565d615dc7b7ffdec07a8057544f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d76a053-cff3-4051-923b-3ef00646c6ee", "node_type": "1", "metadata": {"window": "Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n", "original_text": "Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n"}, "hash": "81f3b9626adab49078c6ec7eb4d12f8eeb498f1a2521951b171997558bbcfd40", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n", "start_char_idx": 2307, "end_char_idx": 2574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d76a053-cff3-4051-923b-3ef00646c6ee": {"__data__": {"id_": "9d76a053-cff3-4051-923b-3ef00646c6ee", "embedding": null, "metadata": {"window": "Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n", "original_text": "Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de8937de-c087-40cc-be25-dd6144df57f7", "node_type": "1", "metadata": {"window": "In our work to support US government's COVID -19 domestic and international vaccine, kitting efforts continues to \ncontribute to growth in addition to the momentum we h ave built across the business.  Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year. ", "original_text": "Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a52c242e211ffa37d36121e0e2fe1761e3191fa5d3325ea2d1bc9ff8d269b6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c497d2e4-f57e-4c3a-a4f9-b4056f822ca1", "node_type": "1", "metadata": {"window": "This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter. ", "original_text": "Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year. "}, "hash": "2840c9b310cace5c58a969dca1578571d74d5920017ab9bbe4339ecc635cae88", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n", "start_char_idx": 2574, "end_char_idx": 2912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c497d2e4-f57e-4c3a-a4f9-b4056f822ca1": {"__data__": {"id_": "c497d2e4-f57e-4c3a-a4f9-b4056f822ca1", "embedding": null, "metadata": {"window": "This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter. ", "original_text": "Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d76a053-cff3-4051-923b-3ef00646c6ee", "node_type": "1", "metadata": {"window": "Second quarter adjusted \nearnings per diluted share was $6.15, an increase of 28% compared to the prior year.  This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n", "original_text": "Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1708336e7f80539129606769ed4a30bfaeef6d3a96b41ac9e28e22c9b21c82ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2be07b2a-92e6-49a4-9a7b-0b86d1634d1e", "node_type": "1", "metadata": {"window": "Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations. ", "original_text": "Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year. "}, "hash": "cda6f90e4b0c258cde6e97af238472b69f929ddf01c4228ede54dd4f9f588535", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year. ", "start_char_idx": 2912, "end_char_idx": 3003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2be07b2a-92e6-49a4-9a7b-0b86d1634d1e": {"__data__": {"id_": "2be07b2a-92e6-49a4-9a7b-0b86d1634d1e", "embedding": null, "metadata": {"window": "Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations. ", "original_text": "Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c497d2e4-f57e-4c3a-a4f9-b4056f822ca1", "node_type": "1", "metadata": {"window": "This result was driven by \nthe contribution from COVID -19 vaccine kitting, distribution, and growth in the Medical -Surgical Solutions \nsegment, partially offset by higher tax rate.  \n \n Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter. ", "original_text": "Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e143e343613d32df416404a8190baf96873fa2ab969e778e085bdc9e477d3fbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24eed68b-b64a-4bb9-8c81-0a1bcf0f5848", "node_type": "1", "metadata": {"window": "Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n", "original_text": "Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n"}, "hash": "4345e991ce07d2d0bebbc682c7bcb17e12d8316c7103252cdada7211200259b5", "class_name": "RelatedNodeInfo"}}, "text": "Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year. ", "start_char_idx": 3003, "end_char_idx": 3099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24eed68b-b64a-4bb9-8c81-0a1bcf0f5848": {"__data__": {"id_": "24eed68b-b64a-4bb9-8c81-0a1bcf0f5848", "embedding": null, "metadata": {"window": "Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n", "original_text": "Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2be07b2a-92e6-49a4-9a7b-0b86d1634d1e", "node_type": "1", "metadata": {"window": "Second quarter adjusted earnings per diluted share also includes net pre -tax gains of approximately $97 million or \n$0.46 per diluted share, associated with McKesson Ventures' equity investment s as compared to $49 million in \nthe second quarter of fiscal 2021.  \n \n Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations. ", "original_text": "Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95bf3061d33f7d904eb249d0b6a332bdfb2046996c227e90692d9f7d3668a5fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f88a1afe-40f9-4ae9-bcd7-a03f1485717c", "node_type": "1", "metadata": {"window": "Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical. ", "original_text": "Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter. "}, "hash": "e90710b9beb975f7799c0a5637238220ab5e6f1dbc2935900031f6b6c5e8baa3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n", "start_char_idx": 3099, "end_char_idx": 3342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f88a1afe-40f9-4ae9-bcd7-a03f1485717c": {"__data__": {"id_": "f88a1afe-40f9-4ae9-bcd7-a03f1485717c", "embedding": null, "metadata": {"window": "Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical. ", "original_text": "Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24eed68b-b64a-4bb9-8c81-0a1bcf0f5848", "node_type": "1", "metadata": {"window": "Consolidated revenues of $66.6 billion increased 9% above the prior year, principally driven by growth in the US \nPharmaceutical segment, largely due to increased pharmaceutical volumes inc luding growth in specialty products \nand our largest retail national account customers, and partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n", "original_text": "Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "811d7d5d81616723da701e2bf0501b3e1ad349b43c67a634a049e1468c2b753a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b92650f-a360-4932-865d-9e2fd803589d", "node_type": "1", "metadata": {"window": "Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations. "}, "hash": "0e4d8cadd66d4822933b6d6ed9e49ab40bf39f049cdeecfebe9df6221ffe0c56", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter. ", "start_char_idx": 3342, "end_char_idx": 3489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b92650f-a360-4932-865d-9e2fd803589d": {"__data__": {"id_": "6b92650f-a360-4932-865d-9e2fd803589d", "embedding": null, "metadata": {"window": "Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f88a1afe-40f9-4ae9-bcd7-a03f1485717c", "node_type": "1", "metadata": {"window": "Adjusted gross profit was $3.3 billion for the quarter, up 12% compared to the prior year.  Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical. ", "original_text": "Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "467147b92823f615bf98e544740b8a3f8e1b544252a74b826d6eb49080a5b1ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78a0c186-253c-4c81-81e3-ffeb7c957ecc", "node_type": "1", "metadata": {"window": "Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n"}, "hash": "a9554798c298304f657d908b33eb7c894ba1b1963b6e2f5ab5bc4e951837e484", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations. ", "start_char_idx": 3489, "end_char_idx": 3581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78a0c186-253c-4c81-81e3-ffeb7c957ecc": {"__data__": {"id_": "78a0c186-253c-4c81-81e3-ffeb7c957ecc", "embedding": null, "metadata": {"window": "Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b92650f-a360-4932-865d-9e2fd803589d", "node_type": "1", "metadata": {"window": "Comparable adjusted \ngross margin for the quarter was up 10 basis points versus the prior year.  Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4c8a597cc7c109914ca8566a717149ec14da4b67897c2580e5e1c7dc7e6494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f429c90-7422-4d80-a354-acd058666400", "node_type": "1", "metadata": {"window": "Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical. "}, "hash": "729780ed1d817dcd71e6a1d79a7824091bb87ec3325e346de1e3421173e1a88f", "class_name": "RelatedNodeInfo"}}, "text": "In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n", "start_char_idx": 3581, "end_char_idx": 3729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f429c90-7422-4d80-a354-acd058666400": {"__data__": {"id_": "7f429c90-7422-4d80-a354-acd058666400", "embedding": null, "metadata": {"window": "Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78a0c186-253c-4c81-81e3-ffeb7c957ecc", "node_type": "1", "metadata": {"window": "Adjusted operating expenses in the \nquarter increased 4% year -over-year and adjusted operating profit of $1.3 billion for the quarter was an increase \nof 34% compared to the prior year  and reflected double -digit growth in each segment.  \n \n Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c2c6d8c509b28132a854c0598790990b68ed9f54a34df7269ff91ea2683352b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aebb428-0fd1-4d10-9caa-8cd6bb870605", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n "}, "hash": "64ee9b738350bf174c2af482d68fbdf026bf951cd28723e7cad59d3f85a862d3", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical. ", "start_char_idx": 3729, "end_char_idx": 3863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aebb428-0fd1-4d10-9caa-8cd6bb870605": {"__data__": {"id_": "3aebb428-0fd1-4d10-9caa-8cd6bb870605", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395af6b19aa03c73080083bb30dd4b284375dbb811a6bee9990a061e3431be25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f429c90-7422-4d80-a354-acd058666400", "node_type": "1", "metadata": {"window": "Interest expense was $45 million in the quarter, a decline of 10% compared to the prior year, driven by the net \nreduction of debt in the quarter.  Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical. ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc344cdc4c2cb80f0d03c44d4dbe6529178a8ae2b3486bffbf04d6feaeff1f7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23ec26b0-7baf-463f-86bd-95e4b12b4479", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. ", "original_text": "McKesson Corp.  "}, "hash": "f60d49337f589dc88f9e507e054a29048de0903ef14168643e557ce1455ccea3", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "start_char_idx": 3863, "end_char_idx": 4117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23ec26b0-7baf-463f-86bd-95e4b12b4479": {"__data__": {"id_": "23ec26b0-7baf-463f-86bd-95e4b12b4479", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aebb428-0fd1-4d10-9caa-8cd6bb870605", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 18.8% for the quarter, which wa s in line with our \nexpectations.  In wrapping up our consolidated results, second quarter diluted weighted average shares were \n$155.8 million, a decrease of 5% year -over-year.  \n \n Moving now to our second quarter segment results, which can be found on slides 8  through 13, and I'll start with \nUS Pharmaceutical.  Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "original_text": "Revenues were $53.4 billion, an increase of 11% year -over-year as increased \npharmaceutical volumes, including growth in specialty products and our largest retail national account customers, \nwere partially  offset by branded to generic conversions.  \n ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38460679455572196eaf04e6aac1a063635c075c982f8ef53140fd88a18c964d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d761151-2212-409a-a679-f5014ff9ba3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution. "}, "hash": "21c0fd92e8b57996d3fe4a28a16bd8a1364d95d558d8f54b628e581aa699a1b7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d761151-2212-409a-a679-f5014ff9ba3a": {"__data__": {"id_": "5d761151-2212-409a-a679-f5014ff9ba3a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23ec26b0-7baf-463f-86bd-95e4b12b4479", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f3480c3c31a807cfb23613afe4feb09be043d03f87da6986a2e1cef56783265", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e09ea273-f233-4e98-9d60-8c13ab0572f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n"}, "hash": "10a79370657e24a0ad1641ece94de7153c5cea9ad45f46a2dc0ec2609a581168", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution. ", "start_char_idx": 16, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e09ea273-f233-4e98-9d60-8c13ab0572f1": {"__data__": {"id_": "e09ea273-f233-4e98-9d60-8c13ab0572f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d761151-2212-409a-a679-f5014ff9ba3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "534b03c912865850f1e7b52bae842f8c2fa82e1d87f33219c450cdb744798aa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77ce9666-e03c-4034-ba1e-9196730afb58", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business. ", "original_text": "In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. "}, "hash": "c4bb871c7d740a36aae285ec65dd33de1f902ab0393bbcbe08ced37a593e2778", "class_name": "RelatedNodeInfo"}}, "text": "The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n", "start_char_idx": 387, "end_char_idx": 604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77ce9666-e03c-4034-ba1e-9196730afb58": {"__data__": {"id_": "77ce9666-e03c-4034-ba1e-9196730afb58", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business. ", "original_text": "In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e09ea273-f233-4e98-9d60-8c13ab0572f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0330706ff2e489be5ae718fae7418e68eee3ca0f2cb39b55b57eade9e2074254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8caa337a-8405-4b23-bbbe-168fe5a686e8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram. ", "original_text": "Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n"}, "hash": "9b0db1a22c518c161b2bde2f52666da621e0b1da0c8a95fa7f386daf3fecbfac", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. ", "start_char_idx": 604, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8caa337a-8405-4b23-bbbe-168fe5a686e8": {"__data__": {"id_": "8caa337a-8405-4b23-bbbe-168fe5a686e8", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram. ", "original_text": "Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77ce9666-e03c-4034-ba1e-9196730afb58", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business. ", "original_text": "In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d94b36b63f0874ceb694744061dd2904bfbb2944a6cb4100be8419e03cca4f4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0851e4a-5782-47f5-9c62-ab0895ae3967", "node_type": "1", "metadata": {"window": "The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. "}, "hash": "411ad4c989e7382efb6cd24adc30d5337fa9b646426425fd7d99aa40f1b64f39", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n", "start_char_idx": 896, "end_char_idx": 1021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0851e4a-5782-47f5-9c62-ab0895ae3967": {"__data__": {"id_": "e0851e4a-5782-47f5-9c62-ab0895ae3967", "embedding": null, "metadata": {"window": "The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8caa337a-8405-4b23-bbbe-168fe5a686e8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram. ", "original_text": "Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f19013cb285fac9c2e0dfc9ecd68a3c42432da104c0f117c12843d19218b40c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9eed8f9-a3e4-4d9a-9d07-77f0a80905b8", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results. ", "original_text": "Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business. "}, "hash": "590d97a5eec09bdbe78737947aedd6e7b55218d6779c755b7d0a5c1fb72fae1d", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions. ", "start_char_idx": 1021, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9eed8f9-a3e4-4d9a-9d07-77f0a80905b8": {"__data__": {"id_": "d9eed8f9-a3e4-4d9a-9d07-77f0a80905b8", "embedding": null, "metadata": {"window": "In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results. ", "original_text": "Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0851e4a-5782-47f5-9c62-ab0895ae3967", "node_type": "1", "metadata": {"window": "The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64ae7d3dfdb0db077021d0da13c5044802c1f0a3015ed0b5ed3b1b34b9930ef3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ded3b79-6cdb-48a5-aecd-30afe95f76f0", "node_type": "1", "metadata": {"window": "Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n", "original_text": "Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram. "}, "hash": "f454630df9bfcb072f776be13215969d4c2cc03c778c921204abc366796f76a9", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business. ", "start_char_idx": 1064, "end_char_idx": 1200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ded3b79-6cdb-48a5-aecd-30afe95f76f0": {"__data__": {"id_": "5ded3b79-6cdb-48a5-aecd-30afe95f76f0", "embedding": null, "metadata": {"window": "Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n", "original_text": "Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9eed8f9-a3e4-4d9a-9d07-77f0a80905b8", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes.  Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results. ", "original_text": "Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "233277a6b10ca1f43ea6fa25e39239541ba2796e4b1abe5320fbf4aa38bfaa4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be9db5f2-8eb7-4116-b1bc-e8b464712c39", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n", "original_text": "The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n"}, "hash": "e7fb7b85772282f8a1342ee8f0a4a90c8417be3ada767066315b74552459cc1b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram. ", "start_char_idx": 1200, "end_char_idx": 1477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be9db5f2-8eb7-4116-b1bc-e8b464712c39": {"__data__": {"id_": "be9db5f2-8eb7-4116-b1bc-e8b464712c39", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n", "original_text": "The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ded3b79-6cdb-48a5-aecd-30afe95f76f0", "node_type": "1", "metadata": {"window": "Adjusted operating pr ofit increased 38% to \n$144 million, driven by organic growth from access and adherence solutions.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n", "original_text": "Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc11aa8ce23a738b2b2f1f89dcf99ad90a06894da493994847e1d9945f852d35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e285a6d-a1b4-4681-89c5-899f5a860150", "node_type": "1", "metadata": {"window": "Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million. ", "original_text": "Next, let me address our International results. "}, "hash": "3047d9439488487230919ca0e113d9fd2b7350210d0d28f9feb92306e038c818", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n", "start_char_idx": 1477, "end_char_idx": 1746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e285a6d-a1b4-4681-89c5-899f5a860150": {"__data__": {"id_": "4e285a6d-a1b4-4681-89c5-899f5a860150", "embedding": null, "metadata": {"window": "Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million. ", "original_text": "Next, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be9db5f2-8eb7-4116-b1bc-e8b464712c39", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n", "original_text": "The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74b2c44d4a0728f618061571be053527b42d87e6e1066c1795619fd2c7e7de25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "063b2b36-6ac4-4310-9f55-69d321b6465c", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022. ", "original_text": "Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n"}, "hash": "5a27fdbe16ace3ea0bca9bc637baa4a3a64ece9e8a26af2b9fca2dba9d2da7d7", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our International results. ", "start_char_idx": 1746, "end_char_idx": 1794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "063b2b36-6ac4-4310-9f55-69d321b6465c": {"__data__": {"id_": "063b2b36-6ac4-4310-9f55-69d321b6465c", "embedding": null, "metadata": {"window": "Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022. ", "original_text": "Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e285a6d-a1b4-4681-89c5-899f5a860150", "node_type": "1", "metadata": {"window": "Revenues were $3.1 billion, an increase of 23%, driven by increased \nsales of COVID -19 tests and growth in the prima ry care business.  Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million. ", "original_text": "Next, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4d0d7ca7b06a9ee429e17af32e63c0bb2d0f3c8dc8999b6799d30c5ae10ffeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "291397ab-808f-4a18-930c-ad5fd063cf8a", "node_type": "1", "metadata": {"window": "The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n", "original_text": "Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n"}, "hash": "3850f94eb5ec34da81722fdfd5906c9f31315f8041d8a6058066b72a8b46bd71", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n", "start_char_idx": 1794, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "291397ab-808f-4a18-930c-ad5fd063cf8a": {"__data__": {"id_": "291397ab-808f-4a18-930c-ad5fd063cf8a", "embedding": null, "metadata": {"window": "The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n", "original_text": "Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "063b2b36-6ac4-4310-9f55-69d321b6465c", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 52% to \n$319 million, driven by growth in the primary care business, increased sales of COVID -19 tests, and the \ncontribution from kitting, storage and distribution of ancillary supplies for the US govern ment's COVID -19 vaccine \nprogram.  The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022. ", "original_text": "Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81ad82ac30c76661564ccc83a4c7f16683d1dcfbd6ebf7e79b26587321c0ac13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37825d74-83ea-4b3b-8bb1-92855d64c092", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate. ", "original_text": "Adjusted operating profit increased 41% year -over-year to $163 million. "}, "hash": "c8cb48a9deef3a6c26479d50626ab811b90c5145d7a6d41d7f55215da9db7195", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n", "start_char_idx": 2081, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37825d74-83ea-4b3b-8bb1-92855d64c092": {"__data__": {"id_": "37825d74-83ea-4b3b-8bb1-92855d64c092", "embedding": null, "metadata": {"window": "Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate. ", "original_text": "Adjusted operating profit increased 41% year -over-year to $163 million. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "291397ab-808f-4a18-930c-ad5fd063cf8a", "node_type": "1", "metadata": {"window": "The contribution from our contract with the US government related to the kitting, distribution and storage \nof ancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.14 per share in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n", "original_text": "Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef62cd479dc12f2be2df4f931056152abae543a99854771f29e55b109756aaa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5493218-35cd-48c6-b949-3fb11cebeecb", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022. "}, "hash": "539f40061131d4fe32791cdea748337240bd0aaf4dc552a3fe28d8ddfe028238", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased 41% year -over-year to $163 million. ", "start_char_idx": 2304, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5493218-35cd-48c6-b949-3fb11cebeecb": {"__data__": {"id_": "e5493218-35cd-48c6-b949-3fb11cebeecb", "embedding": null, "metadata": {"window": "Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37825d74-83ea-4b3b-8bb1-92855d64c092", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate. ", "original_text": "Adjusted operating profit increased 41% year -over-year to $163 million. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8698bc14c98d79def415f4cdc9c04cdc5ac339fabbe8bb2a795f09e386000c26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c69ea80-0c61-4b93-a253-375d9a1dc51c", "node_type": "1", "metadata": {"window": "Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n", "original_text": "The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n"}, "hash": "e3bd200d27f88529a3cec16ba31d71566a0677a4e4dd7f5d5441ca98cb4556ed", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022. ", "start_char_idx": 2377, "end_char_idx": 2630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c69ea80-0c61-4b93-a253-375d9a1dc51c": {"__data__": {"id_": "7c69ea80-0c61-4b93-a253-375d9a1dc51c", "embedding": null, "metadata": {"window": "Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n", "original_text": "The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5493218-35cd-48c6-b949-3fb11cebeecb", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $9.1 billion, a decrease of 5%, \nprimarily driven by the contribution of McKesson's German wholesale business to a joint venture with Walgre ens \nBoots Alliance, partially offset by volume increases in the pharmaceutical distribution and retail businesses. \n Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ec23835ea5ab722f75c82ad6d0b4ec5bec22a3f6b420bf1df47b5ce12b44f52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "865c378a-e8d9-4be1-97fb-5d1b82da3008", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n", "original_text": "Moving on to corporate. "}, "hash": "26297b81bf31d53a73c47cc918b1be90f7ae19bc3b93f5d812ea166f8a926a31", "class_name": "RelatedNodeInfo"}}, "text": "The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n", "start_char_idx": 2630, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "865c378a-e8d9-4be1-97fb-5d1b82da3008": {"__data__": {"id_": "865c378a-e8d9-4be1-97fb-5d1b82da3008", "embedding": null, "metadata": {"window": "Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n", "original_text": "Moving on to corporate. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c69ea80-0c61-4b93-a253-375d9a1dc51c", "node_type": "1", "metadata": {"window": "Excluding the impact of the contribution of our German wholesale business, which was completed in the third \nquarter of fiscal 2021, segment r evenue increased 13% year -over-year and was up 9% on an FX adjusted basis.  \n \n Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n", "original_text": "The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a3889d6c73a4597e7d3c9b7b9a1c003ee0b28e14222e8fb4ea3e3426f7c41b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a149578-af6c-42b1-bbf7-a31b4b10c279", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur. ", "original_text": "Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n"}, "hash": "8778b39c8762cc4ef9c6c40f058fd2ea2d17d3bce0d89da3740712bb66342dc5", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to corporate. ", "start_char_idx": 2774, "end_char_idx": 2798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a149578-af6c-42b1-bbf7-a31b4b10c279": {"__data__": {"id_": "3a149578-af6c-42b1-bbf7-a31b4b10c279", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur. ", "original_text": "Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "865c378a-e8d9-4be1-97fb-5d1b82da3008", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 41% year -over-year to $163 million.  On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n", "original_text": "Moving on to corporate. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2fb2abab0c5a3ec5d82bfccfe3f99549253dc6935fc662a9a3ce1e4a6dc4c13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f12507c-eb3f-477e-bcc5-e352baed018b", "node_type": "1", "metadata": {"window": "The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n", "original_text": "This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n"}, "hash": "7f8fda43c56cc171396adca0d7407c04f97273a2440a2c4ab99e2bf0b30331af", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n", "start_char_idx": 2798, "end_char_idx": 3001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f12507c-eb3f-477e-bcc5-e352baed018b": {"__data__": {"id_": "3f12507c-eb3f-477e-bcc5-e352baed018b", "embedding": null, "metadata": {"window": "The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n", "original_text": "This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a149578-af6c-42b1-bbf7-a31b4b10c279", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 34% to $155 million, driven by the discontinuat ion of depreciation and amortization on \ncertain European assets classified as held -for-sale beginning in the second quarter of fiscal 2022.  The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur. ", "original_text": "Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f5fbda5d5625683f502b3be321f96313e6b65d77ac9506ea6b449c7977ef36a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44bcd7e1-151c-4654-98b9-38e8e4973361", "node_type": "1", "metadata": {"window": "Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million. ", "original_text": "Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n"}, "hash": "bc20bbc823d7e09700e7d25d96c5be1233afa73f37ec16ac5b8ce180ce3ccb77", "class_name": "RelatedNodeInfo"}}, "text": "This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n", "start_char_idx": 3001, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44bcd7e1-151c-4654-98b9-38e8e4973361": {"__data__": {"id_": "44bcd7e1-151c-4654-98b9-38e8e4973361", "embedding": null, "metadata": {"window": "Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million. ", "original_text": "Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f12507c-eb3f-477e-bcc5-e352baed018b", "node_type": "1", "metadata": {"window": "The held -for-\nsale accounting in our International business contributed $0.13 to adjusted earnings in our second quar ter of \nfiscal 2022.  \n \n Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n", "original_text": "This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f678b01669d53573f2ba1d93a36c8f832afe74c731a0186698bda5c650346565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b5d926a-5deb-4706-9ee5-215eea9e4471", "node_type": "1", "metadata": {"window": "Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n", "original_text": "As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur. "}, "hash": "85fc5b35dffe469a929bc3e245c8c55a98fe9eb4a7a9e67b78620fca0b8d64c0", "class_name": "RelatedNodeInfo"}}, "text": "Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n", "start_char_idx": 3113, "end_char_idx": 3206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b5d926a-5deb-4706-9ee5-215eea9e4471": {"__data__": {"id_": "0b5d926a-5deb-4706-9ee5-215eea9e4471", "embedding": null, "metadata": {"window": "Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n", "original_text": "As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44bcd7e1-151c-4654-98b9-38e8e4973361", "node_type": "1", "metadata": {"window": "Moving on to corporate.  Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million. ", "original_text": "Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d706d07a258cded34821f18376168e93bce793921b4d718ea5cb345479ef4a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fb5121b-529b-4354-9f6b-764aa855bb08", "node_type": "1", "metadata": {"window": "This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14. ", "original_text": "And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n"}, "hash": "0101ebf977818ce7cab58757542e647128bbe4e59a7e0b70eeeb3114621ce9ff", "class_name": "RelatedNodeInfo"}}, "text": "As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur. ", "start_char_idx": 3206, "end_char_idx": 3330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fb5121b-529b-4354-9f6b-764aa855bb08": {"__data__": {"id_": "2fb5121b-529b-4354-9f6b-764aa855bb08", "embedding": null, "metadata": {"window": "This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14. ", "original_text": "And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b5d926a-5deb-4706-9ee5-215eea9e4471", "node_type": "1", "metadata": {"window": "Adjusted corporate expenses were $83 million, a decrease of 39% year -over-year, driven \nby gains of approximately $97 million, or $0.46, from equity investments within our McKesson Ventures portfolio. \n This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n", "original_text": "As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fe5fd17a43bca937a086ad4fd0325c01723a8a291c08e7f5589e9bf65a7d44a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da459ec2-c506-4f1b-91c6-895d61e57160", "node_type": "1", "metadata": {"window": "Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion. ", "original_text": "We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million. "}, "hash": "35dfa74c3c955f61079614d66e44a61edcc571ac726f8cea2b7533b441571f28", "class_name": "RelatedNodeInfo"}}, "text": "And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n", "start_char_idx": 3330, "end_char_idx": 3455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da459ec2-c506-4f1b-91c6-895d61e57160": {"__data__": {"id_": "da459ec2-c506-4f1b-91c6-895d61e57160", "embedding": null, "metadata": {"window": "Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion. ", "original_text": "We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fb5121b-529b-4354-9f6b-764aa855bb08", "node_type": "1", "metadata": {"window": "This quarte r, we had fair value adjustments related to multiple portfolio companies within McKesson Ventures. \n Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14. ", "original_text": "And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd9c2be7cae6f090a91e0e9dd1e8a0e9ae93ebaf8e9171d69f2b0a0ba283d0b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1305a02d-300b-4bf7-8225-d42c80bf319e", "node_type": "1", "metadata": {"window": "As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million. ", "original_text": "Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n"}, "hash": "8142a60fd2d9a4e3ba9f8c646d3c5be928ff6c3de1dbdd1b9605ab0e374b8433", "class_name": "RelatedNodeInfo"}}, "text": "We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million. ", "start_char_idx": 3455, "end_char_idx": 3653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1305a02d-300b-4bf7-8225-d42c80bf319e": {"__data__": {"id_": "1305a02d-300b-4bf7-8225-d42c80bf319e", "embedding": null, "metadata": {"window": "As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million. ", "original_text": "Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da459ec2-c506-4f1b-91c6-895d61e57160", "node_type": "1", "metadata": {"window": "Compared to fiscal 2021, gains from McKesson Ventures contributed $0.24 year -over-year.  \n \n As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion. ", "original_text": "We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7aa6677c577c697c89b26f9b331388c093d24803cbd9d3ee2f2778be13dfd89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edf1554f-eecf-4d99-965e-453d583f3422", "node_type": "1", "metadata": {"window": "And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions. ", "original_text": "Let me now turn to our cash position, which can be found on slide 14. "}, "hash": "a1ea4abe0a31e472d3492cf952e75ed4da213038a7c244d5ca3b6e4ab0d7958e", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n", "start_char_idx": 3653, "end_char_idx": 3818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edf1554f-eecf-4d99-965e-453d583f3422": {"__data__": {"id_": "edf1554f-eecf-4d99-965e-453d583f3422", "embedding": null, "metadata": {"window": "And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions. ", "original_text": "Let me now turn to our cash position, which can be found on slide 14. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1305a02d-300b-4bf7-8225-d42c80bf319e", "node_type": "1", "metadata": {"window": "As previously discussed, it's difficult to predict when gains or los ses on our ventures portfolio of companies may \noccur.  And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million. ", "original_text": "Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c58ef33832eaa3d9934fa340c228137de07f5ddc978a62960ada58be74f5e92a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a7f32ea-c863-451d-a94b-26fc50472136", "node_type": "1", "metadata": {"window": "We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "We ended the quarter with a cash balance \nof $2.2 billion. "}, "hash": "859c0e49c070149b564098f692268a4207f87c4b3ec6b957bcdab1214b56f1ca", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to our cash position, which can be found on slide 14. ", "start_char_idx": 3818, "end_char_idx": 3888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a7f32ea-c863-451d-a94b-26fc50472136": {"__data__": {"id_": "9a7f32ea-c863-451d-a94b-26fc50472136", "embedding": null, "metadata": {"window": "We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "We ended the quarter with a cash balance \nof $2.2 billion. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edf1554f-eecf-4d99-965e-453d583f3422", "node_type": "1", "metadata": {"window": "And therefore, our practice has been and will continue to be to not include Ventures portfolio impacts in our \nguidance.  \n \n We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions. ", "original_text": "Let me now turn to our cash position, which can be found on slide 14. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61f8e3923715f7227719f6b6301dc411d778b6b16276e6fd4b933703447701a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9edc12e3-1936-49b8-95ff-d01c00506ff2", "node_type": "1", "metadata": {"window": "Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "And for the first six months of the fiscal year, we had negative free cash flow of $109 million. "}, "hash": "48b9413d6167539e62807b2a9be3506eb69a778af166c702528a51a2d5ec0e6b", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance \nof $2.2 billion. ", "start_char_idx": 3888, "end_char_idx": 3947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9edc12e3-1936-49b8-95ff-d01c00506ff2": {"__data__": {"id_": "9edc12e3-1936-49b8-95ff-d01c00506ff2", "embedding": null, "metadata": {"window": "Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "And for the first six months of the fiscal year, we had negative free cash flow of $109 million. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a7f32ea-c863-451d-a94b-26fc50472136", "node_type": "1", "metadata": {"window": "We also reported opioid -related litigation expenses of $36 million for the second  quarter, and anticipate that fiscal \n2022 opioid -related litigation expenses will be approximately $155 million.  Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "We ended the quarter with a cash balance \nof $2.2 billion. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1384294505d5a4d22a2c317edeca0545194c825d46b4e095a5c61590c424b872", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b2ae835-a4a4-4256-9f4e-55b25fbd9775", "node_type": "1", "metadata": {"window": "Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "In Q2, \nwe comp leted several debt transactions. "}, "hash": "7f115adc02eef333e06b231f382d5c6ca971708e81a36c51405f5dcd0a64e7cf", "class_name": "RelatedNodeInfo"}}, "text": "And for the first six months of the fiscal year, we had negative free cash flow of $109 million. ", "start_char_idx": 3947, "end_char_idx": 4044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b2ae835-a4a4-4256-9f4e-55b25fbd9775": {"__data__": {"id_": "0b2ae835-a4a4-4256-9f4e-55b25fbd9775", "embedding": null, "metadata": {"window": "Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "In Q2, \nwe comp leted several debt transactions. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9edc12e3-1936-49b8-95ff-d01c00506ff2", "node_type": "1", "metadata": {"window": "Consistent with the proposed \nsettlement announced in July, we also made the first annual payment into escrow of approximately $354 million \nduring the quarter.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "And for the first six months of the fiscal year, we had negative free cash flow of $109 million. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed86c974f7e5339afcdf2048cd3063c8e0014176544f7b40acd535d2282a42f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "009204e6-6970-4fed-8148-e20adedc164e", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  "}, "hash": "d24249f89703e1dd30b326af01d9827abd309b763128073820fc5e44d9968f89", "class_name": "RelatedNodeInfo"}}, "text": "In Q2, \nwe comp leted several debt transactions. ", "start_char_idx": 4044, "end_char_idx": 4093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "009204e6-6970-4fed-8148-e20adedc164e": {"__data__": {"id_": "009204e6-6970-4fed-8148-e20adedc164e", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45374a78f12d206daaa3aff9e1e1fddd02e6c565c7489f23a59862fb0dbee12f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b2ae835-a4a4-4256-9f4e-55b25fbd9775", "node_type": "1", "metadata": {"window": "Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "In Q2, \nwe comp leted several debt transactions. ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c7d60d18599da5b74aff61287c34c1535549a95d039b55b06c050225f0d5db9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d7eead-7bab-429a-84c5-c6dca66b8362", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "5584fdc2c861222cf9a7383b7cedfcd942750e396058080d5eafb4932db61ad5", "class_name": "RelatedNodeInfo"}}, "text": "In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "start_char_idx": 4093, "end_char_idx": 4172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d7eead-7bab-429a-84c5-c6dca66b8362": {"__data__": {"id_": "d7d7eead-7bab-429a-84c5-c6dca66b8362", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "009204e6-6970-4fed-8148-e20adedc164e", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $2.2 billion.  And for the first six months of the fiscal year, we had negative free cash flow of $109 million.  In Q2, \nwe comp leted several debt transactions.  In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "original_text": "In July, we redeemed a 600 million euro -denominated note prior to \nmaturity.  ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7809643c095102580a160c9edae769f630c835f090c5d29ef65f8fdabe46a603", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "584380b9-474d-48c2-8417-185fe2e4fd84", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt. "}, "hash": "416e5fb8c15cac26d1b8d466370e7043a58e4a2c6183aecc40b41e71e652f6d1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "584380b9-474d-48c2-8417-185fe2e4fd84": {"__data__": {"id_": "584380b9-474d-48c2-8417-185fe2e4fd84", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d7eead-7bab-429a-84c5-c6dca66b8362", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1548d214ac543fcdeb6c850920631b82eee3152460f1452110cfff1350523cb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96cc169e-4fe8-4644-ac42-34069426591d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n", "original_text": "And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%. "}, "hash": "97f97b890cf721e13921b7166df9218f433ef3c3895df65417717fcee0e6b9f7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt. ", "start_char_idx": 16, "end_char_idx": 321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96cc169e-4fe8-4644-ac42-34069426591d": {"__data__": {"id_": "96cc169e-4fe8-4644-ac42-34069426591d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n", "original_text": "And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "584380b9-474d-48c2-8417-185fe2e4fd84", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99106c1f9991111d3fcf5fb46b726d5a523a55f8cd500c790f33c2cf6c95ce9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33642ae0-4fde-4fe3-a581-270b427c44be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n", "original_text": "These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n"}, "hash": "63b15223caf4d0c0487ad0dbed331e75917e07a635107a49d7a01bc83de628ca", "class_name": "RelatedNodeInfo"}}, "text": "And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%. ", "start_char_idx": 321, "end_char_idx": 426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33642ae0-4fde-4fe3-a581-270b427c44be": {"__data__": {"id_": "33642ae0-4fde-4fe3-a581-270b427c44be", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n", "original_text": "These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96cc169e-4fe8-4644-ac42-34069426591d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n", "original_text": "And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "792c6e703d950e1f725bfe550e1ef5d0fd46da58d9a9ea1b1635afdee90510a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0d99f51-cfa5-4626-a7ff-a6e0eb9bc092", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022. ", "original_text": "Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services. "}, "hash": "7107318097ca7451889bbc1b12b8813683c0c4d83ae459569856f12495478783", "class_name": "RelatedNodeInfo"}}, "text": "These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n", "start_char_idx": 426, "end_char_idx": 573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0d99f51-cfa5-4626-a7ff-a6e0eb9bc092": {"__data__": {"id_": "b0d99f51-cfa5-4626-a7ff-a6e0eb9bc092", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022. ", "original_text": "Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33642ae0-4fde-4fe3-a581-270b427c44be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n", "original_text": "These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708d273ecdf25da686b29551380e2f6d9019e4668695e2629c12c26570120f9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03a9b762-29f5-45c5-9f29-3d461367c9f6", "node_type": "1", "metadata": {"window": "And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation. ", "original_text": "For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n"}, "hash": "7c08a33b2f8b04dc25230be7218eea83b7f543dbcd05ced4ff50fd363730d595", "class_name": "RelatedNodeInfo"}}, "text": "Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services. ", "start_char_idx": 573, "end_char_idx": 732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03a9b762-29f5-45c5-9f29-3d461367c9f6": {"__data__": {"id_": "03a9b762-29f5-45c5-9f29-3d461367c9f6", "embedding": null, "metadata": {"window": "And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation. ", "original_text": "For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0d99f51-cfa5-4626-a7ff-a6e0eb9bc092", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022. ", "original_text": "Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a3defe03ded592f70a2cfbd12d43c73000813fe8b88e31a08705da2983c8350", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52f732db-7bc2-4cef-92c9-353168e50d07", "node_type": "1", "metadata": {"window": "These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n", "original_text": "We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n"}, "hash": "7a9b543aa6de362d3b9fa12ebe43d8cf059f288d0e018f97f9e3951a1c570e50", "class_name": "RelatedNodeInfo"}}, "text": "For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n", "start_char_idx": 732, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52f732db-7bc2-4cef-92c9-353168e50d07": {"__data__": {"id_": "52f732db-7bc2-4cef-92c9-353168e50d07", "embedding": null, "metadata": {"window": "These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n", "original_text": "We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03a9b762-29f5-45c5-9f29-3d461367c9f6", "node_type": "1", "metadata": {"window": "And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation. ", "original_text": "For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef958c97f46b3884d6472f4254412d63881b70573b40951632243de1216c2661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75858345-16fd-491a-8ddf-6a00422791d9", "node_type": "1", "metadata": {"window": "Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments. ", "original_text": "Let me transition now and speak to our outlook for the remainder of fiscal 2022. "}, "hash": "39090e57484b9e7854559686e69bbb4ed1087bb9514bfae1215eaee397ebb05a", "class_name": "RelatedNodeInfo"}}, "text": "We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n", "start_char_idx": 920, "end_char_idx": 1123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75858345-16fd-491a-8ddf-6a00422791d9": {"__data__": {"id_": "75858345-16fd-491a-8ddf-6a00422791d9", "embedding": null, "metadata": {"window": "Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments. ", "original_text": "Let me transition now and speak to our outlook for the remainder of fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52f732db-7bc2-4cef-92c9-353168e50d07", "node_type": "1", "metadata": {"window": "These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n", "original_text": "We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9a4059dfea1f225582081172d7ba3d9d0af72f06bdb2936745059fe7f941863", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c3b29c7-3102-4bf3-ab3c-d259dee692bb", "node_type": "1", "metadata": {"window": "For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date. ", "original_text": "For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation. "}, "hash": "d29a3e5b3cb25be2b0611a7d09bbaa8917973bb14d397ef0237fb8c8d299b84d", "class_name": "RelatedNodeInfo"}}, "text": "Let me transition now and speak to our outlook for the remainder of fiscal 2022. ", "start_char_idx": 1123, "end_char_idx": 1204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c3b29c7-3102-4bf3-ab3c-d259dee692bb": {"__data__": {"id_": "1c3b29c7-3102-4bf3-ab3c-d259dee692bb", "embedding": null, "metadata": {"window": "For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date. ", "original_text": "For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75858345-16fd-491a-8ddf-6a00422791d9", "node_type": "1", "metadata": {"window": "Year -to-date, we ma de $279 million of capital expenditures, which included investments to support our strategic \npillars of oncology and biopharma services.  For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments. ", "original_text": "Let me transition now and speak to our outlook for the remainder of fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4eb3dc046ef0e5b20cbf895efe7a84fb5fc7b15aee997db5e456a37222e48d43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27d38ccf-9c25-44e0-9fcb-0fba4a479f28", "node_type": "1", "metadata": {"window": "We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n", "original_text": "As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n"}, "hash": "44eeb4b65c05299c97821096edd62a252b0fb90e099bd4b8c98239b8c4552c1e", "class_name": "RelatedNodeInfo"}}, "text": "For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation. ", "start_char_idx": 1204, "end_char_idx": 1327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27d38ccf-9c25-44e0-9fcb-0fba4a479f28": {"__data__": {"id_": "27d38ccf-9c25-44e0-9fcb-0fba4a479f28", "embedding": null, "metadata": {"window": "We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n", "original_text": "As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c3b29c7-3102-4bf3-ab3c-d259dee692bb", "node_type": "1", "metadata": {"window": "For the first six months of the fiscal year, we returned $1.4 billion in \ncash to our shareholders through $1.3 billion of share repurchases and the payment of $134 million in dividends. \n We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date. ", "original_text": "For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f72eadf40d0b7abb63ca5c01638b399e9decb5118319d082b39659299b74c52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "658f14e3-5134-4ca9-be98-b2fe4fdb5146", "node_type": "1", "metadata": {"window": "Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance. ", "original_text": "Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments. "}, "hash": "9112050db007273d3d440ec0f1bf028455090ddbd78a03da2d0559fb9f0be07f", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n", "start_char_idx": 1327, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "658f14e3-5134-4ca9-be98-b2fe4fdb5146": {"__data__": {"id_": "658f14e3-5134-4ca9-be98-b2fe4fdb5146", "embedding": null, "metadata": {"window": "Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance. ", "original_text": "Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27d38ccf-9c25-44e0-9fcb-0fba4a479f28", "node_type": "1", "metadata": {"window": "We have $1.5 billion remaining on our share repurchase authorization, and continue to expect diluted weighted \naverage shares outstanding to range from $154 million to $156 million for fisca l 2022.  \n \n Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n", "original_text": "As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4ecf3f7c0fc839bd0c8819d24be9aa5c7c522a6423ac86adb3e5b626dc2c3a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "674837f0-b4d5-4265-b800-03a232b60835", "node_type": "1", "metadata": {"window": "For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance. ", "original_text": "Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date. "}, "hash": "8ab95b54aea51028e3ac4a84e9ac0b7dc99e93e3abd4148c96b2eeedb2de0cf3", "class_name": "RelatedNodeInfo"}}, "text": "Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments. ", "start_char_idx": 1596, "end_char_idx": 1768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "674837f0-b4d5-4265-b800-03a232b60835": {"__data__": {"id_": "674837f0-b4d5-4265-b800-03a232b60835", "embedding": null, "metadata": {"window": "For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance. ", "original_text": "Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "658f14e3-5134-4ca9-be98-b2fe4fdb5146", "node_type": "1", "metadata": {"window": "Let me transition now and speak to our outlook for the remainder of fiscal 2022.  For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance. ", "original_text": "Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92a97448e2d51eb5446f88cfe4064aff0ebe8ca5acebb5687e6ec49fa263d9c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92d5f7f4-dd6e-442b-aa44-ea32c7c57bf3", "node_type": "1", "metadata": {"window": "As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n", "original_text": "Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n"}, "hash": "3efe041ea4ee6e406981d8e49e8438eaca32a114874247fffb2b6aa043fb1a75", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date. ", "start_char_idx": 1768, "end_char_idx": 2472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92d5f7f4-dd6e-442b-aa44-ea32c7c57bf3": {"__data__": {"id_": "92d5f7f4-dd6e-442b-aa44-ea32c7c57bf3", "embedding": null, "metadata": {"window": "As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n", "original_text": "Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "674837f0-b4d5-4265-b800-03a232b60835", "node_type": "1", "metadata": {"window": "For our full list of fiscal 2022 \nassumptions, please refer to slide 16 through 19 in our supplemental slide presentation.  As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance. ", "original_text": "Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a971166b3bbc5265d7dc51cbac9a40093ecdad3248bfdf481b85ac2507e9bcae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0552b3a8-d0cb-4a3d-879f-7c7381cd3d07", "node_type": "1", "metadata": {"window": "Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals. ", "original_text": "Let me provide a few additional assumptions related to our gu idance. "}, "hash": "871accbee01414921ef8de34d590888aa6dfa6e1bfb9684ee047625ec0e0cb5d", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n", "start_char_idx": 2472, "end_char_idx": 2615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0552b3a8-d0cb-4a3d-879f-7c7381cd3d07": {"__data__": {"id_": "0552b3a8-d0cb-4a3d-879f-7c7381cd3d07", "embedding": null, "metadata": {"window": "Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals. ", "original_text": "Let me provide a few additional assumptions related to our gu idance. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92d5f7f4-dd6e-442b-aa44-ea32c7c57bf3", "node_type": "1", "metadata": {"window": "As a result of our strong \nfirst half perform ance and our outlook for the remainder of the year, we are raising our previous adjusted earnings \nper share guidance range for fiscal 2022 to $21.95 to $22.55, which is up from our previous range of $19.80 to \n$20.40.  \n \n Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n", "original_text": "Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e12c23aba73587fd636db963e6b96ec6374a3f2606e08735b9c0becdc5bc06f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d090e98-2a51-401f-be5c-4c2b9558a137", "node_type": "1", "metadata": {"window": "Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022. ", "original_text": "We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance. "}, "hash": "2eb0463561e0d618bc70210e12981078774b5cfd2ad3267f0ac077a2e733663e", "class_name": "RelatedNodeInfo"}}, "text": "Let me provide a few additional assumptions related to our gu idance. ", "start_char_idx": 2615, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d090e98-2a51-401f-be5c-4c2b9558a137": {"__data__": {"id_": "8d090e98-2a51-401f-be5c-4c2b9558a137", "embedding": null, "metadata": {"window": "Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022. ", "original_text": "We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0552b3a8-d0cb-4a3d-879f-7c7381cd3d07", "node_type": "1", "metadata": {"window": "Our updated outlook for adjusted earni ngs per diluted share reflects 27.5% to 31% growth from the prior year, and \nour guidance assumes growth across all of our segments.  Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals. ", "original_text": "Let me provide a few additional assumptions related to our gu idance. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80f3ffc69d7a005b38e69b1b506c7c66d13a8161125fdd0ba6ed465653bb59cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3737e843-3641-4773-950f-8848823633c1", "node_type": "1", "metadata": {"window": "Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n", "original_text": "In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n"}, "hash": "31fa8b01f7957a6cdceb1ffc7fdbbd3a21658bc8f6e3867157267381d0a15ca6", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance. ", "start_char_idx": 2685, "end_char_idx": 2870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3737e843-3641-4773-950f-8848823633c1": {"__data__": {"id_": "3737e843-3641-4773-950f-8848823633c1", "embedding": null, "metadata": {"window": "Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n", "original_text": "In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d090e98-2a51-401f-be5c-4c2b9558a137", "node_type": "1", "metadata": {"window": "Additionally, fiscal 2022 adjusted earnings per diluted \nshare guidance includes $2.30 to $3.05 of impacts attributable to th e following items: $0.50 to $0.70 related to the \nUS government's COVID -19 vaccine distribution, which is an increase from the previous range of $0.45 to $0.55; \n$0.80 to $1.10 related to the kitting, storage, and distribution of ancillary supplies, an incre ase from the previous \nrange of $0.50 to $0.70 as discussed at a recent conference; $0.50 to $0.75 related to COVID -19 tests and \nimpairments for PPE and related products; and approximately $0.49 from gains or losses associated with \nMcKesson Ventures' equity  investments within our Corporate segment year -to-date.  Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022. ", "original_text": "We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b612466bbb4f7fe287b80f9187afa1ced608cc1f0b4cabb7426f3d63b8c4254b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e52ebe43-1c44-499b-a485-0055be50a818", "node_type": "1", "metadata": {"window": "Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution. ", "original_text": "We continue to see stable fundamentals. "}, "hash": "ae39a871bf5684c2b66e142512047cf2c9dd2157585f50839ae5ac3c1fcdc3df", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n", "start_char_idx": 2870, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e52ebe43-1c44-499b-a485-0055be50a818": {"__data__": {"id_": "e52ebe43-1c44-499b-a485-0055be50a818", "embedding": null, "metadata": {"window": "Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution. ", "original_text": "We continue to see stable fundamentals. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3737e843-3641-4773-950f-8848823633c1", "node_type": "1", "metadata": {"window": "Excluding the impacts of \nthese items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 20% to 29% forecasted growth.  \n \n Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n", "original_text": "In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f89896a451bcf06773dd5aad27f6357047677d0a0c7399e874ab88ef1782dc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31ab3d2b-9875-4583-b299-70f11cf488ab", "node_type": "1", "metadata": {"window": "We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions. ", "original_text": "Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022. "}, "hash": "abf0c4a424046e0b0af9e9232a0dcb7216afc44e42061212ed240254cab342e6", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see stable fundamentals. ", "start_char_idx": 3036, "end_char_idx": 3076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31ab3d2b-9875-4583-b299-70f11cf488ab": {"__data__": {"id_": "31ab3d2b-9875-4583-b299-70f11cf488ab", "embedding": null, "metadata": {"window": "We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions. ", "original_text": "Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e52ebe43-1c44-499b-a485-0055be50a818", "node_type": "1", "metadata": {"window": "Let me provide a few additional assumptions related to our gu idance.  We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution. ", "original_text": "We continue to see stable fundamentals. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4e171548a88b65410e53b0d1c9d30a87b1860ef8fd3910152f814ddc3fd898c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da5b9c00-6060-40bd-b406-ef2b4b77d158", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.  ", "original_text": "And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n"}, "hash": "526a2e3022dcccfa02d29b9622191c764e5e9e068b2987520d22d439dbb83ef9", "class_name": "RelatedNodeInfo"}}, "text": "Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022. ", "start_char_idx": 3076, "end_char_idx": 3252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da5b9c00-6060-40bd-b406-ef2b4b77d158": {"__data__": {"id_": "da5b9c00-6060-40bd-b406-ef2b4b77d158", "embedding": null, "metadata": {"window": "In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.  ", "original_text": "And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31ab3d2b-9875-4583-b299-70f11cf488ab", "node_type": "1", "metadata": {"window": "We continue to expect prescription and \npatient engagement volumes will return to pre -COVID levels in the second half of our fiscal 2022, which is in line \nwith our original guidance.  In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions. ", "original_text": "Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be3cb399095c85eaae0ec2edd502abc4dd508f17bbbeacf211c14155d5ce443d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "062116e6-4114-46a9-8c02-8defc02c6899", "node_type": "1", "metadata": {"window": "We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC. ", "original_text": "Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution. "}, "hash": "57ef2c58f96c6501fa1873b5a128b8cce58eb48e2b24d3764347ad64cf94a1e2", "class_name": "RelatedNodeInfo"}}, "text": "And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n", "start_char_idx": 3252, "end_char_idx": 3398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "062116e6-4114-46a9-8c02-8defc02c6899": {"__data__": {"id_": "062116e6-4114-46a9-8c02-8defc02c6899", "embedding": null, "metadata": {"window": "We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC. ", "original_text": "Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da5b9c00-6060-40bd-b406-ef2b4b77d158", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we now expect revenue to increas e 8% to 11% \nand adjusted operating profit to deliver 4.5% to 7.5% growth over the prior year.  \n \n We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.  ", "original_text": "And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bcaa1c66a9946343a232da8f99ceb092bc2c299f659490dd50541a731414672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "035bd5e9-12b4-4e7d-bceb-e0e1033b64b2", "node_type": "1", "metadata": {"window": "Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n", "original_text": "This includes work preparing vaccines for international missions. "}, "hash": "1990c2561e6e12ddaf0d87711394ced10c0db400280773831a289028199df564", "class_name": "RelatedNodeInfo"}}, "text": "Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution. ", "start_char_idx": 3398, "end_char_idx": 3540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "035bd5e9-12b4-4e7d-bceb-e0e1033b64b2": {"__data__": {"id_": "035bd5e9-12b4-4e7d-bceb-e0e1033b64b2", "embedding": null, "metadata": {"window": "Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n", "original_text": "This includes work preparing vaccines for international missions. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "062116e6-4114-46a9-8c02-8defc02c6899", "node_type": "1", "metadata": {"window": "We continue to see stable fundamentals.  Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC. ", "original_text": "Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50327edad7caa603bdc34b6ec62d828a84116314174a98b2d747eadd111f57f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a770ceb3-8a17-4730-99cc-10e4bc7a8844", "node_type": "1", "metadata": {"window": "And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth. ", "original_text": "Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.  "}, "hash": "66565e14e0e10a747d273b019db347cdbdb695da824d3fe84a907acac429e86f", "class_name": "RelatedNodeInfo"}}, "text": "This includes work preparing vaccines for international missions. ", "start_char_idx": 3540, "end_char_idx": 3606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a770ceb3-8a17-4730-99cc-10e4bc7a8844": {"__data__": {"id_": "a770ceb3-8a17-4730-99cc-10e4bc7a8844", "embedding": null, "metadata": {"window": "And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth. ", "original_text": "Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.  ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "035bd5e9-12b4-4e7d-bceb-e0e1033b64b2", "node_type": "1", "metadata": {"window": "Specifically, our outlook for branded pharmaceutical pricing remains \nconsistent with our original guidance and the prior year of mid -single -digits increases in fiscal 2022.  And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n", "original_text": "This includes work preparing vaccines for international missions. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40d6f50db8ecc4bd4154528fbdc875be31e3459b156da740600fd37df67fc4da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac3bbbf-11b4-4752-b8e7-ce7bf08e1c55", "node_type": "1", "metadata": {"window": "Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC. "}, "hash": "6884c985a4dd908cf31b4273a2b7362d13ec099eb31543e72b62c13201c5f3e3", "class_name": "RelatedNodeInfo"}}, "text": "Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.  ", "start_char_idx": 3606, "end_char_idx": 3723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac3bbbf-11b4-4752-b8e7-ce7bf08e1c55": {"__data__": {"id_": "6ac3bbbf-11b4-4752-b8e7-ce7bf08e1c55", "embedding": null, "metadata": {"window": "Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a770ceb3-8a17-4730-99cc-10e4bc7a8844", "node_type": "1", "metadata": {"window": "And our view \nis that the generics market remains competitive yet stable, as our volumes have continued to improve in the \nSeptember quarter.  \n \n Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth. ", "original_text": "Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.  ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c42f4f976d68e973f6028736454544d1fc3ea1fe7d56eaafafb0df52159fb585", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c638c24f-9663-4d26-aa0e-8679461b8cb3", "node_type": "1", "metadata": {"window": "This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "We will continue to update you on the progress and contribution from \nthis program.  \n \n"}, "hash": "eb5dc209d164e74f2db1d367a7a930f4d697c158c387389eab9d709ec0878fbe", "class_name": "RelatedNodeInfo"}}, "text": "The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC. ", "start_char_idx": 3723, "end_char_idx": 3889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c638c24f-9663-4d26-aa0e-8679461b8cb3": {"__data__": {"id_": "c638c24f-9663-4d26-aa0e-8679461b8cb3", "embedding": null, "metadata": {"window": "This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "We will continue to update you on the progress and contribution from \nthis program.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac3bbbf-11b4-4752-b8e7-ce7bf08e1c55", "node_type": "1", "metadata": {"window": "Our guidance includes contribution related to our role as a cen tralized distributor for the US government's COVID -\n19 vaccine distribution.  This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bebb8c024f91cd3b8d1b849f268994382bf34fc2e308b2392a6bae9541345171", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5cc9a9c-91c7-4bc6-a742-45c55d219e2a", "node_type": "1", "metadata": {"window": "Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth. "}, "hash": "6a48aca714afa06c6dd0fdf7b2f35fcac5308a7a7d9f60aa962bb30ae3ffac7a", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to update you on the progress and contribution from \nthis program.  \n \n", "start_char_idx": 3889, "end_char_idx": 3977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5cc9a9c-91c7-4bc6-a742-45c55d219e2a": {"__data__": {"id_": "c5cc9a9c-91c7-4bc6-a742-45c55d219e2a", "embedding": null, "metadata": {"window": "Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c638c24f-9663-4d26-aa0e-8679461b8cb3", "node_type": "1", "metadata": {"window": "This includes work preparing vaccines for international missions.  Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "We will continue to update you on the progress and contribution from \nthis program.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2fdd8113bf6f93ca3ffedfb5b403821a9a695b0d4be53b805baaf39307cb8ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "371298cc-a828-4b97-a846-6d8ee0ddcded", "node_type": "1", "metadata": {"window": "The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  "}, "hash": "a5cd6acd3b378d9605a24ead4a7c9ac74cfa1c42bd800ee53883aeb700d8e1f3", "class_name": "RelatedNodeInfo"}}, "text": "When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth. ", "start_char_idx": 3977, "end_char_idx": 4108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "371298cc-a828-4b97-a846-6d8ee0ddcded": {"__data__": {"id_": "371298cc-a828-4b97-a846-6d8ee0ddcded", "embedding": null, "metadata": {"window": "The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe62e8bd643f353e2e8b7ac066c1ce0633c028867c8119eec427cd10bf9b80b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5cc9a9c-91c7-4bc6-a742-45c55d219e2a", "node_type": "1", "metadata": {"window": "Our current outlook \nremains aligned to the volume distribution schedule provided by the CDC and the US government.   The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth. ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef3f8de4cae0657d7693474eff4f0fae171564cd907e6bf7a829cbbf3004bb93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d54c29d-9bee-45a2-8638-af37430828f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical. ", "original_text": "McKesson Corp.  "}, "hash": "192ec39f84934a063f3be23c6c325f869f0c2afec317757b428234dde5052413", "class_name": "RelatedNodeInfo"}}, "text": "In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "start_char_idx": 4108, "end_char_idx": 4268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d54c29d-9bee-45a2-8638-af37430828f3": {"__data__": {"id_": "1d54c29d-9bee-45a2-8638-af37430828f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "371298cc-a828-4b97-a846-6d8ee0ddcded", "node_type": "1", "metadata": {"window": "The current \nguidance excludes booster shots due to the timing of the recent approvals, as well as vaccines for pediatrics, \nwhich have not been approved by the CDC.  We will continue to update you on the progress and contribution from \nthis program.  \n \n When ex cluding COVID -19 vaccine distribution in the segment, we expect approximately 3% to 6% adjusted \noperating profit growth.  In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "original_text": "In addition, our investments in our leading and differentiated position in oncology will \ncontinue to represent an approximate $0.20 hea dwind in fiscal 2022.  ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "282381102552054fcc9743600ca75cb002c8fd0e34d5710222138e4025e80691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c598bfe-3e26-4076-90ee-7cc2c96158b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%. "}, "hash": "aab716fa3f0d2c613c6c5b90ca73d09d06a4e1d02263a6280c10f878239a99af", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c598bfe-3e26-4076-90ee-7cc2c96158b5": {"__data__": {"id_": "2c598bfe-3e26-4076-90ee-7cc2c96158b5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d54c29d-9bee-45a2-8638-af37430828f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f54bd93ac2ce956389432fce42f17d54fb93ec177cb215af3de446845c9e63b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5eb6743-3447-4c36-8b10-4171b8480645", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products. ", "original_text": "This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n"}, "hash": "65eb04f28eada20a17af503a66b0793b3aae25d72c264fc22bd7f8f877d80d67", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%. ", "start_char_idx": 16, "end_char_idx": 323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5eb6743-3447-4c36-8b10-4171b8480645": {"__data__": {"id_": "a5eb6743-3447-4c36-8b10-4171b8480645", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products. ", "original_text": "This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c598bfe-3e26-4076-90ee-7cc2c96158b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8a2c72816df4a1e420dda2c239dd28ccb42205ff5a5be56180b742ba5a61881", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13399cfe-ea54-4cd4-9d72-eae08c3cd1f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n", "original_text": "Now transit ioning to Medical -Surgical. "}, "hash": "54f566717400650d0212d49a83c2eaa52183b21d6227f0795897bd722f7ab59c", "class_name": "RelatedNodeInfo"}}, "text": "This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n", "start_char_idx": 323, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13399cfe-ea54-4cd4-9d72-eae08c3cd1f2": {"__data__": {"id_": "13399cfe-ea54-4cd4-9d72-eae08c3cd1f2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n", "original_text": "Now transit ioning to Medical -Surgical. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5eb6743-3447-4c36-8b10-4171b8480645", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products. ", "original_text": "This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e235253e40b209abe27345aae19250f3e2761e0734d2b111b6b62b65e77f4c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e39d7d-314c-4422-b5a2-5556e09b5259", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses. ", "original_text": "Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year. "}, "hash": "0aca9280af6e65373f3c319991a409c7eaf418b27995934451addf0995e573cf", "class_name": "RelatedNodeInfo"}}, "text": "Now transit ioning to Medical -Surgical. ", "start_char_idx": 410, "end_char_idx": 451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e39d7d-314c-4422-b5a2-5556e09b5259": {"__data__": {"id_": "31e39d7d-314c-4422-b5a2-5556e09b5259", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses. ", "original_text": "Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13399cfe-ea54-4cd4-9d72-eae08c3cd1f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n", "original_text": "Now transit ioning to Medical -Surgical. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccae782e84b93d83c147b922ab837b63cd87db1b48932416c4d6d57de01929ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92a52618-c21f-4690-8b57-3811a2671f33", "node_type": "1", "metadata": {"window": "This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare. ", "original_text": "As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products. "}, "hash": "2ebeffca44a33b8f1c5e94b665ea0afc5576c6b9fb32f8c375d97ca2d9d56f80", "class_name": "RelatedNodeInfo"}}, "text": "Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year. ", "start_char_idx": 451, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92a52618-c21f-4690-8b57-3811a2671f33": {"__data__": {"id_": "92a52618-c21f-4690-8b57-3811a2671f33", "embedding": null, "metadata": {"window": "This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare. ", "original_text": "As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e39d7d-314c-4422-b5a2-5556e09b5259", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses. ", "original_text": "Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f42ee465366a61c1c22bcc00a9978cd3d8bc5d5b9fc46814f3f46bbbee737c96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b0f7166-2d2e-495a-aefa-229d497ea422", "node_type": "1", "metadata": {"window": "Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year. ", "original_text": "Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n"}, "hash": "ed01a4b7034c0213a7ccb5860812b7c674ee852b2e92eec6d6a7310878d2eca7", "class_name": "RelatedNodeInfo"}}, "text": "As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products. ", "start_char_idx": 577, "end_char_idx": 838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b0f7166-2d2e-495a-aefa-229d497ea422": {"__data__": {"id_": "9b0f7166-2d2e-495a-aefa-229d497ea422", "embedding": null, "metadata": {"window": "Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year. ", "original_text": "Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92a52618-c21f-4690-8b57-3811a2671f33", "node_type": "1", "metadata": {"window": "This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare. ", "original_text": "As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2552d48d1d39878b58954b446c62e5f3a60eb8faa3bc1fa60896934317297a7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cc43cc6-46e2-474f-b8e1-0567e580fef2", "node_type": "1", "metadata": {"window": "Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n", "original_text": "One additional note related to our US distribution businesses. "}, "hash": "525418ee0a599200282fbbfabd5ab13b9164c85b335806f13c6e5fb59054d687", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n", "start_char_idx": 838, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cc43cc6-46e2-474f-b8e1-0567e580fef2": {"__data__": {"id_": "5cc43cc6-46e2-474f-b8e1-0567e580fef2", "embedding": null, "metadata": {"window": "Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n", "original_text": "One additional note related to our US distribution businesses. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b0f7166-2d2e-495a-aefa-229d497ea422", "node_type": "1", "metadata": {"window": "Now transit ioning to Medical -Surgical.  Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year. ", "original_text": "Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7764067312568aa5338fb4fe4812d9c2a457279ed200aa031ce4ba6247036d6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "645a88c8-da8d-46ac-95a8-14a94f293e4d", "node_type": "1", "metadata": {"window": "As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear. ", "original_text": "One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare. "}, "hash": "54861b554e546b18facc8a23ec4fc47db45234bce1416c3f22cc99fa0d45b4e7", "class_name": "RelatedNodeInfo"}}, "text": "One additional note related to our US distribution businesses. ", "start_char_idx": 985, "end_char_idx": 1048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "645a88c8-da8d-46ac-95a8-14a94f293e4d": {"__data__": {"id_": "645a88c8-da8d-46ac-95a8-14a94f293e4d", "embedding": null, "metadata": {"window": "As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear. ", "original_text": "One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cc43cc6-46e2-474f-b8e1-0567e580fef2", "node_type": "1", "metadata": {"window": "Our revenue outlook assumes 8% to 14% growth and adjusted operating \nprofit to deliver 35% to 45% growth over the prior year.  As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n", "original_text": "One additional note related to our US distribution businesses. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77879e5698417912e835d4b11213dfe1db0a94090f4fe85a9c7900fc05d0ad99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1fbe1bf-3d86-40df-a5f1-6bd5b2b4f61a", "node_type": "1", "metadata": {"window": "Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance. ", "original_text": "The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year. "}, "hash": "e0d97fa5dd6712e4e4e24bdff99e5f96870fddee0c63957c531c73378b73554d", "class_name": "RelatedNodeInfo"}}, "text": "One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare. ", "start_char_idx": 1048, "end_char_idx": 1174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1fbe1bf-3d86-40df-a5f1-6bd5b2b4f61a": {"__data__": {"id_": "b1fbe1bf-3d86-40df-a5f1-6bd5b2b4f61a", "embedding": null, "metadata": {"window": "Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance. ", "original_text": "The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "645a88c8-da8d-46ac-95a8-14a94f293e4d", "node_type": "1", "metadata": {"window": "As mentioned previously, our outlook includes $0.80 to \n$1.10 related to the contribution from the US go vernment's distribution of ancillary supply kits and storage \nprograms and $0.50 to $0.75 related to COVID -19 tests and PPE impairments -related products.  Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear. ", "original_text": "One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b38c34042d384820a6a1c1a9d5a311f28de4142d49ead0ca98dbbf413a240b0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbfaa442-5917-4e45-95da-d569b8bcd01b", "node_type": "1", "metadata": {"window": "One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup. ", "original_text": "Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n"}, "hash": "6d8ffdde72a92659055f86bddd4424cdf8de8681366b855e07abb11f5a7123fb", "class_name": "RelatedNodeInfo"}}, "text": "The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year. ", "start_char_idx": 1174, "end_char_idx": 1372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbfaa442-5917-4e45-95da-d569b8bcd01b": {"__data__": {"id_": "fbfaa442-5917-4e45-95da-d569b8bcd01b", "embedding": null, "metadata": {"window": "One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup. ", "original_text": "Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1fbe1bf-3d86-40df-a5f1-6bd5b2b4f61a", "node_type": "1", "metadata": {"window": "Excluding the \nimpacts from these items from both fiscal 2022 guidance and fiscal 2021 results, this ind icates 13% to 19% \nforecasted growth.  \n \n One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance. ", "original_text": "The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fac61cc38223977ab5182f230262f0a95d57d4e482a9685522db24828e939648", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17318181-cbb0-4025-b2d2-5ea08d4e2c17", "node_type": "1", "metadata": {"window": "One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n", "original_text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear. "}, "hash": "312b6766ca2364953d842f5cc7e2f0623c9e48c8b5204220689736ae641c0bd2", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n", "start_char_idx": 1372, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17318181-cbb0-4025-b2d2-5ea08d4e2c17": {"__data__": {"id_": "17318181-cbb0-4025-b2d2-5ea08d4e2c17", "embedding": null, "metadata": {"window": "One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n", "original_text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbfaa442-5917-4e45-95da-d569b8bcd01b", "node_type": "1", "metadata": {"window": "One additional note related to our US distribution businesses.  One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup. ", "original_text": "Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75adbe26e94bcd512c5afe14df81c0c211b8954f0bfbb33bffc361b497c3dd4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22af26f2-cdd4-49f0-a54e-e55e50e3ee21", "node_type": "1", "metadata": {"window": "The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view. ", "original_text": "As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance. "}, "hash": "f6088654d67020544fcc7a304bf6115dfa3277d5399076ff8af0f377d080f1f7", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear. ", "start_char_idx": 1593, "end_char_idx": 1712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22af26f2-cdd4-49f0-a54e-e55e50e3ee21": {"__data__": {"id_": "22af26f2-cdd4-49f0-a54e-e55e50e3ee21", "embedding": null, "metadata": {"window": "The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view. ", "original_text": "As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17318181-cbb0-4025-b2d2-5ea08d4e2c17", "node_type": "1", "metadata": {"window": "One of the pillars of our enterprise strategy is \ntalent, the ability to attract and retain the best workforce in healthcare.  The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n", "original_text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b343cb656f964c7d49b9176000c88fa25c69d10a85044c6459585c8abc3b3685", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83bdd5e1-6f76-4105-bf1a-9195afb4c0f0", "node_type": "1", "metadata": {"window": "Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021. ", "original_text": "For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup. "}, "hash": "6961856d4e34c4cdd1505436bc90c701c66ea1aaca08b4ebc374e9ba91b5032e", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance. ", "start_char_idx": 1712, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83bdd5e1-6f76-4105-bf1a-9195afb4c0f0": {"__data__": {"id_": "83bdd5e1-6f76-4105-bf1a-9195afb4c0f0", "embedding": null, "metadata": {"window": "Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021. ", "original_text": "For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22af26f2-cdd4-49f0-a54e-e55e50e3ee21", "node_type": "1", "metadata": {"window": "The labor market remains compe titive, and \nwe have assumed a modest expense impact to ensure there is continued service continuity through the holiday \nseason and the back half of our fiscal year.  Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view. ", "original_text": "As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7ce4aca1c0c55d4e47da2daa5a6fd3e15a44b2d6c96a16d3eaeb2d27080c446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2a1a370-f4f1-44cb-8893-86e8585dbfb4", "node_type": "1", "metadata": {"window": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n", "original_text": "It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n"}, "hash": "0735df7169cb40bcf994e080b47aa120d3d6f25173430865f0edd3270bb2e8b4", "class_name": "RelatedNodeInfo"}}, "text": "For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup. ", "start_char_idx": 1857, "end_char_idx": 2165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2a1a370-f4f1-44cb-8893-86e8585dbfb4": {"__data__": {"id_": "f2a1a370-f4f1-44cb-8893-86e8585dbfb4", "embedding": null, "metadata": {"window": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n", "original_text": "It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83bdd5e1-6f76-4105-bf1a-9195afb4c0f0", "node_type": "1", "metadata": {"window": "Therefore, the guidance that we're providing today includes \napproximately $0.10 to $0.20 of  adjusted operating expense impact for labor investments in our US distribution \nbusinesses in the second half of the year.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021. ", "original_text": "For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac8aa3c4c03f7865427d475eb79da16cec9407d48f4cefb670565c65d1ca172b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23363178-3960-412f-8d28-7ee70be8f8ae", "node_type": "1", "metadata": {"window": "As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility. ", "original_text": "Turning now to the consolidated view. "}, "hash": "9dc32599cd19dd436cfee6e1fce8999aa83a8bd91aa4cecf6b810418c5394322", "class_name": "RelatedNodeInfo"}}, "text": "It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n", "start_char_idx": 2165, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23363178-3960-412f-8d28-7ee70be8f8ae": {"__data__": {"id_": "23363178-3960-412f-8d28-7ee70be8f8ae", "embedding": null, "metadata": {"window": "As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility. ", "original_text": "Turning now to the consolidated view. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2a1a370-f4f1-44cb-8893-86e8585dbfb4", "node_type": "1", "metadata": {"window": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compared to the prior \nyear.  As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n", "original_text": "It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66a16a99f8125f69d8bb653babd8b4ea4e383d5ca6c38ec41cd558e578ad06ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9631e2cc-4393-4707-b44d-3f1b5e4380e2", "node_type": "1", "metadata": {"window": "For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative. ", "original_text": "Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021. "}, "hash": "3b7bd855b973f92663ea2446ff63cc0f371d7c1564ad1bd78865cc086cca72b0", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to the consolidated view. ", "start_char_idx": 2306, "end_char_idx": 2344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9631e2cc-4393-4707-b44d-3f1b5e4380e2": {"__data__": {"id_": "9631e2cc-4393-4707-b44d-3f1b5e4380e2", "embedding": null, "metadata": {"window": "For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative. ", "original_text": "Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23363178-3960-412f-8d28-7ee70be8f8ae", "node_type": "1", "metadata": {"window": "As a reminder,  this reflects the impact of the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance.  For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility. ", "original_text": "Turning now to the consolidated view. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9470867bd416b1a135599ae3af54b66600174f02d44a71d8ef11c87f0b004dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "272c9897-5ffa-4979-8481-aa010ebc8f67", "node_type": "1", "metadata": {"window": "It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented. ", "original_text": "Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n"}, "hash": "34a32fa988a054c425bab59e7b58bc38a081e33fd103eb3c34798e1f17cd4d51", "class_name": "RelatedNodeInfo"}}, "text": "Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021. ", "start_char_idx": 2344, "end_char_idx": 2474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "272c9897-5ffa-4979-8481-aa010ebc8f67": {"__data__": {"id_": "272c9897-5ffa-4979-8481-aa010ebc8f67", "embedding": null, "metadata": {"window": "It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented. ", "original_text": "Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9631e2cc-4393-4707-b44d-3f1b5e4380e2", "node_type": "1", "metadata": {"window": "For adjusted operating profit, our guidance reflects growth in the segment \nof 39% to 43%, which includes approximately $0.38 of  expected adjusted earnings accretion in fiscal 2022 as a \nresult of the held -for-sale accounting related to our agreement to sell certain European assets to the Phoenix \nGroup.  It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative. ", "original_text": "Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0d760568d2047fa68140ce030963a9e797028f4912e2bd502d22cfbef5bfef2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2ed3620-07a8-4198-9ec0-c58ec196114c", "node_type": "1", "metadata": {"window": "Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n", "original_text": "On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility. "}, "hash": "bae3a457690399949f623f039ccae332332f42672564b2eb412a617744c61b52", "class_name": "RelatedNodeInfo"}}, "text": "Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n", "start_char_idx": 2474, "end_char_idx": 2648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2ed3620-07a8-4198-9ec0-c58ec196114c": {"__data__": {"id_": "c2ed3620-07a8-4198-9ec0-c58ec196114c", "embedding": null, "metadata": {"window": "Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n", "original_text": "On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "272c9897-5ffa-4979-8481-aa010ebc8f67", "node_type": "1", "metadata": {"window": "It also includes our strong performance in the second quarter and the contributi on from COVID -19 vaccine \ndistribution in the segment.  \n \n Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented. ", "original_text": "Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dd89a76495488b73fab86a9426477a55862925d423baca7b746436a1e8d7895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "876b96ef-c365-4991-9bc1-b0f93bbfcd3f", "node_type": "1", "metadata": {"window": "Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "We've made good progress against this initiative. "}, "hash": "7051579099ca1f9ee70b8b6d568308075a573a8dfbc5834b5608b165de6d1f09", "class_name": "RelatedNodeInfo"}}, "text": "On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility. ", "start_char_idx": 2648, "end_char_idx": 2812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "876b96ef-c365-4991-9bc1-b0f93bbfcd3f": {"__data__": {"id_": "876b96ef-c365-4991-9bc1-b0f93bbfcd3f", "embedding": null, "metadata": {"window": "Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "We've made good progress against this initiative. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2ed3620-07a8-4198-9ec0-c58ec196114c", "node_type": "1", "metadata": {"window": "Turning now to the consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n", "original_text": "On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fd6874d9cd48fcd3201c60b46d57a0333c49f59a6cdb42fb7615f32ec598c61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc50696f-bca1-456d-a625-b843576c5b56", "node_type": "1", "metadata": {"window": "Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n", "original_text": "And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented. "}, "hash": "33c266de1b53639b122aae8ec706245f12e955e8ead86bed51869e514a86d5be", "class_name": "RelatedNodeInfo"}}, "text": "We've made good progress against this initiative. ", "start_char_idx": 2812, "end_char_idx": 2862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc50696f-bca1-456d-a625-b843576c5b56": {"__data__": {"id_": "cc50696f-bca1-456d-a625-b843576c5b56", "embedding": null, "metadata": {"window": "Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n", "original_text": "And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "876b96ef-c365-4991-9bc1-b0f93bbfcd3f", "node_type": "1", "metadata": {"window": "Our increased guidance assumes 8% to 11% revenue growth and 18% to \n22% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "We've made good progress against this initiative. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d776c12f19326ef1c5b1090683581747dfe2edf252acd2b67818b3f4067929f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dcc3df1-b8b6-43c6-b15e-fffdfac7de48", "node_type": "1", "metadata": {"window": "On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year. ", "original_text": "These savings will be realized across all of our segments.  \n \n"}, "hash": "297853888606c69f59d8262843a84a43db184ef278970566d1f2beacc979f09f", "class_name": "RelatedNodeInfo"}}, "text": "And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented. ", "start_char_idx": 2862, "end_char_idx": 3163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dcc3df1-b8b6-43c6-b15e-fffdfac7de48": {"__data__": {"id_": "9dcc3df1-b8b6-43c6-b15e-fffdfac7de48", "embedding": null, "metadata": {"window": "On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year. ", "original_text": "These savings will be realized across all of our segments.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc50696f-bca1-456d-a625-b843576c5b56", "node_type": "1", "metadata": {"window": "Our full year adjusted effective t ax rate guidance of \n18% to 19% remains unchanged, and we anticipate corporate expenses in the range of $610 million to $660 \nmillion.  \n \n On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n", "original_text": "And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7223aa73d46e1c4d7730bca619e33b2f1116e2350ddbe893b3bb456cf49ea53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "810096df-9872-48c9-8953-4d9b1ed934be", "node_type": "1", "metadata": {"window": "We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases. ", "original_text": "Let me now turn to cash flow and capital deployment. "}, "hash": "1692f86afe4d7149895167853712a08e7d0752019a1149cb68d9a6baefa4e407", "class_name": "RelatedNodeInfo"}}, "text": "These savings will be realized across all of our segments.  \n \n", "start_char_idx": 3163, "end_char_idx": 3226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "810096df-9872-48c9-8953-4d9b1ed934be": {"__data__": {"id_": "810096df-9872-48c9-8953-4d9b1ed934be", "embedding": null, "metadata": {"window": "We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases. ", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dcc3df1-b8b6-43c6-b15e-fffdfac7de48", "node_type": "1", "metadata": {"window": "On our May 6 earnings call, we outlined an initiative to rationalize office space in North America, to increase \nefficiencies, and to support employee flexibility.  We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year. ", "original_text": "These savings will be realized across all of our segments.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885ec3dd9fd004a18d859c8fa310ca14c3d6d7f97bacbd9e05fef785f9a34cd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "194800c1-b233-47e0-82a1-bc51f8b9a121", "node_type": "1", "metadata": {"window": "And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n"}, "hash": "dac07309d29de2999d14055a208622079dfc5c775ed74e3995486ccf479b4e6e", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to cash flow and capital deployment. ", "start_char_idx": 3226, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "194800c1-b233-47e0-82a1-bc51f8b9a121": {"__data__": {"id_": "194800c1-b233-47e0-82a1-bc51f8b9a121", "embedding": null, "metadata": {"window": "And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "810096df-9872-48c9-8953-4d9b1ed934be", "node_type": "1", "metadata": {"window": "We've made good progress against this initiative.  And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases. ", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df725c1b10a082d292b383aad15421b007527f5a17021f7a21b8d66da347ab6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "863b7cd5-b84a-48ab-b839-1d0b8de8c86d", "node_type": "1", "metadata": {"window": "These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year. "}, "hash": "3c41f87d93978513fd7fa8cb2ba623f0e523497cde3dc83521747e1ab787e828", "class_name": "RelatedNodeInfo"}}, "text": "W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n", "start_char_idx": 3279, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "863b7cd5-b84a-48ab-b839-1d0b8de8c86d": {"__data__": {"id_": "863b7cd5-b84a-48ab-b839-1d0b8de8c86d", "embedding": null, "metadata": {"window": "These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "194800c1-b233-47e0-82a1-bc51f8b9a121", "node_type": "1", "metadata": {"window": "And based on \nthis progress, we now expect earlier benefits from these actions, resulting in the realization of annual operating \nexpense savings of approxim ately $15 million to $25 million in the second half of fiscal 2022, with annual savings \nof $50 million to $70 million when fully implemented.  These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec28e629c084e3f90dee0e47b1943150799e0e3bf9a376c7734b4d3e2c81926b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f944d22-e9bb-4963-b21b-5584779d2c17", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases. "}, "hash": "2332db28abaf17723e3e76d75bb314cde76e36b449d94eecbb6a3ea3a5d8dc09", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year. ", "start_char_idx": 3445, "end_char_idx": 3560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f944d22-e9bb-4963-b21b-5584779d2c17": {"__data__": {"id_": "0f944d22-e9bb-4963-b21b-5584779d2c17", "embedding": null, "metadata": {"window": "Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "863b7cd5-b84a-48ab-b839-1d0b8de8c86d", "node_type": "1", "metadata": {"window": "These savings will be realized across all of our segments.  \n \n Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95b30f5fa45870afaed1e6b69ddb90783cc06423a6d6e71458fecb39423ff04c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90637c96-c397-49b2-95df-3b5c1dc31fdd", "node_type": "1", "metadata": {"window": "W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n "}, "hash": "f5d37d49eb06d2a3215a741949b5d52aa7bd4bcc87faf8e503b7547d9ef3a893", "class_name": "RelatedNodeInfo"}}, "text": "This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases. ", "start_char_idx": 3560, "end_char_idx": 3901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90637c96-c397-49b2-95df-3b5c1dc31fdd": {"__data__": {"id_": "90637c96-c397-49b2-95df-3b5c1dc31fdd", "embedding": null, "metadata": {"window": "W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7e28cbf80f62b27a87cdfb8728fb3a4ddfc61aedfa4c8a34b9c32da93b9c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f944d22-e9bb-4963-b21b-5584779d2c17", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases. ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c0ee6a6260952e10f264757eaaebfdc22d7cb1aa78deaf5721f9abc9e5f07a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7587010d-8ab2-41c8-9199-48dedada6f44", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. ", "original_text": "McKesson Corp.  "}, "hash": "0029c3ddd85d1f7e697644cc24f2329854d5405dd6fe1367d747148b272b7320", "class_name": "RelatedNodeInfo"}}, "text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "start_char_idx": 3901, "end_char_idx": 4001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7587010d-8ab2-41c8-9199-48dedada6f44": {"__data__": {"id_": "7587010d-8ab2-41c8-9199-48dedada6f44", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90637c96-c397-49b2-95df-3b5c1dc31fdd", "node_type": "1", "metadata": {"window": "W e expect free cash flow of approximately $3.5 billion to \n$3.9 billion in fiscal 2022, which is net of property acquisitions and capitalized software expenses.  \n \n As a reminder, historically, we generate the majority of our cash flows in the fourth quarter of  our fiscal year.  This \nstrong cash flow generation provides the financial flexibility to execute a balanced capital allocation approach, \ninvesting in our strategies of oncology and biopharma services, positioning our business for long -term growth \nwhile rem aining committed to returning capital to shareholders through our dividend and share repurchases.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "original_text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02dbe7bb96f3fb444892ace29a8ccdca6b1ea7b24645fe06eb599a2f37802511", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "870acf29-4570-408a-9eaa-74710b49e96a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year. "}, "hash": "affe9b950fda666eb6d119f6c31aba725d47ed38c73c543f84ecf63c215fa515", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "870acf29-4570-408a-9eaa-74710b49e96a": {"__data__": {"id_": "870acf29-4570-408a-9eaa-74710b49e96a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7587010d-8ab2-41c8-9199-48dedada6f44", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b48fc89f640d47dba36887babe0cde6fbc5c09f03016cc9a6e3cfc6e63981105", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac46ef1-d7c4-452a-a282-0c2f10e26149", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n ", "original_text": "The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n"}, "hash": "f56f9e283245463581c3950ccb8139742469b750083af61e99f71797152faa85", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year. ", "start_char_idx": 16, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac46ef1-d7c4-452a-a282-0c2f10e26149": {"__data__": {"id_": "6ac46ef1-d7c4-452a-a282-0c2f10e26149", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n ", "original_text": "The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "870acf29-4570-408a-9eaa-74710b49e96a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48903ee942fe6c98d200ebf7f1501fdcaafd31cd09b3070776443155ffbb6d5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99482e58-cb0e-41ca-a434-061dbcf9d104", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. "}, "hash": "6a44a2817c783fe220a7be2b12730b431f4f6e314d235dcd2e11b76b2a757c86", "class_name": "RelatedNodeInfo"}}, "text": "The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n", "start_char_idx": 276, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99482e58-cb0e-41ca-a434-061dbcf9d104": {"__data__": {"id_": "99482e58-cb0e-41ca-a434-061dbcf9d104", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac46ef1-d7c4-452a-a282-0c2f10e26149", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n ", "original_text": "The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1c56cdfa392bc36c1d6387e197d734062a3ef9750ac2a75454daa1e2d216989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9c26dba-0f77-4fff-bc00-f732f5d9c327", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n ", "original_text": "Thank you for your time.  \n \n"}, "hash": "84dacc3946526a1e7c280d57c428e0dd77ce1137f32dc8c053621a1d0cbb46bc", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. ", "start_char_idx": 443, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9c26dba-0f77-4fff-bc00-f732f5d9c327": {"__data__": {"id_": "a9c26dba-0f77-4fff-bc00-f732f5d9c327", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n ", "original_text": "Thank you for your time.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99482e58-cb0e-41ca-a434-061dbcf9d104", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "927c523eec5e8fc27f9e586faf6d4b4e2d21c0c25f8f02ec760b7e22b1103ec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc219016-7ff3-4af8-a3e8-cbaf5f90b5c2", "node_type": "1", "metadata": {"window": "The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much. ", "original_text": "And now, I'll turn the call over to the operator for your questions.  \n "}, "hash": "a4a07820d31742343a64b60071a976157ba1744dd57a723912a7a8bee71140ac", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your time.  \n \n", "start_char_idx": 605, "end_char_idx": 634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc219016-7ff3-4af8-a3e8-cbaf5f90b5c2": {"__data__": {"id_": "dc219016-7ff3-4af8-a3e8-cbaf5f90b5c2", "embedding": null, "metadata": {"window": "The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much. ", "original_text": "And now, I'll turn the call over to the operator for your questions.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9c26dba-0f77-4fff-bc00-f732f5d9c327", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n ", "original_text": "Thank you for your time.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f6c7b6ce2ef11995504f16929a9565a4404ebf61b760b75bea778ed40ba3e8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e22f8cb-8dcc-46f2-80c0-70eda22a6959", "node_type": "1", "metadata": {"window": "Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "97b1a0f9a9d2741db656b893e6183380fe27e3e4f60392ab0ef49fc80e3ca82b", "class_name": "RelatedNodeInfo"}}, "text": "And now, I'll turn the call over to the operator for your questions.  \n ", "start_char_idx": 634, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e22f8cb-8dcc-46f2-80c0-70eda22a6959": {"__data__": {"id_": "0e22f8cb-8dcc-46f2-80c0-70eda22a6959", "embedding": null, "metadata": {"window": "Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc219016-7ff3-4af8-a3e8-cbaf5f90b5c2", "node_type": "1", "metadata": {"window": "The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much. ", "original_text": "And now, I'll turn the call over to the operator for your questions.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5702e3443a13d4393ae9953a28392415333c5d5b7fd39df7f3a90772676f4a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb4e5f64-9d84-4558-afbf-3b08c95986d7", "node_type": "1", "metadata": {"window": "Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes. ", "original_text": "[Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n "}, "hash": "fee10ce5d70c87a828c94fe7e487f883171033d9f85b1307d0909179cffe9e07", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 706, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb4e5f64-9d84-4558-afbf-3b08c95986d7": {"__data__": {"id_": "bb4e5f64-9d84-4558-afbf-3b08c95986d7", "embedding": null, "metadata": {"window": "Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes. ", "original_text": "[Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e22f8cb-8dcc-46f2-80c0-70eda22a6959", "node_type": "1", "metadata": {"window": "Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8.  Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d01cd5950a1eb549b22d43141846bf02aecf69e9969af5291fe88cd03764c8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44762c8b-00d4-4213-823b-7f0275ffac70", "node_type": "1", "metadata": {"window": "And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much. "}, "hash": "adc7d360bc8e77637c5f9094c95831c9f3d912c6508319f5ca27be0a04853c33", "class_name": "RelatedNodeInfo"}}, "text": "[Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n ", "start_char_idx": 1019, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44762c8b-00d4-4213-823b-7f0275ffac70": {"__data__": {"id_": "44762c8b-00d4-4213-823b-7f0275ffac70", "embedding": null, "metadata": {"window": "And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb4e5f64-9d84-4558-afbf-3b08c95986d7", "node_type": "1", "metadata": {"window": "Thank you for your time.  \n \n And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes. ", "original_text": "[Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85c92fa70dcd64d02e444431633455370a83d03d5efbf9763af97e5e6ca43841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae876694-832e-40b8-84f3-07c6c82eda8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor? ", "original_text": "Good afternoon, and congratulations on a great quarter. "}, "hash": "44a8e43c189bda0092b6fe58502dd64a588a38a8e80ccb17ffad4c3a180f9823", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much. ", "start_char_idx": 1111, "end_char_idx": 1466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae876694-832e-40b8-84f3-07c6c82eda8e": {"__data__": {"id_": "ae876694-832e-40b8-84f3-07c6c82eda8e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor? ", "original_text": "Good afternoon, and congratulations on a great quarter. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44762c8b-00d4-4213-823b-7f0275ffac70", "node_type": "1", "metadata": {"window": "And now, I'll turn the call over to the operator for your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd6796bf9b232f4895a28950a81bdd3abb965ac546fc8e34e36205af861b8145", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d19cfa6e-7ede-458c-9689-e5cb9ab2ebe9", "node_type": "1", "metadata": {"window": "[Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective? ", "original_text": "Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes. "}, "hash": "8fdea6f90773f73528e127e0255ec49537806ed16e0dba40e42cd873c9f682c2", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, and congratulations on a great quarter. ", "start_char_idx": 1466, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d19cfa6e-7ede-458c-9689-e5cb9ab2ebe9": {"__data__": {"id_": "d19cfa6e-7ede-458c-9689-e5cb9ab2ebe9", "embedding": null, "metadata": {"window": "[Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective? ", "original_text": "Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae876694-832e-40b8-84f3-07c6c82eda8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor? ", "original_text": "Good afternoon, and congratulations on a great quarter. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5226f396dec85aef3cc075c2ccffd45827fea4fc97e5a6ea718bd9ed53556238", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e83f386-df4e-49e6-835f-0f655238a284", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs? ", "original_text": "But one of the other \nquestions we've gotten around inflation is around freight costs. "}, "hash": "3ddfc4cea878a4b96d6a1da84a671980ba09a5332e4354e594a96d35afe63431", "class_name": "RelatedNodeInfo"}}, "text": "Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes. ", "start_char_idx": 1522, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e83f386-df4e-49e6-835f-0f655238a284": {"__data__": {"id_": "7e83f386-df4e-49e6-835f-0f655238a284", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs? ", "original_text": "But one of the other \nquestions we've gotten around inflation is around freight costs. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d19cfa6e-7ede-458c-9689-e5cb9ab2ebe9", "node_type": "1", "metadata": {"window": "[Operator  Instructions] And we'll take our first question from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective? ", "original_text": "Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cd91573688eaa36a714925528f7dbb7c79387ef8c021c9c1a20441147948f0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "623ed1fb-db78-41b0-be76-ef296b537dd1", "node_type": "1", "metadata": {"window": "Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer? ", "original_text": "Can you remind us of how that works between the \nmanufacturer and the drug distributor? "}, "hash": "d0e9463537e39ae412dc69360c4cc9b7acef1f5c27ac0f5c5e83f1fb2be10463", "class_name": "RelatedNodeInfo"}}, "text": "But one of the other \nquestions we've gotten around inflation is around freight costs. ", "start_char_idx": 1615, "end_char_idx": 1702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "623ed1fb-db78-41b0-be76-ef296b537dd1": {"__data__": {"id_": "623ed1fb-db78-41b0-be76-ef296b537dd1", "embedding": null, "metadata": {"window": "Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer? ", "original_text": "Can you remind us of how that works between the \nmanufacturer and the drug distributor? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e83f386-df4e-49e6-835f-0f655238a284", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much and good \u2013 thanks very much.  Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs? ", "original_text": "But one of the other \nquestions we've gotten around inflation is around freight costs. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84d983215224c5fcc8ea757603871afc50c35f81570fef242838d07480f65b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a5f3cb2-5b20-4bdd-885c-030800aea8b9", "node_type": "1", "metadata": {"window": "Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n ", "original_text": "And if you'l l bear any of those costs from a distribution perspective? "}, "hash": "e4e74fb235a61f1852acd2a8d9a6541b371a8fc2cee4bbc2f105811edf594a9c", "class_name": "RelatedNodeInfo"}}, "text": "Can you remind us of how that works between the \nmanufacturer and the drug distributor? ", "start_char_idx": 1702, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a5f3cb2-5b20-4bdd-885c-030800aea8b9": {"__data__": {"id_": "4a5f3cb2-5b20-4bdd-885c-030800aea8b9", "embedding": null, "metadata": {"window": "Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n ", "original_text": "And if you'l l bear any of those costs from a distribution perspective? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "623ed1fb-db78-41b0-be76-ef296b537dd1", "node_type": "1", "metadata": {"window": "Good afternoon, and congratulations on a great quarter.  Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer? ", "original_text": "Can you remind us of how that works between the \nmanufacturer and the drug distributor? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdadf1981da0e6a9dbc1f409ee9e3d2fb896b17fbf06179813fbbd17f52febba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91139d65-c0a0-4810-bfc3-eb26c7739645", "node_type": "1", "metadata": {"window": "But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "original_text": "Or is it \njust the manufacturer that bears that costs? "}, "hash": "4e51d8ecfd5dddbe78a045fee18a532e1369614d94a410f6f33992fd50a0a14b", "class_name": "RelatedNodeInfo"}}, "text": "And if you'l l bear any of those costs from a distribution perspective? ", "start_char_idx": 1790, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91139d65-c0a0-4810-bfc3-eb26c7739645": {"__data__": {"id_": "91139d65-c0a0-4810-bfc3-eb26c7739645", "embedding": null, "metadata": {"window": "But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "original_text": "Or is it \njust the manufacturer that bears that costs? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a5f3cb2-5b20-4bdd-885c-030800aea8b9", "node_type": "1", "metadata": {"window": "Britt, I \nappreciated your comments around what you're seeing as far as wage inflation goes.  But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n ", "original_text": "And if you'l l bear any of those costs from a distribution perspective? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a64ca1be854bf0e351c4cf47b85013b9891facb3c56bdc30ed0e44a6bab35ea7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba43d4b5-e316-47c6-ae95-0c701e4d03c2", "node_type": "1", "metadata": {"window": "Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes. ", "original_text": "Are you able to pass it on to the customer? "}, "hash": "aeca0e7cda8b0270a0390e7cd5c7dc3717ddd3ec9db10b2fd6e88aff0aedc896", "class_name": "RelatedNodeInfo"}}, "text": "Or is it \njust the manufacturer that bears that costs? ", "start_char_idx": 1862, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba43d4b5-e316-47c6-ae95-0c701e4d03c2": {"__data__": {"id_": "ba43d4b5-e316-47c6-ae95-0c701e4d03c2", "embedding": null, "metadata": {"window": "Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes. ", "original_text": "Are you able to pass it on to the customer? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91139d65-c0a0-4810-bfc3-eb26c7739645", "node_type": "1", "metadata": {"window": "But one of the other \nquestions we've gotten around inflation is around freight costs.  Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "original_text": "Or is it \njust the manufacturer that bears that costs? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd97707cbe53553d84ab495583213be122972204f3e9b277a209a0b2f8ec8b21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39c36584-880b-4885-85f4-076ca2163bd2", "node_type": "1", "metadata": {"window": "And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa. ", "original_text": "Just any color around that \nwould be helpful.  \n "}, "hash": "c27c849a70a1e447bd50fd414cc77ca17a1a6256d5ffcdeb1307a05ad42a34cb", "class_name": "RelatedNodeInfo"}}, "text": "Are you able to pass it on to the customer? ", "start_char_idx": 1917, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39c36584-880b-4885-85f4-076ca2163bd2": {"__data__": {"id_": "39c36584-880b-4885-85f4-076ca2163bd2", "embedding": null, "metadata": {"window": "And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa. ", "original_text": "Just any color around that \nwould be helpful.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba43d4b5-e316-47c6-ae95-0c701e4d03c2", "node_type": "1", "metadata": {"window": "Can you remind us of how that works between the \nmanufacturer and the drug distributor?  And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes. ", "original_text": "Are you able to pass it on to the customer? ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2240e08dcb5b32dfafd9f65f1b8a227cf4bb45c11b08e374afdae1223ad76c48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46f882c4-12d6-4d37-9f8e-a612262975ca", "node_type": "1", "metadata": {"window": "Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  "}, "hash": "96fb7922528d3b6266fd6262a683c84fe631829e684d3bb3c882dd211a88b691", "class_name": "RelatedNodeInfo"}}, "text": "Just any color around that \nwould be helpful.  \n ", "start_char_idx": 1961, "end_char_idx": 2010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46f882c4-12d6-4d37-9f8e-a612262975ca": {"__data__": {"id_": "46f882c4-12d6-4d37-9f8e-a612262975ca", "embedding": null, "metadata": {"window": "Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39c36584-880b-4885-85f4-076ca2163bd2", "node_type": "1", "metadata": {"window": "And if you'l l bear any of those costs from a distribution perspective?  Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa. ", "original_text": "Just any color around that \nwould be helpful.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4879cdfa019172f5bb63d62b265ad0eefc7ed0e76b668e09d14893e0bdd7d28c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1168737-d670-42b1-b431-cd7efb1e7bbc", "node_type": "1", "metadata": {"window": "Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business. ", "original_text": "A \nYes. "}, "hash": "b4ed7c4ee8c099a5daf16b20d2cd9c7a86abeab4be5e188dd667f726842623ce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "start_char_idx": 2010, "end_char_idx": 2353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1168737-d670-42b1-b431-cd7efb1e7bbc": {"__data__": {"id_": "e1168737-d670-42b1-b431-cd7efb1e7bbc", "embedding": null, "metadata": {"window": "Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business. ", "original_text": "A \nYes. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46f882c4-12d6-4d37-9f8e-a612262975ca", "node_type": "1", "metadata": {"window": "Or is it \njust the manufacturer that bears that costs?  Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2918ba9c7a26da9d13b19d51dbf0ea7162686ce785959e800b190bc56ae4dff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e2049e-5f0d-4f0e-a2b4-3ec839b4815f", "node_type": "1", "metadata": {"window": "Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers. ", "original_text": "Thanks for your question, Lisa. "}, "hash": "d331acc33245fe09fe9a9f311ddd2299bdf68cdb5627e03c6938c14e3d1a7e8f", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 2353, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e2049e-5f0d-4f0e-a2b4-3ec839b4815f": {"__data__": {"id_": "80e2049e-5f0d-4f0e-a2b4-3ec839b4815f", "embedding": null, "metadata": {"window": "Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers. ", "original_text": "Thanks for your question, Lisa. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1168737-d670-42b1-b431-cd7efb1e7bbc", "node_type": "1", "metadata": {"window": "Are you able to pass it on to the customer?  Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business. ", "original_text": "A \nYes. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9f8c284c56e753e2aa6d0ed7702dbe3494982a1e510a6f799ac71e0f2edcdd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3b920ef-48c3-4983-9270-cafc28eaa7ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue. ", "original_text": "Certainly, we will bear some costs for freight. "}, "hash": "7360e156b4a73a7f24835ab289e7cfef6a838f56fa8ec8da229cbe6e823a2cee", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for your question, Lisa. ", "start_char_idx": 2361, "end_char_idx": 2393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3b920ef-48c3-4983-9270-cafc28eaa7ec": {"__data__": {"id_": "d3b920ef-48c3-4983-9270-cafc28eaa7ec", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue. ", "original_text": "Certainly, we will bear some costs for freight. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e2049e-5f0d-4f0e-a2b4-3ec839b4815f", "node_type": "1", "metadata": {"window": "Just any color around that \nwould be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers. ", "original_text": "Thanks for your question, Lisa. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "618fa7925825d6f1d34f759a28e5cea1bc9d20feddc90003d121b9671b32ff1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfa71ed7-899a-41f5-8c1d-1c6bbd79f3a3", "node_type": "1", "metadata": {"window": "A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year. ", "original_text": "We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business. "}, "hash": "4c1856d587a56f317812557c893da8f1f3672fa85f11f1f7f854077248b435c0", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, we will bear some costs for freight. ", "start_char_idx": 2393, "end_char_idx": 2441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfa71ed7-899a-41f5-8c1d-1c6bbd79f3a3": {"__data__": {"id_": "cfa71ed7-899a-41f5-8c1d-1c6bbd79f3a3", "embedding": null, "metadata": {"window": "A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year. ", "original_text": "We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3b920ef-48c3-4983-9270-cafc28eaa7ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue. ", "original_text": "Certainly, we will bear some costs for freight. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76c416cee55a144be1c9e475e98a7b8b4306c992217f8f3450458e7cf830e02c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a49c12de-ef07-457d-a6ce-05de07060a66", "node_type": "1", "metadata": {"window": "Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n ", "original_text": "We are responsible for the freigh t from \nour distribution locations to our customers. "}, "hash": "aa10f6f43cb3e694948951c3d00a30dc852a7fecb0243c149b5b8b4c5070602f", "class_name": "RelatedNodeInfo"}}, "text": "We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business. ", "start_char_idx": 2441, "end_char_idx": 2547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a49c12de-ef07-457d-a6ce-05de07060a66": {"__data__": {"id_": "a49c12de-ef07-457d-a6ce-05de07060a66", "embedding": null, "metadata": {"window": "Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n ", "original_text": "We are responsible for the freigh t from \nour distribution locations to our customers. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfa71ed7-899a-41f5-8c1d-1c6bbd79f3a3", "node_type": "1", "metadata": {"window": "A \nYes.  Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year. ", "original_text": "We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a8da9ea82b33a94ddd39481accfa718a217c1d86af9585def84ad3c76894955", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd8a44f5-0de2-419f-b962-fe46e0a27d82", "node_type": "1", "metadata": {"window": "Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue. "}, "hash": "d2114beb87aa2d441b2e3b92ca83a5202ca718f06f73d8368ad62ba70f122392", "class_name": "RelatedNodeInfo"}}, "text": "We are responsible for the freigh t from \nour distribution locations to our customers. ", "start_char_idx": 2547, "end_char_idx": 2634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd8a44f5-0de2-419f-b962-fe46e0a27d82": {"__data__": {"id_": "dd8a44f5-0de2-419f-b962-fe46e0a27d82", "embedding": null, "metadata": {"window": "Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a49c12de-ef07-457d-a6ce-05de07060a66", "node_type": "1", "metadata": {"window": "Thanks for your question, Lisa.  Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n ", "original_text": "We are responsible for the freigh t from \nour distribution locations to our customers. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cb934ca2a8d6acbfb852f4a582f51ec3b06c3704f4ff3787c195c269d6ff242", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "902fd331-313d-454e-b648-191086da350a", "node_type": "1", "metadata": {"window": "We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n ", "original_text": "We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year. "}, "hash": "7c1c719fa25b18f2f85bc7a7b8edb35739c01377656c0a18fcf6e9c260e72f86", "class_name": "RelatedNodeInfo"}}, "text": "And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue. ", "start_char_idx": 2634, "end_char_idx": 2797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "902fd331-313d-454e-b648-191086da350a": {"__data__": {"id_": "902fd331-313d-454e-b648-191086da350a", "embedding": null, "metadata": {"window": "We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n ", "original_text": "We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd8a44f5-0de2-419f-b962-fe46e0a27d82", "node_type": "1", "metadata": {"window": "Certainly, we will bear some costs for freight.  We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89e8fddc68b206409209737844a4700bf341b16be3a8a4516334b1bbcb2fa065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42be638c-cf75-46a0-a9ea-ed0ff48ea134", "node_type": "1", "metadata": {"window": "We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n "}, "hash": "74304fd751f5e694d2cfa3f3fa8beea5c5fc34f4a5d50190bf0f74121ba9b05f", "class_name": "RelatedNodeInfo"}}, "text": "We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year. ", "start_char_idx": 2797, "end_char_idx": 2947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42be638c-cf75-46a0-a9ea-ed0ff48ea134": {"__data__": {"id_": "42be638c-cf75-46a0-a9ea-ed0ff48ea134", "embedding": null, "metadata": {"window": "We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "902fd331-313d-454e-b648-191086da350a", "node_type": "1", "metadata": {"window": "We've been able to pass that \non to this point in time, both our Pharmaceutical and our Medical business.  We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n ", "original_text": "We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d130304bcbace10fdc70be8bbd7089c8d1ff73974cdf495450ad03e4950c37e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82714da5-e7f9-40ab-9443-3d65b759ac36", "node_type": "1", "metadata": {"window": "And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "0055a18b21526c41ad11a48da1f86eac2ae56191a2eac3ff5fe43a9b91b9f88d", "class_name": "RelatedNodeInfo"}}, "text": "But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n ", "start_char_idx": 2947, "end_char_idx": 3338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82714da5-e7f9-40ab-9443-3d65b759ac36": {"__data__": {"id_": "82714da5-e7f9-40ab-9443-3d65b759ac36", "embedding": null, "metadata": {"window": "And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42be638c-cf75-46a0-a9ea-ed0ff48ea134", "node_type": "1", "metadata": {"window": "We are responsible for the freigh t from \nour distribution locations to our customers.  And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca1e9c6d1bde37176cfaaa4d89c957c4cf6514d9e2261d7a0811eeb8b1673132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b6cda48-72fb-4233-8594-46e9bc9857c7", "node_type": "1", "metadata": {"window": "We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nWe'll go ahead and take the next question.  \n "}, "hash": "e0b821ae34b8ac8b2dd64034dd3def54bf5a83ecdd1a90cc76752bfe13cac0ea", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3338, "end_char_idx": 3680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b6cda48-72fb-4233-8594-46e9bc9857c7": {"__data__": {"id_": "9b6cda48-72fb-4233-8594-46e9bc9857c7", "embedding": null, "metadata": {"window": "We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nWe'll go ahead and take the next question.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82714da5-e7f9-40ab-9443-3d65b759ac36", "node_type": "1", "metadata": {"window": "And to this point, we've been able to manage through that without any \nmaterial impact, and our guidance for the rest of the year assumes that that will continue.  We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "276bb42f5abe23361a70ff7f214b0435e0c72716c181c874236cc99eecba9755", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40a1c9c5-b10c-4fbb-9457-982e8ba36320", "node_type": "1", "metadata": {"window": "But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "a1a15b3629a1bdba3bdd13f0df8a743f3dc940f11a190575a5809d9c97c2709b", "class_name": "RelatedNodeInfo"}}, "text": "A \nWe'll go ahead and take the next question.  \n ", "start_char_idx": 3680, "end_char_idx": 3729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40a1c9c5-b10c-4fbb-9457-982e8ba36320": {"__data__": {"id_": "40a1c9c5-b10c-4fbb-9457-982e8ba36320", "embedding": null, "metadata": {"window": "But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b6cda48-72fb-4233-8594-46e9bc9857c7", "node_type": "1", "metadata": {"window": "We did call out the \nincremental labor impa ct, the investment that we're making, to make sure that we have continuity through the rest \nof the year.  But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nWe'll go ahead and take the next question.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d42951722a8c5d936a21405bda61b3c8120028daa1fae015a9a3bc2af521ce04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aac1d1b-d620-4e0b-a1c4-48ef5c63fb3e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "We'll take our next question from Michael Cherny with Bank of America.  \n "}, "hash": "fffc43f2df6ea1c651653871aac71fd3df0e319d02b1c8787e29343e4c621e58", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 3729, "end_char_idx": 4010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aac1d1b-d620-4e0b-a1c4-48ef5c63fb3e": {"__data__": {"id_": "7aac1d1b-d620-4e0b-a1c4-48ef5c63fb3e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "We'll take our next question from Michael Cherny with Bank of America.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40a1c9c5-b10c-4fbb-9457-982e8ba36320", "node_type": "1", "metadata": {"window": "But as it relates to freight, we are responsible from...  \n \n[Technical Difficulty] (36:14 -38:27)  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Please proceed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e6650dc96ea6d7634ea36db1fe50cc790962f2b0fd347cc460b3f3fb805b951", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "350f6ceb-d78b-45ab-ad9d-d7602755bf69", "node_type": "1", "metadata": {"window": "A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "a553abb657062153559d9e424475ff047633e7b85624aff2b2b8443d134db25d", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Michael Cherny with Bank of America.  \n ", "start_char_idx": 4010, "end_char_idx": 4084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "350f6ceb-d78b-45ab-ad9d-d7602755bf69": {"__data__": {"id_": "350f6ceb-d78b-45ab-ad9d-d7602755bf69", "embedding": null, "metadata": {"window": "A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aac1d1b-d620-4e0b-a1c4-48ef5c63fb3e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "We'll take our next question from Michael Cherny with Bank of America.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce56050b39536b9c53ebcccd79b480b491aa49f4ae9296a0423c7b18575b15f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2129128c-e4dd-4777-a5fb-a8e921c37078", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "Q "}, "hash": "cf2dcce3ee69cae8d5824318f54767697e68f7b20e2a54c8d5c06d486a8297b2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 4084, "end_char_idx": 4390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2129128c-e4dd-4777-a5fb-a8e921c37078": {"__data__": {"id_": "2129128c-e4dd-4777-a5fb-a8e921c37078", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "Q ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa6cca707d4fa1d515aced817ebd447253e86ce15eceac8573b704c3a6201d71", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "350f6ceb-d78b-45ab-ad9d-d7602755bf69", "node_type": "1", "metadata": {"window": "A \nWe'll go ahead and take the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12e5d586f7c22940d210e307a908647ac6e3c91bdcddf0de5392d8984bd97e30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce64e808-9f9f-4855-a5e4-173131876e1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. ", "original_text": "McKesson Corp.  "}, "hash": "d98db368ea07cc0b95b0c8f7bf9ad42a7cc4af1d461b83319108a7a45638d10e", "class_name": "RelatedNodeInfo"}}, "text": "Q ", "start_char_idx": 1417, "end_char_idx": 1419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce64e808-9f9f-4855-a5e4-173131876e1e": {"__data__": {"id_": "ce64e808-9f9f-4855-a5e4-173131876e1e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2129128c-e4dd-4777-a5fb-a8e921c37078", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q ", "original_text": "Q ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8b3bb92fa3953ebb63aea2c6f0321ea6a5e34d1739dbbccfe1ae2c03afdfc0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "befd9623-a933-44c4-afb5-25b26618ed4e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon. "}, "hash": "1c4ea9a0845036b8fd6f50f06289e262226854c8ab7415f9b422613fd3715ac6", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "befd9623-a933-44c4-afb5-25b26618ed4e": {"__data__": {"id_": "befd9623-a933-44c4-afb5-25b26618ed4e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce64e808-9f9f-4855-a5e4-173131876e1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6c18144c500908c2701b759ec0490ec208b2e2e5a197a0efc8d24ab18fd1292", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ef4cf66-f29f-40dd-83ce-a5d318d380e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements. ", "original_text": "Thanks for taking the question. "}, "hash": "a9f82105030acfab007638be664cfa6828c4c2ab925eabdecbbd7b919fbac307", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon. ", "start_char_idx": 16, "end_char_idx": 197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ef4cf66-f29f-40dd-83ce-a5d318d380e8": {"__data__": {"id_": "1ef4cf66-f29f-40dd-83ce-a5d318d380e8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements. ", "original_text": "Thanks for taking the question. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "befd9623-a933-44c4-afb5-25b26618ed4e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f546dac99e588eba7a272ba989d2311e16d4150ff8bbab362548c26a78a3001", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c5b7d6d-ce43-441f-8f7a-444282a8b7e6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year. ", "original_text": "First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. "}, "hash": "c53ed2d32487b145b463a99597ce88dc4294cd4b4021b42109d682dae486d6e9", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 197, "end_char_idx": 229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c5b7d6d-ce43-441f-8f7a-444282a8b7e6": {"__data__": {"id_": "3c5b7d6d-ce43-441f-8f7a-444282a8b7e6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year. ", "original_text": "First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ef4cf66-f29f-40dd-83ce-a5d318d380e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements. ", "original_text": "Thanks for taking the question. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea2fffeda1a8ebc2939166b0f4e72a824605dce8761514e27b9d958698892fa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5890d9a-5872-486a-aef3-0357d35e6488", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n ", "original_text": "I don't know if you want to highlight that again. "}, "hash": "19ce73bab5f76b33f33519628bc6d14a9ee360087cce2deb8f735e7f5f98526f", "class_name": "RelatedNodeInfo"}}, "text": "First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. ", "start_char_idx": 229, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5890d9a-5872-486a-aef3-0357d35e6488": {"__data__": {"id_": "e5890d9a-5872-486a-aef3-0357d35e6488", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n ", "original_text": "I don't know if you want to highlight that again. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c5b7d6d-ce43-441f-8f7a-444282a8b7e6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year. ", "original_text": "First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91d4888069ca633ba3e3a7b1a1ee8a45068291ebb189d706396b78f6f337a5d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06d67dfb-232e-4ff6-acf5-b05cac10db4d", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements. "}, "hash": "9d5d512275e67efdae8043f45d5dda2bc3b651581c4589fe1a2d89d1ec67182f", "class_name": "RelatedNodeInfo"}}, "text": "I don't know if you want to highlight that again. ", "start_char_idx": 341, "end_char_idx": 391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06d67dfb-232e-4ff6-acf5-b05cac10db4d": {"__data__": {"id_": "06d67dfb-232e-4ff6-acf5-b05cac10db4d", "embedding": null, "metadata": {"window": "Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5890d9a-5872-486a-aef3-0357d35e6488", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n ", "original_text": "I don't know if you want to highlight that again. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "268682f3e1556bc92ba12b031341473e53454f247591853448cc7026437a6dc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e479f1c-2d7a-4385-a62d-2c94bbed49b9", "node_type": "1", "metadata": {"window": "First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt. ", "original_text": "I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year. "}, "hash": "2b59d87e9cf3ae267b16ea9e31f93f718db393578d5900a2f9c6627057291abe", "class_name": "RelatedNodeInfo"}}, "text": "And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements. ", "start_char_idx": 391, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e479f1c-2d7a-4385-a62d-2c94bbed49b9": {"__data__": {"id_": "2e479f1c-2d7a-4385-a62d-2c94bbed49b9", "embedding": null, "metadata": {"window": "First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt. ", "original_text": "I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06d67dfb-232e-4ff6-acf5-b05cac10db4d", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec12ad2803f76db7237925f0ec99395d7854b58c47647d7401a7faebc37bf9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bd7758e-c79d-4327-93b2-c3cddcd35b2a", "node_type": "1", "metadata": {"window": "I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there. ", "original_text": "Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n "}, "hash": "990ef51233df1a0d1ae9c19fd2856cced66df05885846586b84355b3953ce80e", "class_name": "RelatedNodeInfo"}}, "text": "I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year. ", "start_char_idx": 631, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bd7758e-c79d-4327-93b2-c3cddcd35b2a": {"__data__": {"id_": "5bd7758e-c79d-4327-93b2-c3cddcd35b2a", "embedding": null, "metadata": {"window": "I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there. ", "original_text": "Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e479f1c-2d7a-4385-a62d-2c94bbed49b9", "node_type": "1", "metadata": {"window": "First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight.  I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt. ", "original_text": "I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bbaf8dce3014658ab6f2746982dede8f047ce14e144cb3c37b67dfbc84ef39f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bb4b6fd-c12c-4575-b578-fdc5de04d404", "node_type": "1", "metadata": {"window": "And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "192775fdd798be7549d8cb221025a332266b00c7a4345c7f0cf6c6a7e0f7ac24", "class_name": "RelatedNodeInfo"}}, "text": "Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n ", "start_char_idx": 917, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bb4b6fd-c12c-4575-b578-fdc5de04d404": {"__data__": {"id_": "9bb4b6fd-c12c-4575-b578-fdc5de04d404", "embedding": null, "metadata": {"window": "And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bd7758e-c79d-4327-93b2-c3cddcd35b2a", "node_type": "1", "metadata": {"window": "I don't know if you want to highlight that again.  And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there. ", "original_text": "Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "786a23b6e3bd966a6df56ed9ebea0fc884d94a6fc45166aa7ad1ce621926ad7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a827da38-f43b-4ea1-9b70-97681c71c14a", "node_type": "1", "metadata": {"window": "I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers. ", "original_text": "A \nHey, Mike, t his is Britt. "}, "hash": "ba95366a2500cfb16833d0c6a3f0d8582dfafd217fde1d8d9e8354d85ef1940d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1120, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a827da38-f43b-4ea1-9b70-97681c71c14a": {"__data__": {"id_": "a827da38-f43b-4ea1-9b70-97681c71c14a", "embedding": null, "metadata": {"window": "I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers. ", "original_text": "A \nHey, Mike, t his is Britt. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bb4b6fd-c12c-4575-b578-fdc5de04d404", "node_type": "1", "metadata": {"window": "And then I guess just \nfrom my perspective, I do n't want to get too far ahead of things, especially with the Analyst Day coming up, but I \nappreciate all the breakout you have on the strong work tied to all of the COVID -related elements.  I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b1084648c1947af3253f8edb75e31e0f98a0eb0489a1db47c7283152b2a4d6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5357fcbd-417a-427d-8ae6-1af705956ecf", "node_type": "1", "metadata": {"window": "Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight. ", "original_text": "Thanks for hanging in there. "}, "hash": "4897f67980d2f81eed4a162c8ab4ff57d17a2e87684f902abb10640142c14046", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey, Mike, t his is Britt. ", "start_char_idx": 1462, "end_char_idx": 1492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5357fcbd-417a-427d-8ae6-1af705956ecf": {"__data__": {"id_": "5357fcbd-417a-427d-8ae6-1af705956ecf", "embedding": null, "metadata": {"window": "Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight. ", "original_text": "Thanks for hanging in there. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a827da38-f43b-4ea1-9b70-97681c71c14a", "node_type": "1", "metadata": {"window": "I know one of \nthe questions that I'm guessing will come up is what that means into next year, given that you outlined some of \nthe benefits that you're seeing specifically this year that, for all our sakes, we all hope that don't [audio gap] \n(39:19) growth trajectory into next year.  Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers. ", "original_text": "A \nHey, Mike, t his is Britt. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "294752a7d63f3c3f477828eff985894bbab3d5cd0c6883f734c214253317735a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3547ee16-6280-4de1-9e4c-ad7e255d1e38", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well. ", "original_text": "Let me just get back to Lisa's question, just to finish that up. \n"}, "hash": "da4f1f3c9bc0bad1d44a2442f1bc3c1a5b8cfbc5cb1b3b95d46338d5626a83e4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for hanging in there. ", "start_char_idx": 1492, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3547ee16-6280-4de1-9e4c-ad7e255d1e38": {"__data__": {"id_": "3547ee16-6280-4de1-9e4c-ad7e255d1e38", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well. ", "original_text": "Let me just get back to Lisa's question, just to finish that up. \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5357fcbd-417a-427d-8ae6-1af705956ecf", "node_type": "1", "metadata": {"window": "Is there any way to think about that $23 0 million to $305 million and how \nwe have to think about that as a whole in terms of your overall growth versus what your core business will \ncontinue to do?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight. ", "original_text": "Thanks for hanging in there. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03db0f3d776c08089407b29935537b2981479017476f4b22cd7c25d71e09bc3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0c7e112-344b-44b4-8169-c9434b44b451", "node_type": "1", "metadata": {"window": "A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n", "original_text": "We are responsible for the freight from our distribution centers to our customers. "}, "hash": "6b89d9999318cce6a0f456d290b8f2d100e44d1d934a4b864c1d55f010984711", "class_name": "RelatedNodeInfo"}}, "text": "Let me just get back to Lisa's question, just to finish that up. \n", "start_char_idx": 1521, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0c7e112-344b-44b4-8169-c9434b44b451": {"__data__": {"id_": "c0c7e112-344b-44b4-8169-c9434b44b451", "embedding": null, "metadata": {"window": "A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n", "original_text": "We are responsible for the freight from our distribution centers to our customers. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3547ee16-6280-4de1-9e4c-ad7e255d1e38", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well. ", "original_text": "Let me just get back to Lisa's question, just to finish that up. \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3195c693b50c87d75fc22209b73779847418a49a551280e41533394657d5cfe9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14b7114a-8a60-494a-a863-301ad2d560fd", "node_type": "1", "metadata": {"window": "Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year. ", "original_text": "To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight. "}, "hash": "aa6d41e57ac72d90b47c7e48fd17d22c4edf6e4412feb19bb49a66e558f8151c", "class_name": "RelatedNodeInfo"}}, "text": "We are responsible for the freight from our distribution centers to our customers. ", "start_char_idx": 1587, "end_char_idx": 1670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14b7114a-8a60-494a-a863-301ad2d560fd": {"__data__": {"id_": "14b7114a-8a60-494a-a863-301ad2d560fd", "embedding": null, "metadata": {"window": "Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year. ", "original_text": "To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0c7e112-344b-44b4-8169-c9434b44b451", "node_type": "1", "metadata": {"window": "A \nHey, Mike, t his is Britt.  Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n", "original_text": "We are responsible for the freight from our distribution centers to our customers. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4b34dc493a8cebebf220e3007ba584beaad07e2cc21a4693c0753723c8330d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15904a43-a154-4689-93b5-4e7aed277ab7", "node_type": "1", "metadata": {"window": "Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business. ", "original_text": "And we don't expect any of that in \nour guidance as well. "}, "hash": "700bcc87acfc581ef6e88fcd839ce33900ca08cb59843f2a38df50137627c0bc", "class_name": "RelatedNodeInfo"}}, "text": "To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight. ", "start_char_idx": 1670, "end_char_idx": 1785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15904a43-a154-4689-93b5-4e7aed277ab7": {"__data__": {"id_": "15904a43-a154-4689-93b5-4e7aed277ab7", "embedding": null, "metadata": {"window": "Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business. ", "original_text": "And we don't expect any of that in \nour guidance as well. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14b7114a-8a60-494a-a863-301ad2d560fd", "node_type": "1", "metadata": {"window": "Thanks for hanging in there.  Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year. ", "original_text": "To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "568679f385bebe4f70cf4d5c54674e0ab03f5678cb60d8064399e745a9bbecbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbcec476-023a-4c4c-8f7d-01fe344560b0", "node_type": "1", "metadata": {"window": "We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic. ", "original_text": "So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n"}, "hash": "68058e7d4b9ab44334d31259dc964c8839c0157ec7847ec2f01e66b968e0cd5d", "class_name": "RelatedNodeInfo"}}, "text": "And we don't expect any of that in \nour guidance as well. ", "start_char_idx": 1785, "end_char_idx": 1843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbcec476-023a-4c4c-8f7d-01fe344560b0": {"__data__": {"id_": "bbcec476-023a-4c4c-8f7d-01fe344560b0", "embedding": null, "metadata": {"window": "We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic. ", "original_text": "So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15904a43-a154-4689-93b5-4e7aed277ab7", "node_type": "1", "metadata": {"window": "Let me just get back to Lisa's question, just to finish that up. \n We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business. ", "original_text": "And we don't expect any of that in \nour guidance as well. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab16f313d2045476bdb24ad560fb8eee89662ac5506e6edecbf0e858cb1e1606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d90a6038-d1af-4b55-9f05-b67d578736a8", "node_type": "1", "metadata": {"window": "To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n", "original_text": "As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year. "}, "hash": "1ed5dca578da9ceb486e06a36befbfad7fe9a3ef6e252d9ea264e06b0463c36f", "class_name": "RelatedNodeInfo"}}, "text": "So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n", "start_char_idx": 1843, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d90a6038-d1af-4b55-9f05-b67d578736a8": {"__data__": {"id_": "d90a6038-d1af-4b55-9f05-b67d578736a8", "embedding": null, "metadata": {"window": "To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n", "original_text": "As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbcec476-023a-4c4c-8f7d-01fe344560b0", "node_type": "1", "metadata": {"window": "We are responsible for the freight from our distribution centers to our customers.  To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic. ", "original_text": "So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f63f71b30de0b3eb5f02a048d9f0562a5cc59bfb53b1ef9e2eb021ab107d570", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8354447e-fb36-45c7-878f-81dbd5b507f6", "node_type": "1", "metadata": {"window": "And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n", "original_text": "We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business. "}, "hash": "fe1f9e6badadcfdcd3953765d247d7f6cb49871e7ed89727f02095bb4f2787e1", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year. ", "start_char_idx": 2076, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8354447e-fb36-45c7-878f-81dbd5b507f6": {"__data__": {"id_": "8354447e-fb36-45c7-878f-81dbd5b507f6", "embedding": null, "metadata": {"window": "And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n", "original_text": "We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d90a6038-d1af-4b55-9f05-b67d578736a8", "node_type": "1", "metadata": {"window": "To this point this year, we have \nnot had an impact in our financi al statements as a result of increased freight.  And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n", "original_text": "As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e776a84fdef35c7f591e6115477b0b1e241c2ab3deb2bfc9289f5aa2836a82f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff57b910-6996-444e-a3a5-6bc63b17de75", "node_type": "1", "metadata": {"window": "So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far. ", "original_text": "I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic. "}, "hash": "750503c32453116d0d8751b2cd28850d75c98019710827186c7f79b4b063a0c6", "class_name": "RelatedNodeInfo"}}, "text": "We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business. ", "start_char_idx": 2399, "end_char_idx": 2512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff57b910-6996-444e-a3a5-6bc63b17de75": {"__data__": {"id_": "ff57b910-6996-444e-a3a5-6bc63b17de75", "embedding": null, "metadata": {"window": "So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far. ", "original_text": "I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8354447e-fb36-45c7-878f-81dbd5b507f6", "node_type": "1", "metadata": {"window": "And we don't expect any of that in \nour guidance as well.  So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n", "original_text": "We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7219deda062275a43a94e44d91146e38b6f9f7f5be6ac67a7f376b82e49f844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6fe5db1-da58-4446-9ec4-14a2eff0e1ff", "node_type": "1", "metadata": {"window": "As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well. ", "original_text": "So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n"}, "hash": "dbf4674b56ae4f34c07e1c04398d9597646bc90d3b82e96c912fa5d1d62d0166", "class_name": "RelatedNodeInfo"}}, "text": "I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic. ", "start_char_idx": 2512, "end_char_idx": 2681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6fe5db1-da58-4446-9ec4-14a2eff0e1ff": {"__data__": {"id_": "f6fe5db1-da58-4446-9ec4-14a2eff0e1ff", "embedding": null, "metadata": {"window": "As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well. ", "original_text": "So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff57b910-6996-444e-a3a5-6bc63b17de75", "node_type": "1", "metadata": {"window": "So, just to be clear on that, we did call out for you investments that we're making in labor in \nthe back half of the year so that we can ensure the hol iday season in the back half of the year for our customers \nhas continuity.  \n \n As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far. ", "original_text": "I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e209c6530eeee33acddd78381fd78ef7ea4b9cc5c479e1d55de2bbddf73b4b97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbab295e-7026-4626-945f-81d894b27b84", "node_type": "1", "metadata": {"window": "We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n ", "original_text": "So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n"}, "hash": "97018d4c381658209bb937194d9b9074b8da242beb96ac5be9c628b514076a89", "class_name": "RelatedNodeInfo"}}, "text": "So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n", "start_char_idx": 2681, "end_char_idx": 2830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbab295e-7026-4626-945f-81d894b27b84": {"__data__": {"id_": "cbab295e-7026-4626-945f-81d894b27b84", "embedding": null, "metadata": {"window": "We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n ", "original_text": "So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6fe5db1-da58-4446-9ec4-14a2eff0e1ff", "node_type": "1", "metadata": {"window": "As it relates to your question, Mike, what we've really tried to do here is to provide you some clarity on those items \nthat are related to our distribution of COVID vaccines and ancillary kits, as well as the increase that we've seen in \nCOVID test kits, which vary quite a bit from quarter to quarter over the last year.  We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well. ", "original_text": "So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10cc0293b21581ecd756300aa3c6f548d0a9f9e6cf4cecb87b7f9f83f169bf61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "941ad6c4-c790-4cc1-81ed-f6345a9021ff", "node_type": "1", "metadata": {"window": "I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We're very pleased with the performance that we've seen thus far. "}, "hash": "66650a3fd4dae5a723d55bd55aeadafe2cfd843bfeb58073782c334b49ca7517", "class_name": "RelatedNodeInfo"}}, "text": "So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n", "start_char_idx": 2830, "end_char_idx": 2945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "941ad6c4-c790-4cc1-81ed-f6345a9021ff": {"__data__": {"id_": "941ad6c4-c790-4cc1-81ed-f6345a9021ff", "embedding": null, "metadata": {"window": "I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We're very pleased with the performance that we've seen thus far. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbab295e-7026-4626-945f-81d894b27b84", "node_type": "1", "metadata": {"window": "We've tried to isolate those for \nyou so that you can have a good view into the operations of our core business.  I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n ", "original_text": "So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41a4db00636f2050dc100de58b97c67152e37b336f3782b508408f59f1ded7a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c72aa6-c431-4fee-a936-811ace44c272", "node_type": "1", "metadata": {"window": "So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation. ", "original_text": "Our core business has p erformed well. "}, "hash": "d9ee20655a6bf71fddf216aec13202f535c85de7697087b0405a901e9820207f", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased with the performance that we've seen thus far. ", "start_char_idx": 2945, "end_char_idx": 3011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c72aa6-c431-4fee-a936-811ace44c272": {"__data__": {"id_": "57c72aa6-c431-4fee-a936-811ace44c272", "embedding": null, "metadata": {"window": "So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation. ", "original_text": "Our core business has p erformed well. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "941ad6c4-c790-4cc1-81ed-f6345a9021ff", "node_type": "1", "metadata": {"window": "I  would remind you that the first \nquarter of this year was lapping a very low quarter from the prior year, which is really the first quarter post the \nCOVID pandemic.  So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We're very pleased with the performance that we've seen thus far. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2698858cb17a194e122e8ec625bcf5d88e5da85a4e3528d1ab1a5a14279f73c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc52265c-d898-4c2e-a2eb-3a170a858ce3", "node_type": "1", "metadata": {"window": "So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n", "original_text": "But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n "}, "hash": "88e1243f68c83ce3a238fb79bcc92f16119610f25a5bb088c7e88ecd77a087c6", "class_name": "RelatedNodeInfo"}}, "text": "Our core business has p erformed well. ", "start_char_idx": 3011, "end_char_idx": 3050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc52265c-d898-4c2e-a2eb-3a170a858ce3": {"__data__": {"id_": "bc52265c-d898-4c2e-a2eb-3a170a858ce3", "embedding": null, "metadata": {"window": "So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n", "original_text": "But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c72aa6-c431-4fee-a936-811ace44c272", "node_type": "1", "metadata": {"window": "So, the growth that you're seeing this year, while strong, includes the first quarter which  lapped \na very low quarter due to COVID in FY 2021.  \n \n So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation. ", "original_text": "Our core business has p erformed well. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01daa94bb77daa4112a1869c00c92dd84d0c06deafbc1fc95f360d18c16797f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb0f99dd-d15e-4e58-879d-6f51a039cb58", "node_type": "1", "metadata": {"window": "We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "33c18bc9f32298d755c4d1661cfe15006377b0976698f1ea0f74f6bd713a6248", "class_name": "RelatedNodeInfo"}}, "text": "But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n ", "start_char_idx": 3050, "end_char_idx": 3168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb0f99dd-d15e-4e58-879d-6f51a039cb58": {"__data__": {"id_": "eb0f99dd-d15e-4e58-879d-6f51a039cb58", "embedding": null, "metadata": {"window": "We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc52265c-d898-4c2e-a2eb-3a170a858ce3", "node_type": "1", "metadata": {"window": "So, we'll provide more detail for you on sort of the core components of each of the segments at our Investor Day. \n We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n", "original_text": "But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee727e5c1042783df61e28a52fc3d09b047999726c3596385b2cf2db985575b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b1b575c-2ea4-41d4-aa7c-55827417ac04", "node_type": "1", "metadata": {"window": "Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n ", "original_text": "A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation. "}, "hash": "226b8144d3102d876361e6f06c1ce7177e78a7dd2917fd41915e091b5b8d167d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3168, "end_char_idx": 3497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b1b575c-2ea4-41d4-aa7c-55827417ac04": {"__data__": {"id_": "5b1b575c-2ea4-41d4-aa7c-55827417ac04", "embedding": null, "metadata": {"window": "Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n ", "original_text": "A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb0f99dd-d15e-4e58-879d-6f51a039cb58", "node_type": "1", "metadata": {"window": "We're very pleased with the performance that we've seen thus far.  Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1f8f6cdca0d7c90b5035e704acd0180a579210f1edc1a96312c7f07a132cba7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88a527da-f3a8-451d-9a94-8169a8899258", "node_type": "1", "metadata": {"window": "But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n"}, "hash": "6632a7e1cd16261dd0197695ffe41842b82e82128279a08e612c4d3412d1372f", "class_name": "RelatedNodeInfo"}}, "text": "A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation. ", "start_char_idx": 3497, "end_char_idx": 3594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88a527da-f3a8-451d-9a94-8169a8899258": {"__data__": {"id_": "88a527da-f3a8-451d-9a94-8169a8899258", "embedding": null, "metadata": {"window": "But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b1b575c-2ea4-41d4-aa7c-55827417ac04", "node_type": "1", "metadata": {"window": "Our core business has p erformed well.  But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n ", "original_text": "A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41384dcc3a7ce0c8be6aff7dc061f689c716a7b088baeb33af22ac7db972ec56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdcdd3f9-aef8-4e2e-8199-704754ee0f36", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "It's obviously been quite dynamic over the past months. "}, "hash": "f11b5e26452eb1d4a62cb54e8d7cc1b88781176866a64ddde0cb074f37d5d730", "class_name": "RelatedNodeInfo"}}, "text": "We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n", "start_char_idx": 3594, "end_char_idx": 3733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdcdd3f9-aef8-4e2e-8199-704754ee0f36": {"__data__": {"id_": "fdcdd3f9-aef8-4e2e-8199-704754ee0f36", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "It's obviously been quite dynamic over the past months. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88a527da-f3a8-451d-9a94-8169a8899258", "node_type": "1", "metadata": {"window": "But \nagain, I just would remind you that in addition to that, we did have that low quarter lap in Q1 of last year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff3de1f49789fc3d60ac0d9c7395df167122115b37b2eeae84394ff97ba631ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c31a1fa-e80e-4a77-9ca0-6d3aa6cf5d89", "node_type": "1", "metadata": {"window": "A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n ", "original_text": "We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n "}, "hash": "096e4351bd4e96289e2a146cf6a78fd5a46a78205cd0c6a4032c746257af13d6", "class_name": "RelatedNodeInfo"}}, "text": "It's obviously been quite dynamic over the past months. ", "start_char_idx": 3733, "end_char_idx": 3789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c31a1fa-e80e-4a77-9ca0-6d3aa6cf5d89": {"__data__": {"id_": "4c31a1fa-e80e-4a77-9ca0-6d3aa6cf5d89", "embedding": null, "metadata": {"window": "A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n ", "original_text": "We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdcdd3f9-aef8-4e2e-8199-704754ee0f36", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "It's obviously been quite dynamic over the past months. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdaecab1de12f45d0b69c0142aa7c1aef933a1ff39ee9ca966e3897563b7c5a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c318ab98-2199-4a52-a3d2-4668f8efbaa0", "node_type": "1", "metadata": {"window": "We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  "}, "hash": "88064561c80005e6075e6ce03e375eb3e8b4e9fccea70d0515628be8d2332695", "class_name": "RelatedNodeInfo"}}, "text": "We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n ", "start_char_idx": 3789, "end_char_idx": 3909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c318ab98-2199-4a52-a3d2-4668f8efbaa0": {"__data__": {"id_": "c318ab98-2199-4a52-a3d2-4668f8efbaa0", "embedding": null, "metadata": {"window": "We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c31a1fa-e80e-4a77-9ca0-6d3aa6cf5d89", "node_type": "1", "metadata": {"window": "A \n[indiscernible] (41:22) question, Michael, was just a bout the vaccine and kitting operation.  We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n ", "original_text": "We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce544f3459bc1be9cc3f8f505cd6bbf98af31b5b6db657c144e240ba78f59512", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18f85ee5-ed99-4b9e-a371-cf3ef504226f", "node_type": "1", "metadata": {"window": "It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "A \nNext question, please.  \n "}, "hash": "b0780f507ef0a779aa7403f2a05ffb259ec5a7804892a3bd7813fb248399e9c3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "start_char_idx": 3909, "end_char_idx": 4238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18f85ee5-ed99-4b9e-a371-cf3ef504226f": {"__data__": {"id_": "18f85ee5-ed99-4b9e-a371-cf3ef504226f", "embedding": null, "metadata": {"window": "It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "A \nNext question, please.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c318ab98-2199-4a52-a3d2-4668f8efbaa0", "node_type": "1", "metadata": {"window": "We continue to run that \noperation at the direction of the CDC in accordance with the schedules, production schedules, that they give us. \n It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e78f792845fbbd1d5c37630b046e719bba7225e6d5ab8a907e2b8c6574e050f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1ad15be-b8fa-4b5a-9572-a44988f523be", "node_type": "1", "metadata": {"window": "We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n "}, "hash": "6b241e29d48da964f38bb28a697f788736bdfe55fd84cb2f5ee668f7f778e848", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 4238, "end_char_idx": 4267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1ad15be-b8fa-4b5a-9572-a44988f523be": {"__data__": {"id_": "c1ad15be-b8fa-4b5a-9572-a44988f523be", "embedding": null, "metadata": {"window": "We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18f85ee5-ed99-4b9e-a371-cf3ef504226f", "node_type": "1", "metadata": {"window": "It's obviously been quite dynamic over the past months.  We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "A \nNext question, please.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3409ef15c9a36a78bb0376e6fb09d2514946881e581836b06445070e1e2e5a3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd53171e-dd58-46ae-ac00-0366b2b83f8f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "f1caa77c92c6a25651bbf5e5253df2edc3700f14f5fa5ac6310578af66692db0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n ", "start_char_idx": 4267, "end_char_idx": 4600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd53171e-dd58-46ae-ac00-0366b2b83f8f": {"__data__": {"id_": "dd53171e-dd58-46ae-ac00-0366b2b83f8f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1ad15be-b8fa-4b5a-9572-a44988f523be", "node_type": "1", "metadata": {"window": "We are prepared and we' ll continue to run that operation \nas long as the CDC sees value in it and asks us to do it.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d599d776cc7f267bb2d66f5d3e3fb91fab846767a4851ae67f3d22cf52a5c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c54b2e3e-2f0b-47af-9dce-52d0d7297433", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "LLC  Q "}, "hash": "5956788bf01e506be3b771649fddb6b998f238ff21d8a74f3aba9b0792bcc6e1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 4600, "end_char_idx": 4894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c54b2e3e-2f0b-47af-9dce-52d0d7297433": {"__data__": {"id_": "c54b2e3e-2f0b-47af-9dce-52d0d7297433", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "LLC  Q ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73d644b9-ab65-40f0-a3eb-32ca012da062", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b69eb2d96c2d9260fb3d44f69efa690f877d544dbf4a7b444846ae049d9ad01c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd53171e-dd58-46ae-ac00-0366b2b83f8f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfdfd8e5f19489993af5f109a0d7c1e4207f7fdbb8b1fb491d786757e537171f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7b22f6a-549f-4e81-b972-a2f0b05a3b53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n", "original_text": "McKesson Corp.  "}, "hash": "24c53dc696c465d9d4d3feb11d430a9f91e9c86e01cb0bea0d6d9dae2dc62f53", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q ", "start_char_idx": 4894, "end_char_idx": 4901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7b22f6a-549f-4e81-b972-a2f0b05a3b53": {"__data__": {"id_": "e7b22f6a-549f-4e81-b972-a2f0b05a3b53", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c54b2e3e-2f0b-47af-9dce-52d0d7297433", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We'll take our next question from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q ", "original_text": "LLC  Q ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76ab14342810ba1292de3bed39e6c6ce56b641ee8ae5ad034dc0b5d742b1ce90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ade4db9-fa61-47bd-99f5-b74e7872b40f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah. "}, "hash": "a09e62a0c4391bb6bae6191b0cbda4ee7f9fe3fbe72f274cc3f2b57b0645467c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ade4db9-fa61-47bd-99f5-b74e7872b40f": {"__data__": {"id_": "4ade4db9-fa61-47bd-99f5-b74e7872b40f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7b22f6a-549f-4e81-b972-a2f0b05a3b53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ad34250c834dd9dcfeab08a902bfb3cea03855f5f41fd1a11bd26b81b8f315a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c156ffaa-0604-4a9f-b3e7-e9aad995c0dc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook. ", "original_text": "Thanks for taking the question. "}, "hash": "280a4661976f63ed6e64e7c8857784b9dca16ebbd679dab9887750baea09be28", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah. ", "start_char_idx": 16, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c156ffaa-0604-4a9f-b3e7-e9aad995c0dc": {"__data__": {"id_": "c156ffaa-0604-4a9f-b3e7-e9aad995c0dc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook. ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ade4db9-fa61-47bd-99f5-b74e7872b40f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb4af841ba8e1f9779676e1174dfa9d611070f7bf7e10f72c17912d2c53194c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe13713-13d7-4d89-9f98-8f8f30837df3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here? ", "original_text": "Wanted to ask a little bit about Prescription Technology Solutions. \n"}, "hash": "7368e93466fa5d90b037dcac9d49feeeae87bc1d09907f7d35827e5bc8e41118", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 187, "end_char_idx": 219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebe13713-13d7-4d89-9f98-8f8f30837df3": {"__data__": {"id_": "ebe13713-13d7-4d89-9f98-8f8f30837df3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here? ", "original_text": "Wanted to ask a little bit about Prescription Technology Solutions. \n", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c156ffaa-0604-4a9f-b3e7-e9aad995c0dc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook. ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb4d74afebf8b107809fdb5a0b476b71b74514425012294017847d017b0c043d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4267b03b-1710-41ef-8c44-0aaff4270ada", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization. ", "original_text": "Obviously, very strong growth here in the quarter. "}, "hash": "b9329cf80eeac89c782cff7e8362f7c6cb1391b326c6554033a3b06dc203a616", "class_name": "RelatedNodeInfo"}}, "text": "Wanted to ask a little bit about Prescription Technology Solutions. \n", "start_char_idx": 219, "end_char_idx": 288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4267b03b-1710-41ef-8c44-0aaff4270ada": {"__data__": {"id_": "4267b03b-1710-41ef-8c44-0aaff4270ada", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization. ", "original_text": "Obviously, very strong growth here in the quarter. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebe13713-13d7-4d89-9f98-8f8f30837df3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here? ", "original_text": "Wanted to ask a little bit about Prescription Technology Solutions. \n", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a8a9663359e7a4480153a0b2bfb25b232b14ea2faee7fe4dc3b668a59053823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66c679c9-97de-45c5-966f-9ce52aad61ef", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period. ", "original_text": "And you raised for the full year outlook. "}, "hash": "e674bf76a7bf5ad8dea2c79706d9ebf3ca7cbcf68cdf00229a9287cfef70b91a", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, very strong growth here in the quarter. ", "start_char_idx": 288, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66c679c9-97de-45c5-966f-9ce52aad61ef": {"__data__": {"id_": "66c679c9-97de-45c5-966f-9ce52aad61ef", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period. ", "original_text": "And you raised for the full year outlook. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4267b03b-1710-41ef-8c44-0aaff4270ada", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization. ", "original_text": "Obviously, very strong growth here in the quarter. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e9078222522604af804b75c256e36a41c49a52879144446c84e68feef02d91e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c376c9c4-377f-4f69-a3c8-ecdd488f49e7", "node_type": "1", "metadata": {"window": "Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services? ", "original_text": "When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here? "}, "hash": "1b3028cbdd0c853c5d02edec4f35cb990eaece55bbf42102ec3c067bffb14e16", "class_name": "RelatedNodeInfo"}}, "text": "And you raised for the full year outlook. ", "start_char_idx": 339, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c376c9c4-377f-4f69-a3c8-ecdd488f49e7": {"__data__": {"id_": "c376c9c4-377f-4f69-a3c8-ecdd488f49e7", "embedding": null, "metadata": {"window": "Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services? ", "original_text": "When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66c679c9-97de-45c5-966f-9ce52aad61ef", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period. ", "original_text": "And you raised for the full year outlook. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b54541777772bd182ba43ebefb4e7db9834a4c37b5f41a97485130fc82c8730a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db5bc63-c5bd-46fc-a486-f9d057583043", "node_type": "1", "metadata": {"window": "Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels? ", "original_text": "Obviously, some of it is tied to prescription \nutilization. "}, "hash": "61a0eb8c3199263b6627ae5896086ced41d1b21cde54f9c2b2515332b9f1555b", "class_name": "RelatedNodeInfo"}}, "text": "When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here? ", "start_char_idx": 381, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db5bc63-c5bd-46fc-a486-f9d057583043": {"__data__": {"id_": "9db5bc63-c5bd-46fc-a486-f9d057583043", "embedding": null, "metadata": {"window": "Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels? ", "original_text": "Obviously, some of it is tied to prescription \nutilization. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c376c9c4-377f-4f69-a3c8-ecdd488f49e7", "node_type": "1", "metadata": {"window": "Wanted to ask a little bit about Prescription Technology Solutions. \n Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services? ", "original_text": "When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78d7a468223b959c86f9612ccda6e2a8fddc9574770d569eacf7c359634de4b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1169e45a-5534-484a-a82e-e7e3c009820f", "node_type": "1", "metadata": {"window": "And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And  I know that we are still kind of coming out of the COVID period. "}, "hash": "07b9aae9fafd90e7d82857b047d3c6365f17e7659f10c0f6097f54175f970bf5", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, some of it is tied to prescription \nutilization. ", "start_char_idx": 584, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1169e45a-5534-484a-a82e-e7e3c009820f": {"__data__": {"id_": "1169e45a-5534-484a-a82e-e7e3c009820f", "embedding": null, "metadata": {"window": "And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And  I know that we are still kind of coming out of the COVID period. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db5bc63-c5bd-46fc-a486-f9d057583043", "node_type": "1", "metadata": {"window": "Obviously, very strong growth here in the quarter.  And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels? ", "original_text": "Obviously, some of it is tied to prescription \nutilization. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bd31bf48e9bb2b60d76d19ced05f9164eba6291b532cc93aee9729cc3e6cdb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0014ac81-1a7e-4abc-999d-402f8489780e", "node_type": "1", "metadata": {"window": "When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question. ", "original_text": "But maybe any comments around \ngrowth among some of these various services? "}, "hash": "d5d1cb93952c49ba3842615fa79395437ca8df1d60d83053f5a958d7fd66a6fe", "class_name": "RelatedNodeInfo"}}, "text": "And  I know that we are still kind of coming out of the COVID period. ", "start_char_idx": 644, "end_char_idx": 714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0014ac81-1a7e-4abc-999d-402f8489780e": {"__data__": {"id_": "0014ac81-1a7e-4abc-999d-402f8489780e", "embedding": null, "metadata": {"window": "When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question. ", "original_text": "But maybe any comments around \ngrowth among some of these various services? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1169e45a-5534-484a-a82e-e7e3c009820f", "node_type": "1", "metadata": {"window": "And you raised for the full year outlook.  When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And  I know that we are still kind of coming out of the COVID period. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "409838182dd57639f09059a542ccb5bea5f70b780fdb730211704a0cf7f0db43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74754e23-5613-42ea-b6c6-e9057138a62c", "node_type": "1", "metadata": {"window": "Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market. ", "original_text": "And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels? "}, "hash": "c86d56e051f7286019ef7ebe29c68d216ed42156cf6477b7a4b6e1ecc3351366", "class_name": "RelatedNodeInfo"}}, "text": "But maybe any comments around \ngrowth among some of these various services? ", "start_char_idx": 714, "end_char_idx": 790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74754e23-5613-42ea-b6c6-e9057138a62c": {"__data__": {"id_": "74754e23-5613-42ea-b6c6-e9057138a62c", "embedding": null, "metadata": {"window": "Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market. ", "original_text": "And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0014ac81-1a7e-4abc-999d-402f8489780e", "node_type": "1", "metadata": {"window": "When w e look at sort of \nthe like slide 4 and you talk about the various services within in this for biopharma services, can you kind of \nhighlight which of the ones are really driving the growth here?  Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question. ", "original_text": "But maybe any comments around \ngrowth among some of these various services? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe29d1135a8bd2323ad06c8bab6b557674adc3606b551a9469f0ff0fcbcbdd91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f36a3f80-8b73-4ff8-9465-8fa8f7b3d6c1", "node_type": "1", "metadata": {"window": "And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings. ", "original_text": "Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "a13a5a28650af500bec5f2298b00b7251830c723e56dde7ae23756636253ea6e", "class_name": "RelatedNodeInfo"}}, "text": "And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels? ", "start_char_idx": 790, "end_char_idx": 901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f36a3f80-8b73-4ff8-9465-8fa8f7b3d6c1": {"__data__": {"id_": "f36a3f80-8b73-4ff8-9465-8fa8f7b3d6c1", "embedding": null, "metadata": {"window": "And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings. ", "original_text": "Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74754e23-5613-42ea-b6c6-e9057138a62c", "node_type": "1", "metadata": {"window": "Obviously, some of it is tied to prescription \nutilization.  And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market. ", "original_text": "And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ffbee5b23d84cb61937c2bd676ab6a875bed6fc08dfd6e42d722215898f4602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4e5a7be-947e-4b3a-bcd0-32e23919d9ed", "node_type": "1", "metadata": {"window": "But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio. ", "original_text": "A \nThank you for the question. "}, "hash": "c900c69c5ee99d3af94e4676f0c204abc817f3095569a0ebf40395e4a0384660", "class_name": "RelatedNodeInfo"}}, "text": "Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 901, "end_char_idx": 1240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4e5a7be-947e-4b3a-bcd0-32e23919d9ed": {"__data__": {"id_": "c4e5a7be-947e-4b3a-bcd0-32e23919d9ed", "embedding": null, "metadata": {"window": "But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio. ", "original_text": "A \nThank you for the question. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f36a3f80-8b73-4ff8-9465-8fa8f7b3d6c1", "node_type": "1", "metadata": {"window": "And  I know that we are still kind of coming out of the COVID period.  But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings. ", "original_text": "Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8beab9a16a9c8312e7bc6acdd9253dcc2fbacd9b2deba95b0f9e410cab8a4b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e56e160-2839-4ad2-9632-1c6c6122c7fe", "node_type": "1", "metadata": {"window": "And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes. ", "original_text": "Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market. "}, "hash": "facde9401fbe9f2d0fbf8ef09cf49f3d925a28f9bda5d5318a7459fcda5489ac", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you for the question. ", "start_char_idx": 1240, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e56e160-2839-4ad2-9632-1c6c6122c7fe": {"__data__": {"id_": "5e56e160-2839-4ad2-9632-1c6c6122c7fe", "embedding": null, "metadata": {"window": "And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes. ", "original_text": "Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4e5a7be-947e-4b3a-bcd0-32e23919d9ed", "node_type": "1", "metadata": {"window": "But maybe any comments around \ngrowth among some of these various services?  And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio. ", "original_text": "A \nThank you for the question. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5acfbe90c419ed7618dd1aea169d765028190326b07e8276f46e405e81e81ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec9850dd-3f4a-4f16-a73d-44e83bcac825", "node_type": "1", "metadata": {"window": "Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers. ", "original_text": "We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings. "}, "hash": "ebb9495ef12ba1a5bb5254c6723ceb89edfde06f8ba0daa055c703f2eee8eb23", "class_name": "RelatedNodeInfo"}}, "text": "Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market. ", "start_char_idx": 1271, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec9850dd-3f4a-4f16-a73d-44e83bcac825": {"__data__": {"id_": "ec9850dd-3f4a-4f16-a73d-44e83bcac825", "embedding": null, "metadata": {"window": "Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers. ", "original_text": "We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e56e160-2839-4ad2-9632-1c6c6122c7fe", "node_type": "1", "metadata": {"window": "And I guess, just a sense on which ones will benefit as we \ncontinue to kind of recover from the COVID levels?  Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes. ", "original_text": "Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "458e5e18bc2e9f0787627d05095ad6d2db2cdadb740ba6804dc676d16ff44284", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4328413d-b581-43fd-84cc-3cca48892fda", "node_type": "1", "metadata": {"window": "A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that. ", "original_text": "We do see good underlying growth across the portfolio. "}, "hash": "ebb0d8654263859bb24fb3fbf398eb8476209bc2844cafb05ee8bc99bc8358c5", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings. ", "start_char_idx": 1399, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4328413d-b581-43fd-84cc-3cca48892fda": {"__data__": {"id_": "4328413d-b581-43fd-84cc-3cca48892fda", "embedding": null, "metadata": {"window": "A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that. ", "original_text": "We do see good underlying growth across the portfolio. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec9850dd-3f4a-4f16-a73d-44e83bcac825", "node_type": "1", "metadata": {"window": "Thank s \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers. ", "original_text": "We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6957dfcb387cc77523cc2531860d5ce2c14172e004befa3317e03a9b4c26145f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e25fba5-9220-4b7e-bc69-f9858c07c916", "node_type": "1", "metadata": {"window": "Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n ", "original_text": "Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes. "}, "hash": "085403b79cdf5c31827e6195d9257584e96917f92e9dae63339d6ed65cc1938d", "class_name": "RelatedNodeInfo"}}, "text": "We do see good underlying growth across the portfolio. ", "start_char_idx": 1507, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e25fba5-9220-4b7e-bc69-f9858c07c916": {"__data__": {"id_": "6e25fba5-9220-4b7e-bc69-f9858c07c916", "embedding": null, "metadata": {"window": "Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n ", "original_text": "Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4328413d-b581-43fd-84cc-3cca48892fda", "node_type": "1", "metadata": {"window": "A \nThank you for the question.  Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that. ", "original_text": "We do see good underlying growth across the portfolio. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e667523f36826ab3cf80ec362862573c98e8886fc57260eb5086b9bec190a8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44bdf80f-88db-4e8d-b01b-6f74ce9f25a4", "node_type": "1", "metadata": {"window": "We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers. "}, "hash": "d746553e35c88bfe1e8ef1627a329cd4ed2ec7bc36ce55358dbcc9a5d6ab1aac", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes. ", "start_char_idx": 1562, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44bdf80f-88db-4e8d-b01b-6f74ce9f25a4": {"__data__": {"id_": "44bdf80f-88db-4e8d-b01b-6f74ce9f25a4", "embedding": null, "metadata": {"window": "We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e25fba5-9220-4b7e-bc69-f9858c07c916", "node_type": "1", "metadata": {"window": "Look, we continue \u2013 this business is responsive to absolute levels of activity relative \nto prescription volumes in the market.  We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n ", "original_text": "Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "291f6757c948e9584326edad0abf1b48af544d457ae1a3ea27f3ede6c887191c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd7ee590-160e-4ce2-969b-c6ffbcc73aba", "node_type": "1", "metadata": {"window": "We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay. ", "original_text": "So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that. "}, "hash": "a49b63019f202cb070b2d150b0443a6c5180d33acd5b1471ac986e11308970d7", "class_name": "RelatedNodeInfo"}}, "text": "And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers. ", "start_char_idx": 1645, "end_char_idx": 1892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd7ee590-160e-4ce2-969b-c6ffbcc73aba": {"__data__": {"id_": "cd7ee590-160e-4ce2-969b-c6ffbcc73aba", "embedding": null, "metadata": {"window": "We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay. ", "original_text": "So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44bdf80f-88db-4e8d-b01b-6f74ce9f25a4", "node_type": "1", "metadata": {"window": "We continue to see benefi ts from the prior investments we've made in \nthese technology services offerings.  We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91aa72ca4c978420097a05fccc6d51b77dec9ea44cede4be4978a5004467a3cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a2600d5-3198-4183-a23c-c6250be92254", "node_type": "1", "metadata": {"window": "Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n ", "original_text": "We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n "}, "hash": "c00de9f9deaca23b08b63a9c88d3be550f4b5a5b75c59c1ae1fe2999e4c54316", "class_name": "RelatedNodeInfo"}}, "text": "So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that. ", "start_char_idx": 1892, "end_char_idx": 2097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a2600d5-3198-4183-a23c-c6250be92254": {"__data__": {"id_": "1a2600d5-3198-4183-a23c-c6250be92254", "embedding": null, "metadata": {"window": "Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n ", "original_text": "We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd7ee590-160e-4ce2-969b-c6ffbcc73aba", "node_type": "1", "metadata": {"window": "We do see good underlying growth across the portfolio.  Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay. ", "original_text": "So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "351a4bb487e52420e19b641e8436f266e2284d0b6d2298c93c3d683a7596e972", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45cea5c3-46b6-4c17-94b7-9ae6451a71af", "node_type": "1", "metadata": {"window": "And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  "}, "hash": "4b7bc93d257820b242b6bcd825729bde418877c83ece9129507f32b9e13dc77b", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n ", "start_char_idx": 2097, "end_char_idx": 2344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45cea5c3-46b6-4c17-94b7-9ae6451a71af": {"__data__": {"id_": "45cea5c3-46b6-4c17-94b7-9ae6451a71af", "embedding": null, "metadata": {"window": "And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a2600d5-3198-4183-a23c-c6250be92254", "node_type": "1", "metadata": {"window": "Clearly, we've \nbenefited from the recovery in COVID -19-related pandemic volumes.  And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n ", "original_text": "We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63582999b2d868de93d14f8d6d3541ea09ab9e0270533727765eb21551c15b9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02c45896-dd82-4bee-936b-00fcda9aa2c1", "node_type": "1", "metadata": {"window": "So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n ", "original_text": "A \nOkay. "}, "hash": "efe8a780d58e59ae06e045378bad48b02002c9b3733787b7386078c670b976d1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "start_char_idx": 2344, "end_char_idx": 2673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02c45896-dd82-4bee-936b-00fcda9aa2c1": {"__data__": {"id_": "02c45896-dd82-4bee-936b-00fcda9aa2c1", "embedding": null, "metadata": {"window": "So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n ", "original_text": "A \nOkay. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45cea5c3-46b6-4c17-94b7-9ae6451a71af", "node_type": "1", "metadata": {"window": "And honestly, some of the policy decisi ons \npayers would have made around the way they manage prior authorization, we're really seeing that market kind of \nreturn to pre -COVID level kinds of conditions and requirements coming out of the payers.  So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2bd7708ca0c9f6ed9fea3f5fcc0f39d36bf8985ffe53d941eef1308c5150657e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1671da03-5e9c-4eb9-96a2-7bf41a701708", "node_type": "1", "metadata": {"window": "We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "Next question, please.  \n "}, "hash": "360510292557ef679b42fe7fce3cc71748ed9c6d11d922e46e760973a5a76b5d", "class_name": "RelatedNodeInfo"}}, "text": "A \nOkay. ", "start_char_idx": 2673, "end_char_idx": 2682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1671da03-5e9c-4eb9-96a2-7bf41a701708": {"__data__": {"id_": "1671da03-5e9c-4eb9-96a2-7bf41a701708", "embedding": null, "metadata": {"window": "We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "Next question, please.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02c45896-dd82-4bee-936b-00fcda9aa2c1", "node_type": "1", "metadata": {"window": "So, we believe, as \npatients continue to start on new  prescriptions, this business is well -positioned to support the access and \nadherence to those medications, and we will continue to invest from that.  We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n ", "original_text": "A \nOkay. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6060c04776acead768ca29bae19e4a85db449657c4d76183d8b8d3f7726ef03c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1331b53-6bfc-4430-9feb-5290f44c65e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "9ecd858051a488bf51d67bcacce651d887889e2fcba18803274c480d73842c73", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n ", "start_char_idx": 2682, "end_char_idx": 2708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1331b53-6bfc-4430-9feb-5290f44c65e5": {"__data__": {"id_": "f1331b53-6bfc-4430-9feb-5290f44c65e5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1671da03-5e9c-4eb9-96a2-7bf41a701708", "node_type": "1", "metadata": {"window": "We are seeing returns on some of the \ninvestments we highlighted for you in previous calls in things like AM P. And there are components of this \nbusiness that we haven't talked much about like 3PL, and we saw strong 3PL growth in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "Next question, please.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e27d4678597526d73c9fb1afbfd75b5115959cf93911a478a16513da4389457", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0eb2f52-d934-4f01-aa56-7730fe244f3e", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer. ", "original_text": "We'll take our next question from Kevin Caliendo with UBS.  \n "}, "hash": "cf4931d9f025614f6bb40d8c826be49f4deb6747e3c3dda606bc752839996573", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 2708, "end_char_idx": 2989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0eb2f52-d934-4f01-aa56-7730fe244f3e": {"__data__": {"id_": "a0eb2f52-d934-4f01-aa56-7730fe244f3e", "embedding": null, "metadata": {"window": "A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer. ", "original_text": "We'll take our next question from Kevin Caliendo with UBS.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1331b53-6bfc-4430-9feb-5290f44c65e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa12515e1ec41b08bec07de25998dcd1075b1223716c24953bdf4b3bf88f9c2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "010147e2-5fa8-471d-9c45-df2ac371fa71", "node_type": "1", "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. "}, "hash": "0fe8e98d819ce9d1826e5f0f49c5c83f3b715c6604d65aedf0160a9241619345", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Kevin Caliendo with UBS.  \n ", "start_char_idx": 2989, "end_char_idx": 3051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "010147e2-5fa8-471d-9c45-df2ac371fa71": {"__data__": {"id_": "010147e2-5fa8-471d-9c45-df2ac371fa71", "embedding": null, "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0eb2f52-d934-4f01-aa56-7730fe244f3e", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer. ", "original_text": "We'll take our next question from Kevin Caliendo with UBS.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b843a554da8ae94ccdd8ec20691cf624cb6358aac58da16782671eb52e3b915", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bde223f6-d6ec-455d-b01d-e722be4df210", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there? ", "original_text": "Thanks for taking my call. "}, "hash": "e90f8191a37199c68c7560b91255d3b15cc8b60e79656e480862f1d1d45b1a89", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "start_char_idx": 3051, "end_char_idx": 3361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bde223f6-d6ec-455d-b01d-e722be4df210": {"__data__": {"id_": "bde223f6-d6ec-455d-b01d-e722be4df210", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there? ", "original_text": "Thanks for taking my call. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "010147e2-5fa8-471d-9c45-df2ac371fa71", "node_type": "1", "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75f0f30e15cc6fdf904e7270f9a21821db2b2fabbb28dcbe368e25b447d86efb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82920ffe-39e9-4744-be50-33af84fc9831", "node_type": "1", "metadata": {"window": "We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all. ", "original_text": "So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer. "}, "hash": "656bea68ac929ebd39bc0e29c5edca992b03bdde0b223b5c65d6ec1e7c447722", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my call. ", "start_char_idx": 3361, "end_char_idx": 3388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82920ffe-39e9-4744-be50-33af84fc9831": {"__data__": {"id_": "82920ffe-39e9-4744-be50-33af84fc9831", "embedding": null, "metadata": {"window": "We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all. ", "original_text": "So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bde223f6-d6ec-455d-b01d-e722be4df210", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there? ", "original_text": "Thanks for taking my call. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15535a80c4524a842949d1aaf39cea26be92a57f2c2d09d932b92e02b30ac88b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4d5696a-35fa-4d8f-a37b-572a50a7f34b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n ", "original_text": "It's now 3% to 6% versus 5% to 8% at the end of 1Q. "}, "hash": "fb0cc0090138aa381431f446830248680ae3ce02da5ad3b117e9342ef3a30fcb", "class_name": "RelatedNodeInfo"}}, "text": "So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer. ", "start_char_idx": 3388, "end_char_idx": 3509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4d5696a-35fa-4d8f-a37b-572a50a7f34b": {"__data__": {"id_": "f4d5696a-35fa-4d8f-a37b-572a50a7f34b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n ", "original_text": "It's now 3% to 6% versus 5% to 8% at the end of 1Q. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82920ffe-39e9-4744-be50-33af84fc9831", "node_type": "1", "metadata": {"window": "We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all. ", "original_text": "So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fddaebb4750ce33eeba035f4b4c013bddaf6b680ee9612151c05ebf09c9f402d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b23fc13a-2aa0-48df-b098-afec98581e39", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you just walk us \nthrough what the delta \u2013 what's changed there? "}, "hash": "03607b0c4b5c6dfbf4ad390c541b37b1cbfd0de3afb4e82f68edfe4f5362d84b", "class_name": "RelatedNodeInfo"}}, "text": "It's now 3% to 6% versus 5% to 8% at the end of 1Q. ", "start_char_idx": 3509, "end_char_idx": 3561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b23fc13a-2aa0-48df-b098-afec98581e39": {"__data__": {"id_": "b23fc13a-2aa0-48df-b098-afec98581e39", "embedding": null, "metadata": {"window": "Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you just walk us \nthrough what the delta \u2013 what's changed there? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4d5696a-35fa-4d8f-a37b-572a50a7f34b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n ", "original_text": "It's now 3% to 6% versus 5% to 8% at the end of 1Q. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a177474eedd84f8511f531533d208fc4e58bb57094a2ab511cb60d6ae78a528b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "915991c5-266b-453d-9354-a5d990b7e828", "node_type": "1", "metadata": {"window": "So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "I know part of it is probably labor, but doesn't explain it all. "}, "hash": "1831bb53d1c15ee991caedb5bb7720466073e1ffdce9814ee309f7230cfef964", "class_name": "RelatedNodeInfo"}}, "text": "Can you just walk us \nthrough what the delta \u2013 what's changed there? ", "start_char_idx": 3561, "end_char_idx": 3630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "915991c5-266b-453d-9354-a5d990b7e828": {"__data__": {"id_": "915991c5-266b-453d-9354-a5d990b7e828", "embedding": null, "metadata": {"window": "So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "I know part of it is probably labor, but doesn't explain it all. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b23fc13a-2aa0-48df-b098-afec98581e39", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you just walk us \nthrough what the delta \u2013 what's changed there? ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86bbc13316b698cfada271bdd9fb102f85379f70daff6f5ca132ad3cc5daa9ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3e550a9-bc75-4fef-a2ed-264e388dbef2", "node_type": "1", "metadata": {"window": "It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin. ", "original_text": "And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n "}, "hash": "8f3a8ba7ff2b4355cc25cbe79d0ed43910b6e775ffce412be166bcf959d17b6a", "class_name": "RelatedNodeInfo"}}, "text": "I know part of it is probably labor, but doesn't explain it all. ", "start_char_idx": 3630, "end_char_idx": 3695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3e550a9-bc75-4fef-a2ed-264e388dbef2": {"__data__": {"id_": "f3e550a9-bc75-4fef-a2ed-264e388dbef2", "embedding": null, "metadata": {"window": "It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin. ", "original_text": "And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "915991c5-266b-453d-9354-a5d990b7e828", "node_type": "1", "metadata": {"window": "So, I was wondering, it looks like in the slide presentation, the non -COVID pharma \ngrowth estimate is slightly lo wer.  It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "I know part of it is probably labor, but doesn't explain it all. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c544bcc584702015fa6de15ff75ca83f5d3b9506418e1b2d1eb086b5f18cb8d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1109a807-48fc-42c1-aba0-08d375980876", "node_type": "1", "metadata": {"window": "Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "c901c66e58ee45a17cdaf655ff68ed86ac16feabe6f01473e4365d38090eb1b9", "class_name": "RelatedNodeInfo"}}, "text": "And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n ", "start_char_idx": 3695, "end_char_idx": 3814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1109a807-48fc-42c1-aba0-08d375980876": {"__data__": {"id_": "1109a807-48fc-42c1-aba0-08d375980876", "embedding": null, "metadata": {"window": "Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3e550a9-bc75-4fef-a2ed-264e388dbef2", "node_type": "1", "metadata": {"window": "It's now 3% to 6% versus 5% to 8% at the end of 1Q.  Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin. ", "original_text": "And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6e43b834ca9d1f95572c3039a3f26d5c7741c6850b4d441c137a100d014c61b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "852449ff-104b-42dc-b751-4949f1ffe1cb", "node_type": "1", "metadata": {"window": "I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment. ", "original_text": "A \nYeah. "}, "hash": "4a03ef8e46b7919aa6eb3713d6bf99db8c7f62783309e5beb74e9c1247245b56", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3814, "end_char_idx": 4156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "852449ff-104b-42dc-b751-4949f1ffe1cb": {"__data__": {"id_": "852449ff-104b-42dc-b751-4949f1ffe1cb", "embedding": null, "metadata": {"window": "I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment. ", "original_text": "A \nYeah. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1109a807-48fc-42c1-aba0-08d375980876", "node_type": "1", "metadata": {"window": "Can you just walk us \nthrough what the delta \u2013 what's changed there?  I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a392891dd785584817273ef0232dfc786389f402cb569bc7acd962cb80b9d743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a70d03f-03a7-4e43-91c9-3bcb7b8b4da0", "node_type": "1", "metadata": {"window": "And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good. ", "original_text": "Thanks for that question, Kevin. "}, "hash": "8119c914b6e13d242b71eebfb10ce04e02108c76c1839affe05065113abc2797", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 4156, "end_char_idx": 4165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a70d03f-03a7-4e43-91c9-3bcb7b8b4da0": {"__data__": {"id_": "8a70d03f-03a7-4e43-91c9-3bcb7b8b4da0", "embedding": null, "metadata": {"window": "And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good. ", "original_text": "Thanks for that question, Kevin. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "852449ff-104b-42dc-b751-4949f1ffe1cb", "node_type": "1", "metadata": {"window": "I know part of it is probably labor, but doesn't explain it all.  And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment. ", "original_text": "A \nYeah. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63d82d789d2066ec37c0ee9f10b3e0c3076bdfb4b4377a8fa3c8c6f492e01973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cca8f2b-ee36-465a-bd1e-bf8714b24373", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments. ", "original_text": "Let me just maybe point out a couple of things. "}, "hash": "a4e70e844325f6a31fcdaaffd260edb470457dd42e60980f5390e9584870f5c6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question, Kevin. ", "start_char_idx": 4165, "end_char_idx": 4198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cca8f2b-ee36-465a-bd1e-bf8714b24373": {"__data__": {"id_": "0cca8f2b-ee36-465a-bd1e-bf8714b24373", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments. ", "original_text": "Let me just maybe point out a couple of things. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a70d03f-03a7-4e43-91c9-3bcb7b8b4da0", "node_type": "1", "metadata": {"window": "And \nthen maybe do the same for Med -Surg which is also now higher t han what you saw or expected at the end of 1Q.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good. ", "original_text": "Thanks for that question, Kevin. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b483741057f5cf21a19d1af88ffe1eb598b6e492f6a96af12a5be848e9b5311d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44aaa3b0-6e61-442e-8047-7478174a901b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n", "original_text": "First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment. "}, "hash": "50e82a1fe886a34c40b0cf26bf0ec495e74394eaa073b7b6904bcf9ac0fb54e3", "class_name": "RelatedNodeInfo"}}, "text": "Let me just maybe point out a couple of things. ", "start_char_idx": 4198, "end_char_idx": 4246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44aaa3b0-6e61-442e-8047-7478174a901b": {"__data__": {"id_": "44aaa3b0-6e61-442e-8047-7478174a901b", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n", "original_text": "First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cca8f2b-ee36-465a-bd1e-bf8714b24373", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments. ", "original_text": "Let me just maybe point out a couple of things. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "084056e3cf567537d5695bb08342d0760cb12ea71093d38c2858cf45238a73f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6a6e2e7-757c-440f-b533-e1372e47f108", "node_type": "1", "metadata": {"window": "Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses. ", "original_text": "The momentum there is really good. "}, "hash": "7f5c8e52270bb1295347123a105e4ae066f310d589633e9d6dfb29ff21a702e0", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment. ", "start_char_idx": 4246, "end_char_idx": 4340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6a6e2e7-757c-440f-b533-e1372e47f108": {"__data__": {"id_": "a6a6e2e7-757c-440f-b533-e1372e47f108", "embedding": null, "metadata": {"window": "Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses. ", "original_text": "The momentum there is really good. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44aaa3b0-6e61-442e-8047-7478174a901b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n", "original_text": "First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ffe27e7b1e3d74662583afed714604fafaecd8ebcbd693633816cb203848454", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3c7c1fc-0a6f-4496-a240-ad6e398e031c", "node_type": "1", "metadata": {"window": "Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n", "original_text": "There's \na couple of things that we called out for you, or I called out for you in my opening comments. "}, "hash": "e3ac514a3363ba23a64262c06f78e9084d7445c848525d1ddb5faa8c79406a2f", "class_name": "RelatedNodeInfo"}}, "text": "The momentum there is really good. ", "start_char_idx": 4340, "end_char_idx": 4375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3c7c1fc-0a6f-4496-a240-ad6e398e031c": {"__data__": {"id_": "e3c7c1fc-0a6f-4496-a240-ad6e398e031c", "embedding": null, "metadata": {"window": "Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n", "original_text": "There's \na couple of things that we called out for you, or I called out for you in my opening comments. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6a6e2e7-757c-440f-b533-e1372e47f108", "node_type": "1", "metadata": {"window": "Thanks for that question, Kevin.  Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses. ", "original_text": "The momentum there is really good. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "830a54374a74e55f5a935b9d581e2267a7a00260959e8af8a6113dc43d1c1947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b710299-d879-43fe-a0b6-5ea809d42fd7", "node_type": "1", "metadata": {"window": "First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n"}, "hash": "52eaf061b37019c68bfb831cf74858f8c34d54a125e09371f40d4d265f4544e8", "class_name": "RelatedNodeInfo"}}, "text": "There's \na couple of things that we called out for you, or I called out for you in my opening comments. ", "start_char_idx": 4375, "end_char_idx": 4479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b710299-d879-43fe-a0b6-5ea809d42fd7": {"__data__": {"id_": "7b710299-d879-43fe-a0b6-5ea809d42fd7", "embedding": null, "metadata": {"window": "First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3c7c1fc-0a6f-4496-a240-ad6e398e031c", "node_type": "1", "metadata": {"window": "Let me just maybe point out a couple of things.  First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n", "original_text": "There's \na couple of things that we called out for you, or I called out for you in my opening comments. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d6c26ce5ef373c40407c5d062b93fd2889dbbc67db2983dbf222502cc83d0eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5207d818-56c9-4db6-aaea-92fc40e8d30f", "node_type": "1", "metadata": {"window": "The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses. "}, "hash": "5c423ce51e6597c07a650955e94797c4a085eb7f7552ecdc70bcd49a85bb1ab6", "class_name": "RelatedNodeInfo"}}, "text": "First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n", "start_char_idx": 4479, "end_char_idx": 4636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5207d818-56c9-4db6-aaea-92fc40e8d30f": {"__data__": {"id_": "5207d818-56c9-4db6-aaea-92fc40e8d30f", "embedding": null, "metadata": {"window": "The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b710299-d879-43fe-a0b6-5ea809d42fd7", "node_type": "1", "metadata": {"window": "First of all, we're pleased \nwith the continued performance of our US Pharmaceutical segment.  The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66944d58eff717e0e9336e09399a2cb7eb284bee824610810d6ec8bb58826e25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da6dab38-8cab-4716-a554-0a948077bc6c", "node_type": "1", "metadata": {"window": "There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "Those two things really ha d an impact on the growth of US Pharma.  \n \n"}, "hash": "a4f99441f7b2aeea6b30d93b0c90539bcbce38e6584cc8dc8ddca5de2c1e7472", "class_name": "RelatedNodeInfo"}}, "text": "And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses. ", "start_char_idx": 4636, "end_char_idx": 4775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da6dab38-8cab-4716-a554-0a948077bc6c": {"__data__": {"id_": "da6dab38-8cab-4716-a554-0a948077bc6c", "embedding": null, "metadata": {"window": "There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "Those two things really ha d an impact on the growth of US Pharma.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5207d818-56c9-4db6-aaea-92fc40e8d30f", "node_type": "1", "metadata": {"window": "The momentum there is really good.  There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses. ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "837aee27f2dcf3c57e4b77b10239e4b855c3438a7dca1d4c53cf80f4c82e2a89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a48c6ed9-3d41-4adc-9ba4-9b0d6d656cb2", "node_type": "1", "metadata": {"window": "First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns "}, "hash": "1aaa9cd4b3847abcfb13b57269f2bd17aa97ae6839fbbfa646624efb5b3bc5ec", "class_name": "RelatedNodeInfo"}}, "text": "Those two things really ha d an impact on the growth of US Pharma.  \n \n", "start_char_idx": 4775, "end_char_idx": 4846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a48c6ed9-3d41-4adc-9ba4-9b0d6d656cb2": {"__data__": {"id_": "a48c6ed9-3d41-4adc-9ba4-9b0d6d656cb2", "embedding": null, "metadata": {"window": "First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0e2e448-9843-40c6-9444-18e505a2516c", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b96c7d8ff859355c819626ae9df4179df28e0b9bf4ad11b7a4570e7aa6ea33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da6dab38-8cab-4716-a554-0a948077bc6c", "node_type": "1", "metadata": {"window": "There's \na couple of things that we called out for you, or I called out for you in my opening comments.  First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "Those two things really ha d an impact on the growth of US Pharma.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54991d374004cf9ccfe9cc7834dfd6aa325de2f837bb64e050f8c43c1ca26299", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6d2400d-2379-41cb-a3e6-2b7b85066cab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n ", "original_text": "McKesson Corp.  "}, "hash": "fc8ffa912ee44dd570e38b248e25bb71acbc2538ae18e55abc43e55310d03fa8", "class_name": "RelatedNodeInfo"}}, "text": "And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "start_char_idx": 4846, "end_char_idx": 5066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6d2400d-2379-41cb-a3e6-2b7b85066cab": {"__data__": {"id_": "b6d2400d-2379-41cb-a3e6-2b7b85066cab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a48c6ed9-3d41-4adc-9ba4-9b0d6d656cb2", "node_type": "1", "metadata": {"window": "First of all, the \ninvestments that we're continuing to mak e in our oncology business, and Ontada called that out as a $0.20 \nheadwind year -over-year.  \n \n And then as I also talked about and you referenced, the labor investments that we made into our business, our \nUS distribution businesses.  Those two things really ha d an impact on the growth of US Pharma.  \n \n And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "original_text": "And in our Medical business, we're really pleased with not only the performance against the US government \nprogram and the increase in COVID test kitting, which is really reflective of the strength of our lab solutio ns ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85197bbc3b1ae73a4982b79c45ffea35ebf904a9d6ea5f02c8957a2dc418b1b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c2a316c-8c35-4b7d-8c2b-e4bb10ec415f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out. "}, "hash": "abacc1d8b5229a532f09df7a8089b19400d0fe6d4a823069c40603c0592f6729", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c2a316c-8c35-4b7d-8c2b-e4bb10ec415f": {"__data__": {"id_": "9c2a316c-8c35-4b7d-8c2b-e4bb10ec415f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6d2400d-2379-41cb-a3e6-2b7b85066cab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a99aeac2a085ed955692a27159e38961b2addf446196a4d368b286154c9b29b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc028ad8-9fd3-4cc3-a003-41bece537121", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So, both businesses continue to have good \nmomentum.  \n \n"}, "hash": "351f0df6d34bf0051f57dfb502a9b9f0625db35ca1322b6fb454bd41cfe57a25", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out. ", "start_char_idx": 16, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc028ad8-9fd3-4cc3-a003-41bece537121": {"__data__": {"id_": "fc028ad8-9fd3-4cc3-a003-41bece537121", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So, both businesses continue to have good \nmomentum.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c2a316c-8c35-4b7d-8c2b-e4bb10ec415f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49828e8e658badaae9f715b037fc7f4032dc4bb19e46915397a90c073bb4782b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a21b02a4-ef94-42c9-8ea5-eb50cb606e38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n "}, "hash": "08d7dc2f22e7e3594050c0fe97f82951d0d0983c15030a413f2c9b9df7af01da", "class_name": "RelatedNodeInfo"}}, "text": "So, both businesses continue to have good \nmomentum.  \n \n", "start_char_idx": 365, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a21b02a4-ef94-42c9-8ea5-eb50cb606e38": {"__data__": {"id_": "a21b02a4-ef94-42c9-8ea5-eb50cb606e38", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc028ad8-9fd3-4cc3-a003-41bece537121", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "So, both businesses continue to have good \nmomentum.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd2d5133ac08b19cafa4778fd3a38c261df118ed99b50d4339dc9e161a5c9907", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cb07ea0-9417-475c-a8ed-b3faff72bd17", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  "}, "hash": "02d53f1626ecce66125186ff7442a4f33fbd89694dbf241e13e8551dac6eb25e", "class_name": "RelatedNodeInfo"}}, "text": "In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n ", "start_char_idx": 422, "end_char_idx": 728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cb07ea0-9417-475c-a8ed-b3faff72bd17": {"__data__": {"id_": "1cb07ea0-9417-475c-a8ed-b3faff72bd17", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a21b02a4-ef94-42c9-8ea5-eb50cb606e38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "754b4ba85d1b0c13c0ebbef946d575940482710b70e78805a44ed9140da68a05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70d4d3ee-065b-4b7a-9eb0-321b34784dcb", "node_type": "1", "metadata": {"window": "So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please.  \n "}, "hash": "1c834de257f916e3eb06cdd1091e23ad7a282b58737b489f5eac7b35cbff7063", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "start_char_idx": 728, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70d4d3ee-065b-4b7a-9eb0-321b34784dcb": {"__data__": {"id_": "70d4d3ee-065b-4b7a-9eb0-321b34784dcb", "embedding": null, "metadata": {"window": "So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cb07ea0-9417-475c-a8ed-b3faff72bd17", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38f538f38656fc3be739256bcef86313dade193294b871a61f5d964e3280f040", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2acf0f6-d791-4a10-9b1a-300804e039e4", "node_type": "1", "metadata": {"window": "In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "39fd7a76e93d06ce2851008155385a2795b7bb788d61d40f5b795be96bde9555", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 1057, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2acf0f6-d791-4a10-9b1a-300804e039e4": {"__data__": {"id_": "e2acf0f6-d791-4a10-9b1a-300804e039e4", "embedding": null, "metadata": {"window": "In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70d4d3ee-065b-4b7a-9eb0-321b34784dcb", "node_type": "1", "metadata": {"window": "So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f372eb61a572455f1a3d6786342a35a7dcc366b9f77b91db610d36b97cb59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d5a0114-15c4-42a7-ac21-c9ce7e0e3757", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases. ", "original_text": "Eric Percher with Nephron Research.  \n "}, "hash": "3863d0c020ad91aeae96edfb4cdb3eb5e93c0d90117ce2fad9d988b035607bf7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 1086, "end_char_idx": 1367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d5a0114-15c4-42a7-ac21-c9ce7e0e3757": {"__data__": {"id_": "1d5a0114-15c4-42a7-ac21-c9ce7e0e3757", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases. ", "original_text": "Eric Percher with Nephron Research.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2acf0f6-d791-4a10-9b1a-300804e039e4", "node_type": "1", "metadata": {"window": "In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1357f4f52d375957ff7645439db727d667c85bb351409cb99d5eac9eccc78879", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "409be16d-a4b8-497f-8a73-a903afcc3736", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "e7c3a4c93cd40c540e34bb8b2623f56159de86dd9f66ecbb0d9a323b17ec9a07", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher with Nephron Research.  \n ", "start_char_idx": 1367, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "409be16d-a4b8-497f-8a73-a903afcc3736": {"__data__": {"id_": "409be16d-a4b8-497f-8a73-a903afcc3736", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d5a0114-15c4-42a7-ac21-c9ce7e0e3757", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases. ", "original_text": "Eric Percher with Nephron Research.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1614a7d7624f66b2f715235cb176f6e85ac28f837970c2a477cff4b1dad11351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36ac1dd7-ded7-4401-bbd3-c6b8474195a6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "A question on the brand marketplace or maybe brand pricing in particular. "}, "hash": "c4190f2b072559b894461176420134ebcae5e5968e6faef79f02a38afcfcb9d2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 1406, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36ac1dd7-ded7-4401-bbd3-c6b8474195a6": {"__data__": {"id_": "36ac1dd7-ded7-4401-bbd3-c6b8474195a6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "A question on the brand marketplace or maybe brand pricing in particular. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "409be16d-a4b8-497f-8a73-a903afcc3736", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a62b74eda5d2b6b8c07e200fd8c543a10701bb5239be42742e4a64daf5574b57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2faa0771-3c50-4b89-a6c0-66c7150aa5e2", "node_type": "1", "metadata": {"window": "Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases. "}, "hash": "3bfa6b177f10cdd526e3730e9798cfcbc44ed743e7aa9381a6703df52b8e2da6", "class_name": "RelatedNodeInfo"}}, "text": "A question on the brand marketplace or maybe brand pricing in particular. ", "start_char_idx": 1723, "end_char_idx": 1797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2faa0771-3c50-4b89-a6c0-66c7150aa5e2": {"__data__": {"id_": "2faa0771-3c50-4b89-a6c0-66c7150aa5e2", "embedding": null, "metadata": {"window": "Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36ac1dd7-ded7-4401-bbd3-c6b8474195a6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "A question on the brand marketplace or maybe brand pricing in particular. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa3ecb8f40a455aea3b0092fbfacf029cda1e118df912fd1573ae51eac443f2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f2d2a74-5a16-4095-a2c5-f242e3d09c06", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece. ", "original_text": "Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n "}, "hash": "d185d8e77a45a1debdc5c0a2f0b0eca16e3c59cfa74a33e6500697885fdf9890", "class_name": "RelatedNodeInfo"}}, "text": "I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases. ", "start_char_idx": 1797, "end_char_idx": 1910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f2d2a74-5a16-4095-a2c5-f242e3d09c06": {"__data__": {"id_": "1f2d2a74-5a16-4095-a2c5-f242e3d09c06", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece. ", "original_text": "Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2faa0771-3c50-4b89-a6c0-66c7150aa5e2", "node_type": "1", "metadata": {"window": "Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35606e62cff1db11b92d15ef07d20a40425b5cc6d1b41af79d4a4b7c649b93f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad32f58b-706a-461a-9853-34a86030ea4d", "node_type": "1", "metadata": {"window": "A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "566628dbf558c692cdc1505a31520d5652941cca8809a7fc1abfbf9277ce856f", "class_name": "RelatedNodeInfo"}}, "text": "Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n ", "start_char_idx": 1910, "end_char_idx": 2138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad32f58b-706a-461a-9853-34a86030ea4d": {"__data__": {"id_": "ad32f58b-706a-461a-9853-34a86030ea4d", "embedding": null, "metadata": {"window": "A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f2d2a74-5a16-4095-a2c5-f242e3d09c06", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece. ", "original_text": "Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96c1da5589519e4c66f721af70d7fea75fec17ebbf7833f23f507716f9db7750", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c9436c4-39fa-4039-9e1c-1055270f09ba", "node_type": "1", "metadata": {"window": "I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have. ", "original_text": "A \nThanks for the question, Eric. "}, "hash": "0f0f3f39a61197e612ada8f1deae6aed4cc4d4cfd89b7e46f820070ce2536f56", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2138, "end_char_idx": 2480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c9436c4-39fa-4039-9e1c-1055270f09ba": {"__data__": {"id_": "9c9436c4-39fa-4039-9e1c-1055270f09ba", "embedding": null, "metadata": {"window": "I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad32f58b-706a-461a-9853-34a86030ea4d", "node_type": "1", "metadata": {"window": "A question on the brand marketplace or maybe brand pricing in particular.  I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5436dac247da993f030cf5309fe5d72b94b32175a6d29d969f3902d3078e288", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d140e15a-374a-4ab2-b715-785cbc0d9ff0", "node_type": "1", "metadata": {"window": "Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past. ", "original_text": "Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece. "}, "hash": "2b0aa173036f06ecd1f7812b400331718afadea868bfb4d3814c92baa62c92fe", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Eric. ", "start_char_idx": 2480, "end_char_idx": 2514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d140e15a-374a-4ab2-b715-785cbc0d9ff0": {"__data__": {"id_": "d140e15a-374a-4ab2-b715-785cbc0d9ff0", "embedding": null, "metadata": {"window": "Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past. ", "original_text": "Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c9436c4-39fa-4039-9e1c-1055270f09ba", "node_type": "1", "metadata": {"window": "I think you've made it pretty \nclear that the book is no longer tied in a material way to brand price increases.  Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "384c98e97473eca62cfc14517740d8af294dbfceb4d137e72429361237e5b967", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ffea2b7-c0ce-4ea1-9130-62932e17d028", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years. ", "original_text": "You're right. "}, "hash": "51344d53e590a31a9cb87b44ece45207421645cd628732c24f0e13733830efbe", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece. ", "start_char_idx": 2514, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ffea2b7-c0ce-4ea1-9130-62932e17d028": {"__data__": {"id_": "4ffea2b7-c0ce-4ea1-9130-62932e17d028", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years. ", "original_text": "You're right. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d140e15a-374a-4ab2-b715-785cbc0d9ff0", "node_type": "1", "metadata": {"window": "Given the reimbursement and \npolicy debate going on, can you remind us what your view  is of what could happen if we saw a change in list \nprices, particularly a downward change and how you may or may not be exposed to that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past. ", "original_text": "Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17dc64118c7cf916ac24023c54bf4a8cc99a87131877808714a5d3a63580d524", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e19ddc6-4ac2-4195-97c0-fdc587b464d6", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n ", "original_text": "We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have. "}, "hash": "16189f987c4cfb43465478a8e3fe80baaf10011e89f0738b8f631c0984c09c83", "class_name": "RelatedNodeInfo"}}, "text": "You're right. ", "start_char_idx": 2622, "end_char_idx": 2636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e19ddc6-4ac2-4195-97c0-fdc587b464d6": {"__data__": {"id_": "7e19ddc6-4ac2-4195-97c0-fdc587b464d6", "embedding": null, "metadata": {"window": "A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n ", "original_text": "We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ffea2b7-c0ce-4ea1-9130-62932e17d028", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years. ", "original_text": "You're right. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70cc54fa39f1e77537977e94913e67738e2bdff04fcbb10e98935a1446b3bca6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "395d81a8-55f0-4a10-9533-2ba7fc234f25", "node_type": "1", "metadata": {"window": "Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And it is less \u2013 the brand inflation is less impactful than it has been in the past. "}, "hash": "7a4886398476460849f08550fc825161c6a5f7eee75f3d6b2d204109341fbd9b", "class_name": "RelatedNodeInfo"}}, "text": "We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have. ", "start_char_idx": 2636, "end_char_idx": 2851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "395d81a8-55f0-4a10-9533-2ba7fc234f25": {"__data__": {"id_": "395d81a8-55f0-4a10-9533-2ba7fc234f25", "embedding": null, "metadata": {"window": "Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And it is less \u2013 the brand inflation is less impactful than it has been in the past. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e19ddc6-4ac2-4195-97c0-fdc587b464d6", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n ", "original_text": "We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d76d4a016b7a33b727431492b6c11fe17e4bf41b17f321bcd57aed14f31c0316", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4928f669-3824-4413-8eeb-165c3998f740", "node_type": "1", "metadata": {"window": "You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "We've \ntalked about that a lot over the last few years. "}, "hash": "8dc1246323bed08bd949d8d2ca728b359058965a53430857acc64ac20176de09", "class_name": "RelatedNodeInfo"}}, "text": "And it is less \u2013 the brand inflation is less impactful than it has been in the past. ", "start_char_idx": 2851, "end_char_idx": 2936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4928f669-3824-4413-8eeb-165c3998f740": {"__data__": {"id_": "4928f669-3824-4413-8eeb-165c3998f740", "embedding": null, "metadata": {"window": "You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "We've \ntalked about that a lot over the last few years. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "395d81a8-55f0-4a10-9533-2ba7fc234f25", "node_type": "1", "metadata": {"window": "Maybe I'll start and take the first part of that question and Brian can maybe respond \nto the policy piece.  You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And it is less \u2013 the brand inflation is less impactful than it has been in the past. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1621b63424b2e5ada5c56c0685a836a75ae82985249a17f0df87e81db0b52bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aa839f8-7e29-4d6f-b523-39f386b16f20", "node_type": "1", "metadata": {"window": "We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on. ", "original_text": "As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n "}, "hash": "1d163886bf90d20313f66ae8a0a155071ceacf227c59c028fa929da5d67b94ff", "class_name": "RelatedNodeInfo"}}, "text": "We've \ntalked about that a lot over the last few years. ", "start_char_idx": 2936, "end_char_idx": 2992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aa839f8-7e29-4d6f-b523-39f386b16f20": {"__data__": {"id_": "0aa839f8-7e29-4d6f-b523-39f386b16f20", "embedding": null, "metadata": {"window": "We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on. ", "original_text": "As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4928f669-3824-4413-8eeb-165c3998f740", "node_type": "1", "metadata": {"window": "You're right.  We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "We've \ntalked about that a lot over the last few years. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3574257b8ed65367ce647702b939421237d09c17266bcdc6d11716bd8f966277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbddeb51-4d56-4ebe-964a-724fcb239ada", "node_type": "1", "metadata": {"window": "And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "a323e0c35f78220d5192cbdf417d65f37d8c4c10b2651a5ee76decb7da20fa59", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n ", "start_char_idx": 2992, "end_char_idx": 3082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbddeb51-4d56-4ebe-964a-724fcb239ada": {"__data__": {"id_": "dbddeb51-4d56-4ebe-964a-724fcb239ada", "embedding": null, "metadata": {"window": "And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aa839f8-7e29-4d6f-b523-39f386b16f20", "node_type": "1", "metadata": {"window": "We've continued to evolve our business over really the last several years in terms \nof tying the services that we provide to our custome rs and for our manufacturers to the pricing and the \nagreements that we have.  And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on. ", "original_text": "As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7df31f84156701ffc33d7a70c657b5c0ba3877f72b4d5e0a710d38334d0e8607", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56a0ca6d-8fbe-4bf2-9fc4-1f49a4b85d4e", "node_type": "1", "metadata": {"window": "We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n", "original_text": "A \nYeah. "}, "hash": "f3248904a6e7ab8a053e3d263e03fbe1a619e5f92753834d30df5752f4bf5a35", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3082, "end_char_idx": 3411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56a0ca6d-8fbe-4bf2-9fc4-1f49a4b85d4e": {"__data__": {"id_": "56a0ca6d-8fbe-4bf2-9fc4-1f49a4b85d4e", "embedding": null, "metadata": {"window": "We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbddeb51-4d56-4ebe-964a-724fcb239ada", "node_type": "1", "metadata": {"window": "And it is less \u2013 the brand inflation is less impactful than it has been in the past.  We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0be2e9b268b3faee733585d0ec46936905a1520b67cd38b488a364a16beafd8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca4a7261-4efc-45d6-b876-a4cc76025959", "node_type": "1", "metadata": {"window": "As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed. ", "original_text": "Just to build on that comment before we move on. "}, "hash": "89dda9aa1da6ca47384acabb95a0a96a643bc483c4b5fd651f279bfa5dd87cda", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3411, "end_char_idx": 3420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca4a7261-4efc-45d6-b876-a4cc76025959": {"__data__": {"id_": "ca4a7261-4efc-45d6-b876-a4cc76025959", "embedding": null, "metadata": {"window": "As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed. ", "original_text": "Just to build on that comment before we move on. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56a0ca6d-8fbe-4bf2-9fc4-1f49a4b85d4e", "node_type": "1", "metadata": {"window": "We've \ntalked about that a lot over the last few years.  As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76bb644d14cd7cb7e0c31ab362ee8745eb7b47d7e96e2a9705d483d3c63f91b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcf840d6-b1c0-4908-b507-39761d494d4b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities. ", "original_text": "I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n"}, "hash": "7b3b6afb0764ef27ef2a3b970d2b8c80026d4c0514820c6abaef16db8d2a96fa", "class_name": "RelatedNodeInfo"}}, "text": "Just to build on that comment before we move on. ", "start_char_idx": 3420, "end_char_idx": 3469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcf840d6-b1c0-4908-b507-39761d494d4b": {"__data__": {"id_": "bcf840d6-b1c0-4908-b507-39761d494d4b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities. ", "original_text": "I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca4a7261-4efc-45d6-b876-a4cc76025959", "node_type": "1", "metadata": {"window": "As it relates to really the policy piec e, Brian, I'll maybe let you talk \nabout that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed. ", "original_text": "Just to build on that comment before we move on. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cb60e071cab71deebd396da544eff0d8670f1987ae5c7850484c3c5d718ac87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "702c4a2f-a561-4983-8f49-d6a402d1fb51", "node_type": "1", "metadata": {"window": "A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n", "original_text": "And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n"}, "hash": "e02c87b05b058b0ff7320b7b1ed004857817ca33a87cd345b8f2529882c04a0c", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n", "start_char_idx": 3469, "end_char_idx": 3638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "702c4a2f-a561-4983-8f49-d6a402d1fb51": {"__data__": {"id_": "702c4a2f-a561-4983-8f49-d6a402d1fb51", "embedding": null, "metadata": {"window": "A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n", "original_text": "And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcf840d6-b1c0-4908-b507-39761d494d4b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities. ", "original_text": "I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65074631d9115c2404b1888067606186b908fd3b0bce15e3f9e078a7c285f5b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ce35227-1ba2-4563-90d4-79d4aaf1e010", "node_type": "1", "metadata": {"window": "Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community. ", "original_text": "As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed. "}, "hash": "5cc58b493e4352a2af2224b50ad95216145e068fec645748a82a5aa17c06a0b2", "class_name": "RelatedNodeInfo"}}, "text": "And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n", "start_char_idx": 3638, "end_char_idx": 3784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ce35227-1ba2-4563-90d4-79d4aaf1e010": {"__data__": {"id_": "8ce35227-1ba2-4563-90d4-79d4aaf1e010", "embedding": null, "metadata": {"window": "Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community. ", "original_text": "As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "702c4a2f-a561-4983-8f49-d6a402d1fb51", "node_type": "1", "metadata": {"window": "A \nYeah.  Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n", "original_text": "And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c645d3eba1c31c65a700c440ec49699dc8fa578b326b14e6bd0b2cfb2b27994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9b51701-9342-4601-b3f0-7b7be34c17d0", "node_type": "1", "metadata": {"window": "I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n", "original_text": "I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities. "}, "hash": "3958ad25e7d6b0295026f7e6455a182f909091098becc75c3f7627af5d07e8f9", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed. ", "start_char_idx": 3784, "end_char_idx": 3970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9b51701-9342-4601-b3f0-7b7be34c17d0": {"__data__": {"id_": "e9b51701-9342-4601-b3f0-7b7be34c17d0", "embedding": null, "metadata": {"window": "I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n", "original_text": "I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ce35227-1ba2-4563-90d4-79d4aaf1e010", "node_type": "1", "metadata": {"window": "Just to build on that comment before we move on.  I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community. ", "original_text": "As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9633ab647db2827a8d3d0cbceae80bda3402dd643fe4658fde66e5e6024a3e3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0451e4b-0da5-48cb-83f4-ac659828760f", "node_type": "1", "metadata": {"window": "And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care. ", "original_text": "We track these discussions very carefully.  \n \n"}, "hash": "9e9a315c248894bef64a70f2e8828a0a5305ca286161a35753c0d1065a653f95", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities. ", "start_char_idx": 3970, "end_char_idx": 4085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0451e4b-0da5-48cb-83f4-ac659828760f": {"__data__": {"id_": "e0451e4b-0da5-48cb-83f4-ac659828760f", "embedding": null, "metadata": {"window": "And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care. ", "original_text": "We track these discussions very carefully.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9b51701-9342-4601-b3f0-7b7be34c17d0", "node_type": "1", "metadata": {"window": "I mean, I think one of the tenets we've always held \nthrough multiple changes in d ynamics in the industry over my career here is that our services provide real value. \n And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n", "original_text": "I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d939256bdd68f42506acd8c25215798b1230003590d64c26f669a61717808c83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e15d76e-a96c-434a-b368-f5ee094bc09c", "node_type": "1", "metadata": {"window": "As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We're always advocating for the role of care being provided in the community. "}, "hash": "707f452dccf6549a1ede2d2050c1a944000285a5488e6b40bf6e5f8c0192eec1", "class_name": "RelatedNodeInfo"}}, "text": "We track these discussions very carefully.  \n \n", "start_char_idx": 4085, "end_char_idx": 4132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e15d76e-a96c-434a-b368-f5ee094bc09c": {"__data__": {"id_": "9e15d76e-a96c-434a-b368-f5ee094bc09c", "embedding": null, "metadata": {"window": "As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We're always advocating for the role of care being provided in the community. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0451e4b-0da5-48cb-83f4-ac659828760f", "node_type": "1", "metadata": {"window": "And regardless of what sorts of mechanisms get changed in the marketplace, we will continue to be paid fair \nmarket value for those services.  \n \n As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care. ", "original_text": "We track these discussions very carefully.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e095760a8b54807ee5cce049a36b1721b8346d6acb2532b23a50bcd82d5f91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03a9d7c5-37e1-4893-90e3-bb8f34a9d9b0", "node_type": "1", "metadata": {"window": "I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n"}, "hash": "1d4fcc0bf79ab686072508a6306b91b6b4c2b39a17f0ee4105f21284cbdd2672", "class_name": "RelatedNodeInfo"}}, "text": "We're always advocating for the role of care being provided in the community. ", "start_char_idx": 4132, "end_char_idx": 4210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03a9d7c5-37e1-4893-90e3-bb8f34a9d9b0": {"__data__": {"id_": "03a9d7c5-37e1-4893-90e3-bb8f34a9d9b0", "embedding": null, "metadata": {"window": "I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e15d76e-a96c-434a-b368-f5ee094bc09c", "node_type": "1", "metadata": {"window": "As it relates to the public policy debate, and it's as dynamic now as ever, I suppose, I think the main issues that \nwe're discussing are issues that, frankly, have been long discussed.  I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We're always advocating for the role of care being provided in the community. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28c56203b6b69373a61964894a05bfc26e00bcc9579adf45c08e48122e8b4d1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a2fc72f-3569-4da4-b5b0-faf3e833bfab", "node_type": "1", "metadata": {"window": "We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care. "}, "hash": "484c883b1ad7ed3700b764749dde0eb6e0b3bf942f3b6c67376aa80873efba3d", "class_name": "RelatedNodeInfo"}}, "text": "We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n", "start_char_idx": 4210, "end_char_idx": 4398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a2fc72f-3569-4da4-b5b0-faf3e833bfab": {"__data__": {"id_": "8a2fc72f-3569-4da4-b5b0-faf3e833bfab", "embedding": null, "metadata": {"window": "We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03a9d7c5-37e1-4893-90e3-bb8f34a9d9b0", "node_type": "1", "metadata": {"window": "I mean, we are active at the company with \nelected officials on both sides of the aisle on key polic y priorities.  We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ea901651544ce28c744fdbd5e0d425530b4620f87c4851e28e178517272ef7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c371fd8-a786-42e1-822b-dd622babd975", "node_type": "1", "metadata": {"window": "We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We've had robust participation in the oncology ca re model that's delivered "}, "hash": "30e190cf9529870653525edf55091aa31cfa370cd035a516ee7e96c2ffa2dbec", "class_name": "RelatedNodeInfo"}}, "text": "We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care. ", "start_char_idx": 4398, "end_char_idx": 4545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c371fd8-a786-42e1-822b-dd622babd975": {"__data__": {"id_": "8c371fd8-a786-42e1-822b-dd622babd975", "embedding": null, "metadata": {"window": "We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We've had robust participation in the oncology ca re model that's delivered ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "476c2dac235efe59e64ecc9dd4a2badd0da99e98d3c2e2b08b61af21169fa566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a2fc72f-3569-4da4-b5b0-faf3e833bfab", "node_type": "1", "metadata": {"window": "We track these discussions very carefully.  \n \n We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care. ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1308e33edee45e9f9b409849eb6437901d91e33b0b68fc01d4777ff45159c832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86b5f846-937b-4a81-8167-177111e34949", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets. ", "original_text": "McKesson Corp.  "}, "hash": "1e26e0c008ed5a15935a8d77b04ce2359c266a6d94f4177969b58de6a915fea1", "class_name": "RelatedNodeInfo"}}, "text": "We've had robust participation in the oncology ca re model that's delivered ", "start_char_idx": 4545, "end_char_idx": 4621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86b5f846-937b-4a81-8167-177111e34949": {"__data__": {"id_": "86b5f846-937b-4a81-8167-177111e34949", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c371fd8-a786-42e1-822b-dd622babd975", "node_type": "1", "metadata": {"window": "We're always advocating for the role of care being provided in the community.  We obviously have very strong \npresences in the community channels, but we believe that fundamentally, that's where you g et the best access, \nthe best care, and equally good quality.  \n \n We have been at the forefront in many of the experiments, I suppose you could call them, think about [ph] USAN \n(48:45) and our value -based care.  We've had robust participation in the oncology ca re model that's delivered ", "original_text": "We've had robust participation in the oncology ca re model that's delivered ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "248bacb6117f3c6ac390581ba14005edcfc08d04a4b38eaa491e1e5ecc8d0ceb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38fdaae7-7f9c-4f1b-a91b-e0d8527a2b30", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS. "}, "hash": "29f075b781ca3fb841bb66f0822eba1dc907a71b6494fa86d90ad30a64d4da80", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38fdaae7-7f9c-4f1b-a91b-e0d8527a2b30": {"__data__": {"id_": "38fdaae7-7f9c-4f1b-a91b-e0d8527a2b30", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86b5f846-937b-4a81-8167-177111e34949", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee6fe40ad43922638741d8cf2160bd4bed85a628fbd607c490aa5873c17ead49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "979ccb41-6528-4d5b-8ef2-3413c768573e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n ", "original_text": "So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go. "}, "hash": "f8bc0eae698729f21eb352343bcf41e2e5db05f4d7c49d88e17a0c2bf29b3ec4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS. ", "start_char_idx": 16, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "979ccb41-6528-4d5b-8ef2-3413c768573e": {"__data__": {"id_": "979ccb41-6528-4d5b-8ef2-3413c768573e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n ", "original_text": "So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38fdaae7-7f9c-4f1b-a91b-e0d8527a2b30", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d73ff5132e6467396d931d7e0fccfde8b87dbd27896ea92af5d4947ac663bd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58c2f43d-3a80-4557-85e6-e57b58347874", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "I think we \nhave a lot of assets. "}, "hash": "5b518eeea4cb9f9991854bbfc331360ec98e5b723dd93dadab6cb5c397daf5b1", "class_name": "RelatedNodeInfo"}}, "text": "So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go. ", "start_char_idx": 209, "end_char_idx": 290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58c2f43d-3a80-4557-85e6-e57b58347874": {"__data__": {"id_": "58c2f43d-3a80-4557-85e6-e57b58347874", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "I think we \nhave a lot of assets. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "979ccb41-6528-4d5b-8ef2-3413c768573e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n ", "original_text": "So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbb185d0b205aeecd8cb392b625391c61ce01d4a7ef4d618bf7f3a417fe26424", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e680722-6e67-4407-8b01-2c940b747d13", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay. ", "original_text": "We're engaged in the discussion. "}, "hash": "7d02251db0080563610d7629915095c6f5fcbe14c1e308bec961c061085b11bf", "class_name": "RelatedNodeInfo"}}, "text": "I think we \nhave a lot of assets. ", "start_char_idx": 290, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e680722-6e67-4407-8b01-2c940b747d13": {"__data__": {"id_": "9e680722-6e67-4407-8b01-2c940b747d13", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay. ", "original_text": "We're engaged in the discussion. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58c2f43d-3a80-4557-85e6-e57b58347874", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "I think we \nhave a lot of assets. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3788ae21f14c3ba4153873758c087872084a72896862c6ed58c8e18d6204e4c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7acae5d9-06e7-4d86-8488-bc188b45e465", "node_type": "1", "metadata": {"window": "So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n ", "original_text": "We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n "}, "hash": "b8e1e161e1fa9cedd9ffcb92ca58035630bbffbaf45f5872956836ec98858f51", "class_name": "RelatedNodeInfo"}}, "text": "We're engaged in the discussion. ", "start_char_idx": 324, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7acae5d9-06e7-4d86-8488-bc188b45e465": {"__data__": {"id_": "7acae5d9-06e7-4d86-8488-bc188b45e465", "embedding": null, "metadata": {"window": "So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n ", "original_text": "We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e680722-6e67-4407-8b01-2c940b747d13", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay. ", "original_text": "We're engaged in the discussion. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e4bdf0080b5dabfbd56d242460d8c5a102e6e5ad35667456b1046bdfd7d3e40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a28369d9-4927-4138-9c7c-3f455ae837cd", "node_type": "1", "metadata": {"window": "I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  "}, "hash": "87608b91f33e533efd84991324202186804afd1ee640397aaa087fdea6460828", "class_name": "RelatedNodeInfo"}}, "text": "We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n ", "start_char_idx": 357, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a28369d9-4927-4138-9c7c-3f455ae837cd": {"__data__": {"id_": "a28369d9-4927-4138-9c7c-3f455ae837cd", "embedding": null, "metadata": {"window": "I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7acae5d9-06e7-4d86-8488-bc188b45e465", "node_type": "1", "metadata": {"window": "So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n ", "original_text": "We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0f3e63cbbc1f6ccc4483f4c18e16339f97b04704f21d31d45d40e0a607c414a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb92e3aa-e60d-4328-b0a7-f08a2209205b", "node_type": "1", "metadata": {"window": "We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n ", "original_text": "A \nOkay. "}, "hash": "b73421977fc274e0c39508027074e712beb04593016432e5bcf9ee4b596b3ce9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "start_char_idx": 505, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb92e3aa-e60d-4328-b0a7-f08a2209205b": {"__data__": {"id_": "cb92e3aa-e60d-4328-b0a7-f08a2209205b", "embedding": null, "metadata": {"window": "We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n ", "original_text": "A \nOkay. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a28369d9-4927-4138-9c7c-3f455ae837cd", "node_type": "1", "metadata": {"window": "I think we \nhave a lot of assets.  We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef57427bcd385232ee8d221d038e19fc4c8cbd6779cab0ddf39aa9bb9500e22a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ba55358-713c-4e33-a65c-376f5883287d", "node_type": "1", "metadata": {"window": "We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  ", "original_text": "Next question, please.  \n "}, "hash": "700a61e2cbf84253ef9a86d4a325d431e217c98c549aff7ad36a763fe7c117f2", "class_name": "RelatedNodeInfo"}}, "text": "A \nOkay. ", "start_char_idx": 834, "end_char_idx": 843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ba55358-713c-4e33-a65c-376f5883287d": {"__data__": {"id_": "7ba55358-713c-4e33-a65c-376f5883287d", "embedding": null, "metadata": {"window": "We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  ", "original_text": "Next question, please.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb92e3aa-e60d-4328-b0a7-f08a2209205b", "node_type": "1", "metadata": {"window": "We're engaged in the discussion.  We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n ", "original_text": "A \nOkay. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d7bb0bde1712e071e1fd37eb1948f8abed6e4859d8c13b069f2b2b28f6b4e27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "697a1893-9e42-44de-a797-73b2a48cf833", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "081e2b701ba93a03f89b24a6aa946b86d27b22b31e97d309cdfb458afb1cb124", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n ", "start_char_idx": 843, "end_char_idx": 869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "697a1893-9e42-44de-a797-73b2a48cf833": {"__data__": {"id_": "697a1893-9e42-44de-a797-73b2a48cf833", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ba55358-713c-4e33-a65c-376f5883287d", "node_type": "1", "metadata": {"window": "We'll find a way to navigate through them as they unfol d. I \nmean, right now, I think these issues have been long discussed and well discussed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  ", "original_text": "Next question, please.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f3fc0904ee8dd4de86a291d24650484a70985bb272d69bc27e0971bf3fde797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36044bbe-415c-4009-bf74-294f5f04c1e5", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations. ", "original_text": "From Brian Tanquilut with Jefferies.  \n "}, "hash": "ce8149fd955d44ae0386780148699de938cc1d086cf41fc26c65c8f8c1999ab6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 869, "end_char_idx": 1150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36044bbe-415c-4009-bf74-294f5f04c1e5": {"__data__": {"id_": "36044bbe-415c-4009-bf74-294f5f04c1e5", "embedding": null, "metadata": {"window": "A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations. ", "original_text": "From Brian Tanquilut with Jefferies.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "697a1893-9e42-44de-a797-73b2a48cf833", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2272b97fd8f90bd1437834e8a40e905496f5fc20e71ddca915845d2579fc65a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "137adcdb-8ed0-4c11-a98e-c162c6f30cf0", "node_type": "1", "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  "}, "hash": "af33863e08dae9b510724696bf0652f0d6f8bc028743f2841f1ec6c0d6ca8c2b", "class_name": "RelatedNodeInfo"}}, "text": "From Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 1150, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "137adcdb-8ed0-4c11-a98e-c162c6f30cf0": {"__data__": {"id_": "137adcdb-8ed0-4c11-a98e-c162c6f30cf0", "embedding": null, "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36044bbe-415c-4009-bf74-294f5f04c1e5", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations. ", "original_text": "From Brian Tanquilut with Jefferies.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72ca9978770b9ab3706aa8345a4b63738085b1f70c0916916dc2572847e05008", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "169b0a24-5cc4-4e69-b490-5cb0f38cc82e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing. ", "original_text": "Q \nHey, good afternoon, guys. "}, "hash": "9e5d3a8f1fbe24ff7d17c039643231c1834dadc8100cd3a42c28953d5ef5f3ec", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  ", "start_char_idx": 1190, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "169b0a24-5cc4-4e69-b490-5cb0f38cc82e": {"__data__": {"id_": "169b0a24-5cc4-4e69-b490-5cb0f38cc82e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing. ", "original_text": "Q \nHey, good afternoon, guys. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "137adcdb-8ed0-4c11-a98e-c162c6f30cf0", "node_type": "1", "metadata": {"window": "Next question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2ac14dda4c5f9df4245054a7c41b994d83f5984bd968536373baa0f1c617bd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17e672e4-edd7-4104-b03f-6da53bea4d84", "node_type": "1", "metadata": {"window": "From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure? ", "original_text": "Congratulations. "}, "hash": "1e1c06efa3d91c45d46bbf21d8c9a91d4b3d60e1e65301450253543fc0fb6a76", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey, good afternoon, guys. ", "start_char_idx": 1501, "end_char_idx": 1531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17e672e4-edd7-4104-b03f-6da53bea4d84": {"__data__": {"id_": "17e672e4-edd7-4104-b03f-6da53bea4d84", "embedding": null, "metadata": {"window": "From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure? ", "original_text": "Congratulations. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "169b0a24-5cc4-4e69-b490-5cb0f38cc82e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing. ", "original_text": "Q \nHey, good afternoon, guys. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79ab99949e6facc4b81c45554ec03f45a36e6ce15cc9ff5d23f71e2927c11870", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63d4033a-2f42-4fde-aa93-beb4a1183b21", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n ", "original_text": "I just have one question. "}, "hash": "a887100a3ac1c4da3bc4493a65f118e29569a462fba0d5292b39d02760071a3b", "class_name": "RelatedNodeInfo"}}, "text": "Congratulations. ", "start_char_idx": 1531, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63d4033a-2f42-4fde-aa93-beb4a1183b21": {"__data__": {"id_": "63d4033a-2f42-4fde-aa93-beb4a1183b21", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n ", "original_text": "I just have one question. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17e672e4-edd7-4104-b03f-6da53bea4d84", "node_type": "1", "metadata": {"window": "From Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure? ", "original_text": "Congratulations. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffebb50b2d8ac5f19d3063f44461d47e24b0e5f3fecdee0d683d290c0dbe9eff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7045885d-156e-4cfc-98be-cedcae7216ee", "node_type": "1", "metadata": {"window": "Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing. "}, "hash": "a4d96f9a8af984a72e8d15e1212afaf169b1b3219d51e47cfd8e9f335722758e", "class_name": "RelatedNodeInfo"}}, "text": "I just have one question. ", "start_char_idx": 1548, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7045885d-156e-4cfc-98be-cedcae7216ee": {"__data__": {"id_": "7045885d-156e-4cfc-98be-cedcae7216ee", "embedding": null, "metadata": {"window": "Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63d4033a-2f42-4fde-aa93-beb4a1183b21", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Tanquilut  \nAnalyst, Jefferies & Company, Inc.   Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n ", "original_text": "I just have one question. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0728820ce902e55ff5a357a7bf4eeb7b295adda7e7c1e5a51d916fa9af879fd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07f6b04c-a772-4fa3-af30-553e1fdf1ede", "node_type": "1", "metadata": {"window": "Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it a bonus structure? "}, "hash": "b881c7586d29e63be625050a813c5813a76c4898a8b0d00ded7bdcc9961bb04e", "class_name": "RelatedNodeInfo"}}, "text": "Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing. ", "start_char_idx": 1574, "end_char_idx": 1685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07f6b04c-a772-4fa3-af30-553e1fdf1ede": {"__data__": {"id_": "07f6b04c-a772-4fa3-af30-553e1fdf1ede", "embedding": null, "metadata": {"window": "Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it a bonus structure? ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7045885d-156e-4cfc-98be-cedcae7216ee", "node_type": "1", "metadata": {"window": "Q \nHey, good afternoon, guys.  Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bede2e15a2ec29f87a0c6d110b14022dd27f31d2fa7881aa48cd3169a5cd7472", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc161c00-834d-4e30-a0be-fed8aa982cfa", "node_type": "1", "metadata": {"window": "I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian. ", "original_text": "Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n "}, "hash": "1f2d88be4dd27fb039234f0d5a43d17398e658121c97fa25665175a3fbba3bba", "class_name": "RelatedNodeInfo"}}, "text": "Is it a bonus structure? ", "start_char_idx": 1685, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc161c00-834d-4e30-a0be-fed8aa982cfa": {"__data__": {"id_": "fc161c00-834d-4e30-a0be-fed8aa982cfa", "embedding": null, "metadata": {"window": "I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian. ", "original_text": "Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07f6b04c-a772-4fa3-af30-553e1fdf1ede", "node_type": "1", "metadata": {"window": "Congratulations.  I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it a bonus structure? ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d37f409ca3c781894ddfbf111796877b5f42d34f55dd7f83d0c97bd360ec6f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e35e2b97-ec56-4041-b857-32919d865d82", "node_type": "1", "metadata": {"window": "Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b31bc6b836dbefaed93231e3893e1ff494ed6be0f9bfd81b3a748f7e84751853", "class_name": "RelatedNodeInfo"}}, "text": "Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n ", "start_char_idx": 1710, "end_char_idx": 1839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e35e2b97-ec56-4041-b857-32919d865d82": {"__data__": {"id_": "e35e2b97-ec56-4041-b857-32919d865d82", "embedding": null, "metadata": {"window": "Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc161c00-834d-4e30-a0be-fed8aa982cfa", "node_type": "1", "metadata": {"window": "I just have one question.  Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian. ", "original_text": "Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e7eaed0900f04fff89d26958069b80a920e2120f862268c180c290bcd84eff8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "311b7cd8-aaee-49de-b5ed-6f9fff0c48ba", "node_type": "1", "metadata": {"window": "Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity. ", "original_text": "A \nYeah. "}, "hash": "b1be5da5cd7500cd65bc51c849fae380d6e721566d4628def558b0fee46d850e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1839, "end_char_idx": 2181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "311b7cd8-aaee-49de-b5ed-6f9fff0c48ba": {"__data__": {"id_": "311b7cd8-aaee-49de-b5ed-6f9fff0c48ba", "embedding": null, "metadata": {"window": "Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e35e2b97-ec56-4041-b857-32919d865d82", "node_type": "1", "metadata": {"window": "Britt, as we think about the investments in \nlabor that you called out, it sounds like it's a back half thing.  Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6db2513a22097ef16e1d2178bb7658c7d37c7c9f7da0dc086abb9433cc91de08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c823b97d-69d9-44df-9668-8c8773008581", "node_type": "1", "metadata": {"window": "Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.  ", "original_text": "Thanks for the question, Br ian. "}, "hash": "983d30bb9b0aeff690cdf2ab90c04f5935a86956372409eec8066ddb4ff38792", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2181, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c823b97d-69d9-44df-9668-8c8773008581": {"__data__": {"id_": "c823b97d-69d9-44df-9668-8c8773008581", "embedding": null, "metadata": {"window": "Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.  ", "original_text": "Thanks for the question, Br ian. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "311b7cd8-aaee-49de-b5ed-6f9fff0c48ba", "node_type": "1", "metadata": {"window": "Is it a bonus structure?  Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f77e5df763e8f244395e46736eaf5fa783220ed52275d63cefb940df40366f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e15f9dd6-d800-4150-bafe-482ba13f6421", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n ", "original_text": "We're just going to guide today to fiscal 2022. "}, "hash": "784e6f3dc91b48dcc070251e7c243b97901bfb0ef24a38a214a066f2f18c14f1", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, Br ian. ", "start_char_idx": 2190, "end_char_idx": 2223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e15f9dd6-d800-4150-bafe-482ba13f6421": {"__data__": {"id_": "e15f9dd6-d800-4150-bafe-482ba13f6421", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n ", "original_text": "We're just going to guide today to fiscal 2022. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c823b97d-69d9-44df-9668-8c8773008581", "node_type": "1", "metadata": {"window": "Or is this a reset in the wage \nrates that we should be thinking about as we start thinking about our models for fiscal 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.  ", "original_text": "Thanks for the question, Br ian. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9abf9a958cc1bfe5c2521e905aa6164f351e92a3b3fa776bce297b476783a9a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5561ced5-18ae-42c5-88fc-4fd8352399b3", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity. "}, "hash": "af2baa20f8bc3521aa93ea7b78d5527ad155be0bcf2bd949b6375c066ac0850c", "class_name": "RelatedNodeInfo"}}, "text": "We're just going to guide today to fiscal 2022. ", "start_char_idx": 2223, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5561ced5-18ae-42c5-88fc-4fd8352399b3": {"__data__": {"id_": "5561ced5-18ae-42c5-88fc-4fd8352399b3", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e15f9dd6-d800-4150-bafe-482ba13f6421", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n ", "original_text": "We're just going to guide today to fiscal 2022. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a0c9dd74f8d6cf6d35d65fbf2f84b4fa02da770c631f624687c9a68636f2084", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "936c9b8f-42f8-4e5f-a1f9-7f409a0cc96b", "node_type": "1", "metadata": {"window": "Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n ", "original_text": "We're not guiding anything beyond that.  "}, "hash": "133ac1c142140de475bbac16f8546b8b619ec55fcbd53df19c2e608515720be5", "class_name": "RelatedNodeInfo"}}, "text": "We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity. ", "start_char_idx": 2271, "end_char_idx": 2437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "936c9b8f-42f8-4e5f-a1f9-7f409a0cc96b": {"__data__": {"id_": "936c9b8f-42f8-4e5f-a1f9-7f409a0cc96b", "embedding": null, "metadata": {"window": "Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n ", "original_text": "We're not guiding anything beyond that.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5561ced5-18ae-42c5-88fc-4fd8352399b3", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08cb4c38a954ab104c0ce04f54e7f2496da5a0f5609d2e72453f5659e08aecc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b27d3e43-2783-4a3b-83ed-23ee19742efb", "node_type": "1", "metadata": {"window": "We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n "}, "hash": "63cd28d13a6904221785b9c4a51d4e919d6e4644265cbe7abcb2e7a7bae0cb1a", "class_name": "RelatedNodeInfo"}}, "text": "We're not guiding anything beyond that.  ", "start_char_idx": 2437, "end_char_idx": 2478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b27d3e43-2783-4a3b-83ed-23ee19742efb": {"__data__": {"id_": "b27d3e43-2783-4a3b-83ed-23ee19742efb", "embedding": null, "metadata": {"window": "We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "936c9b8f-42f8-4e5f-a1f9-7f409a0cc96b", "node_type": "1", "metadata": {"window": "Thanks for the question, Br ian.  We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n ", "original_text": "We're not guiding anything beyond that.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df0fc3be93a70bed87f3919be95d33d676999af0034a9068bdf5ead06384f547", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bda0a599-4626-49c8-9edd-cfb12594164b", "node_type": "1", "metadata": {"window": "We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "cc973e7eba62c7a130aeeba98141418bdf6f6341494fcb5e34f4b35c45f9e683", "class_name": "RelatedNodeInfo"}}, "text": "So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n ", "start_char_idx": 2478, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bda0a599-4626-49c8-9edd-cfb12594164b": {"__data__": {"id_": "bda0a599-4626-49c8-9edd-cfb12594164b", "embedding": null, "metadata": {"window": "We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b27d3e43-2783-4a3b-83ed-23ee19742efb", "node_type": "1", "metadata": {"window": "We're just going to guide today to fiscal 2022.  We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c09456357f51b61e5f9cf082dcb2b3bd3616d17adbdf486164d7446e7066d9d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c42d0bf4-29ee-44bc-b6a4-58fbddca4b13", "node_type": "1", "metadata": {"window": "We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call. ", "original_text": "We'll move on to our next que stion with George Hill, Deutsche Bank.  \n "}, "hash": "3256fe517be7efb37eecf09d8efa33be38082f3fa277bb1402d38ce109fec269", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 869, "end_char_idx": 1150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c42d0bf4-29ee-44bc-b6a4-58fbddca4b13": {"__data__": {"id_": "c42d0bf4-29ee-44bc-b6a4-58fbddca4b13", "embedding": null, "metadata": {"window": "We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call. ", "original_text": "We'll move on to our next que stion with George Hill, Deutsche Bank.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bda0a599-4626-49c8-9edd-cfb12594164b", "node_type": "1", "metadata": {"window": "We thought that this was an \ninvestment that was important for our frontline associates, for our delivery drivers and others to get us through \n2022 with continuity.  We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ec85ecd3b5ec70b652113393884d5b46e359addc3a578f4816987da1b61e9b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a660a6b-1396-4264-ba5b-a58e3ef76e1c", "node_type": "1", "metadata": {"window": "So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "457a8d679bd0c4a361ccc7ce4a81d5c7e895ee1425e0822617936a9a466ad190", "class_name": "RelatedNodeInfo"}}, "text": "We'll move on to our next que stion with George Hill, Deutsche Bank.  \n ", "start_char_idx": 2966, "end_char_idx": 3038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a660a6b-1396-4264-ba5b-a58e3ef76e1c": {"__data__": {"id_": "1a660a6b-1396-4264-ba5b-a58e3ef76e1c", "embedding": null, "metadata": {"window": "So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c42d0bf4-29ee-44bc-b6a4-58fbddca4b13", "node_type": "1", "metadata": {"window": "We're not guiding anything beyond that.   So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call. ", "original_text": "We'll move on to our next que stion with George Hill, Deutsche Bank.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1e52949a1850d1a014b7dfa88530805626f6c3f10b5d1ff56bbc44f45113587", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "810a8229-7eb8-4d39-bbe2-e6e30ac3aff0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n ", "original_text": "Q \nYeah. "}, "hash": "a1d410feda5298358455fffac8bc61e5e04a875fa3c435bfc118f887000de214", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 3038, "end_char_idx": 3350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "810a8229-7eb8-4d39-bbe2-e6e30ac3aff0": {"__data__": {"id_": "810a8229-7eb8-4d39-bbe2-e6e30ac3aff0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n ", "original_text": "Q \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a660a6b-1396-4264-ba5b-a58e3ef76e1c", "node_type": "1", "metadata": {"window": "So I think you'd take this as an important investment \nto make sure that our customers have the continued service that they would expect from McKesson to the holiday \nseason in the back half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4919ab59631cf4b56c5737434045625864e93a0fed291c9bfd48323d872e4a82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd56bc6c-5197-4c88-96f7-d9c6027af72c", "node_type": "1", "metadata": {"window": "We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Good afternoon, guys and thanks for taking the call. "}, "hash": "fd4881b5e825bf651919f97666347c9c0e281990ecd2ad9f470df8595eb728f8", "class_name": "RelatedNodeInfo"}}, "text": "Q \nYeah. ", "start_char_idx": 3350, "end_char_idx": 3359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd56bc6c-5197-4c88-96f7-d9c6027af72c": {"__data__": {"id_": "fd56bc6c-5197-4c88-96f7-d9c6027af72c", "embedding": null, "metadata": {"window": "We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Good afternoon, guys and thanks for taking the call. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "810a8229-7eb8-4d39-bbe2-e6e30ac3aff0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n ", "original_text": "Q \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7836e10699686528ac78c275043027d9297a113749937985ee29ce2c0867cd8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7073da2f-923d-455b-bf4e-bdc4aa6583ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed. ", "original_text": "I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses. "}, "hash": "b0b4184ab7601df8ae841af094cd48ee93512f5624be9f447b7c03c2f8c9ba00", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys and thanks for taking the call. ", "start_char_idx": 3359, "end_char_idx": 3412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7073da2f-923d-455b-bf4e-bdc4aa6583ec": {"__data__": {"id_": "7073da2f-923d-455b-bf4e-bdc4aa6583ec", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed. ", "original_text": "I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd56bc6c-5197-4c88-96f7-d9c6027af72c", "node_type": "1", "metadata": {"window": "We'll move on to our next que stion with George Hill, Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Good afternoon, guys and thanks for taking the call. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d552783d8b340372dd110fba8c4460a3bf95762d1f18663730046661efb9e71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56f3d31a-a3f5-449f-806a-34e31c0203fc", "node_type": "1", "metadata": {"window": "Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment. ", "original_text": "But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n "}, "hash": "6e9fd16d9487efd120c1c9767e5bd5e19b5b0f680dc2461515430fe00df901a4", "class_name": "RelatedNodeInfo"}}, "text": "I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses. ", "start_char_idx": 3412, "end_char_idx": 3591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56f3d31a-a3f5-449f-806a-34e31c0203fc": {"__data__": {"id_": "56f3d31a-a3f5-449f-806a-34e31c0203fc", "embedding": null, "metadata": {"window": "Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment. ", "original_text": "But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7073da2f-923d-455b-bf4e-bdc4aa6583ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed. ", "original_text": "I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f45d06cad0407843dc6729232ef94b007f3b7e04f2dbab29df069a4a18a91d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7e325d8-4a6a-43bd-9d4c-e493da39de6a", "node_type": "1", "metadata": {"window": "Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "a0a26d889efc9594eb2de8336291790a77158cd6aa2954bf2c36f9974f781383", "class_name": "RelatedNodeInfo"}}, "text": "But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n ", "start_char_idx": 3591, "end_char_idx": 3801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7e325d8-4a6a-43bd-9d4c-e493da39de6a": {"__data__": {"id_": "e7e325d8-4a6a-43bd-9d4c-e493da39de6a", "embedding": null, "metadata": {"window": "Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56f3d31a-a3f5-449f-806a-34e31c0203fc", "node_type": "1", "metadata": {"window": "Q \nYeah.  Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment. ", "original_text": "But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0eb0d6eaf6fc63d39f77f0f304c2316151f4fb928f3c1f6e0d14bde47c166b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf6a680a-4448-40b4-b8c4-d7ab7017ad1d", "node_type": "1", "metadata": {"window": "I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy. ", "original_text": "A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed. "}, "hash": "c7613b5c997a2f47854434a6f37f0970df94f78c29c2bfd56b30750e07319ffc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3801, "end_char_idx": 4130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf6a680a-4448-40b4-b8c4-d7ab7017ad1d": {"__data__": {"id_": "cf6a680a-4448-40b4-b8c4-d7ab7017ad1d", "embedding": null, "metadata": {"window": "I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy. ", "original_text": "A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7e325d8-4a6a-43bd-9d4c-e493da39de6a", "node_type": "1", "metadata": {"window": "Good afternoon, guys and thanks for taking the call.  I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a8b5aab8fa2358305e9726415a1d6efc6b876bd900b9cc0e96c7cbda04a9e37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c235363-2a27-4595-8e37-7e6a8292e7a1", "node_type": "1", "metadata": {"window": "But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas. ", "original_text": "We take a \nbalanced approach to capital deployment. "}, "hash": "141a3d6e7a8f6e0d4b5f184d40a3ea3d17fb349faa473fbee3432053784f1e70", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed. ", "start_char_idx": 4130, "end_char_idx": 4235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c235363-2a27-4595-8e37-7e6a8292e7a1": {"__data__": {"id_": "9c235363-2a27-4595-8e37-7e6a8292e7a1", "embedding": null, "metadata": {"window": "But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas. ", "original_text": "We take a \nbalanced approach to capital deployment. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf6a680a-4448-40b4-b8c4-d7ab7017ad1d", "node_type": "1", "metadata": {"window": "I guess, Brian, I would ask you \u2013 or Britt, like I know \nthat you guys have said \u2013 been on the record in the past just talking about not wanting to enter any big new \nbusinesses.  But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy. ", "original_text": "A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "930b493d57efa8d82f6d46acb394cf88786f6da118dd9c713861fd6f33095c75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f288c12c-123d-4782-92e4-a91885896603", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n", "original_text": "We w ant to prioritize strategic growth. "}, "hash": "e42de7d6bc1e8571dc0c8755b2fa34b2b7487e98123fee36252ddcb25e94279f", "class_name": "RelatedNodeInfo"}}, "text": "We take a \nbalanced approach to capital deployment. ", "start_char_idx": 4235, "end_char_idx": 4287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f288c12c-123d-4782-92e4-a91885896603": {"__data__": {"id_": "f288c12c-123d-4782-92e4-a91885896603", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n", "original_text": "We w ant to prioritize strategic growth. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c235363-2a27-4595-8e37-7e6a8292e7a1", "node_type": "1", "metadata": {"window": "But as you continue to retrench away from Europe with a focus towards the United States, I guess, is \nthere any rethinking of the capital deployment priorities or an appetite for ma ybe bigger transactions?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas. ", "original_text": "We take a \nbalanced approach to capital deployment. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "541c33f3722cc8c72016b493d054ef1003eb4724b09dab1c16318d8b3ea5c4df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52b28768-fb86-42af-883d-fd604f22a4a3", "node_type": "1", "metadata": {"window": "A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for. ", "original_text": "We think we've got a really \nclearly defined strategy. "}, "hash": "bb75032d7acfef25336b42b1d662df73653075cb919cbb0ce042a4dc21b269c0", "class_name": "RelatedNodeInfo"}}, "text": "We w ant to prioritize strategic growth. ", "start_char_idx": 4287, "end_char_idx": 4328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52b28768-fb86-42af-883d-fd604f22a4a3": {"__data__": {"id_": "52b28768-fb86-42af-883d-fd604f22a4a3", "embedding": null, "metadata": {"window": "A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for. ", "original_text": "We think we've got a really \nclearly defined strategy. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f288c12c-123d-4782-92e4-a91885896603", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n", "original_text": "We w ant to prioritize strategic growth. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "645d3b5bc39113f40412df631a9677bbe60410ed09452c9521c6a616bc6b317a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e9ecc9e-8b2d-4d2e-9fe8-9edce61f36b8", "node_type": "1", "metadata": {"window": "We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n ", "original_text": "We've laid out what we consider our strategic growth areas. "}, "hash": "a99b0c3d03fdb10efe1e9c2be321125160563f2d90ce4a9c1fda740e64bc56fc", "class_name": "RelatedNodeInfo"}}, "text": "We think we've got a really \nclearly defined strategy. ", "start_char_idx": 4328, "end_char_idx": 4383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e9ecc9e-8b2d-4d2e-9fe8-9edce61f36b8": {"__data__": {"id_": "7e9ecc9e-8b2d-4d2e-9fe8-9edce61f36b8", "embedding": null, "metadata": {"window": "We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n ", "original_text": "We've laid out what we consider our strategic growth areas. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52b28768-fb86-42af-883d-fd604f22a4a3", "node_type": "1", "metadata": {"window": "A \nWell, I would start by saying that I don't think our overall capital deployment strategy has changed.  We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for. ", "original_text": "We think we've got a really \nclearly defined strategy. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79b70e2b2e5711045e4e7db3e998d64035aaed18751362ef4da230abfe19e210", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26dc5bbc-1884-4635-8aa6-301fc8e78d97", "node_type": "1", "metadata": {"window": "We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n"}, "hash": "64d4cd31543807dde3957de133e202c58e12405e93cf404516e01e266e1c4c2b", "class_name": "RelatedNodeInfo"}}, "text": "We've laid out what we consider our strategic growth areas. ", "start_char_idx": 4383, "end_char_idx": 4443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26dc5bbc-1884-4635-8aa6-301fc8e78d97": {"__data__": {"id_": "26dc5bbc-1884-4635-8aa6-301fc8e78d97", "embedding": null, "metadata": {"window": "We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e9ecc9e-8b2d-4d2e-9fe8-9edce61f36b8", "node_type": "1", "metadata": {"window": "We take a \nbalanced approach to capital deployment.  We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n ", "original_text": "We've laid out what we consider our strategic growth areas. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40d1cd2021fde877650ce08db7959e79e90629437814b6ce02194346d47c2a60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b654fa-360e-4ef2-81ca-45f4971fbd15", "node_type": "1", "metadata": {"window": "We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for. "}, "hash": "35d2eeb1510061d9f0726092d3e0d3af8700604978454f310108e6c37d6ab3b2", "class_name": "RelatedNodeInfo"}}, "text": "And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n", "start_char_idx": 4443, "end_char_idx": 4664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76b654fa-360e-4ef2-81ca-45f4971fbd15": {"__data__": {"id_": "76b654fa-360e-4ef2-81ca-45f4971fbd15", "embedding": null, "metadata": {"window": "We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26dc5bbc-1884-4635-8aa6-301fc8e78d97", "node_type": "1", "metadata": {"window": "We w ant to prioritize strategic growth.  We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "513b58b450b307c9390353e4c75db07fab658bb584dac5340ee616634e3b7e80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffb464b0-6ebb-42e1-be48-e9eee33747c9", "node_type": "1", "metadata": {"window": "We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n "}, "hash": "20b9fb136da027cf40590b1140dfd80a3d8ea329861536598a5befbd7a42643d", "class_name": "RelatedNodeInfo"}}, "text": "We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for. ", "start_char_idx": 4664, "end_char_idx": 5016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffb464b0-6ebb-42e1-be48-e9eee33747c9": {"__data__": {"id_": "ffb464b0-6ebb-42e1-be48-e9eee33747c9", "embedding": null, "metadata": {"window": "We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b654fa-360e-4ef2-81ca-45f4971fbd15", "node_type": "1", "metadata": {"window": "We think we've got a really \nclearly defined strategy.  We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for. ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45a3becce012a1879e967070deff725d3fdd8449d598057383c590680d939ed0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c3b6125-cbad-4c29-ba3f-fd3b2d9ffe6c", "node_type": "1", "metadata": {"window": "And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "6c63ded2334d1612e2552b2e89ea8d0f0b75ad6647d88897104045e546287f1c", "class_name": "RelatedNodeInfo"}}, "text": "So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n ", "start_char_idx": 5016, "end_char_idx": 5114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c3b6125-cbad-4c29-ba3f-fd3b2d9ffe6c": {"__data__": {"id_": "6c3b6125-cbad-4c29-ba3f-fd3b2d9ffe6c", "embedding": null, "metadata": {"window": "And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb78cca2-9143-477b-9ec3-de5e991d0773", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7974a14f5260d3a3f075e0744666d39143c12a8632524680a84f2d5972c733ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffb464b0-6ebb-42e1-be48-e9eee33747c9", "node_type": "1", "metadata": {"window": "We've laid out what we consider our strategic growth areas.  And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa52fd6b39ae85a05fedd0edf4e8286de33f9785bb8625817b1385148f7c7dd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bb21e63-061b-4c0d-bed7-597fb48e4faa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n ", "original_text": "McKesson Corp.  "}, "hash": "38a05bdb957beb56604d070125ffe9ecad248ccdd0fc99421afd20606cb929c6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 505, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bb21e63-061b-4c0d-bed7-597fb48e4faa": {"__data__": {"id_": "4bb21e63-061b-4c0d-bed7-597fb48e4faa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c3b6125-cbad-4c29-ba3f-fd3b2d9ffe6c", "node_type": "1", "metadata": {"window": "And assuming the alignment \nto those strategies and assuming they meet our disciplined financial review pro cess and create value for our \nshareholders, we would love to be deploying capital against those strategies.  \n \n We obviously always balance that against returning capital to shareholders through stock buybacks and our \nmodestly growing dividend, but we think w e've really identified \u2013 we had a set of differentiated assets in good \nmarkets and focused in North America that when we execute against, we'll deliver at the long -term growth that \nwe're looking for.  So, a strategic alignment, financial discipline that's r eally what drives capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db2509422eea4a89a02983595058a09be0aba745e0a70fb8e7845627a1b96134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a94e2a2a-dff1-4803-b873-df1ff48557dd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "6e2a32cd832268fa8773a659666d081e8a73b8298bb4a23c61beec8aeab0ec19", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a94e2a2a-dff1-4803-b873-df1ff48557dd": {"__data__": {"id_": "a94e2a2a-dff1-4803-b873-df1ff48557dd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bb21e63-061b-4c0d-bed7-597fb48e4faa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f7624f95877cd028b862521c10893f1a2d9dfaeb610a9bdce02086777121b34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0adaa64-8805-4987-b00d-19b2efca2d5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company. "}, "hash": "ae5198c2673a1ab1088a64e3853bdebfdfb352b17a04fbfac6c0652a1d7ec794", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0adaa64-8805-4987-b00d-19b2efca2d5c": {"__data__": {"id_": "b0adaa64-8805-4987-b00d-19b2efca2d5c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a94e2a2a-dff1-4803-b873-df1ff48557dd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86272b4c9d7c5e25464d0415dd1f211a75915ea617b43cf61464284014c3add0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb2ad34c-5afa-4ffe-ac8d-872779990f73", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n ", "original_text": "And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n "}, "hash": "947755d2cc053efe9b1dd4604d1cd6ee536d5d1191c514ac8cf81013f7919d16", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company. ", "start_char_idx": 266, "end_char_idx": 463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb2ad34c-5afa-4ffe-ac8d-872779990f73": {"__data__": {"id_": "fb2ad34c-5afa-4ffe-ac8d-872779990f73", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n ", "original_text": "And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0adaa64-8805-4987-b00d-19b2efca2d5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c4c6191dd1201558106b465f0cff431e51a2e5070d5707afbf6a7aaeccc9483", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "784a0c91-6929-43c0-98ed-7ed31ac9c363", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n "}, "hash": "b1c525bae8735100c8c5e9823c3c946d1c4a529c4ece479b64ff5bd0585e6792", "class_name": "RelatedNodeInfo"}}, "text": "And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n ", "start_char_idx": 463, "end_char_idx": 709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "784a0c91-6929-43c0-98ed-7ed31ac9c363": {"__data__": {"id_": "784a0c91-6929-43c0-98ed-7ed31ac9c363", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb2ad34c-5afa-4ffe-ac8d-872779990f73", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n ", "original_text": "And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b3157aa6e7b172d95d3a9088a2c5fb6039279a4397c8f6df533d0201a2af17d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b113e33b-0afc-4330-bd3d-355a5f5c5442", "node_type": "1", "metadata": {"window": "A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "4c36d1b4143b952eacf608466f2d5e811b83808378a49d70d8a2b3c2c84527f6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n ", "start_char_idx": 709, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b113e33b-0afc-4330-bd3d-355a5f5c5442": {"__data__": {"id_": "b113e33b-0afc-4330-bd3d-355a5f5c5442", "embedding": null, "metadata": {"window": "A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "784a0c91-6929-43c0-98ed-7ed31ac9c363", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "678342edfd1749366b13cb1b9dcb979250f78fe61af3baf22948a5e54304acaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f41fe671-c2c3-4361-b8b5-d81ed3bbf433", "node_type": "1", "metadata": {"window": "And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "A \nNext question?  \n "}, "hash": "4320801489e41ce989986b57e34b2309a93a44fc9e78900e64fc78a583dd6016", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 993, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f41fe671-c2c3-4361-b8b5-d81ed3bbf433": {"__data__": {"id_": "f41fe671-c2c3-4361-b8b5-d81ed3bbf433", "embedding": null, "metadata": {"window": "And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "A \nNext question?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b113e33b-0afc-4330-bd3d-355a5f5c5442", "node_type": "1", "metadata": {"window": "A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ae55cdb07db803d1a4401b04defb60607edd5332a46980bef72639e5f3a4042", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a39d3b5f-47ad-4d10-82cd-150145562870", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n "}, "hash": "2817274e809e16570c7527d55531a0a7dc84ccd4ca310173c7d9b1ec287617e4", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 1322, "end_char_idx": 1343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a39d3b5f-47ad-4d10-82cd-150145562870": {"__data__": {"id_": "a39d3b5f-47ad-4d10-82cd-150145562870", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f41fe671-c2c3-4361-b8b5-d81ed3bbf433", "node_type": "1", "metadata": {"window": "And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "A \nNext question?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48b7f8a8fa0a11c3c6d82aff4bf3716434e94d35481ea52bd23d7627048280ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e76c33b-35e6-4522-9c1f-8f0f96eb37f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "85049b055153130ea4d31bf940470fc9f4733216b9f248dc5aafb5b2d8580921", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n ", "start_char_idx": 1343, "end_char_idx": 1657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e76c33b-35e6-4522-9c1f-8f0f96eb37f8": {"__data__": {"id_": "2e76c33b-35e6-4522-9c1f-8f0f96eb37f8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a39d3b5f-47ad-4d10-82cd-150145562870", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "035465b2302507388668b8ab73cfcaf7d522408caaa20b933634613d61de9eab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa829da8-6124-4c8f-abfd-6bcd3bd03784", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers. ", "original_text": "Q \nThanks. "}, "hash": "216ac158830b2ee621cb17366b84f177e40efa0d8212e243f710c9a3c263f7dd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 1657, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa829da8-6124-4c8f-abfd-6bcd3bd03784": {"__data__": {"id_": "aa829da8-6124-4c8f-abfd-6bcd3bd03784", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers. ", "original_text": "Q \nThanks. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e76c33b-35e6-4522-9c1f-8f0f96eb37f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7bb0f18808574c2fae117b873fd7cd6cdee310903c0c0c5d711698e99da15ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1339128d-e9d2-4f42-9647-7c553af0cde7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits? ", "original_text": "Good afternoon, everybody. "}, "hash": "79b1623383eb52606c0f1ca0c918986c5ef0dbd648860f466418d9d06e4af555", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks. ", "start_char_idx": 1970, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1339128d-e9d2-4f42-9647-7c553af0cde7": {"__data__": {"id_": "1339128d-e9d2-4f42-9647-7c553af0cde7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits? ", "original_text": "Good afternoon, everybody. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa829da8-6124-4c8f-abfd-6bcd3bd03784", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers. ", "original_text": "Q \nThanks. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7c1e272129d52c12ecf14be2e43cd404c258c394780c997c7cb4e6e5a7f4114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be5b6881-e430-4cfd-b008-8fd2a5a1b3c5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n ", "original_text": "So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there. "}, "hash": "1eb2bbf22d0fc4b51ba6d889799f148e47ead50aa377307b8fc590e734222ce4", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, everybody. ", "start_char_idx": 1981, "end_char_idx": 2008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be5b6881-e430-4cfd-b008-8fd2a5a1b3c5": {"__data__": {"id_": "be5b6881-e430-4cfd-b008-8fd2a5a1b3c5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n ", "original_text": "So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1339128d-e9d2-4f42-9647-7c553af0cde7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : ...from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits? ", "original_text": "Good afternoon, everybody. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91452de921bc9352db8b35b208a7fae0984be3eb490521c69978441339164b3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6584a356-e918-41cf-91e1-bd2f53527a14", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "On slide 10, you mentioned the increased primary care business as one of those drivers. "}, "hash": "c4d2c18036c3cdeb6fd861a7883f74703adbb4f45b1e5922f4457dace3db0a20", "class_name": "RelatedNodeInfo"}}, "text": "So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there. ", "start_char_idx": 2008, "end_char_idx": 2110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6584a356-e918-41cf-91e1-bd2f53527a14": {"__data__": {"id_": "6584a356-e918-41cf-91e1-bd2f53527a14", "embedding": null, "metadata": {"window": "Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "On slide 10, you mentioned the increased primary care business as one of those drivers. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be5b6881-e430-4cfd-b008-8fd2a5a1b3c5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n ", "original_text": "So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1129edebf7290e92c67fd9c270709c49e8f68ff7259db7ac7adfc528dcb9450", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "040edf54-e66d-4488-9a49-02c5836a71c7", "node_type": "1", "metadata": {"window": "Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits? "}, "hash": "849246dbb25b8d389839dcaebe892bbc075c20e7a2018d8c99f771ad1257010d", "class_name": "RelatedNodeInfo"}}, "text": "On slide 10, you mentioned the increased primary care business as one of those drivers. ", "start_char_idx": 2110, "end_char_idx": 2198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "040edf54-e66d-4488-9a49-02c5836a71c7": {"__data__": {"id_": "040edf54-e66d-4488-9a49-02c5836a71c7", "embedding": null, "metadata": {"window": "Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits? ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6584a356-e918-41cf-91e1-bd2f53527a14", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "On slide 10, you mentioned the increased primary care business as one of those drivers. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c4684e2f6fbe88e92bb226b4156514c825f9d81382bbfa3d0b3aff77169ba0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1aad11b-cdaf-4a47-bf91-24b00941a3a9", "node_type": "1", "metadata": {"window": "So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like. ", "original_text": "Thanks.  \n "}, "hash": "0fa656dd8919842da8a5ee4fcd9a824dcc24f7ce7137256f1c6881d957e301b7", "class_name": "RelatedNodeInfo"}}, "text": "Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits? ", "start_char_idx": 2198, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1aad11b-cdaf-4a47-bf91-24b00941a3a9": {"__data__": {"id_": "b1aad11b-cdaf-4a47-bf91-24b00941a3a9", "embedding": null, "metadata": {"window": "So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "040edf54-e66d-4488-9a49-02c5836a71c7", "node_type": "1", "metadata": {"window": "Good afternoon, everybody.  So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits? ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f94da78d5596a0156c62e8ec2cabf4fc9703271bd697b5543292fe8902271a20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0b99814-865c-466f-9157-02a392c0be4a", "node_type": "1", "metadata": {"window": "On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "ca7c0a01cd2dceadc3b3921eac7a3f09ac2eeb37cc62124adea337bf7cc1562f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2448, "end_char_idx": 2459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0b99814-865c-466f-9157-02a392c0be4a": {"__data__": {"id_": "f0b99814-865c-466f-9157-02a392c0be4a", "embedding": null, "metadata": {"window": "On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1aad11b-cdaf-4a47-bf91-24b00941a3a9", "node_type": "1", "metadata": {"window": "So within the Med -Surg segment, clearly, a lot of variables driving the strong \nprofit growth there.  On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca3cb93035922e7733e72cf01c49cfdf4aa77251da3789c8ac8d1b5dabbea580", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc8ae448-92b0-45d0-bd41-c04d2c12b23d", "node_type": "1", "metadata": {"window": "Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures. ", "original_text": "A \nYeah. "}, "hash": "ed6df3c7a09a90db8a3f5fd171751c0665dc7c883ca256c36a074324427c17a0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 993, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc8ae448-92b0-45d0-bd41-c04d2c12b23d": {"__data__": {"id_": "bc8ae448-92b0-45d0-bd41-c04d2c12b23d", "embedding": null, "metadata": {"window": "Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0b99814-865c-466f-9157-02a392c0be4a", "node_type": "1", "metadata": {"window": "On slide 10, you mentioned the increased primary care business as one of those drivers.  Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39a6c7ff404a8f83cdc01cdec331e57a57f7f2270c7f14e153f35bee8740e3f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8a5e74a-cad2-4e76-b557-5f965e9099ce", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty. ", "original_text": "I mean, I'll start and Britt can add some comments, if he'd like. "}, "hash": "aeb16dc36f6e70bf83507d34e4f28fd1b96043cf1b351ed16a425f655d8db68d", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2788, "end_char_idx": 2797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8a5e74a-cad2-4e76-b557-5f965e9099ce": {"__data__": {"id_": "b8a5e74a-cad2-4e76-b557-5f965e9099ce", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty. ", "original_text": "I mean, I'll start and Britt can add some comments, if he'd like. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc8ae448-92b0-45d0-bd41-c04d2c12b23d", "node_type": "1", "metadata": {"window": "Are \nyou able to comment just on the current level of patient volumes in the quarter, either as a percent of the pre -\nCOVID baseline, either for your customer base or just your assessment of the overall US marketplace for \nphysician patient visits?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac0b7d6e573aea61b208fb97d3c2ac42ed8a8f023f5caf6f0355d6777a63a286", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e953a471-d32d-4b37-b0b1-4a6de39c199e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery. ", "original_text": "Obviously, we think about patient visits. "}, "hash": "b0f617f39205e131ebc010e4b515473446f9f433251b9857988a048f78aa549c", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I'll start and Britt can add some comments, if he'd like. ", "start_char_idx": 2797, "end_char_idx": 2863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e953a471-d32d-4b37-b0b1-4a6de39c199e": {"__data__": {"id_": "e953a471-d32d-4b37-b0b1-4a6de39c199e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery. ", "original_text": "Obviously, we think about patient visits. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8a5e74a-cad2-4e76-b557-5f965e9099ce", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty. ", "original_text": "I mean, I'll start and Britt can add some comments, if he'd like. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f397fbdef95b96e37898aef8b42d547efcd7d1a74b3eae93086a3155522ceb97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84ffbd29-fd3e-486b-b168-26d1614a4089", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear. ", "original_text": "We \nthink about elective procedures. "}, "hash": "8a9445bc8700dad48d4031fed787c192aa1c16165a53df2d94f917cb15a2ecd8", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, we think about patient visits. ", "start_char_idx": 2863, "end_char_idx": 2905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84ffbd29-fd3e-486b-b168-26d1614a4089": {"__data__": {"id_": "84ffbd29-fd3e-486b-b168-26d1614a4089", "embedding": null, "metadata": {"window": "A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear. ", "original_text": "We \nthink about elective procedures. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e953a471-d32d-4b37-b0b1-4a6de39c199e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery. ", "original_text": "Obviously, we think about patient visits. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "128335a2663fbf5d33651293428d5fcf21460cabce469fff0f5a626fc8f19de8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d496ceae-1033-4a2a-95c4-b11ae836ab77", "node_type": "1", "metadata": {"window": "I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels. ", "original_text": "You think about then primary care versus speci alty. "}, "hash": "70a5bb59f0cd9301c656d60d57fe0e41f2b7568e48c369b716aebf0acc83ca1e", "class_name": "RelatedNodeInfo"}}, "text": "We \nthink about elective procedures. ", "start_char_idx": 2905, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d496ceae-1033-4a2a-95c4-b11ae836ab77": {"__data__": {"id_": "d496ceae-1033-4a2a-95c4-b11ae836ab77", "embedding": null, "metadata": {"window": "I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels. ", "original_text": "You think about then primary care versus speci alty. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84ffbd29-fd3e-486b-b168-26d1614a4089", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear. ", "original_text": "We \nthink about elective procedures. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffac247ad8f2393e69c6989772a29f171c7863d842972491426b1fda1eced3be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2a5fe8d-bb3b-4213-91fa-7151dcf32bf9", "node_type": "1", "metadata": {"window": "Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n ", "original_text": "I would say, generally, we \nhave been pleased with the market recovery. "}, "hash": "4d78ba54b2af9a76e44170c76e5c00a819a705f41efc0ec450534c7d7f4462db", "class_name": "RelatedNodeInfo"}}, "text": "You think about then primary care versus speci alty. ", "start_char_idx": 2942, "end_char_idx": 2995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2a5fe8d-bb3b-4213-91fa-7151dcf32bf9": {"__data__": {"id_": "d2a5fe8d-bb3b-4213-91fa-7151dcf32bf9", "embedding": null, "metadata": {"window": "Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n ", "original_text": "I would say, generally, we \nhave been pleased with the market recovery. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d496ceae-1033-4a2a-95c4-b11ae836ab77", "node_type": "1", "metadata": {"window": "I mean, I'll start and Britt can add some comments, if he'd like.  Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels. ", "original_text": "You think about then primary care versus speci alty. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5cef8c8877c77f3c9fb9bd7f90a631b56192fe79c44b52aec95f08ba96e9134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a979e3c-889d-4027-9824-a1443a994b4a", "node_type": "1", "metadata": {"window": "We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.  ", "original_text": "It's recovering in line with how we expected it to at the outset of the \nyear. "}, "hash": "e52c3572f437a161164d6e1d8125c2ca66046ee56855a512ae7a721b3a9c71fc", "class_name": "RelatedNodeInfo"}}, "text": "I would say, generally, we \nhave been pleased with the market recovery. ", "start_char_idx": 2995, "end_char_idx": 3067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a979e3c-889d-4027-9824-a1443a994b4a": {"__data__": {"id_": "7a979e3c-889d-4027-9824-a1443a994b4a", "embedding": null, "metadata": {"window": "We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.  ", "original_text": "It's recovering in line with how we expected it to at the outset of the \nyear. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2a5fe8d-bb3b-4213-91fa-7151dcf32bf9", "node_type": "1", "metadata": {"window": "Obviously, we think about patient visits.  We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n ", "original_text": "I would say, generally, we \nhave been pleased with the market recovery. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "865a4339d98f649e89764a9f2c9b164eb41c71ad7104736bbbb43f17b40fa6cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11fa7371-442b-4605-b7f0-ab863f26b602", "node_type": "1", "metadata": {"window": "You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels. "}, "hash": "f7f339350af2564dcdb5b1cc574dbaf4905a7650ab90dedbeabd713e28b9a8a6", "class_name": "RelatedNodeInfo"}}, "text": "It's recovering in line with how we expected it to at the outset of the \nyear. ", "start_char_idx": 3067, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11fa7371-442b-4605-b7f0-ab863f26b602": {"__data__": {"id_": "11fa7371-442b-4605-b7f0-ab863f26b602", "embedding": null, "metadata": {"window": "You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a979e3c-889d-4027-9824-a1443a994b4a", "node_type": "1", "metadata": {"window": "We \nthink about elective procedures.  You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.  ", "original_text": "It's recovering in line with how we expected it to at the outset of the \nyear. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1561cbdfe0aded324585c1bbb7321fdc256d834a97ada3c1319f6a1b1452aab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40863518-9a5c-41e2-b479-597667e70d1d", "node_type": "1", "metadata": {"window": "I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n "}, "hash": "867ef404a7934e29e8047744c9268c7feabe100d3644872801d347e8505d1bd8", "class_name": "RelatedNodeInfo"}}, "text": "It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels. ", "start_char_idx": 3146, "end_char_idx": 3306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40863518-9a5c-41e2-b479-597667e70d1d": {"__data__": {"id_": "40863518-9a5c-41e2-b479-597667e70d1d", "embedding": null, "metadata": {"window": "I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11fa7371-442b-4605-b7f0-ab863f26b602", "node_type": "1", "metadata": {"window": "You think about then primary care versus speci alty.  I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n ", "original_text": "It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63c3cdec110372b502ade7a34af8f15f2f5a6a7a33b9ed9db2b1975a888b2e6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "943ee088-4c32-422e-8e47-4febff37375e", "node_type": "1", "metadata": {"window": "It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.  "}, "hash": "1d54ce5a204576e23f9a8dc38a21d63d931d93e433a83dc1e7580366735cf7bf", "class_name": "RelatedNodeInfo"}}, "text": "So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n ", "start_char_idx": 3306, "end_char_idx": 3459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "943ee088-4c32-422e-8e47-4febff37375e": {"__data__": {"id_": "943ee088-4c32-422e-8e47-4febff37375e", "embedding": null, "metadata": {"window": "It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40863518-9a5c-41e2-b479-597667e70d1d", "node_type": "1", "metadata": {"window": "I would say, generally, we \nhave been pleased with the market recovery.  It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7569a342c72f87db4c059dd69c1357fbca26df482c37be47b6dffa2ebcdc1080", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fc160c1-6a37-44cd-b380-3956b514092e", "node_type": "1", "metadata": {"window": "It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext question, please.  \n "}, "hash": "f499f7d85ce8c1b9831ef75aaadedadf5f1711e281968b4b1cde2968b3f0687e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.  ", "start_char_idx": 3459, "end_char_idx": 3789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fc160c1-6a37-44cd-b380-3956b514092e": {"__data__": {"id_": "3fc160c1-6a37-44cd-b380-3956b514092e", "embedding": null, "metadata": {"window": "It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "943ee088-4c32-422e-8e47-4febff37375e", "node_type": "1", "metadata": {"window": "It's recovering in line with how we expected it to at the outset of the \nyear.  It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "602da23d101d45238ec17d1984bccf7614cb35335ae89754be3692027d6afdc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "870fad3e-f1cc-41db-a70a-d12a7a575a54", "node_type": "1", "metadata": {"window": "So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "172fdb3119a4ddb57fcb3db8901fe2311770e732f435308a5dece79cb3ef2578", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please.  \n ", "start_char_idx": 3789, "end_char_idx": 3818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "870fad3e-f1cc-41db-a70a-d12a7a575a54": {"__data__": {"id_": "870fad3e-f1cc-41db-a70a-d12a7a575a54", "embedding": null, "metadata": {"window": "So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fc160c1-6a37-44cd-b380-3956b514092e", "node_type": "1", "metadata": {"window": "It is \u2013 we think it's continuing to strengthen, but as we'll reach in the second half of our year, li ke what we \ncall, I guess, people call pre -COVID levels.  So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext question, please.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1317e46fad2de780f47bd4fdddeaf2f909739199cffa167ddc76062350362e8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c86c1ae7-49ca-4ae7-9462-78c33ff87b93", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "9ffd5b8c1e661b24b5ee4d4b4e4e7f5e20b533e136c51a4e8c9b378ef218c2bd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 3818, "end_char_idx": 4144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c86c1ae7-49ca-4ae7-9462-78c33ff87b93": {"__data__": {"id_": "c86c1ae7-49ca-4ae7-9462-78c33ff87b93", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "870fad3e-f1cc-41db-a70a-d12a7a575a54", "node_type": "1", "metadata": {"window": "So we think we're more or less right in line with our expectations, and \nwe're really pleased with the performance of the Medical -Surgical business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "940c9f7de88daf05bc9ffcd2bddeaba4ae3695ba671fbfd395a7b397c7039f2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "124d58e9-15e1-4d7d-9fcd-1c131eac9201", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi. ", "original_text": "LLC  Q \nYeah. "}, "hash": "c04ad1abc6081f9212b83e463199b46c881a8726c9882ee749023db3b29981d7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 4144, "end_char_idx": 4453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "124d58e9-15e1-4d7d-9fcd-1c131eac9201": {"__data__": {"id_": "124d58e9-15e1-4d7d-9fcd-1c131eac9201", "embedding": null, "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi. ", "original_text": "LLC  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c86c1ae7-49ca-4ae7-9462-78c33ff87b93", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investor s, McKesson Corp.   A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18578fc0a7a9b3ccedd150d787f27d9c8e8452ccfd714195c59c239e49bebae6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0214d6a5-43ff-4195-814e-434b911d6f40", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n ", "original_text": "Hi. "}, "hash": "e5d26dce62e08c259a5c47781ddab13844f64396740acfc714ab437e88890bd8", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 4453, "end_char_idx": 4467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0214d6a5-43ff-4195-814e-434b911d6f40": {"__data__": {"id_": "0214d6a5-43ff-4195-814e-434b911d6f40", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n ", "original_text": "Hi. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "124d58e9-15e1-4d7d-9fcd-1c131eac9201", "node_type": "1", "metadata": {"window": "A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi. ", "original_text": "LLC  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "493c38c0f817695acf4c9ed10539d7a54b714fd023fff67d990ecf5262f1b4e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "849a9679-84fb-4a5e-9266-2c783f07e1fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Yeah. "}, "hash": "aa60aa2f0a3ece78d5a2e8672c0a34d38b0108e77ed77dd8530304e272b687a5", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 4467, "end_char_idx": 4471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "849a9679-84fb-4a5e-9266-2c783f07e1fd": {"__data__": {"id_": "849a9679-84fb-4a5e-9266-2c783f07e1fd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Yeah. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0214d6a5-43ff-4195-814e-434b911d6f40", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Will come from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n ", "original_text": "Hi. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a765a7fe1579122c0583edf8e08cbefd8e98e3cbe0a6615cd87bb0ac08923e59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ec8ddc-1a42-4d08-a857-320de96d7b92", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "Hi. "}, "hash": "c0f0d7b95aa41874ad5c66c1c1dc26fe5c2e573a75eb82e829e7b4190e2dc4da", "class_name": "RelatedNodeInfo"}}, "text": "Yeah. ", "start_char_idx": 2791, "end_char_idx": 2797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ec8ddc-1a42-4d08-a857-320de96d7b92": {"__data__": {"id_": "c0ec8ddc-1a42-4d08-a857-320de96d7b92", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "Hi. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "849a9679-84fb-4a5e-9266-2c783f07e1fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Yeah. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c4c22e7ab880ccd8e769077072dfa4c6f5e0f7dfce2ad37a78e7b76a3356bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf9844f7-71da-438b-bb63-8357ae0d8898", "node_type": "1", "metadata": {"window": "Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "Good evening.  \n "}, "hash": "93d676c9b9110e9afab79e0c8f1ce3190bd4d4d9b5b99094a3ca50747ca654b5", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 4467, "end_char_idx": 4471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf9844f7-71da-438b-bb63-8357ae0d8898": {"__data__": {"id_": "bf9844f7-71da-438b-bb63-8357ae0d8898", "embedding": null, "metadata": {"window": "Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "Good evening.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ec8ddc-1a42-4d08-a857-320de96d7b92", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "Hi. ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10008fcf9e16811953204b5f312f2f2dd78ea8e8796daca2ffe8f7b6082a60fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3a0dc9c-4769-42e3-b07f-36ec5195963d", "node_type": "1", "metadata": {"window": "Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "40e7a50a2c78789ce83bf554c4600f255c5fd5177de5aa2f012415051f5f8407", "class_name": "RelatedNodeInfo"}}, "text": "Good evening.  \n ", "start_char_idx": 4481, "end_char_idx": 4498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3a0dc9c-4769-42e3-b07f-36ec5195963d": {"__data__": {"id_": "a3a0dc9c-4769-42e3-b07f-36ec5195963d", "embedding": null, "metadata": {"window": "Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf9844f7-71da-438b-bb63-8357ae0d8898", "node_type": "1", "metadata": {"window": "Hi.  Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "Good evening.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c1fd1ff57f876eb1572bce672da083adf61ca3f1ee001f4f3b3db544485a654", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a2c2406-5e85-426b-b897-79060c9a7c59", "node_type": "1", "metadata": {"window": "Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "A \nHi, Ricky.  "}, "hash": "67afa0e651d82fea8d4ef39e04981bcbb6fe48d2f2c684c77fbdbbe174c546f4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 993, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a2c2406-5e85-426b-b897-79060c9a7c59": {"__data__": {"id_": "9a2c2406-5e85-426b-b897-79060c9a7c59", "embedding": null, "metadata": {"window": "Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "A \nHi, Ricky.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "270bb366-14e3-4684-8f2b-c987d802abeb", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dbb0280c98837f94a1b8df68c27364e423db749a73fb21ebf62f6ba41f076d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3a0dc9c-4769-42e3-b07f-36ec5195963d", "node_type": "1", "metadata": {"window": "Yeah.  Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8a2a7ac20dfaecc6b133dfdfa1e30815882e77253840dbc7ab1e601b89cf5be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c5b9fea-9c9f-4dd1-9df8-0b9980de94f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment. ", "original_text": "McKesson Corp.  "}, "hash": "7fc57fbcf8d27af66cc569c06da274a9cb099f1eb5e3bf2c09d97d563eb91338", "class_name": "RelatedNodeInfo"}}, "text": "A \nHi, Ricky.  ", "start_char_idx": 4827, "end_char_idx": 4842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c5b9fea-9c9f-4dd1-9df8-0b9980de94f0": {"__data__": {"id_": "6c5b9fea-9c9f-4dd1-9df8-0b9980de94f0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a2c2406-5e85-426b-b897-79060c9a7c59", "node_type": "1", "metadata": {"window": "Hi.  Good evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Ricky.  ", "original_text": "A \nHi, Ricky.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bc86486660321f240208e477f89cd22021b3ce9b8b8114410e8945b64ac3183", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a60fbaf-cd37-4ba8-a0c6-37e737626fce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "72aa186ff33f81a4973a0593166dcb3cc9556243ae67a3a954abdb2e69afdada", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a60fbaf-cd37-4ba8-a0c6-37e737626fce": {"__data__": {"id_": "4a60fbaf-cd37-4ba8-a0c6-37e737626fce", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c5b9fea-9c9f-4dd1-9df8-0b9980de94f0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81c0957e8c7a98039bea2a3c8143b50aaed3a924f06544d4131dc6f2a99a2044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "648e04a1-be0d-4619-a1ea-ceaf0544b2aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution? ", "original_text": "LLC  Q \nHi, there. "}, "hash": "9e5059d645e6d202f05316e529faabc9dee9035bbb8fe0c4fdba41f078c3e9aa", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 16, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "648e04a1-be0d-4619-a1ea-ceaf0544b2aa": {"__data__": {"id_": "648e04a1-be0d-4619-a1ea-ceaf0544b2aa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution? ", "original_text": "LLC  Q \nHi, there. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a60fbaf-cd37-4ba8-a0c6-37e737626fce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business. ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a6b68be66b2b1fc38cb0a36d9275bfd230581b2a995eda3098a75fe6dc3dfe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b05b00-b814-4121-8f40-1f8e675024bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there. ", "original_text": "So a quick follow -up on your last comment. "}, "hash": "53f3dfffe221e261236972b2a0f44c4b4c5cc0787d223a424b66cce95b3caa41", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nHi, there. ", "start_char_idx": 233, "end_char_idx": 252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b05b00-b814-4121-8f40-1f8e675024bd": {"__data__": {"id_": "18b05b00-b814-4121-8f40-1f8e675024bd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there. ", "original_text": "So a quick follow -up on your last comment. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "648e04a1-be0d-4619-a1ea-ceaf0544b2aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution? ", "original_text": "LLC  Q \nHi, there. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18ff05f877efed660bc03b3fbe0a8e47704a8391c7e9e9055bac2687855c4a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bf4f2a5-c44b-4ebc-9149-8160fa2bbbe2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core? ", "original_text": "You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business. "}, "hash": "9782d9205bf99f0a6f2ac6d610a0d93d484232316896e909ffea4a4bcdb4e289", "class_name": "RelatedNodeInfo"}}, "text": "So a quick follow -up on your last comment. ", "start_char_idx": 252, "end_char_idx": 296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bf4f2a5-c44b-4ebc-9149-8160fa2bbbe2": {"__data__": {"id_": "5bf4f2a5-c44b-4ebc-9149-8160fa2bbbe2", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core? ", "original_text": "You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b05b00-b814-4121-8f40-1f8e675024bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there. ", "original_text": "So a quick follow -up on your last comment. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f131c2d6e264261d9bc444af21a9662cea8d5630159a4631ded1e9ccd98c3d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d69bb8f-967d-4a84-b8f5-178ebd78ead4", "node_type": "1", "metadata": {"window": "LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question. ", "original_text": "How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution? "}, "hash": "7e3b6f2c88806324e54c8c35d68da5967b54f2fec1a4576a243e1751ced39c22", "class_name": "RelatedNodeInfo"}}, "text": "You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business. ", "start_char_idx": 296, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d69bb8f-967d-4a84-b8f5-178ebd78ead4": {"__data__": {"id_": "6d69bb8f-967d-4a84-b8f5-178ebd78ead4", "embedding": null, "metadata": {"window": "LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question. ", "original_text": "How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf4f2a5-c44b-4ebc-9149-8160fa2bbbe2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core? ", "original_text": "You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c292ada2a16b49be981419700023a68428070637d7e8286ae3bf8ddc18ad342", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ac957de-32de-40d2-abfb-c22cff5fca45", "node_type": "1", "metadata": {"window": "So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember. ", "original_text": "It sounded like specialty is already there. "}, "hash": "aabd872dc8aec05f7c2350c694ecb3026ae17abb8f50fa0964b7dfad20929de5", "class_name": "RelatedNodeInfo"}}, "text": "How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution? ", "start_char_idx": 384, "end_char_idx": 475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ac957de-32de-40d2-abfb-c22cff5fca45": {"__data__": {"id_": "8ac957de-32de-40d2-abfb-c22cff5fca45", "embedding": null, "metadata": {"window": "So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember. ", "original_text": "It sounded like specialty is already there. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d69bb8f-967d-4a84-b8f5-178ebd78ead4", "node_type": "1", "metadata": {"window": "LLC  Q \nHi, there.  So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question. ", "original_text": "How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ce913bc7f08f4ef194b2c46f2e9b9ae0343bce11631687b526945b197fca722", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "305def90-32af-4ee6-b0a2-f4d6783f78bc", "node_type": "1", "metadata": {"window": "You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n ", "original_text": "But how should we think about the segment in its entirety \nand in core? "}, "hash": "3295147b6a2c3b5d544f8bc8a9b6db5df4768ba4fd528b9fd4689abf7a904462", "class_name": "RelatedNodeInfo"}}, "text": "It sounded like specialty is already there. ", "start_char_idx": 475, "end_char_idx": 519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "305def90-32af-4ee6-b0a2-f4d6783f78bc": {"__data__": {"id_": "305def90-32af-4ee6-b0a2-f4d6783f78bc", "embedding": null, "metadata": {"window": "You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n ", "original_text": "But how should we think about the segment in its entirety \nand in core? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ac957de-32de-40d2-abfb-c22cff5fca45", "node_type": "1", "metadata": {"window": "So a quick follow -up on your last comment.  You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember. ", "original_text": "It sounded like specialty is already there. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8802316f898b91bfe475e97324e780353fb3f06f60fa3e73fa7cd2277a4b9054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c7a74e8-d3c1-4093-a6c6-81a29ba4aae8", "node_type": "1", "metadata": {"window": "How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So that was kind of like the follow -up question. "}, "hash": "1aaa058e2bdc0101ee7b7e0a037416a12dd1b85179cfab21cc2f47546fa403fa", "class_name": "RelatedNodeInfo"}}, "text": "But how should we think about the segment in its entirety \nand in core? ", "start_char_idx": 519, "end_char_idx": 591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c7a74e8-d3c1-4093-a6c6-81a29ba4aae8": {"__data__": {"id_": "7c7a74e8-d3c1-4093-a6c6-81a29ba4aae8", "embedding": null, "metadata": {"window": "How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So that was kind of like the follow -up question. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "305def90-32af-4ee6-b0a2-f4d6783f78bc", "node_type": "1", "metadata": {"window": "You said pre -COVID levels second half of your fiscal year \nfor the Med -Surg business.  How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n ", "original_text": "But how should we think about the segment in its entirety \nand in core? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6022987203228f5c97c8309abdee4f1a33a31b655c2394fe4e9faf8061e821d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27ce9137-4d65-439a-b3fd-f5e9958d399e", "node_type": "1", "metadata": {"window": "It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then you're hosting t he Analyst Day in \nDecember. "}, "hash": "33e04538b7c0ad4336ada975e30838f303f469a3b81dd4276bbcd042b2d1b5bb", "class_name": "RelatedNodeInfo"}}, "text": "So that was kind of like the follow -up question. ", "start_char_idx": 591, "end_char_idx": 641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27ce9137-4d65-439a-b3fd-f5e9958d399e": {"__data__": {"id_": "27ce9137-4d65-439a-b3fd-f5e9958d399e", "embedding": null, "metadata": {"window": "It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then you're hosting t he Analyst Day in \nDecember. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c7a74e8-d3c1-4093-a6c6-81a29ba4aae8", "node_type": "1", "metadata": {"window": "How should we think a bout when do we get to pre -COVID levels for the drug \ndistribution?  It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So that was kind of like the follow -up question. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba071eaae9b7ad86b7b39c57eafa6551ca82a7f4c30ae6958611ca3953dac915", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "653d842d-3cd4-4771-b119-76308ebb8290", "node_type": "1", "metadata": {"window": "But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n "}, "hash": "2f08fa621b6f35dcc94b2ec657172550317a48a8fe673834ac21324736e6d081", "class_name": "RelatedNodeInfo"}}, "text": "And then you're hosting t he Analyst Day in \nDecember. ", "start_char_idx": 641, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "653d842d-3cd4-4771-b119-76308ebb8290": {"__data__": {"id_": "653d842d-3cd4-4771-b119-76308ebb8290", "embedding": null, "metadata": {"window": "But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27ce9137-4d65-439a-b3fd-f5e9958d399e", "node_type": "1", "metadata": {"window": "It sounded like specialty is already there.  But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then you're hosting t he Analyst Day in \nDecember. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "425776d55c272c15ae01dca5b18ed574b85b3d26b7c2dc241c1fafa9602eafe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf97c747-a546-42ec-9bb1-d9ab12e0d29e", "node_type": "1", "metadata": {"window": "So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "75278e6a524954a8a8ffceef2f2ee5d1ff306adefc6d7bc86fca8d6fad60cf56", "class_name": "RelatedNodeInfo"}}, "text": "So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n ", "start_char_idx": 696, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf97c747-a546-42ec-9bb1-d9ab12e0d29e": {"__data__": {"id_": "bf97c747-a546-42ec-9bb1-d9ab12e0d29e", "embedding": null, "metadata": {"window": "So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "653d842d-3cd4-4771-b119-76308ebb8290", "node_type": "1", "metadata": {"window": "But how should we think about the segment in its entirety \nand in core?  So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f08963f281104a370ef9f02142ebb2149c6c4cf061019cfcd9ed47defde64274", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19b6c15a-75f5-43e4-960c-292d7af4e07e", "node_type": "1", "metadata": {"window": "And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected. ", "original_text": "A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "0d12a02a5dc68437da2c4687254e5161fd02e120f8bbc7057ee8b51acc80b649", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 802, "end_char_idx": 1131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19b6c15a-75f5-43e4-960c-292d7af4e07e": {"__data__": {"id_": "19b6c15a-75f5-43e4-960c-292d7af4e07e", "embedding": null, "metadata": {"window": "And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected. ", "original_text": "A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf97c747-a546-42ec-9bb1-d9ab12e0d29e", "node_type": "1", "metadata": {"window": "So that was kind of like the follow -up question.  And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4564d0db3d0008b911150579dace719b488f01c9a54f72e36fe69f59e3d72d6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a60571b1-1968-4b83-acda-1bed4e9cb0b7", "node_type": "1", "metadata": {"window": "So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels. ", "original_text": "A \nYeah. "}, "hash": "60b7bdb224ac7d4c0cb80d9fca54dc717f66336c97e0fea5a5e6c21928b64074", "class_name": "RelatedNodeInfo"}}, "text": "A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1131, "end_char_idx": 1543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a60571b1-1968-4b83-acda-1bed4e9cb0b7": {"__data__": {"id_": "a60571b1-1968-4b83-acda-1bed4e9cb0b7", "embedding": null, "metadata": {"window": "So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels. ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19b6c15a-75f5-43e4-960c-292d7af4e07e", "node_type": "1", "metadata": {"window": "And then you're hosting t he Analyst Day in \nDecember.  So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected. ", "original_text": "A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c2f08271d07cce4181c40bb540618ebc1aee5d49447b714460a128dfa8f0a98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80de4d9d-fdb6-4479-8fdf-e8829c707d32", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics. ", "original_text": "I think similar to Medical, we are pleased with the performance of \u2013 volumes. "}, "hash": "3def6461a66e2a4a57c313cd2f2f74a1562b1e3ed91bc12e096d63818af46bf3", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1543, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80de4d9d-fdb6-4479-8fdf-e8829c707d32": {"__data__": {"id_": "80de4d9d-fdb6-4479-8fdf-e8829c707d32", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics. ", "original_text": "I think similar to Medical, we are pleased with the performance of \u2013 volumes. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a60571b1-1968-4b83-acda-1bed4e9cb0b7", "node_type": "1", "metadata": {"window": "So maybe can you give us a sense of granularity around what should we expect from the day next \nmonth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels. ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93fc36905e5603f8aeb715d28cc010ca2a82a719def200a481f23f95009b3805", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be792133-4b0b-4ebe-a8de-1d7407420fb3", "node_type": "1", "metadata": {"window": "A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n ", "original_text": "They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected. "}, "hash": "20619504e63be4911815c221161684188993c91b8c022e9bfc1ea8d2ca09c235", "class_name": "RelatedNodeInfo"}}, "text": "I think similar to Medical, we are pleased with the performance of \u2013 volumes. ", "start_char_idx": 1552, "end_char_idx": 1630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be792133-4b0b-4ebe-a8de-1d7407420fb3": {"__data__": {"id_": "be792133-4b0b-4ebe-a8de-1d7407420fb3", "embedding": null, "metadata": {"window": "A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n ", "original_text": "They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80de4d9d-fdb6-4479-8fdf-e8829c707d32", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics. ", "original_text": "I think similar to Medical, we are pleased with the performance of \u2013 volumes. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00b057f16f8c9fffa8aa263272681bc6c41da9e59df11135b8a1aa4b96fc980c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f445f5ec-a8cc-4de5-95eb-7e142a320c14", "node_type": "1", "metadata": {"window": "A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels. "}, "hash": "3c866e83b50c3fad2a5a54c32794548ec6de9efa5e3694d6b4eaca259bcd81b3", "class_name": "RelatedNodeInfo"}}, "text": "They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected. ", "start_char_idx": 1630, "end_char_idx": 1726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f445f5ec-a8cc-4de5-95eb-7e142a320c14": {"__data__": {"id_": "f445f5ec-a8cc-4de5-95eb-7e142a320c14", "embedding": null, "metadata": {"window": "A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be792133-4b0b-4ebe-a8de-1d7407420fb3", "node_type": "1", "metadata": {"window": "A \nDo you want to start with Pharma, and I'll take the Investor...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n ", "original_text": "They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5f981a62f9d44c85fbadd173bc0d00d80cddd974b76c8b9826b6c0a9c86f858", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88f6a298-e000-45f7-8e5a-bc5a70707530", "node_type": "1", "metadata": {"window": "I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat. ", "original_text": "So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics. "}, "hash": "b255ee9197e3427a734dc0d83bbf4466a8c2279085d154962009bcb2c57909d4", "class_name": "RelatedNodeInfo"}}, "text": "So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels. ", "start_char_idx": 1726, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88f6a298-e000-45f7-8e5a-bc5a70707530": {"__data__": {"id_": "88f6a298-e000-45f7-8e5a-bc5a70707530", "embedding": null, "metadata": {"window": "I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat. ", "original_text": "So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f445f5ec-a8cc-4de5-95eb-7e142a320c14", "node_type": "1", "metadata": {"window": "A \nYeah.  I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42b5bed98319e176c9667ba3db02b94f904e018cf6ef018ff74a39c435bd03bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d0e8c25-7dfc-401a-8b79-769d9ed60d7b", "node_type": "1", "metadata": {"window": "They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day. ", "original_text": "We expect that that will continue in the second half of the year.  \n "}, "hash": "d7cc06a69c16d4089537c828fdb91955b71302219f0d7d68a99f41d9895fc4a0", "class_name": "RelatedNodeInfo"}}, "text": "So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics. ", "start_char_idx": 1915, "end_char_idx": 2045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d0e8c25-7dfc-401a-8b79-769d9ed60d7b": {"__data__": {"id_": "5d0e8c25-7dfc-401a-8b79-769d9ed60d7b", "embedding": null, "metadata": {"window": "They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day. ", "original_text": "We expect that that will continue in the second half of the year.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88f6a298-e000-45f7-8e5a-bc5a70707530", "node_type": "1", "metadata": {"window": "I think similar to Medical, we are pleased with the performance of \u2013 volumes.  They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat. ", "original_text": "So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ff19dde6ac68a3f0998259153ac1992b877b131a7b19e0be71686641a0bb628", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df28fadd-33d9-469f-8773-0c2b416a5d3b", "node_type": "1", "metadata": {"window": "So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "e40f4c9159e8a0150fc54843a6259bdf9981ea39bc9020ab6301135433425e92", "class_name": "RelatedNodeInfo"}}, "text": "We expect that that will continue in the second half of the year.  \n ", "start_char_idx": 2045, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df28fadd-33d9-469f-8773-0c2b416a5d3b": {"__data__": {"id_": "df28fadd-33d9-469f-8773-0c2b416a5d3b", "embedding": null, "metadata": {"window": "So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d0e8c25-7dfc-401a-8b79-769d9ed60d7b", "node_type": "1", "metadata": {"window": "They are approaching pre -\nCOVID levels in pharmaceutical prescription volu mes as we expected.  So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day. ", "original_text": "We expect that that will continue in the second half of the year.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db92959e9f3717aae7124b13019595f1c7981ab92ac2c3c2944d8544f96ce338", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c56d208a-b23e-42d4-ba93-7a4d78ad116e", "node_type": "1", "metadata": {"window": "So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months. ", "original_text": "A \nGreat. "}, "hash": "f9ba85831eeb8369dd6a8ccc73b169d6ab3ed92cd5dbe598cbf06f547fa48f21", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 802, "end_char_idx": 1131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c56d208a-b23e-42d4-ba93-7a4d78ad116e": {"__data__": {"id_": "c56d208a-b23e-42d4-ba93-7a4d78ad116e", "embedding": null, "metadata": {"window": "So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months. ", "original_text": "A \nGreat. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df28fadd-33d9-469f-8773-0c2b416a5d3b", "node_type": "1", "metadata": {"window": "So I think as we look to the rest of the \nyear, we expect that these prescription volumes will get back to what we guided originally in May, which is in line \nwith those pre -COVID levels.  So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b038f458688e84ee46aa8e15b815d4dcc9b807507d88b23818381edf7baf9c19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69305aec-f8b7-44c1-933f-a7649d080082", "node_type": "1", "metadata": {"window": "We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you. ", "original_text": "And as it relates to Investor D ay, we are really excited to be able to have an Investor Day. "}, "hash": "647a81e1da9e2de3e4c8dc2b3e222b2bb4efb31fec9bb05a5d1ebab7ffb8246d", "class_name": "RelatedNodeInfo"}}, "text": "A \nGreat. ", "start_char_idx": 2443, "end_char_idx": 2453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69305aec-f8b7-44c1-933f-a7649d080082": {"__data__": {"id_": "69305aec-f8b7-44c1-933f-a7649d080082", "embedding": null, "metadata": {"window": "We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you. ", "original_text": "And as it relates to Investor D ay, we are really excited to be able to have an Investor Day. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c56d208a-b23e-42d4-ba93-7a4d78ad116e", "node_type": "1", "metadata": {"window": "So we're continuing to see improved performance an d improved volumes across all \n\u2013 both brand specialty and as well as generics.  We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months. ", "original_text": "A \nGreat. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbc5aed6cb3482b128f5b082251ab73cc73830a964602405f0d7a0458f51d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cb9f30a-cf27-4654-9c40-5494b47a7cff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n", "original_text": "We're going to \nhost it December 8 in New York City. "}, "hash": "b3bb007e1366c0d165cf0414356df5b0b1bc7567f204a97d32a476cf56a18844", "class_name": "RelatedNodeInfo"}}, "text": "And as it relates to Investor D ay, we are really excited to be able to have an Investor Day. ", "start_char_idx": 2453, "end_char_idx": 2547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cb9f30a-cf27-4654-9c40-5494b47a7cff": {"__data__": {"id_": "3cb9f30a-cf27-4654-9c40-5494b47a7cff", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n", "original_text": "We're going to \nhost it December 8 in New York City. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69305aec-f8b7-44c1-933f-a7649d080082", "node_type": "1", "metadata": {"window": "We expect that that will continue in the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you. ", "original_text": "And as it relates to Investor D ay, we are really excited to be able to have an Investor Day. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "821198546da1e1087e06e35b09e710785626f6cb5c20aaaa55fa186d18591c0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bd22a89-e0c2-4f26-b5ea-66e346acae5a", "node_type": "1", "metadata": {"window": "A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects. ", "original_text": "Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months. "}, "hash": "cdeddd917e952bf0ed928e8a0e171de31dcc34cdc14ed0bf98928c08e4cfa601", "class_name": "RelatedNodeInfo"}}, "text": "We're going to \nhost it December 8 in New York City. ", "start_char_idx": 2547, "end_char_idx": 2600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bd22a89-e0c2-4f26-b5ea-66e346acae5a": {"__data__": {"id_": "7bd22a89-e0c2-4f26-b5ea-66e346acae5a", "embedding": null, "metadata": {"window": "A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects. ", "original_text": "Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cb9f30a-cf27-4654-9c40-5494b47a7cff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n", "original_text": "We're going to \nhost it December 8 in New York City. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "795b41801e9f2a9d5e74a25d5a4afcaaccd89e8698728394c1c7398fb64e0762", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86e33590-37f7-4118-8791-ad17fc40f919", "node_type": "1", "metadata": {"window": "And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day. ", "original_text": "In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you. "}, "hash": "7065395fb5ea608bcec9215c5af6e44cb78a5597d34f1a2b800b8e143ced4a85", "class_name": "RelatedNodeInfo"}}, "text": "Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months. ", "start_char_idx": 2600, "end_char_idx": 2707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86e33590-37f7-4118-8791-ad17fc40f919": {"__data__": {"id_": "86e33590-37f7-4118-8791-ad17fc40f919", "embedding": null, "metadata": {"window": "And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day. ", "original_text": "In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bd22a89-e0c2-4f26-b5ea-66e346acae5a", "node_type": "1", "metadata": {"window": "A \nGreat.  And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects. ", "original_text": "Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfa9f503d7aaa218f7ddfd6eb04b9c3330a154644363b257995ec282362a1cec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "444aadaf-8457-4fe2-9743-845fe7bb2801", "node_type": "1", "metadata": {"window": "We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n ", "original_text": "The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n"}, "hash": "4424951fd11a05119ec902af76cf4a53cdb88175f0622c411067e0db050110c9", "class_name": "RelatedNodeInfo"}}, "text": "In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you. ", "start_char_idx": 2707, "end_char_idx": 2915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "444aadaf-8457-4fe2-9743-845fe7bb2801": {"__data__": {"id_": "444aadaf-8457-4fe2-9743-845fe7bb2801", "embedding": null, "metadata": {"window": "We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n ", "original_text": "The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86e33590-37f7-4118-8791-ad17fc40f919", "node_type": "1", "metadata": {"window": "And as it relates to Investor D ay, we are really excited to be able to have an Investor Day.  We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day. ", "original_text": "In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e8e7cb67f536f38376f63e7b19c801fb5d2eb66ab6c8d2b00696695aa94ca73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b18c8bb-363b-4f51-83e4-09c7ca61de0f", "node_type": "1", "metadata": {"window": "Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "And we plan to begin to outline our long -term growth prospects. "}, "hash": "d54e28616bc809bc9e33d2422cdf47ffc1c315bae103398c5727cc626d28dbf9", "class_name": "RelatedNodeInfo"}}, "text": "The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n", "start_char_idx": 2915, "end_char_idx": 3134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b18c8bb-363b-4f51-83e4-09c7ca61de0f": {"__data__": {"id_": "9b18c8bb-363b-4f51-83e4-09c7ca61de0f", "embedding": null, "metadata": {"window": "Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "And we plan to begin to outline our long -term growth prospects. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "444aadaf-8457-4fe2-9743-845fe7bb2801", "node_type": "1", "metadata": {"window": "We're going to \nhost it December 8 in New York City.  Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n ", "original_text": "The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6945c24995f8a9ec27ebc63089ea65cee5c38572e6c90f234a17f0ae8729ab88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2a58c01-b247-4927-bd99-05eff7266a77", "node_type": "1", "metadata": {"window": "In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n ", "original_text": "So we think it's going to be a great day. "}, "hash": "a181f479972d7c01db588869120cd7420de63b87e4790e41648fec7ede9ef95f", "class_name": "RelatedNodeInfo"}}, "text": "And we plan to begin to outline our long -term growth prospects. ", "start_char_idx": 3134, "end_char_idx": 3199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2a58c01-b247-4927-bd99-05eff7266a77": {"__data__": {"id_": "b2a58c01-b247-4927-bd99-05eff7266a77", "embedding": null, "metadata": {"window": "In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n ", "original_text": "So we think it's going to be a great day. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b18c8bb-363b-4f51-83e4-09c7ca61de0f", "node_type": "1", "metadata": {"window": "Probably would have done it sooner, but it's been quite a crazy environment \nfor the last 18 or 20 months.  In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "original_text": "And we plan to begin to outline our long -term growth prospects. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0043dc7e3dff6adb3ef2c711322657c142532d4981b04ceacc1a315533591500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02aa3147-ba3b-4b62-9ff7-8a90a1a68cbd", "node_type": "1", "metadata": {"window": "The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n ", "original_text": "We hope \nyou can all j oin us.  \n "}, "hash": "60a0684273e1f38cd0d5af46059ffac9eaca820bd07e443f697dc177a212016f", "class_name": "RelatedNodeInfo"}}, "text": "So we think it's going to be a great day. ", "start_char_idx": 3199, "end_char_idx": 3241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02aa3147-ba3b-4b62-9ff7-8a90a1a68cbd": {"__data__": {"id_": "02aa3147-ba3b-4b62-9ff7-8a90a1a68cbd", "embedding": null, "metadata": {"window": "The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n ", "original_text": "We hope \nyou can all j oin us.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2a58c01-b247-4927-bd99-05eff7266a77", "node_type": "1", "metadata": {"window": "In terms of what we hope to see is w e really want to bring some more members of \nthe management team, the executive team that have been leading the results that we've had a great chance to \nreview with you.  The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n ", "original_text": "So we think it's going to be a great day. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7be206ac26af51925584edaccdf937a3ffb5c93e50320aac9567f432d263114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faf3b0af-982a-4824-b29a-e95d2915dd46", "node_type": "1", "metadata": {"window": "And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  "}, "hash": "6a9781ba439b06cff9eed77c535e0b936a00455851b17bac10c56de5bdfa3187", "class_name": "RelatedNodeInfo"}}, "text": "We hope \nyou can all j oin us.  \n ", "start_char_idx": 3241, "end_char_idx": 3275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faf3b0af-982a-4824-b29a-e95d2915dd46": {"__data__": {"id_": "faf3b0af-982a-4824-b29a-e95d2915dd46", "embedding": null, "metadata": {"window": "And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02aa3147-ba3b-4b62-9ff7-8a90a1a68cbd", "node_type": "1", "metadata": {"window": "The team that's been responsible for developing these strategies; we want to provide ju st a little \nbit more insight and granularity into each of our growth strategies and in some of our core distribution businesses. \n And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n ", "original_text": "We hope \nyou can all j oin us.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d7323bee98c94e5a4aed1aa061c17c93435eb8497342ce691fe04f44f187565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f8dad45-d057-4f5d-9999-e2c211dca105", "node_type": "1", "metadata": {"window": "So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here. ", "original_text": "A \nNext, question please.  \n "}, "hash": "77f81cd63eab11aeb5a96ae782ad056de2716f64306a3587c4ae7b2fbb02b523", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "start_char_idx": 3275, "end_char_idx": 3604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f8dad45-d057-4f5d-9999-e2c211dca105": {"__data__": {"id_": "2f8dad45-d057-4f5d-9999-e2c211dca105", "embedding": null, "metadata": {"window": "So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here. ", "original_text": "A \nNext, question please.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faf3b0af-982a-4824-b29a-e95d2915dd46", "node_type": "1", "metadata": {"window": "And we plan to begin to outline our long -term growth prospects.  So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcd83c04fcad740b9bf409aa4cd6bf7fc5683fba90cac7d031575ebb238ab248", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "069b33b6-386d-4737-b0c5-0e2c10fa6af4", "node_type": "1", "metadata": {"window": "We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n "}, "hash": "4493dbed43fc033e1fd91e5f05108b83cd59ed86c4415f0f9e2d63ebd801751a", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext, question please.  \n ", "start_char_idx": 3604, "end_char_idx": 3633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "069b33b6-386d-4737-b0c5-0e2c10fa6af4": {"__data__": {"id_": "069b33b6-386d-4737-b0c5-0e2c10fa6af4", "embedding": null, "metadata": {"window": "We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f8dad45-d057-4f5d-9999-e2c211dca105", "node_type": "1", "metadata": {"window": "So we think it's going to be a great day.  We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here. ", "original_text": "A \nNext, question please.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00c5c6736ab05dff881cb66c7beddb30f8b6aba3f7ffbf1732021ff330becba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69f7b407-53ba-46c1-8b20-2241ad3dd9e8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you. "}, "hash": "f250aae7bf6ac164bf798f60f47a03f0afaad3b7684252fd24929cff1268bef8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n ", "start_char_idx": 3633, "end_char_idx": 3970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69f7b407-53ba-46c1-8b20-2241ad3dd9e8": {"__data__": {"id_": "69f7b407-53ba-46c1-8b20-2241ad3dd9e8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "069b33b6-386d-4737-b0c5-0e2c10fa6af4", "node_type": "1", "metadata": {"window": "We hope \nyou can all j oin us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98debf3563fcd06cc776c8f4beaa4716e9601c36dd32fafb72f75b735c262daf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e2781d4-56af-4a29-80dc-b99c493980e7", "node_type": "1", "metadata": {"window": "A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well? ", "original_text": "Thanks for taking my questions here. "}, "hash": "66c1570945fb09b839df491fd3a2e8b04f23f84d7c9087c060a51d13cc2622bf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you. ", "start_char_idx": 3970, "end_char_idx": 4310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e2781d4-56af-4a29-80dc-b99c493980e7": {"__data__": {"id_": "3e2781d4-56af-4a29-80dc-b99c493980e7", "embedding": null, "metadata": {"window": "A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well? ", "original_text": "Thanks for taking my questions here. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69f7b407-53ba-46c1-8b20-2241ad3dd9e8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.   A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbc4549fa4a1b0387e97f8847dcae264405fb98ddbd654ed24c3be01f08ea773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "820c0dcc-80d8-4039-8015-c9e327a70b5a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n ", "original_text": "Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit? "}, "hash": "c0f725139e7a58ac52c1773031896748a0bb810368479faa91f2f1cbceeec441", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my questions here. ", "start_char_idx": 4310, "end_char_idx": 4347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "820c0dcc-80d8-4039-8015-c9e327a70b5a": {"__data__": {"id_": "820c0dcc-80d8-4039-8015-c9e327a70b5a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n ", "original_text": "Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e2781d4-56af-4a29-80dc-b99c493980e7", "node_type": "1", "metadata": {"window": "A \nNext, question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well? ", "original_text": "Thanks for taking my questions here. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "467f26fdecb94a0b49309cd0229df7189127acd736beaf9ada47b466521104b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb629f1-6a62-4cb9-a3b2-c8a2b7ef5629", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot. "}, "hash": "09fc10843fc1ec49fd14dedbf1caaea3d372288564e2b45992606244355a419b", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit? ", "start_char_idx": 4347, "end_char_idx": 4462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb629f1-6a62-4cb9-a3b2-c8a2b7ef5629": {"__data__": {"id_": "9fb629f1-6a62-4cb9-a3b2-c8a2b7ef5629", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "820c0dcc-80d8-4039-8015-c9e327a70b5a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : We have one final question from Jailendra Singh, Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n ", "original_text": "Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ced59a3088c3eec091d644e16dc8f43350c858e3c2421e8f6516c185dc9f943c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2328d53-ef28-4dfa-a82b-d01a6dd53c75", "node_type": "1", "metadata": {"window": "Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well? "}, "hash": "cfdb1e62d275c45f352c7c69d7d257d154eef73112b67e9e5d4b0efcf9fbabeb", "class_name": "RelatedNodeInfo"}}, "text": "It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot. ", "start_char_idx": 4462, "end_char_idx": 4556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2328d53-ef28-4dfa-a82b-d01a6dd53c75": {"__data__": {"id_": "b2328d53-ef28-4dfa-a82b-d01a6dd53c75", "embedding": null, "metadata": {"window": "Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb629f1-6a62-4cb9-a3b2-c8a2b7ef5629", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYeah, thank you.  Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot. ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0594f6aacabb0a624f45d5b86cd018a2a72f2c86ef1fadbd4347ad6a8c963d62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb46c93a-0e09-467a-9e70-8119fd91b437", "node_type": "1", "metadata": {"window": "Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n "}, "hash": "0bf1fa46b0d38bc01fd1f37be36faafda1a44179ee01f8f1acd70fab8915055d", "class_name": "RelatedNodeInfo"}}, "text": "I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well? ", "start_char_idx": 4556, "end_char_idx": 4687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb46c93a-0e09-467a-9e70-8119fd91b437": {"__data__": {"id_": "eb46c93a-0e09-467a-9e70-8119fd91b437", "embedding": null, "metadata": {"window": "Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2328d53-ef28-4dfa-a82b-d01a6dd53c75", "node_type": "1", "metadata": {"window": "Thanks for taking my questions here.  Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well? ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29954e5996422bcbcd5c965653b1101774dd0146b618ec2cc89a1224373e14ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4194458b-549e-4cec-8092-5f9ffe3127bc", "node_type": "1", "metadata": {"window": "It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "8faf24c58fa00b86152815b9d4e4defe05d85eb23bd911ae24e205d11571113f", "class_name": "RelatedNodeInfo"}}, "text": "Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n ", "start_char_idx": 4687, "end_char_idx": 4853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4194458b-549e-4cec-8092-5f9ffe3127bc": {"__data__": {"id_": "4194458b-549e-4cec-8092-5f9ffe3127bc", "embedding": null, "metadata": {"window": "It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "637d54c8518321f065e164f7b49010d542cbd01008aacdbdc843ef1757192abe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb46c93a-0e09-467a-9e70-8119fd91b437", "node_type": "1", "metadata": {"window": "Just wanted to make sure I understand what is in and \nwhat is not in the guidance with respect to vaccine benefit?  It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b9d6729b48c6eb0fd9589d5b252e43d670e95b24bbd2d01eb72289bf889b0fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "162941fd-7b8b-4ca3-9d3d-8c191fe48e03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. ", "original_text": "McKesson Corp.  "}, "hash": "3735cc45602144ac1949d2de7ca81ea8551bb158d098a1745d2a56493b0fc679", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 802, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "162941fd-7b8b-4ca3-9d3d-8c191fe48e03": {"__data__": {"id_": "162941fd-7b8b-4ca3-9d3d-8c191fe48e03", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4194458b-549e-4cec-8092-5f9ffe3127bc", "node_type": "1", "metadata": {"window": "It seems you're not including the benefit from vaccines \ndesignated for kids or booster shot.  I s that true on both vaccine distribution benefit and the benefit related to the \nkitting storage and ancillary supplies as well?  Just trying to understand if you see a reasonable adoption of \nboosters and vaccine among kids, will that drive incremental reven ue in both Pharma and Med -Surg?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "519bc9c4cbac41c98fe0d067f6ae5d68e27265394f42d43261851a952f45d3f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f324ac8-596e-4f25-9da1-8a55ad5e4df4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "4423aca1611234352fb87ac2006f766fed31647d3aeb275577c093b7bc51c543", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f324ac8-596e-4f25-9da1-8a55ad5e4df4": {"__data__": {"id_": "0f324ac8-596e-4f25-9da1-8a55ad5e4df4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "162941fd-7b8b-4ca3-9d3d-8c191fe48e03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f943f04981e636af5aa73e1d1864f37ea0e2d9ecc736d15dc4c26b71c1e9d998", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a0e19ff-d746-4543-9a32-de438868459a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "A \nSo your first part of the question, I think, answered your question. "}, "hash": "0f062e41c6c8ecdcc06c45a16815805dd1d19d99a462e406394018ae88e4d7db", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a0e19ff-d746-4543-9a32-de438868459a": {"__data__": {"id_": "6a0e19ff-d746-4543-9a32-de438868459a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "A \nSo your first part of the question, I think, answered your question. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f324ac8-596e-4f25-9da1-8a55ad5e4df4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n ", "original_text": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20149f97ee1499953171437a0ebaa09911f84575b3572bcf50f6835de69176a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "182fe6e8-52d8-4dae-aa09-6f707397c5f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n ", "original_text": "We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. "}, "hash": "fac4d979ce92e5ca8667693b34db7c95bb140ceb299b7c46f46933d133c2be3a", "class_name": "RelatedNodeInfo"}}, "text": "A \nSo your first part of the question, I think, answered your question. ", "start_char_idx": 253, "end_char_idx": 325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "182fe6e8-52d8-4dae-aa09-6f707397c5f1": {"__data__": {"id_": "182fe6e8-52d8-4dae-aa09-6f707397c5f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n ", "original_text": "We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a0e19ff-d746-4543-9a32-de438868459a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "original_text": "A \nSo your first part of the question, I think, answered your question. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fafaa9171c9430cd28a5b70a01201a943f264dbc9601ddba03d01709aed62e8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60f9d5f7-b119-459d-a477-a000545ce4ab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "And at this point, that does not include boosters and \npediatric vaccines.  \n "}, "hash": "78197ba55d631114150751946162271c6f3783af69d7e1ee9c95ee02e853a466", "class_name": "RelatedNodeInfo"}}, "text": "We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. ", "start_char_idx": 325, "end_char_idx": 417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60f9d5f7-b119-459d-a477-a000545ce4ab": {"__data__": {"id_": "60f9d5f7-b119-459d-a477-a000545ce4ab", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "And at this point, that does not include boosters and \npediatric vaccines.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "182fe6e8-52d8-4dae-aa09-6f707397c5f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n ", "original_text": "We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50be183415e27fb1df77ba758a0105eaae80bdaf1e2e0fd6c376452d3d39de2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10930c63-f714-4d19-8566-36222be27a77", "node_type": "1", "metadata": {"window": "A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. "}, "hash": "2f9e16d9d8e3ca31bcd36220d53cc0c1ffdecb3dd1d7663041fa4df0e8f23b84", "class_name": "RelatedNodeInfo"}}, "text": "And at this point, that does not include boosters and \npediatric vaccines.  \n ", "start_char_idx": 417, "end_char_idx": 495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10930c63-f714-4d19-8566-36222be27a77": {"__data__": {"id_": "10930c63-f714-4d19-8566-36222be27a77", "embedding": null, "metadata": {"window": "A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60f9d5f7-b119-459d-a477-a000545ce4ab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "And at this point, that does not include boosters and \npediatric vaccines.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc7f1e32ee8ae0977ec40658b1df85651df09eb9e4ad6f80046a949ae7c4da3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a01eafd9-c3cb-41cc-ba23-b679570f7b76", "node_type": "1", "metadata": {"window": "We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call. ", "original_text": "And there are no further questions.  \n "}, "hash": "185b34b95b17c1fdfa07ac29ba44907b35133866128b31499acfe9feb1cc9491", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "start_char_idx": 495, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a01eafd9-c3cb-41cc-ba23-b679570f7b76": {"__data__": {"id_": "a01eafd9-c3cb-41cc-ba23-b679570f7b76", "embedding": null, "metadata": {"window": "We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call. ", "original_text": "And there are no further questions.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10930c63-f714-4d19-8566-36222be27a77", "node_type": "1", "metadata": {"window": "A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7b0ce2e95f40999cdb5a6791cecda08856e632a49c3adf7e3e1d0af3bcc5ef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd2c6e86-f976-4d20-9847-6932030e0ebc", "node_type": "1", "metadata": {"window": "And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "e9842d0c6f167322f79570d2b394dc6b48afae6adc511b10b618e3601613f8d8", "class_name": "RelatedNodeInfo"}}, "text": "And there are no further questions.  \n ", "start_char_idx": 776, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd2c6e86-f976-4d20-9847-6932030e0ebc": {"__data__": {"id_": "cd2c6e86-f976-4d20-9847-6932030e0ebc", "embedding": null, "metadata": {"window": "And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a01eafd9-c3cb-41cc-ba23-b679570f7b76", "node_type": "1", "metadata": {"window": "We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us.  And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call. ", "original_text": "And there are no further questions.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04dd59e64e0692eaf72333ecc06d574e3dde88af0d5bbfe731a3141560cc07ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9d2a32c-1402-46d4-9be2-165c3c08e09f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there. ", "original_text": "Okay. "}, "hash": "3efbb9ef6db25488e892b2b4e0c3dc008fc44dd8100274289e4379e6f50a29eb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 815, "end_char_idx": 1145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9d2a32c-1402-46d4-9be2-165c3c08e09f": {"__data__": {"id_": "b9d2a32c-1402-46d4-9be2-165c3c08e09f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there. ", "original_text": "Okay. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd2c6e86-f976-4d20-9847-6932030e0ebc", "node_type": "1", "metadata": {"window": "And at this point, that does not include boosters and \npediatric vaccines.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00761043e59f6699037b3a1507939aa43ecddf0a11b2ec664a8c1d03e2edc5a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0612f3f3-80f0-40a8-9b68-5e9dbe7ff4e2", "node_type": "1", "metadata": {"window": "And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n", "original_text": "Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call. "}, "hash": "d49f3a133adce83a9dccd30be2bb35669543391a74a97c1a8d5b9b5dab0cd112", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 1145, "end_char_idx": 1151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0612f3f3-80f0-40a8-9b68-5e9dbe7ff4e2": {"__data__": {"id_": "0612f3f3-80f0-40a8-9b68-5e9dbe7ff4e2", "embedding": null, "metadata": {"window": "And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n", "original_text": "Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9d2a32c-1402-46d4-9be2-165c3c08e09f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you.  And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there. ", "original_text": "Okay. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e9bb45252a2ca8372f5c6f73918157f798a800f5fae7c0be5aec6cc7f7b115d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d6767aa-f5cf-4714-99d1-6c6c9334ee7b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars. ", "original_text": "I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in. "}, "hash": "603ba5e8f5f21973d416bc90b8b42c2d28327d006186d4eec6432fef22e18331", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call. ", "start_char_idx": 1151, "end_char_idx": 1250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d6767aa-f5cf-4714-99d1-6c6c9334ee7b": {"__data__": {"id_": "7d6767aa-f5cf-4714-99d1-6c6c9334ee7b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars. ", "original_text": "I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0612f3f3-80f0-40a8-9b68-5e9dbe7ff4e2", "node_type": "1", "metadata": {"window": "And there are no further questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n", "original_text": "Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35c7a3f4eb32ef1974323c9db78970aef34fe05c06091439d42d0b3cf0280c6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8666932-62d8-44f2-aac2-61a4ffcd8a68", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day. ", "original_text": "We're going to have our leadership team there. "}, "hash": "95f260fc9693e40f2694cfcb76f19c031feac811612dce54980ee55d2c62a1cc", "class_name": "RelatedNodeInfo"}}, "text": "I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in. ", "start_char_idx": 1250, "end_char_idx": 1422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8666932-62d8-44f2-aac2-61a4ffcd8a68": {"__data__": {"id_": "e8666932-62d8-44f2-aac2-61a4ffcd8a68", "embedding": null, "metadata": {"window": "Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day. ", "original_text": "We're going to have our leadership team there. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d6767aa-f5cf-4714-99d1-6c6c9334ee7b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars. ", "original_text": "I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f359642823f945261fc5d9bab2bf35b0fad927ddd0518adc9b366b60821f98b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03975480-279c-4420-887c-1716df50644b", "node_type": "1", "metadata": {"window": "Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you. ", "original_text": "The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n"}, "hash": "5b15e78e6431602f63cc4f98c2c787113a4eac9851d0285243120d2d53295155", "class_name": "RelatedNodeInfo"}}, "text": "We're going to have our leadership team there. ", "start_char_idx": 1422, "end_char_idx": 1469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03975480-279c-4420-887c-1716df50644b": {"__data__": {"id_": "03975480-279c-4420-887c-1716df50644b", "embedding": null, "metadata": {"window": "Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you. ", "original_text": "The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8666932-62d8-44f2-aac2-61a4ffcd8a68", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day. ", "original_text": "We're going to have our leadership team there. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9657cdc7fa3f2f04d5d5f750a2e7cb058ab5dd67c37c87bf9d8c85b755b7e43e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef5d0ed3-2083-4b4f-b6c3-98f81eeb813d", "node_type": "1", "metadata": {"window": "I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year. ", "original_text": "We will spend some quality time on our oncology and biopharma strategic growth pillars. "}, "hash": "ff69c0ab9e07d5d86d5d269e2b3ef022af36bc7e6b2eb033f867f39545068cce", "class_name": "RelatedNodeInfo"}}, "text": "The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n", "start_char_idx": 1469, "end_char_idx": 1608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef5d0ed3-2083-4b4f-b6c3-98f81eeb813d": {"__data__": {"id_": "ef5d0ed3-2083-4b4f-b6c3-98f81eeb813d", "embedding": null, "metadata": {"window": "I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year. ", "original_text": "We will spend some quality time on our oncology and biopharma strategic growth pillars. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03975480-279c-4420-887c-1716df50644b", "node_type": "1", "metadata": {"window": "Well, thank you, Sarah, and thank you, everyone, for the great questions and for joining our call.  I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you. ", "original_text": "The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22fe5c3afc947a6aa3a98617ec2f14c77c35dd8d0cd7bac77a0f513b2ce3caa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0bfc667-7481-4601-8542-8353f74f6c27", "node_type": "1", "metadata": {"window": "We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them. ", "original_text": "I think it's going to be a \ngreat day. "}, "hash": "83aafa072bc3c9ff419b5a8876b397670ac58698b147f0708854c726bc19c0de", "class_name": "RelatedNodeInfo"}}, "text": "We will spend some quality time on our oncology and biopharma strategic growth pillars. ", "start_char_idx": 1608, "end_char_idx": 1696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0bfc667-7481-4601-8542-8353f74f6c27": {"__data__": {"id_": "d0bfc667-7481-4601-8542-8353f74f6c27", "embedding": null, "metadata": {"window": "We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them. ", "original_text": "I think it's going to be a \ngreat day. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef5d0ed3-2083-4b4f-b6c3-98f81eeb813d", "node_type": "1", "metadata": {"window": "I want to \nconclude my remarks today by just underscoring that we're hosting an Investor Day on December 8, and we hope \neveryone will get a chance to join us and tune in.  We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year. ", "original_text": "We will spend some quality time on our oncology and biopharma strategic growth pillars. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72946082110e9b328849ddb80aee154aa72c4ac4154861fd06bcf5d4ff4e4ef4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48d7a1dd-6e1c-4b18-9110-54d38dfe7ee7", "node_type": "1", "metadata": {"window": "The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone. ", "original_text": "We are really excited to be with everyone and see you. "}, "hash": "1385d29add5e91b826c29739d62405ae7821a96b1ba9436d7bf2cd452606e9cd", "class_name": "RelatedNodeInfo"}}, "text": "I think it's going to be a \ngreat day. ", "start_char_idx": 1696, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48d7a1dd-6e1c-4b18-9110-54d38dfe7ee7": {"__data__": {"id_": "48d7a1dd-6e1c-4b18-9110-54d38dfe7ee7", "embedding": null, "metadata": {"window": "The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone. ", "original_text": "We are really excited to be with everyone and see you. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0bfc667-7481-4601-8542-8353f74f6c27", "node_type": "1", "metadata": {"window": "We're going to have our leadership team there.  The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them. ", "original_text": "I think it's going to be a \ngreat day. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00b6a150af7f2ae50c692d2cf7343319376584a222bc6e579886760826a5f421", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c44c15e-dd2f-4298-8f98-4bcf57b4cb2a", "node_type": "1", "metadata": {"window": "We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n ", "original_text": "I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year. "}, "hash": "4059061aa56337be7d7a9484a963b28cd38697628e3eccedaf85a9ca7189486b", "class_name": "RelatedNodeInfo"}}, "text": "We are really excited to be with everyone and see you. ", "start_char_idx": 1735, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c44c15e-dd2f-4298-8f98-4bcf57b4cb2a": {"__data__": {"id_": "3c44c15e-dd2f-4298-8f98-4bcf57b4cb2a", "embedding": null, "metadata": {"window": "We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n ", "original_text": "I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48d7a1dd-6e1c-4b18-9110-54d38dfe7ee7", "node_type": "1", "metadata": {"window": "The team that's \nbeen responsible for building the momentum in the business and executing the strategies that have been put in \nplace.  \n \n We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone. ", "original_text": "We are really excited to be with everyone and see you. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe762c57b4aa47b90f78d03a3efdde6281593b63f024131caed246fdcbfb944c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53b62fda-b9c4-4cb6-aee4-70fe74a5e955", "node_type": "1", "metadata": {"window": "I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "That's where the real work gets done, and I'm so proud of them. "}, "hash": "8a007e1c7e74f2f1ae2c15e618e1c06dd0d2b6c383ba6fcf9757b296b0191e03", "class_name": "RelatedNodeInfo"}}, "text": "I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year. ", "start_char_idx": 1790, "end_char_idx": 1966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53b62fda-b9c4-4cb6-aee4-70fe74a5e955": {"__data__": {"id_": "53b62fda-b9c4-4cb6-aee4-70fe74a5e955", "embedding": null, "metadata": {"window": "I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "That's where the real work gets done, and I'm so proud of them. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c44c15e-dd2f-4298-8f98-4bcf57b4cb2a", "node_type": "1", "metadata": {"window": "We will spend some quality time on our oncology and biopharma strategic growth pillars.  I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n ", "original_text": "I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf768ed6760710194baacdb10f4bce96f10c377585d4d9f1873f1f584382aaa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b058630d-8c85-47ed-a8bd-e8364ca07464", "node_type": "1", "metadata": {"window": "We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "So thanks, everyone. "}, "hash": "13eca91b6f9768747636949d8266ef095663e1c4f3dbd71a8e632633d8882094", "class_name": "RelatedNodeInfo"}}, "text": "That's where the real work gets done, and I'm so proud of them. ", "start_char_idx": 1966, "end_char_idx": 2030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b058630d-8c85-47ed-a8bd-e8364ca07464": {"__data__": {"id_": "b058630d-8c85-47ed-a8bd-e8364ca07464", "embedding": null, "metadata": {"window": "We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "So thanks, everyone. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53b62fda-b9c4-4cb6-aee4-70fe74a5e955", "node_type": "1", "metadata": {"window": "I think it's going to be a \ngreat day.  We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "That's where the real work gets done, and I'm so proud of them. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11b707930f061ba7f5bcf6dd37690592af848afe118b7e5920f72553637f5d33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0d09e52-ebac-4679-8aa8-57ddd7890091", "node_type": "1", "metadata": {"window": "I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I hope you have \na great evening.  \n "}, "hash": "7c954e4c6a6af8ecb598e2d0cf96560dabffd2e45fa10aba5443d5fd164b3488", "class_name": "RelatedNodeInfo"}}, "text": "So thanks, everyone. ", "start_char_idx": 2030, "end_char_idx": 2051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0d09e52-ebac-4679-8aa8-57ddd7890091": {"__data__": {"id_": "e0d09e52-ebac-4679-8aa8-57ddd7890091", "embedding": null, "metadata": {"window": "I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I hope you have \na great evening.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b058630d-8c85-47ed-a8bd-e8364ca07464", "node_type": "1", "metadata": {"window": "We are really excited to be with everyone and see you.  I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "So thanks, everyone. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9d6055589ddf06a1eed56b3dfa16c81df156b0398f56614fc4a59d7bb5b21e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50f5d8be-2377-4bbd-9947-7c22deb5dc0e", "node_type": "1", "metadata": {"window": "That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. "}, "hash": "339d0a153204850d7ea1eaa41ef7596f1fde236e30eb6fb67bfe1dbf56043ed9", "class_name": "RelatedNodeInfo"}}, "text": "I hope you have \na great evening.  \n ", "start_char_idx": 2051, "end_char_idx": 2088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50f5d8be-2377-4bbd-9947-7c22deb5dc0e": {"__data__": {"id_": "50f5d8be-2377-4bbd-9947-7c22deb5dc0e", "embedding": null, "metadata": {"window": "That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0d09e52-ebac-4679-8aa8-57ddd7890091", "node_type": "1", "metadata": {"window": "I also don't want to let this call lapse without \nthanking the McKesson team for their incredible work and their dedication as we round out the first half of our \nfiscal year.  That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I hope you have \na great evening.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17ef58fae0468ab1228e9215eb38dd52502e8939c125c6e8d87f4097fe9dfdf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0824d247-faa4-4c04-983e-295fa9a7f0c0", "node_type": "1", "metadata": {"window": "So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n "}, "hash": "97cafe361c12f4cf77517137a8c65ff38d875b9a7653a82a96ac0d2d2bd03693", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 2088, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0824d247-faa4-4c04-983e-295fa9a7f0c0": {"__data__": {"id_": "0824d247-faa4-4c04-983e-295fa9a7f0c0", "embedding": null, "metadata": {"window": "So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50f5d8be-2377-4bbd-9947-7c22deb5dc0e", "node_type": "1", "metadata": {"window": "That's where the real work gets done, and I'm so proud of them.  So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb589238852f88981c72765703dcc2932879d2cbde48a083f9a5c9d0047414ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48ff3e55-35ee-4226-aa01-c51e21402a3b", "node_type": "1", "metadata": {"window": "I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "2b10b74ba28ab17a58b6bb3f7807436a685f84e3f80a146eaf24ddec9da32993", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "start_char_idx": 2405, "end_char_idx": 2474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48ff3e55-35ee-4226-aa01-c51e21402a3b": {"__data__": {"id_": "48ff3e55-35ee-4226-aa01-c51e21402a3b", "embedding": null, "metadata": {"window": "I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0824d247-faa4-4c04-983e-295fa9a7f0c0", "node_type": "1", "metadata": {"window": "So thanks, everyone.  I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48522b54b08d34cd9c89c3ab50aa47f5e9461117cabf7dfdf781eaee3a1c540e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2683d19-236d-48c5-8001-22269599561f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information. "}, "hash": "cc6a507be8c20590461d9e9a79432871911cd6216df860ad7f82b75dbb7d38af", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 2474, "end_char_idx": 2683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2683d19-236d-48c5-8001-22269599561f": {"__data__": {"id_": "f2683d19-236d-48c5-8001-22269599561f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48ff3e55-35ee-4226-aa01-c51e21402a3b", "node_type": "1", "metadata": {"window": "I hope you have \na great evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "834350c00fba226ea5a9934681b79bb8760ac9c238385af38e37d14a964e3082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f99840a-c2c7-458d-8db7-5c85474962c0", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "ef5f2db8451f01311c0c623592c635f8cb67e0f770165b61c25813fc6a17bf80", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 2683, "end_char_idx": 2806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f99840a-c2c7-458d-8db7-5c85474962c0": {"__data__": {"id_": "4f99840a-c2c7-458d-8db7-5c85474962c0", "embedding": null, "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2683d19-236d-48c5-8001-22269599561f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c0113889957df3c81e73b367a6959dd05e7df5c9617ed0570188f1638e52733", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a36fae0e-04c7-4559-b1e8-5549e1af468b", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "1d6926841f30fa53e6e37d49ca1af24a6e04dc6c5385c0d4f4f8822fe0364185", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 2806, "end_char_idx": 3098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a36fae0e-04c7-4559-b1e8-5549e1af468b": {"__data__": {"id_": "a36fae0e-04c7-4559-b1e8-5549e1af468b", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f99840a-c2c7-458d-8db7-5c85474962c0", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "555c91f0effe77154fbff90eaef33de0a69afaea3a47103b9629421a0b0e0cc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ac0c755-4f47-492b-a088-4bcb502402d1", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to c hange without notice. "}, "hash": "fff2658daee78d6bd5261700befa74e440281ad8c5f4de703386a91ca042ff58", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 3098, "end_char_idx": 3461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ac0c755-4f47-492b-a088-4bcb502402d1": {"__data__": {"id_": "5ac0c755-4f47-492b-a088-4bcb502402d1", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to c hange without notice. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a36fae0e-04c7-4559-b1e8-5549e1af468b", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff69c67b25bc6322027d7592deaeae5f8a347c79b1ab6597d170c82d06b2a2df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddfc8364-38e5-4754-a81f-b668d8d279ee", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC. "}, "hash": "9edcdd1059a6cd02c5b50a06c2eb969bb4940afcc50da160f23335bfee92f25d", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to c hange without notice. ", "start_char_idx": 3461, "end_char_idx": 3546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddfc8364-38e5-4754-a81f-b668d8d279ee": {"__data__": {"id_": "ddfc8364-38e5-4754-a81f-b668d8d279ee", "embedding": null, "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ac0c755-4f47-492b-a088-4bcb502402d1", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completen ess, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to c hange without notice. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1b3584e593aed463279f5498ae540085415c9596ddd1f1b7589c569bed351b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b21dba85-0b75-489c-8e9d-9c1f7c5d405e", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "41056d0bc438c03e716e477e7656e4d161a2ea19aac8ee49adb6bd662097937d", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC. ", "start_char_idx": 3546, "end_char_idx": 3674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b21dba85-0b75-489c-8e9d-9c1f7c5d405e": {"__data__": {"id_": "b21dba85-0b75-489c-8e9d-9c1f7c5d405e", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddfc8364-38e5-4754-a81f-b668d8d279ee", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of  any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32286fe39e50da09d7271f0dfbd83645dff0cc3a0f544951f67eca9bd3acade3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b8eeb6f-db4c-4274-94eb-a1f1bdbdff04", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "2c0ad2a0a9521592f1b4a0c525c5de7199e63005904571d54140c1e9716d5379", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 3674, "end_char_idx": 3837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b8eeb6f-db4c-4274-94eb-a1f1bdbdff04": {"__data__": {"id_": "8b8eeb6f-db4c-4274-94eb-a1f1bdbdff04", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b21dba85-0b75-489c-8e9d-9c1f7c5d405e", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and  is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c0d06a6b77be506a6f2c652a7fb95d9fb2bf31a14c884b845550f9cf789d6b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b1ddd2f-dcbc-4f39-858d-d0c7c553aeec", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n"}, "hash": "c1f98745f438054f1cd7fc3f5627dd97a799d45533c201196694e8042a988fd7", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 3837, "end_char_idx": 4271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b1ddd2f-dcbc-4f39-858d-d0c7c553aeec": {"__data__": {"id_": "9b1ddd2f-dcbc-4f39-858d-d0c7c553aeec", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b8eeb6f-db4c-4274-94eb-a1f1bdbdff04", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to c hange without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "051edd4208267304fd47bcc078a026c7a60589d327741eb144f57042ac3c0bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e9b238e-3f38-4039-a934-138e7a7c72c0", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "cb0a282a19ee266090ba6f6263a68aba397311d108dcfbc6e913ab463895deb6", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "start_char_idx": 4271, "end_char_idx": 4950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e9b238e-3f38-4039-a934-138e7a7c72c0": {"__data__": {"id_": "7e9b238e-3f38-4039-a934-138e7a7c72c0", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b1ddd2f-dcbc-4f39-858d-d0c7c553aeec", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of Fa ctSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb2b418824bcd994bc32f490311ff93686d566623109f617d6d36cd9d4dfda9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c5496aa-b14a-450c-959e-c602451968fe", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "e9c375b952a2f7f5cdc939bea079b52055d9260f4fb696280d3aea6562d8a434", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 4950, "end_char_idx": 5140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c5496aa-b14a-450c-959e-c602451968fe": {"__data__": {"id_": "3c5496aa-b14a-450c-959e-c602451968fe", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e9b238e-3f38-4039-a934-138e7a7c72c0", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba7a94519f96ff4d8e94178676b7d3e22af569efa5a9c61bb2b198cfcd14c727", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddad80b3-f780-48fd-a2be-68efb5416689", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "728714a8a59eae4992c0478378ee4166ba3e65ed9addf02187805fdab3046c14", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 5140, "end_char_idx": 5218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddad80b3-f780-48fd-a2be-68efb5416689": {"__data__": {"id_": "ddad80b3-f780-48fd-a2be-68efb5416689", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f381e66-390b-485e-8876-9a33c7c20d11", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7681130c167d8b0b6e0c7f011fe29c698b2367cadaf22aec27345e5b0ea68c82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c5496aa-b14a-450c-959e-c602451968fe", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM A LL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WI THOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILI TY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are t rademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1127f431104e668b505f2dd88ebd599cfef57b749f6b9ac599893d7a5f18b487", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 5218, "end_char_idx": 5240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"4972ee75-c737-4c62-adc6-975003ebb7d2": {"doc_hash": "c77f72b8625015abe345b93d1b8dfd4c1250ca1f7c078d867736030374da32e1", "ref_doc_id": "f43cc1d0-0218-4941-a2a2-4b921ef536d8"}, "fd0e9e2e-5fb9-40c2-adbe-54c6853b322b": {"doc_hash": "c631750e7d0859cc3ec99d519dae692cecfab039069f1001e7b0332d7c522bd4", "ref_doc_id": "f43cc1d0-0218-4941-a2a2-4b921ef536d8"}, "c03e914f-f60c-4e7f-aa8f-b29dd6e865d8": {"doc_hash": "0ebd48c6a4184d4d32cd359d546b7f7efbcbbcfad497ed6aa0787b658eb0b7b0", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "9698887a-5846-49bf-b947-5f85bd0d096f": {"doc_hash": "8d49c35979ff3a0ad1257b1c6522e334687a6c10e064e94ba0efaf4e6fbb238c", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "f438986e-ed83-4a47-9861-e24f7e799d83": {"doc_hash": "81bfbf964d4397b6d9b047ff891a5624c631861b5a08cef9740d170ce2bbeeb7", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "bfb49db0-67d7-45b9-8ab4-117b853430a0": {"doc_hash": "fb132e47ee1e9e69010338be990e51067f2ef2e4f547dec56be60a4957698256", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "77677100-623b-4db3-9022-1b26e28830e7": {"doc_hash": "b46845c51da1b4b1909d2b2f9f86307c63cb48cc4ad7b44e0d87d272e9a91ffa", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "5fdb68c1-027d-4a01-a262-6eddb01bb8b2": {"doc_hash": "65ca60a35e29cef670a7aa1cd4d8bca82782e7abed3dc36f97f1c8fa992fe5a2", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "1653a396-7214-4f45-8ffe-efb60e19fee0": {"doc_hash": "542523e75c7f69cc7b522446c1169abbe5fc9b0cd48ff0661667008be6b7d612", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "8faf3715-f1dd-488f-93fa-2f9ff63fc449": {"doc_hash": "b0c439f095db7f8df579c147417257c1714ae4470d3e3c5593409e3147405cc7", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "03890988-ea69-4f7a-815a-ddbf3631867d": {"doc_hash": "879d26a977cbbe8440aca764cb1e55eac3a3eb3b71248bb22affa87ca1ae2af1", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "8719cd4c-754a-418f-99e6-b4e380ae59f4": {"doc_hash": "6bbd9a88f2b02269618398a1e587c4706ad332e55b0bd1c77fbf49e4fa211a5a", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "7294be3f-2c4b-4c17-8bc1-f7840a1d25e0": {"doc_hash": "dd6ef472e587685f891ff5faf70ef1f3b70f44ad4225386a406fb34bd873e7cf", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "f81b5f3d-df62-4633-93f1-c0954b0f3cd3": {"doc_hash": "57f8dba5174a263edc03588b3e399f3c900309448334dc841cddaf87377789f5", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "1d277702-4ea3-4c50-ba12-02899cfcb02d": {"doc_hash": "120b3f573f24a2ab5495033e879a4853bc20049e33f7dac221e4750d4aa9792d", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "19ee4baf-1c35-4491-b34c-ea993670210c": {"doc_hash": "479b1b92a0006f1b508cc64163c20e8fc227e1869be70e1dbf504c1abe21eb87", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "90676184-35fa-46f6-826f-6334d51adc5a": {"doc_hash": "328cea2308a54d093f9a4bd420afa1d59ff33ec8cfcf4260997e2389e218b204", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "05cf3aea-0273-429d-b6e6-59dda3ce6212": {"doc_hash": "61a81cee383f7b07b436bd2e1d71076e71625a2c4ac8e5b8eabd780ee6df2096", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "91745cef-186d-4347-9f12-aaf8b08cc44d": {"doc_hash": "9f1c4aa3c657de06af103fbfac10836bac7e4f580dfabc71512cba5500c065d0", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "386ecae3-bd0c-49fd-9c57-6c65b14f9c9e": {"doc_hash": "f22888fa681f06aee495935ef4753ce21010628c5eecc5e1be4a1ce20dc630ef", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "1a76bc05-343f-4f56-8972-c8008458898a": {"doc_hash": "21d4aedcdea7493f921177969af609f8728377a51a28bd01a65f4c222e1d94a6", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "dcc3b48a-ab1d-4bbf-a5a2-c705cfa29d96": {"doc_hash": "3140a785d2bb5ca755ad0fa7c9ac32242ccd482a65e4136ef5f0d1942d1c3291", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "ace85974-01eb-4186-a6e6-7b8684524612": {"doc_hash": "1491cdfd1a43fb5b2ce65addda5fcf3c19158898d916f00f2769e3b185d87b3d", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "05085222-e830-462b-9baa-f700c0475121": {"doc_hash": "476439e578ebf1b45412679e696f25efa7c33f137c79d2d53d6023311064f7ea", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "0f89ca5a-7484-4d43-b424-ae05308686a3": {"doc_hash": "2a99e3485eb46018b165707e5be3e0b82edb18010120c92732370b8ec5aa8ad6", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "c0b5ed14-cb7d-4294-b0a5-67a489b8276f": {"doc_hash": "fb23bf392c12ce569107452d8bba894b9c6dc0d05999c432fbcb8912b2e4c041", "ref_doc_id": "6a16dced-c81a-4c27-b101-6755155f7b96"}, "34a304f7-d91e-4536-8ddd-f3cc6e2b6c74": {"doc_hash": "a42db290cf5ba87b403f00e32ff8b4a26bab69742b1b38d7b529bf87408d910e", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "d35235ab-9c1e-4111-afea-8365b511e7a7": {"doc_hash": "e343ed7dacc8feac221bf5f49fb2170b008d472c1038ace523a9cdac820e533f", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "45dc345e-9d05-4ba1-88fe-cc25ef3d158a": {"doc_hash": "e477e7a753486817b5ebae98bdc5e4bb082615d38dcbc86e82978ca2b861d934", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "a1fab1de-4322-40a5-b6cf-7c65ee04a996": {"doc_hash": "609bef1773f70c20dd3a6c28502e858261d9cfcf733cd2c0f5e95413947bdec1", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "c4a98fcd-a082-4d17-9962-65d001ccdc92": {"doc_hash": "8f795af394a05fecd825851f22df3dcbd3efa865b10d49b32ea21117819889ad", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "86a1ec01-4c90-4e4e-bc6d-761bbc8426cf": {"doc_hash": "cbd1dfe090ec1ac13edecac0a99f2287398aa40aade199c3da5fa2c10f797eb1", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "0cfc8f6c-4ec9-4c02-bb0f-0cd91cca5186": {"doc_hash": "387f0ba09a06999d9cab25a1515d58392bdb14477084a6226580f1d09990d489", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "ddba9857-0301-4b02-9dee-07348904aebb": {"doc_hash": "6542e3e208499a6c39f8d75702456c329c982d99357e99ed3e8248c526a0e0af", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "dfe20a8e-80ca-45bf-b1f7-475b19ef3a90": {"doc_hash": "c9dfc77bce9dc28c2f3533a185b5e13182b64d1aae695a2edc2736b5b1c4f060", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "6fdc5ac4-f23d-4391-b6e7-016649d4ffcb": {"doc_hash": "1b82478955df1a9df596400210d8100d31d5cd659ebf6f0c70fb72dbff710820", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "28ca8238-c13a-46c4-bc62-8594df734550": {"doc_hash": "03658739f3666cad0279fd9a801608d215bf4bc68e78445d07c2e7216f97dba6", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "8dc4af81-13d0-4945-9672-15324fc2a1c5": {"doc_hash": "f32499b772db78b487f3bc3fe59187df6c3a8be54ed735030587c18492d329ef", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "759ca668-b276-45dd-a551-a356f04f4add": {"doc_hash": "0cf9df94fab8536a54f9756655a92a43d0bc76ea8e7719e592d395d079885f19", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "8dce0e43-0058-45fa-a356-0456e6209d68": {"doc_hash": "fec1b4dd1c67a856a4a28e3954a3b26843723c40ee168511c1466786038fb6d6", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "fe15e061-c9d4-45ad-a0a7-b8d9f3e0533d": {"doc_hash": "bc6a9c10ea18016b80a20fccd9b8eaa69bf4ac17f0849542851a0e86c07cc684", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "9716f33f-eca4-413e-80e9-34037095cb4b": {"doc_hash": "9dfb4e21346f7fa0f62255da3db4316e9877ae8598882d32050d06ba4bfb238d", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "11e0890f-261b-468e-8c27-c2e612f3fac5": {"doc_hash": "d824b2635f68769a5618046fca44f69527c2942367a1475619611d591e77a295", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "e3b5f654-ebdd-4d14-a143-8a3a59a60e16": {"doc_hash": "9deb97e46a6d6cf6a8ded1fc1bf59d2b719f98124d181af3973e12db9450d231", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "fdaf1edc-00df-472c-aa19-292a9feb015c": {"doc_hash": "ae30cdbce804a11de32fac44a2c14ff7054b2cdf7268b5e627feba82701c0c7a", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "99b51cae-eac2-4f7a-9b6d-61362092aa7a": {"doc_hash": "a74dcc75f1ae6d5afdcf86cefc905c7adc273c3ea96978aa82cc3c3c6764e7eb", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "be0aed15-29b5-4b33-b82f-7eabbcf05600": {"doc_hash": "2e8d87b848ec78aa249aa5074c8d91d63353ab40877be3d1c7ce7d60adade26b", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "5d94f93b-552f-47b0-b015-19b0503d4570": {"doc_hash": "87dc384fceeea489aa419081fcc4ca05d9dfcaa4b15a9aad71afeeb30b7be313", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "e9050348-8720-4ea8-b78a-ba2604a77d98": {"doc_hash": "a42ec0793c23b05acafd56eddcfcf17d7227e1c023734d3ee17456a91ae238d1", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "be9ec31e-5326-4717-ab59-c9eeeb953e51": {"doc_hash": "3e71dd36fc7441bc073802971f7b2f4902645c5600a86215f3601b7ce0780bda", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "408350a7-0960-4395-9b54-0e470131bf56": {"doc_hash": "32abb697842c2a916ac657d65e5b27c45cce06bf5bf97bc3cd412b82b3fed769", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "e41fc4e2-8e86-40d3-8ccf-25832310a5ab": {"doc_hash": "e5a9676ac26b6a31bbc2a4eacf06c1be4e414fe9cdc48da8c37f85a166da9e97", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "3d463d52-7e93-47c6-8e63-9891e3381c17": {"doc_hash": "9523d5eb38a7424d7146b1f670de834a7e016c1a131d6df006b3442d1c004c58", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "6a62fa0f-c731-4a15-854d-0ba670913d70": {"doc_hash": "c3bff449c71ce437e2a671555e51e75ead23017b264144404c5bef6bfa03cb5d", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "5ee20a0e-5f18-4e5a-95b2-16a63e40ee1f": {"doc_hash": "0a03d7acd6ddf93b8e86b9b1416b1eaf7cf5e9b6bf5db5df3002385344447859", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "eb2b5651-1c00-4849-bdce-69512600964c": {"doc_hash": "9da7deca079e57f409ecdb4b628a22daa49c8ccd95985698252b1eb62868be4e", "ref_doc_id": "9bffb322-0dc4-43ec-a89b-103c20c10ef1"}, "4761bf74-8559-4b55-9b99-5459610a6bd9": {"doc_hash": "1e8902bb4b4bf1ca3e39cd8d7852f31a326b9d9e2d530225ac59dcaca64a3f85", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "816be645-f31f-4f1b-8628-ec3e050e6baa": {"doc_hash": "92eef5997733baad6f58b1c6aaf9d0b1f500910f3937f1d5e3a2b07023c589a6", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "2f6a59cb-481e-4680-b482-54413aad6a48": {"doc_hash": "f48217a68a90a5c06fea93c2dfcba1019b09c3bd74902b8097c84e7080dbd2c9", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "81653593-7634-4284-b844-1771f1ac6b6c": {"doc_hash": "32f5ce16fc9e498cbc4d891b84e3f95914621703f88fba67e569acbe5db06b18", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "38173c01-8fcd-466d-b375-d14568b53900": {"doc_hash": "d49730b58102cf12bd22b26d74e31fec2c2fd9aa1296fb71cfa476fefc592f3c", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "21a66825-0a99-41c5-86d9-67192e06fad0": {"doc_hash": "3c5d0dc8070f2b2cd659c8de34dbfdaaedd0545a92ffc6d86ed18024b2d22a08", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "fed2f864-8456-4446-8fa3-28de33a17456": {"doc_hash": "bd7421a1382377ec3b3e0d48b811edb06aacf2857bffb9d2e5fffc8a48459879", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "667067c6-a91f-4f54-8ff7-c5376f129b8b": {"doc_hash": "075595c68890387faa469935fc5adc332119477a41e9d73a05a3edd3e26df7ff", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "ea308ee1-d756-4e0e-bbbe-84bc3ae780ac": {"doc_hash": "921837844e658e7483f87f853688973f038a987143de90c6d49c2a2960e21779", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "55a06f22-c320-4273-9ba1-04fec8db0bde": {"doc_hash": "1d0ab07d67060ed046ac46ce89d215cc471600e03e0b3870c4c7c2ddfc129f4d", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "76f68b29-596a-4c4a-ba46-3f903cf8a9ca": {"doc_hash": "ef244051d426944ce04dfa5a5b320ba84d44ffe598425f63a38c7f9dccaa9b12", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "a0918f91-e83d-4eca-a27a-615767f1329e": {"doc_hash": "013879dcc2ae075caf06fbdbb5f9cbfd50c3bb351404b50c6032896505daddeb", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "6c99776e-0eb7-47ed-9f1d-6bb7654102fb": {"doc_hash": "03a809d801005565af026655c7d451ae4a20afd241cebad10a5281eca4448f1f", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "f00e5e36-bc0d-4266-a586-7d2cc93e4aa5": {"doc_hash": "4b26ee8f970bc1e30948d8c98f160454c2bc26c6562bc457d88fcbcf017d1d01", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "2050ef4d-d9d5-487b-b83b-28ddaf0ec0d4": {"doc_hash": "de0c61ad6b409ef944902948df6bd2c11517d94d753c20ad8c88c08a7e02856a", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "d2e452cd-cdfb-42aa-b859-fa514ffc9888": {"doc_hash": "d2fbee7937c90031424f378945fc7b6e0caf4f97b40c98439f763ddf5a14758d", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "4179669b-dc20-48a3-adf2-6f02936d0ebe": {"doc_hash": "aeb2bfd8f9b2172fccf09f783b4bdd1885edfd237947d5ecb0b8410ed5e414ad", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "4e7db23e-4a92-486a-9f5c-07b6e5772b40": {"doc_hash": "f0c530eee26303fbf4ece020bdff223a3e5699709e693e6d50c5c7e4493e8fb2", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "f97ffe18-3a54-4e76-b799-4231335188f1": {"doc_hash": "156d86d417631ac53aec6966a16c4256e68bae8c4d401b92473e546946663a4f", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "19fab122-5c53-489e-bb1a-62601c60f5d6": {"doc_hash": "f1625a8ae66408a74c20db6dd48334546ea34209f5dfcd1ad151ad427a4d3074", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "c3097d65-a296-4f76-a187-b3b3ef300e54": {"doc_hash": "fc11a00a20be38af2cceec5208ab99ec623d17bf1f4feb125ca938d4b8804f4f", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "3159a24f-25e7-45c0-aad0-0023f5a8dac0": {"doc_hash": "061b8dce72eecb8ee3a3ef9215f76e909be013f27e0d252a70098a515b0f9d84", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "d1ec5762-0224-4517-9b05-cf43c46ee4b4": {"doc_hash": "29e34729ede6225e82c17094710079c23d9c8e87d677006a5eae3b0dfe5adf33", "ref_doc_id": "9ab4e218-d905-45a2-b786-9c74cebc28f2"}, "1b5e6dd4-e7a9-43db-b311-8e1c0d70c3ae": {"doc_hash": "d02bb1b0e086b6fcdac0b1b65e9bfa50b00909b77010d3902c16e1f7528ac39a", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "48ddf2ae-b7db-4571-b411-a91c22b72739": {"doc_hash": "36fcf6704ebf3202018ca4950300b4331a302a5aba9793ae13c7788f185236c2", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "5c91c3fa-43be-4fc6-8529-d9ed31f3cd63": {"doc_hash": "c014e5bff1b963c596205ea81cfa216ccaf0af000b9716324a2f137b7285007f", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "a8180407-fa32-46e2-a182-5d62cc9743fb": {"doc_hash": "79ed37cff5be53cc0b308ff6834aac153fde164f3507e02a5af4a80372f10e9c", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "cbeb1214-53db-4c3f-a9ed-989c2eeac47b": {"doc_hash": "20a3ab8d1f864435b8f4fb12265a338aaf08508fba6b56f7b57941fa66ab8b67", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "b20a446c-a639-4374-8472-24843ec119d7": {"doc_hash": "9e0c1375bd20623e9fbaf9723a2d8b611872753486d20ae64224650a93a680a5", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "ec4ab925-28a4-443f-b8cf-091faf765a30": {"doc_hash": "b02c1ee7402d56bbfc06c387b9a81c949c79d277bb152a78e923bff1e664fdb5", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "9c525ebd-e59d-4b7f-86a6-6bf1cc568516": {"doc_hash": "10a2529364d45daf118a743f2458c39110df513316ea9e47a6b71be045343a95", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "dae4129c-b121-4efe-805a-a0cc00a249ff": {"doc_hash": "459549507e00414b8db0be44c51fb3e63615bc4958761cee48f7a92cf895c8bb", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "a17f6c9d-72aa-49b5-9fed-2bbeb8195a9f": {"doc_hash": "26eeb707cff314a4887ac898d000b8dda7e85a37de918a855f0096ed1d5366ac", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "e183fb6f-6416-4e14-8aab-dfb1f90be615": {"doc_hash": "ecc2b152bb1fb27ab7c8aecb517638c45eaa34f3955f9fa9c962058aff5c9f67", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "6362c647-3296-4d01-af20-a85406979720": {"doc_hash": "e7e49e633cf3b00cf2b237bd9fec90ee57388078076955e90b6ae5d363a57765", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "f29e39b3-4b96-491c-be24-4a9c8106df29": {"doc_hash": "b78a6b70b4a2b209e457e9f09daf2a17bead13912fec217ffde9e52ea4014774", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "bb55197d-adbe-4d8b-b3b8-d0a6a2012c4e": {"doc_hash": "e8bc5dc8da741fe97b9bb8d551607601089306b8a1825485cb8767a794c78989", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "e54576d6-4eeb-4ad1-ad9a-7d7402c831c0": {"doc_hash": "0df15f0570b344029b0785762b973b85df235474094358d699f833e3fefd9b9e", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "c6d14a09-d91f-4889-b09d-7ec6e843e08b": {"doc_hash": "e4a205a72eadad11b204c60357f3af47a167895d2937279cfdc04c215d401e54", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "54e9552e-a613-4060-8402-95a909543f05": {"doc_hash": "5dae9c34c4ddf3e59163bb8cbefd2a8fadee5f31dc96f4f587b5b0ff6204dfde", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "a1045f4a-c4b1-45aa-94e8-e55fc9a79fad": {"doc_hash": "433e3c7d567a301f34460fb19d82444bdb31110e07ca3d32027b0ff2222234c1", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "e937c734-40be-4fac-bc9d-c070eaddfd3a": {"doc_hash": "22df7a307a18b1e045d58c42dbaeb459a7a6dabe69e1e13c488f02edc6856e4a", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "006ff6a7-f48b-4945-8787-07db49735a73": {"doc_hash": "6c364db4d8debf63162b45cad53a481c0589ecb245b274ee907a4fba02346875", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "640382c3-307a-4538-9feb-f75e8d5cd909": {"doc_hash": "00698f7d5790a6510ad6510b444a7940a186d9558fc0a7cc3c636bab710a1fd5", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "4578289b-774d-4860-965a-894454c1c4cb": {"doc_hash": "7783c0df92e9f43ae2be60894e7e6946523a36d0cdeef2092737ae70b5910b83", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "db0ed7b4-863e-4bab-ae88-14bf365e731b": {"doc_hash": "e55085da383b9f27ccd589dee8ce0f5ea9e859c84bf4c6783273df5466efc819", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "3ba5d83c-f41c-470a-9c70-bf1bc6025d92": {"doc_hash": "5703714af4dc0700d8540479497babd540ada4d58b94c1b2f6c63d59d3e3e5bc", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "f2607f03-ec67-4701-979a-c6dc3de98f89": {"doc_hash": "f122f952191b6463560eae7ce7e7c5ee1767918e787a97f530aecbf8f1ba0fb5", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "e570ae5b-5833-4baf-9adc-b915f740a55e": {"doc_hash": "7a2de5ccf8f7cd26f710f5c8ac62b8de4107b5494ef98567327c59ae40aaada7", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "3b551c54-9f86-4c7b-99b3-f0ab8c433fb6": {"doc_hash": "d9965199a481c81c95521fa464ef35c4ed7da0e77ab3123dff7a87b727c5bb85", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "f56cf395-bde0-4a0e-91df-0061fc11e176": {"doc_hash": "635f51fa41a5f3305e25767bb48fb6d4e3b5d78ac840eabbd0d2d67d07883dba", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "43756234-b8ae-46d2-9713-5668919e560c": {"doc_hash": "ee40b744388a84aff792a0516690668307d52509c7ac9f1bb1ecbbdf4c056c79", "ref_doc_id": "54941f87-b696-42fe-b719-ddf222a3bf03"}, "f04e1ea7-114b-451a-aeca-ebda1a43cae9": {"doc_hash": "63ed3e2807ba48742a3fc0e666889aa908b698fbe13c1db42434e0d807f401f8", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "f1b08697-f73b-4213-94c7-9bb42e0e4725": {"doc_hash": "0e2f5c4b25f93206c566231d794366bc100addd0ebc9538da919af67d077301a", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "c7741f89-0c3a-4fb7-9511-652023a7b072": {"doc_hash": "8af823fa0b25e21a16bfa034ad471fd0b8745b510b59afbb91c9d2ba6c734e30", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "b9364745-9987-4132-bd11-8460daa6a7ad": {"doc_hash": "fc4db788d64fdc5f0acd976e0a39b681031cc40bc9437c4d112821b31113e059", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "c93f4a12-5f2e-4691-afcd-55aa44f80c81": {"doc_hash": "317fa78d2384267498a595c5c0b21367753a391dcda68d904f2fe14b5463ef71", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "e0e8b8ff-cc50-4112-978a-5ceee1a2771a": {"doc_hash": "0b2e03d40392c9bc5e84e744f376c0606b28725a19c33dff722af465ac01d180", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "bc3db8b5-665e-49a1-8e0d-af5bcdbcc2b0": {"doc_hash": "7a891e1adf5705b363571831f95c8fc64ec67540366a10f96a6314d3f249156d", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "6a08d0d2-9bc5-45a6-aff5-b046e008a4b4": {"doc_hash": "d28662201660f71d45560d9e4e465c2ddc2e69d56c32ea818a6dfa639cbaf874", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "190b4988-d2bc-430c-9d93-c641a55ed89b": {"doc_hash": "16d724c2a28a95330a38b6539325145ee2b5fd826d75db0586e915df1a61ed36", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "7acb295a-23d4-4685-805c-d1767645f086": {"doc_hash": "069ebecb84ce0bde5c67ce1f875277548803c097e6f1875d94d6e9d75e4db883", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "df731444-ac1c-413c-a43e-ab8ca0306d24": {"doc_hash": "e76b680b754f8ad24ac1d693b79940d84d6beea0da64624bb7b0143a1d027309", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "696874bb-c18d-43b5-a653-328295a098a6": {"doc_hash": "64ddda81a17b101add7d8fd788e6184e8006cabdc32ce2aa1c38c39a5a550f83", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "ca34b33f-f66e-4f78-a92e-c4c45f2ce263": {"doc_hash": "ff847d9019efe8b6b00c828a0cfec28621ed83d88ae40d1cabc49fe3cbac3f4d", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "4a28f04a-eb47-48a1-8ed4-da47866e5dd5": {"doc_hash": "f12cabda4b9fbe95186e539ece3f8ab14c309afdd3b81bb67e67cb13de536fdb", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "75cb6151-ab7e-40bc-8e46-2ae6bd673dfe": {"doc_hash": "eadaefa87f90b2d6e15da9cd6be523a262c030f81a855818c7f3b1f0c61a5113", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "1b536aa8-b5a4-4bbb-8972-12d5ebee2c7c": {"doc_hash": "c5a08ffdf78218cc9f00140c4671e538b14fe9508a9ebeb9c642b3fa1c22bb59", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "73df242d-7750-428e-98c6-dfb31eda065a": {"doc_hash": "678a0e60e96077d1d1c16d0e8c5c2475efde501b7cb2c9292f1adea27a86cc8c", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "d437dce9-f9e4-48da-97ce-b90896c84805": {"doc_hash": "13133915ccadf6129c5345345e670bb85c174d1d3c17413bd59c9027c483a99c", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "e1c2a1ef-5474-4467-9dfd-009a19cf9e81": {"doc_hash": "d904f33c51540038f1df48509f305d1317538833223e9725f63b73dbc3700b29", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "4b3196f6-78c7-4ad3-b918-3ef366f46ba3": {"doc_hash": "721c8353534a3f93c282f5034a7a80d90eebff888ead333cc2a454f195a9ebbe", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "b0698ac6-7cda-4562-a9de-3ab802bb7bdd": {"doc_hash": "829357f35c0fdf15d89b93b1f4a9cdbc23b6f3d2b3eab3e5470952b1b044b584", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "d4645d28-f102-4ea1-a5cb-48c0ab361bab": {"doc_hash": "5ae3d20230adbb6444b13d35adbd4573f73e5aaf505517ca66e6f69470917b7d", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "a3b9c012-562b-4051-b019-b4a97851c4b0": {"doc_hash": "a11553f46f107975949ecd0ad80cc156f84d1ca042189bfbbb9e904ecc12ae6c", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "702dd0b2-b802-4d5d-914b-1538a22ad145": {"doc_hash": "59bb1ea6ab8c21c41737c5936250c2ec4dd70ba2e80e76dc916b092b633e1154", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "e67b1856-8196-48d2-bcd9-6360b887953a": {"doc_hash": "e1471335284ee361e1a50a0c87633927cff2b3f408862a576807471c903eb8a2", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "e8d94c48-57bd-4e2e-a5b7-c64a8af8ae35": {"doc_hash": "d39600e693829a15df0a868ed9edc5f5d0bc97d9ebe89c0b66570c0850e63b01", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "00a36027-2045-40ca-b18b-70e4b6ac9059": {"doc_hash": "c58ed77b519bd43abc86e8eeabc02bf09ed80c1c99981b4c6689ddb4cf88b217", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "f7d48126-42ab-4845-9f85-0ef54daacfc8": {"doc_hash": "4e9984b755c14c81e1d3791fc9b61d8a0cdc02dc237e575518bc94cfdc7164c8", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "9b5163d3-28b9-4e31-9142-c83b9dfe31fb": {"doc_hash": "052ecc1b346c88f34e3d1ccbc3f2245472cc9366f740ef8838c590ba71bc2c47", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "e02f7078-3bdf-4f47-af63-75030f04dbe6": {"doc_hash": "11a96d56fa5981a6045c53bb875f3fb9b085190dbd2f39f956ed6a4c63e813de", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "f615acc2-7089-4860-81e0-6feea9f2f591": {"doc_hash": "616babf90803a2aa9e404902b857dca0846e405a1f26170c721a97bfa954991b", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "33c67cec-d842-4989-8d3a-564bb6a2da79": {"doc_hash": "72f0ef80f60a5de0b6eb0533ae2823d7e630ed2bb002f288148437960fe9a273", "ref_doc_id": "c51dad55-d9fd-45a3-9396-240a2bfdce5b"}, "3ae9a421-4389-4ed3-ab23-3e580a9dedb7": {"doc_hash": "ba65e4db38360d58a0ced17125caaf0b833e24d3a34e78d0407acc9fb373ff14", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "66981b51-07b6-4250-b274-c38ba2655b14": {"doc_hash": "e608a39a71c24201d775774d20fb9b87f25073504d6668c8080f4e6323cd29f5", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "247ca319-2a9e-434c-b808-b2d64f7192bd": {"doc_hash": "8283d58705d5bbfd13f03d9cad80c87d402cb7edb2b57e6f112b3a2ab87f2c95", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "d1f61059-c08d-4f0f-8e84-7cde9144ce9e": {"doc_hash": "2f3c1807df556222bf89c67a5cef10500866ed288b03eae932d37c0c034d0f34", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "3914ccf1-15ab-4fb7-86c5-6a2731febc7f": {"doc_hash": "2f9ca2976d1c755d0b143e37b021bd01d7954af4328fdb9316d52e0bb51c1c89", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "bb257384-d078-433b-b271-89ffbf8ca6ee": {"doc_hash": "94447e49b0e60b0261a5e95f3fe07866688aa22466789b4da3ec996ef84680a7", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "2a4a71ac-fa5d-43f0-becb-bed7601a3c55": {"doc_hash": "d2364a4452eb96633ef2cc779fdacb67cd086de4cd80c9f8801dc63fa063d7d5", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "c39ffa58-444d-4364-97b4-8dc557756bf0": {"doc_hash": "a365b422f80bd19d1a783d51b8213a97685fceb7547f666649f37fd364fd9567", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "c95b6270-63d6-4b19-b7df-824b86730d13": {"doc_hash": "c2f54308d425dc3cfa8ee24e2570788b28c6c16792fa920956bfcc6d21b06c48", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "1b6bc8a4-ea7b-454c-ad9d-7acd628e7431": {"doc_hash": "40fc4a814031789a9955096f2c8417cb7a7fc54d0da1ef260f50a1a7aa0cbe49", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "872fff90-26b0-4f87-ad74-fcbac058bd31": {"doc_hash": "a0c95844015e7a204c3b87d7f11f3311642b30fca1723fcee7e72c3605ca6f03", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "d099e347-6402-4346-9151-2a810f43c1da": {"doc_hash": "4b3a77df4c07881b8c23aec070679becf757e855b6fbe0f8bcc5ee513f537249", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "07cd82b7-6d58-46df-a679-f7eb38781b95": {"doc_hash": "32327af230658bb788382fbc6e04c656988cdeabb409d3de16b023721af4b226", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "d15266d6-3b21-4c9a-bcba-e77e7a3dd795": {"doc_hash": "9e3ce4382bfd5d34df3e0823a3a18399a4571a94c2912bd9a8bfc280d965ae3d", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "6f2a3782-fc19-421d-bd9d-5a5181716c65": {"doc_hash": "18811a91817fd96d049343fbcfa02fd6c352565d615dc7b7ffdec07a8057544f", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "de8937de-c087-40cc-be25-dd6144df57f7": {"doc_hash": "0a52c242e211ffa37d36121e0e2fe1761e3191fa5d3325ea2d1bc9ff8d269b6b", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "9d76a053-cff3-4051-923b-3ef00646c6ee": {"doc_hash": "1708336e7f80539129606769ed4a30bfaeef6d3a96b41ac9e28e22c9b21c82ce", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "c497d2e4-f57e-4c3a-a4f9-b4056f822ca1": {"doc_hash": "e143e343613d32df416404a8190baf96873fa2ab969e778e085bdc9e477d3fbe", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "2be07b2a-92e6-49a4-9a7b-0b86d1634d1e": {"doc_hash": "95bf3061d33f7d904eb249d0b6a332bdfb2046996c227e90692d9f7d3668a5fa", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "24eed68b-b64a-4bb9-8c81-0a1bcf0f5848": {"doc_hash": "811d7d5d81616723da701e2bf0501b3e1ad349b43c67a634a049e1468c2b753a", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "f88a1afe-40f9-4ae9-bcd7-a03f1485717c": {"doc_hash": "467147b92823f615bf98e544740b8a3f8e1b544252a74b826d6eb49080a5b1ed", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "6b92650f-a360-4932-865d-9e2fd803589d": {"doc_hash": "9a4c8a597cc7c109914ca8566a717149ec14da4b67897c2580e5e1c7dc7e6494", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "78a0c186-253c-4c81-81e3-ffeb7c957ecc": {"doc_hash": "8c2c6d8c509b28132a854c0598790990b68ed9f54a34df7269ff91ea2683352b", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "7f429c90-7422-4d80-a354-acd058666400": {"doc_hash": "bc344cdc4c2cb80f0d03c44d4dbe6529178a8ae2b3486bffbf04d6feaeff1f7c", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "3aebb428-0fd1-4d10-9caa-8cd6bb870605": {"doc_hash": "38460679455572196eaf04e6aac1a063635c075c982f8ef53140fd88a18c964d", "ref_doc_id": "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35"}, "23ec26b0-7baf-463f-86bd-95e4b12b4479": {"doc_hash": "0f3480c3c31a807cfb23613afe4feb09be043d03f87da6986a2e1cef56783265", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "5d761151-2212-409a-a679-f5014ff9ba3a": {"doc_hash": "534b03c912865850f1e7b52bae842f8c2fa82e1d87f33219c450cdb744798aa5", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "e09ea273-f233-4e98-9d60-8c13ab0572f1": {"doc_hash": "0330706ff2e489be5ae718fae7418e68eee3ca0f2cb39b55b57eade9e2074254", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "77ce9666-e03c-4034-ba1e-9196730afb58": {"doc_hash": "d94b36b63f0874ceb694744061dd2904bfbb2944a6cb4100be8419e03cca4f4d", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "8caa337a-8405-4b23-bbbe-168fe5a686e8": {"doc_hash": "f19013cb285fac9c2e0dfc9ecd68a3c42432da104c0f117c12843d19218b40c6", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "e0851e4a-5782-47f5-9c62-ab0895ae3967": {"doc_hash": "64ae7d3dfdb0db077021d0da13c5044802c1f0a3015ed0b5ed3b1b34b9930ef3", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "d9eed8f9-a3e4-4d9a-9d07-77f0a80905b8": {"doc_hash": "233277a6b10ca1f43ea6fa25e39239541ba2796e4b1abe5320fbf4aa38bfaa4d", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "5ded3b79-6cdb-48a5-aecd-30afe95f76f0": {"doc_hash": "cc11aa8ce23a738b2b2f1f89dcf99ad90a06894da493994847e1d9945f852d35", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "be9db5f2-8eb7-4116-b1bc-e8b464712c39": {"doc_hash": "74b2c44d4a0728f618061571be053527b42d87e6e1066c1795619fd2c7e7de25", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "4e285a6d-a1b4-4681-89c5-899f5a860150": {"doc_hash": "b4d0d7ca7b06a9ee429e17af32e63c0bb2d0f3c8dc8999b6799d30c5ae10ffeb", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "063b2b36-6ac4-4310-9f55-69d321b6465c": {"doc_hash": "81ad82ac30c76661564ccc83a4c7f16683d1dcfbd6ebf7e79b26587321c0ac13", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "291397ab-808f-4a18-930c-ad5fd063cf8a": {"doc_hash": "ef62cd479dc12f2be2df4f931056152abae543a99854771f29e55b109756aaa1", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "37825d74-83ea-4b3b-8bb1-92855d64c092": {"doc_hash": "8698bc14c98d79def415f4cdc9c04cdc5ac339fabbe8bb2a795f09e386000c26", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "e5493218-35cd-48c6-b949-3fb11cebeecb": {"doc_hash": "2ec23835ea5ab722f75c82ad6d0b4ec5bec22a3f6b420bf1df47b5ce12b44f52", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "7c69ea80-0c61-4b93-a253-375d9a1dc51c": {"doc_hash": "e4a3889d6c73a4597e7d3c9b7b9a1c003ee0b28e14222e8fb4ea3e3426f7c41b", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "865c378a-e8d9-4be1-97fb-5d1b82da3008": {"doc_hash": "c2fb2abab0c5a3ec5d82bfccfe3f99549253dc6935fc662a9a3ce1e4a6dc4c13", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "3a149578-af6c-42b1-bbf7-a31b4b10c279": {"doc_hash": "5f5fbda5d5625683f502b3be321f96313e6b65d77ac9506ea6b449c7977ef36a", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "3f12507c-eb3f-477e-bcc5-e352baed018b": {"doc_hash": "f678b01669d53573f2ba1d93a36c8f832afe74c731a0186698bda5c650346565", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "44bcd7e1-151c-4654-98b9-38e8e4973361": {"doc_hash": "3d706d07a258cded34821f18376168e93bce793921b4d718ea5cb345479ef4a3", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "0b5d926a-5deb-4706-9ee5-215eea9e4471": {"doc_hash": "2fe5fd17a43bca937a086ad4fd0325c01723a8a291c08e7f5589e9bf65a7d44a", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "2fb5121b-529b-4354-9f6b-764aa855bb08": {"doc_hash": "fd9c2be7cae6f090a91e0e9dd1e8a0e9ae93ebaf8e9171d69f2b0a0ba283d0b8", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "da459ec2-c506-4f1b-91c6-895d61e57160": {"doc_hash": "e7aa6677c577c697c89b26f9b331388c093d24803cbd9d3ee2f2778be13dfd89", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "1305a02d-300b-4bf7-8225-d42c80bf319e": {"doc_hash": "c58ef33832eaa3d9934fa340c228137de07f5ddc978a62960ada58be74f5e92a", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "edf1554f-eecf-4d99-965e-453d583f3422": {"doc_hash": "61f8e3923715f7227719f6b6301dc411d778b6b16276e6fd4b933703447701a2", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "9a7f32ea-c863-451d-a94b-26fc50472136": {"doc_hash": "1384294505d5a4d22a2c317edeca0545194c825d46b4e095a5c61590c424b872", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "9edc12e3-1936-49b8-95ff-d01c00506ff2": {"doc_hash": "ed86c974f7e5339afcdf2048cd3063c8e0014176544f7b40acd535d2282a42f7", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "0b2ae835-a4a4-4256-9f4e-55b25fbd9775": {"doc_hash": "7c7d60d18599da5b74aff61287c34c1535549a95d039b55b06c050225f0d5db9", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "009204e6-6970-4fed-8148-e20adedc164e": {"doc_hash": "7809643c095102580a160c9edae769f630c835f090c5d29ef65f8fdabe46a603", "ref_doc_id": "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff"}, "d7d7eead-7bab-429a-84c5-c6dca66b8362": {"doc_hash": "1548d214ac543fcdeb6c850920631b82eee3152460f1452110cfff1350523cb3", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "584380b9-474d-48c2-8417-185fe2e4fd84": {"doc_hash": "99106c1f9991111d3fcf5fb46b726d5a523a55f8cd500c790f33c2cf6c95ce9b", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "96cc169e-4fe8-4644-ac42-34069426591d": {"doc_hash": "792c6e703d950e1f725bfe550e1ef5d0fd46da58d9a9ea1b1635afdee90510a5", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "33642ae0-4fde-4fe3-a581-270b427c44be": {"doc_hash": "708d273ecdf25da686b29551380e2f6d9019e4668695e2629c12c26570120f9f", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "b0d99f51-cfa5-4626-a7ff-a6e0eb9bc092": {"doc_hash": "2a3defe03ded592f70a2cfbd12d43c73000813fe8b88e31a08705da2983c8350", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "03a9b762-29f5-45c5-9f29-3d461367c9f6": {"doc_hash": "ef958c97f46b3884d6472f4254412d63881b70573b40951632243de1216c2661", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "52f732db-7bc2-4cef-92c9-353168e50d07": {"doc_hash": "c9a4059dfea1f225582081172d7ba3d9d0af72f06bdb2936745059fe7f941863", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "75858345-16fd-491a-8ddf-6a00422791d9": {"doc_hash": "4eb3dc046ef0e5b20cbf895efe7a84fb5fc7b15aee997db5e456a37222e48d43", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "1c3b29c7-3102-4bf3-ab3c-d259dee692bb": {"doc_hash": "9f72eadf40d0b7abb63ca5c01638b399e9decb5118319d082b39659299b74c52", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "27d38ccf-9c25-44e0-9fcb-0fba4a479f28": {"doc_hash": "c4ecf3f7c0fc839bd0c8819d24be9aa5c7c522a6423ac86adb3e5b626dc2c3a6", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "658f14e3-5134-4ca9-be98-b2fe4fdb5146": {"doc_hash": "92a97448e2d51eb5446f88cfe4064aff0ebe8ca5acebb5687e6ec49fa263d9c0", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "674837f0-b4d5-4265-b800-03a232b60835": {"doc_hash": "a971166b3bbc5265d7dc51cbac9a40093ecdad3248bfdf481b85ac2507e9bcae", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "92d5f7f4-dd6e-442b-aa44-ea32c7c57bf3": {"doc_hash": "1e12c23aba73587fd636db963e6b96ec6374a3f2606e08735b9c0becdc5bc06f", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "0552b3a8-d0cb-4a3d-879f-7c7381cd3d07": {"doc_hash": "80f3ffc69d7a005b38e69b1b506c7c66d13a8161125fdd0ba6ed465653bb59cc", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "8d090e98-2a51-401f-be5c-4c2b9558a137": {"doc_hash": "b612466bbb4f7fe287b80f9187afa1ced608cc1f0b4cabb7426f3d63b8c4254b", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "3737e843-3641-4773-950f-8848823633c1": {"doc_hash": "9f89896a451bcf06773dd5aad27f6357047677d0a0c7399e874ab88ef1782dc1", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "e52ebe43-1c44-499b-a485-0055be50a818": {"doc_hash": "b4e171548a88b65410e53b0d1c9d30a87b1860ef8fd3910152f814ddc3fd898c", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "31ab3d2b-9875-4583-b299-70f11cf488ab": {"doc_hash": "be3cb399095c85eaae0ec2edd502abc4dd508f17bbbeacf211c14155d5ce443d", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "da5b9c00-6060-40bd-b406-ef2b4b77d158": {"doc_hash": "1bcaa1c66a9946343a232da8f99ceb092bc2c299f659490dd50541a731414672", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "062116e6-4114-46a9-8c02-8defc02c6899": {"doc_hash": "50327edad7caa603bdc34b6ec62d828a84116314174a98b2d747eadd111f57f3", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "035bd5e9-12b4-4e7d-bceb-e0e1033b64b2": {"doc_hash": "40d6f50db8ecc4bd4154528fbdc875be31e3459b156da740600fd37df67fc4da", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "a770ceb3-8a17-4730-99cc-10e4bc7a8844": {"doc_hash": "c42f4f976d68e973f6028736454544d1fc3ea1fe7d56eaafafb0df52159fb585", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "6ac3bbbf-11b4-4752-b8e7-ce7bf08e1c55": {"doc_hash": "bebb8c024f91cd3b8d1b849f268994382bf34fc2e308b2392a6bae9541345171", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "c638c24f-9663-4d26-aa0e-8679461b8cb3": {"doc_hash": "c2fdd8113bf6f93ca3ffedfb5b403821a9a695b0d4be53b805baaf39307cb8ec", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "c5cc9a9c-91c7-4bc6-a742-45c55d219e2a": {"doc_hash": "ef3f8de4cae0657d7693474eff4f0fae171564cd907e6bf7a829cbbf3004bb93", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "371298cc-a828-4b97-a846-6d8ee0ddcded": {"doc_hash": "282381102552054fcc9743600ca75cb002c8fd0e34d5710222138e4025e80691", "ref_doc_id": "12dde7bb-e1b9-4067-9dc8-557030e1fc41"}, "1d54c29d-9bee-45a2-8638-af37430828f3": {"doc_hash": "f54bd93ac2ce956389432fce42f17d54fb93ec177cb215af3de446845c9e63b5", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "2c598bfe-3e26-4076-90ee-7cc2c96158b5": {"doc_hash": "a8a2c72816df4a1e420dda2c239dd28ccb42205ff5a5be56180b742ba5a61881", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "a5eb6743-3447-4c36-8b10-4171b8480645": {"doc_hash": "5e235253e40b209abe27345aae19250f3e2761e0734d2b111b6b62b65e77f4c9", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "13399cfe-ea54-4cd4-9d72-eae08c3cd1f2": {"doc_hash": "ccae782e84b93d83c147b922ab837b63cd87db1b48932416c4d6d57de01929ea", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "31e39d7d-314c-4422-b5a2-5556e09b5259": {"doc_hash": "f42ee465366a61c1c22bcc00a9978cd3d8bc5d5b9fc46814f3f46bbbee737c96", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "92a52618-c21f-4690-8b57-3811a2671f33": {"doc_hash": "2552d48d1d39878b58954b446c62e5f3a60eb8faa3bc1fa60896934317297a7b", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "9b0f7166-2d2e-495a-aefa-229d497ea422": {"doc_hash": "7764067312568aa5338fb4fe4812d9c2a457279ed200aa031ce4ba6247036d6c", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "5cc43cc6-46e2-474f-b8e1-0567e580fef2": {"doc_hash": "77879e5698417912e835d4b11213dfe1db0a94090f4fe85a9c7900fc05d0ad99", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "645a88c8-da8d-46ac-95a8-14a94f293e4d": {"doc_hash": "b38c34042d384820a6a1c1a9d5a311f28de4142d49ead0ca98dbbf413a240b0c", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "b1fbe1bf-3d86-40df-a5f1-6bd5b2b4f61a": {"doc_hash": "fac61cc38223977ab5182f230262f0a95d57d4e482a9685522db24828e939648", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "fbfaa442-5917-4e45-95da-d569b8bcd01b": {"doc_hash": "75adbe26e94bcd512c5afe14df81c0c211b8954f0bfbb33bffc361b497c3dd4e", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "17318181-cbb0-4025-b2d2-5ea08d4e2c17": {"doc_hash": "b343cb656f964c7d49b9176000c88fa25c69d10a85044c6459585c8abc3b3685", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "22af26f2-cdd4-49f0-a54e-e55e50e3ee21": {"doc_hash": "f7ce4aca1c0c55d4e47da2daa5a6fd3e15a44b2d6c96a16d3eaeb2d27080c446", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "83bdd5e1-6f76-4105-bf1a-9195afb4c0f0": {"doc_hash": "ac8aa3c4c03f7865427d475eb79da16cec9407d48f4cefb670565c65d1ca172b", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "f2a1a370-f4f1-44cb-8893-86e8585dbfb4": {"doc_hash": "66a16a99f8125f69d8bb653babd8b4ea4e383d5ca6c38ec41cd558e578ad06ed", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "23363178-3960-412f-8d28-7ee70be8f8ae": {"doc_hash": "e9470867bd416b1a135599ae3af54b66600174f02d44a71d8ef11c87f0b004dd", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "9631e2cc-4393-4707-b44d-3f1b5e4380e2": {"doc_hash": "e0d760568d2047fa68140ce030963a9e797028f4912e2bd502d22cfbef5bfef2", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "272c9897-5ffa-4979-8481-aa010ebc8f67": {"doc_hash": "8dd89a76495488b73fab86a9426477a55862925d423baca7b746436a1e8d7895", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "c2ed3620-07a8-4198-9ec0-c58ec196114c": {"doc_hash": "7fd6874d9cd48fcd3201c60b46d57a0333c49f59a6cdb42fb7615f32ec598c61", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "876b96ef-c365-4991-9bc1-b0f93bbfcd3f": {"doc_hash": "d776c12f19326ef1c5b1090683581747dfe2edf252acd2b67818b3f4067929f1", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "cc50696f-bca1-456d-a625-b843576c5b56": {"doc_hash": "d7223aa73d46e1c4d7730bca619e33b2f1116e2350ddbe893b3bb456cf49ea53", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "9dcc3df1-b8b6-43c6-b15e-fffdfac7de48": {"doc_hash": "885ec3dd9fd004a18d859c8fa310ca14c3d6d7f97bacbd9e05fef785f9a34cd2", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "810096df-9872-48c9-8953-4d9b1ed934be": {"doc_hash": "df725c1b10a082d292b383aad15421b007527f5a17021f7a21b8d66da347ab6a", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "194800c1-b233-47e0-82a1-bc51f8b9a121": {"doc_hash": "ec28e629c084e3f90dee0e47b1943150799e0e3bf9a376c7734b4d3e2c81926b", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "863b7cd5-b84a-48ab-b839-1d0b8de8c86d": {"doc_hash": "95b30f5fa45870afaed1e6b69ddb90783cc06423a6d6e71458fecb39423ff04c", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "0f944d22-e9bb-4963-b21b-5584779d2c17": {"doc_hash": "07c0ee6a6260952e10f264757eaaebfdc22d7cb1aa78deaf5721f9abc9e5f07a", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "90637c96-c397-49b2-95df-3b5c1dc31fdd": {"doc_hash": "02dbe7bb96f3fb444892ace29a8ccdca6b1ea7b24645fe06eb599a2f37802511", "ref_doc_id": "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2"}, "7587010d-8ab2-41c8-9199-48dedada6f44": {"doc_hash": "b48fc89f640d47dba36887babe0cde6fbc5c09f03016cc9a6e3cfc6e63981105", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "870acf29-4570-408a-9eaa-74710b49e96a": {"doc_hash": "48903ee942fe6c98d200ebf7f1501fdcaafd31cd09b3070776443155ffbb6d5d", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "6ac46ef1-d7c4-452a-a282-0c2f10e26149": {"doc_hash": "b1c56cdfa392bc36c1d6387e197d734062a3ef9750ac2a75454daa1e2d216989", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "99482e58-cb0e-41ca-a434-061dbcf9d104": {"doc_hash": "927c523eec5e8fc27f9e586faf6d4b4e2d21c0c25f8f02ec760b7e22b1103ec9", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "a9c26dba-0f77-4fff-bc00-f732f5d9c327": {"doc_hash": "2f6c7b6ce2ef11995504f16929a9565a4404ebf61b760b75bea778ed40ba3e8c", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "dc219016-7ff3-4af8-a3e8-cbaf5f90b5c2": {"doc_hash": "5702e3443a13d4393ae9953a28392415333c5d5b7fd39df7f3a90772676f4a62", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "0e22f8cb-8dcc-46f2-80c0-70eda22a6959": {"doc_hash": "0d01cd5950a1eb549b22d43141846bf02aecf69e9969af5291fe88cd03764c8b", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "bb4e5f64-9d84-4558-afbf-3b08c95986d7": {"doc_hash": "85c92fa70dcd64d02e444431633455370a83d03d5efbf9763af97e5e6ca43841", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "44762c8b-00d4-4213-823b-7f0275ffac70": {"doc_hash": "dd6796bf9b232f4895a28950a81bdd3abb965ac546fc8e34e36205af861b8145", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "ae876694-832e-40b8-84f3-07c6c82eda8e": {"doc_hash": "5226f396dec85aef3cc075c2ccffd45827fea4fc97e5a6ea718bd9ed53556238", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "d19cfa6e-7ede-458c-9689-e5cb9ab2ebe9": {"doc_hash": "0cd91573688eaa36a714925528f7dbb7c79387ef8c021c9c1a20441147948f0a", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "7e83f386-df4e-49e6-835f-0f655238a284": {"doc_hash": "c84d983215224c5fcc8ea757603871afc50c35f81570fef242838d07480f65b0", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "623ed1fb-db78-41b0-be76-ef296b537dd1": {"doc_hash": "cdadf1981da0e6a9dbc1f409ee9e3d2fb896b17fbf06179813fbbd17f52febba", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "4a5f3cb2-5b20-4bdd-885c-030800aea8b9": {"doc_hash": "a64ca1be854bf0e351c4cf47b85013b9891facb3c56bdc30ed0e44a6bab35ea7", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "91139d65-c0a0-4810-bfc3-eb26c7739645": {"doc_hash": "dd97707cbe53553d84ab495583213be122972204f3e9b277a209a0b2f8ec8b21", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "ba43d4b5-e316-47c6-ae95-0c701e4d03c2": {"doc_hash": "2240e08dcb5b32dfafd9f65f1b8a227cf4bb45c11b08e374afdae1223ad76c48", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "39c36584-880b-4885-85f4-076ca2163bd2": {"doc_hash": "4879cdfa019172f5bb63d62b265ad0eefc7ed0e76b668e09d14893e0bdd7d28c", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "46f882c4-12d6-4d37-9f8e-a612262975ca": {"doc_hash": "f2918ba9c7a26da9d13b19d51dbf0ea7162686ce785959e800b190bc56ae4dff", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "e1168737-d670-42b1-b431-cd7efb1e7bbc": {"doc_hash": "e9f8c284c56e753e2aa6d0ed7702dbe3494982a1e510a6f799ac71e0f2edcdd7", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "80e2049e-5f0d-4f0e-a2b4-3ec839b4815f": {"doc_hash": "618fa7925825d6f1d34f759a28e5cea1bc9d20feddc90003d121b9671b32ff1c", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "d3b920ef-48c3-4983-9270-cafc28eaa7ec": {"doc_hash": "76c416cee55a144be1c9e475e98a7b8b4306c992217f8f3450458e7cf830e02c", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "cfa71ed7-899a-41f5-8c1d-1c6bbd79f3a3": {"doc_hash": "4a8da9ea82b33a94ddd39481accfa718a217c1d86af9585def84ad3c76894955", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "a49c12de-ef07-457d-a6ce-05de07060a66": {"doc_hash": "5cb934ca2a8d6acbfb852f4a582f51ec3b06c3704f4ff3787c195c269d6ff242", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "dd8a44f5-0de2-419f-b962-fe46e0a27d82": {"doc_hash": "89e8fddc68b206409209737844a4700bf341b16be3a8a4516334b1bbcb2fa065", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "902fd331-313d-454e-b648-191086da350a": {"doc_hash": "6d130304bcbace10fdc70be8bbd7089c8d1ff73974cdf495450ad03e4950c37e", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "42be638c-cf75-46a0-a9ea-ed0ff48ea134": {"doc_hash": "ca1e9c6d1bde37176cfaaa4d89c957c4cf6514d9e2261d7a0811eeb8b1673132", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "82714da5-e7f9-40ab-9443-3d65b759ac36": {"doc_hash": "276bb42f5abe23361a70ff7f214b0435e0c72716c181c874236cc99eecba9755", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "9b6cda48-72fb-4233-8594-46e9bc9857c7": {"doc_hash": "d42951722a8c5d936a21405bda61b3c8120028daa1fae015a9a3bc2af521ce04", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "40a1c9c5-b10c-4fbb-9457-982e8ba36320": {"doc_hash": "4e6650dc96ea6d7634ea36db1fe50cc790962f2b0fd347cc460b3f3fb805b951", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "7aac1d1b-d620-4e0b-a1c4-48ef5c63fb3e": {"doc_hash": "ce56050b39536b9c53ebcccd79b480b491aa49f4ae9296a0423c7b18575b15f4", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "350f6ceb-d78b-45ab-ad9d-d7602755bf69": {"doc_hash": "12e5d586f7c22940d210e307a908647ac6e3c91bdcddf0de5392d8984bd97e30", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "2129128c-e4dd-4777-a5fb-a8e921c37078": {"doc_hash": "a8b3bb92fa3953ebb63aea2c6f0321ea6a5e34d1739dbbccfe1ae2c03afdfc0a", "ref_doc_id": "2146536e-10ce-4a7f-892f-b5a4655aaf77"}, "ce64e808-9f9f-4855-a5e4-173131876e1e": {"doc_hash": "a6c18144c500908c2701b759ec0490ec208b2e2e5a197a0efc8d24ab18fd1292", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "befd9623-a933-44c4-afb5-25b26618ed4e": {"doc_hash": "3f546dac99e588eba7a272ba989d2311e16d4150ff8bbab362548c26a78a3001", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "1ef4cf66-f29f-40dd-83ce-a5d318d380e8": {"doc_hash": "ea2fffeda1a8ebc2939166b0f4e72a824605dce8761514e27b9d958698892fa3", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "3c5b7d6d-ce43-441f-8f7a-444282a8b7e6": {"doc_hash": "91d4888069ca633ba3e3a7b1a1ee8a45068291ebb189d706396b78f6f337a5d8", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "e5890d9a-5872-486a-aef3-0357d35e6488": {"doc_hash": "268682f3e1556bc92ba12b031341473e53454f247591853448cc7026437a6dc9", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "06d67dfb-232e-4ff6-acf5-b05cac10db4d": {"doc_hash": "bec12ad2803f76db7237925f0ec99395d7854b58c47647d7401a7faebc37bf9a", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "2e479f1c-2d7a-4385-a62d-2c94bbed49b9": {"doc_hash": "3bbaf8dce3014658ab6f2746982dede8f047ce14e144cb3c37b67dfbc84ef39f", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "5bd7758e-c79d-4327-93b2-c3cddcd35b2a": {"doc_hash": "786a23b6e3bd966a6df56ed9ebea0fc884d94a6fc45166aa7ad1ce621926ad7a", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "9bb4b6fd-c12c-4575-b578-fdc5de04d404": {"doc_hash": "8b1084648c1947af3253f8edb75e31e0f98a0eb0489a1db47c7283152b2a4d6d", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "a827da38-f43b-4ea1-9b70-97681c71c14a": {"doc_hash": "294752a7d63f3c3f477828eff985894bbab3d5cd0c6883f734c214253317735a", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "5357fcbd-417a-427d-8ae6-1af705956ecf": {"doc_hash": "03db0f3d776c08089407b29935537b2981479017476f4b22cd7c25d71e09bc3c", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "3547ee16-6280-4de1-9e4c-ad7e255d1e38": {"doc_hash": "3195c693b50c87d75fc22209b73779847418a49a551280e41533394657d5cfe9", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "c0c7e112-344b-44b4-8169-c9434b44b451": {"doc_hash": "a4b34dc493a8cebebf220e3007ba584beaad07e2cc21a4693c0753723c8330d1", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "14b7114a-8a60-494a-a863-301ad2d560fd": {"doc_hash": "568679f385bebe4f70cf4d5c54674e0ab03f5678cb60d8064399e745a9bbecbd", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "15904a43-a154-4689-93b5-4e7aed277ab7": {"doc_hash": "ab16f313d2045476bdb24ad560fb8eee89662ac5506e6edecbf0e858cb1e1606", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "bbcec476-023a-4c4c-8f7d-01fe344560b0": {"doc_hash": "3f63f71b30de0b3eb5f02a048d9f0562a5cc59bfb53b1ef9e2eb021ab107d570", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "d90a6038-d1af-4b55-9f05-b67d578736a8": {"doc_hash": "e776a84fdef35c7f591e6115477b0b1e241c2ab3deb2bfc9289f5aa2836a82f1", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "8354447e-fb36-45c7-878f-81dbd5b507f6": {"doc_hash": "d7219deda062275a43a94e44d91146e38b6f9f7f5be6ac67a7f376b82e49f844", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "ff57b910-6996-444e-a3a5-6bc63b17de75": {"doc_hash": "e209c6530eeee33acddd78381fd78ef7ea4b9cc5c479e1d55de2bbddf73b4b97", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "f6fe5db1-da58-4446-9ec4-14a2eff0e1ff": {"doc_hash": "10cc0293b21581ecd756300aa3c6f548d0a9f9e6cf4cecb87b7f9f83f169bf61", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "cbab295e-7026-4626-945f-81d894b27b84": {"doc_hash": "41a4db00636f2050dc100de58b97c67152e37b336f3782b508408f59f1ded7a0", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "941ad6c4-c790-4cc1-81ed-f6345a9021ff": {"doc_hash": "e2698858cb17a194e122e8ec625bcf5d88e5da85a4e3528d1ab1a5a14279f73c", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "57c72aa6-c431-4fee-a936-811ace44c272": {"doc_hash": "01daa94bb77daa4112a1869c00c92dd84d0c06deafbc1fc95f360d18c16797f5", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "bc52265c-d898-4c2e-a2eb-3a170a858ce3": {"doc_hash": "ee727e5c1042783df61e28a52fc3d09b047999726c3596385b2cf2db985575b5", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "eb0f99dd-d15e-4e58-879d-6f51a039cb58": {"doc_hash": "f1f8f6cdca0d7c90b5035e704acd0180a579210f1edc1a96312c7f07a132cba7", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "5b1b575c-2ea4-41d4-aa7c-55827417ac04": {"doc_hash": "41384dcc3a7ce0c8be6aff7dc061f689c716a7b088baeb33af22ac7db972ec56", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "88a527da-f3a8-451d-9a94-8169a8899258": {"doc_hash": "ff3de1f49789fc3d60ac0d9c7395df167122115b37b2eeae84394ff97ba631ca", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "fdcdd3f9-aef8-4e2e-8199-704754ee0f36": {"doc_hash": "bdaecab1de12f45d0b69c0142aa7c1aef933a1ff39ee9ca966e3897563b7c5a9", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "4c31a1fa-e80e-4a77-9ca0-6d3aa6cf5d89": {"doc_hash": "ce544f3459bc1be9cc3f8f505cd6bbf98af31b5b6db657c144e240ba78f59512", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "c318ab98-2199-4a52-a3d2-4668f8efbaa0": {"doc_hash": "0e78f792845fbbd1d5c37630b046e719bba7225e6d5ab8a907e2b8c6574e050f", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "18f85ee5-ed99-4b9e-a371-cf3ef504226f": {"doc_hash": "3409ef15c9a36a78bb0376e6fb09d2514946881e581836b06445070e1e2e5a3d", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "c1ad15be-b8fa-4b5a-9572-a44988f523be": {"doc_hash": "7d599d776cc7f267bb2d66f5d3e3fb91fab846767a4851ae67f3d22cf52a5c9f", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "dd53171e-dd58-46ae-ac00-0366b2b83f8f": {"doc_hash": "cfdfd8e5f19489993af5f109a0d7c1e4207f7fdbb8b1fb491d786757e537171f", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "c54b2e3e-2f0b-47af-9dce-52d0d7297433": {"doc_hash": "76ab14342810ba1292de3bed39e6c6ce56b641ee8ae5ad034dc0b5d742b1ce90", "ref_doc_id": "73d644b9-ab65-40f0-a3eb-32ca012da062"}, "e7b22f6a-549f-4e81-b972-a2f0b05a3b53": {"doc_hash": "6ad34250c834dd9dcfeab08a902bfb3cea03855f5f41fd1a11bd26b81b8f315a", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "4ade4db9-fa61-47bd-99f5-b74e7872b40f": {"doc_hash": "eb4af841ba8e1f9779676e1174dfa9d611070f7bf7e10f72c17912d2c53194c5", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "c156ffaa-0604-4a9f-b3e7-e9aad995c0dc": {"doc_hash": "eb4d74afebf8b107809fdb5a0b476b71b74514425012294017847d017b0c043d", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "ebe13713-13d7-4d89-9f98-8f8f30837df3": {"doc_hash": "7a8a9663359e7a4480153a0b2bfb25b232b14ea2faee7fe4dc3b668a59053823", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "4267b03b-1710-41ef-8c44-0aaff4270ada": {"doc_hash": "7e9078222522604af804b75c256e36a41c49a52879144446c84e68feef02d91e", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "66c679c9-97de-45c5-966f-9ce52aad61ef": {"doc_hash": "b54541777772bd182ba43ebefb4e7db9834a4c37b5f41a97485130fc82c8730a", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "c376c9c4-377f-4f69-a3c8-ecdd488f49e7": {"doc_hash": "78d7a468223b959c86f9612ccda6e2a8fddc9574770d569eacf7c359634de4b3", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "9db5bc63-c5bd-46fc-a486-f9d057583043": {"doc_hash": "1bd31bf48e9bb2b60d76d19ced05f9164eba6291b532cc93aee9729cc3e6cdb1", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "1169e45a-5534-484a-a82e-e7e3c009820f": {"doc_hash": "409838182dd57639f09059a542ccb5bea5f70b780fdb730211704a0cf7f0db43", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "0014ac81-1a7e-4abc-999d-402f8489780e": {"doc_hash": "fe29d1135a8bd2323ad06c8bab6b557674adc3606b551a9469f0ff0fcbcbdd91", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "74754e23-5613-42ea-b6c6-e9057138a62c": {"doc_hash": "5ffbee5b23d84cb61937c2bd676ab6a875bed6fc08dfd6e42d722215898f4602", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "f36a3f80-8b73-4ff8-9465-8fa8f7b3d6c1": {"doc_hash": "f8beab9a16a9c8312e7bc6acdd9253dcc2fbacd9b2deba95b0f9e410cab8a4b6", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "c4e5a7be-947e-4b3a-bcd0-32e23919d9ed": {"doc_hash": "b5acfbe90c419ed7618dd1aea169d765028190326b07e8276f46e405e81e81ce", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "5e56e160-2839-4ad2-9632-1c6c6122c7fe": {"doc_hash": "458e5e18bc2e9f0787627d05095ad6d2db2cdadb740ba6804dc676d16ff44284", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "ec9850dd-3f4a-4f16-a73d-44e83bcac825": {"doc_hash": "6957dfcb387cc77523cc2531860d5ce2c14172e004befa3317e03a9b4c26145f", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "4328413d-b581-43fd-84cc-3cca48892fda": {"doc_hash": "2e667523f36826ab3cf80ec362862573c98e8886fc57260eb5086b9bec190a8a", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "6e25fba5-9220-4b7e-bc69-f9858c07c916": {"doc_hash": "291f6757c948e9584326edad0abf1b48af544d457ae1a3ea27f3ede6c887191c", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "44bdf80f-88db-4e8d-b01b-6f74ce9f25a4": {"doc_hash": "91aa72ca4c978420097a05fccc6d51b77dec9ea44cede4be4978a5004467a3cc", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "cd7ee590-160e-4ce2-969b-c6ffbcc73aba": {"doc_hash": "351a4bb487e52420e19b641e8436f266e2284d0b6d2298c93c3d683a7596e972", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "1a2600d5-3198-4183-a23c-c6250be92254": {"doc_hash": "63582999b2d868de93d14f8d6d3541ea09ab9e0270533727765eb21551c15b9d", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "45cea5c3-46b6-4c17-94b7-9ae6451a71af": {"doc_hash": "2bd7708ca0c9f6ed9fea3f5fcc0f39d36bf8985ffe53d941eef1308c5150657e", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "02c45896-dd82-4bee-936b-00fcda9aa2c1": {"doc_hash": "6060c04776acead768ca29bae19e4a85db449657c4d76183d8b8d3f7726ef03c", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "1671da03-5e9c-4eb9-96a2-7bf41a701708": {"doc_hash": "3e27d4678597526d73c9fb1afbfd75b5115959cf93911a478a16513da4389457", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "f1331b53-6bfc-4430-9feb-5290f44c65e5": {"doc_hash": "aa12515e1ec41b08bec07de25998dcd1075b1223716c24953bdf4b3bf88f9c2c", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "a0eb2f52-d934-4f01-aa56-7730fe244f3e": {"doc_hash": "7b843a554da8ae94ccdd8ec20691cf624cb6358aac58da16782671eb52e3b915", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "010147e2-5fa8-471d-9c45-df2ac371fa71": {"doc_hash": "75f0f30e15cc6fdf904e7270f9a21821db2b2fabbb28dcbe368e25b447d86efb", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "bde223f6-d6ec-455d-b01d-e722be4df210": {"doc_hash": "15535a80c4524a842949d1aaf39cea26be92a57f2c2d09d932b92e02b30ac88b", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "82920ffe-39e9-4744-be50-33af84fc9831": {"doc_hash": "fddaebb4750ce33eeba035f4b4c013bddaf6b680ee9612151c05ebf09c9f402d", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "f4d5696a-35fa-4d8f-a37b-572a50a7f34b": {"doc_hash": "a177474eedd84f8511f531533d208fc4e58bb57094a2ab511cb60d6ae78a528b", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "b23fc13a-2aa0-48df-b098-afec98581e39": {"doc_hash": "86bbc13316b698cfada271bdd9fb102f85379f70daff6f5ca132ad3cc5daa9ea", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "915991c5-266b-453d-9354-a5d990b7e828": {"doc_hash": "c544bcc584702015fa6de15ff75ca83f5d3b9506418e1b2d1eb086b5f18cb8d2", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "f3e550a9-bc75-4fef-a2ed-264e388dbef2": {"doc_hash": "e6e43b834ca9d1f95572c3039a3f26d5c7741c6850b4d441c137a100d014c61b", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "1109a807-48fc-42c1-aba0-08d375980876": {"doc_hash": "a392891dd785584817273ef0232dfc786389f402cb569bc7acd962cb80b9d743", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "852449ff-104b-42dc-b751-4949f1ffe1cb": {"doc_hash": "63d82d789d2066ec37c0ee9f10b3e0c3076bdfb4b4377a8fa3c8c6f492e01973", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "8a70d03f-03a7-4e43-91c9-3bcb7b8b4da0": {"doc_hash": "b483741057f5cf21a19d1af88ffe1eb598b6e492f6a96af12a5be848e9b5311d", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "0cca8f2b-ee36-465a-bd1e-bf8714b24373": {"doc_hash": "084056e3cf567537d5695bb08342d0760cb12ea71093d38c2858cf45238a73f2", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "44aaa3b0-6e61-442e-8047-7478174a901b": {"doc_hash": "2ffe27e7b1e3d74662583afed714604fafaecd8ebcbd693633816cb203848454", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "a6a6e2e7-757c-440f-b533-e1372e47f108": {"doc_hash": "830a54374a74e55f5a935b9d581e2267a7a00260959e8af8a6113dc43d1c1947", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "e3c7c1fc-0a6f-4496-a240-ad6e398e031c": {"doc_hash": "4d6c26ce5ef373c40407c5d062b93fd2889dbbc67db2983dbf222502cc83d0eb", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "7b710299-d879-43fe-a0b6-5ea809d42fd7": {"doc_hash": "66944d58eff717e0e9336e09399a2cb7eb284bee824610810d6ec8bb58826e25", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "5207d818-56c9-4db6-aaea-92fc40e8d30f": {"doc_hash": "837aee27f2dcf3c57e4b77b10239e4b855c3438a7dca1d4c53cf80f4c82e2a89", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "da6dab38-8cab-4716-a554-0a948077bc6c": {"doc_hash": "54991d374004cf9ccfe9cc7834dfd6aa325de2f837bb64e050f8c43c1ca26299", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "a48c6ed9-3d41-4adc-9ba4-9b0d6d656cb2": {"doc_hash": "85197bbc3b1ae73a4982b79c45ffea35ebf904a9d6ea5f02c8957a2dc418b1b1", "ref_doc_id": "c0e2e448-9843-40c6-9444-18e505a2516c"}, "b6d2400d-2379-41cb-a3e6-2b7b85066cab": {"doc_hash": "8a99aeac2a085ed955692a27159e38961b2addf446196a4d368b286154c9b29b", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "9c2a316c-8c35-4b7d-8c2b-e4bb10ec415f": {"doc_hash": "49828e8e658badaae9f715b037fc7f4032dc4bb19e46915397a90c073bb4782b", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "fc028ad8-9fd3-4cc3-a003-41bece537121": {"doc_hash": "dd2d5133ac08b19cafa4778fd3a38c261df118ed99b50d4339dc9e161a5c9907", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "a21b02a4-ef94-42c9-8ea5-eb50cb606e38": {"doc_hash": "754b4ba85d1b0c13c0ebbef946d575940482710b70e78805a44ed9140da68a05", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "1cb07ea0-9417-475c-a8ed-b3faff72bd17": {"doc_hash": "38f538f38656fc3be739256bcef86313dade193294b871a61f5d964e3280f040", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "70d4d3ee-065b-4b7a-9eb0-321b34784dcb": {"doc_hash": "a37f372eb61a572455f1a3d6786342a35a7dcc366b9f77b91db610d36b97cb59", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "e2acf0f6-d791-4a10-9b1a-300804e039e4": {"doc_hash": "1357f4f52d375957ff7645439db727d667c85bb351409cb99d5eac9eccc78879", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "1d5a0114-15c4-42a7-ac21-c9ce7e0e3757": {"doc_hash": "1614a7d7624f66b2f715235cb176f6e85ac28f837970c2a477cff4b1dad11351", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "409be16d-a4b8-497f-8a73-a903afcc3736": {"doc_hash": "a62b74eda5d2b6b8c07e200fd8c543a10701bb5239be42742e4a64daf5574b57", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "36ac1dd7-ded7-4401-bbd3-c6b8474195a6": {"doc_hash": "fa3ecb8f40a455aea3b0092fbfacf029cda1e118df912fd1573ae51eac443f2c", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "2faa0771-3c50-4b89-a6c0-66c7150aa5e2": {"doc_hash": "35606e62cff1db11b92d15ef07d20a40425b5cc6d1b41af79d4a4b7c649b93f1", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "1f2d2a74-5a16-4095-a2c5-f242e3d09c06": {"doc_hash": "96c1da5589519e4c66f721af70d7fea75fec17ebbf7833f23f507716f9db7750", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "ad32f58b-706a-461a-9853-34a86030ea4d": {"doc_hash": "f5436dac247da993f030cf5309fe5d72b94b32175a6d29d969f3902d3078e288", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "9c9436c4-39fa-4039-9e1c-1055270f09ba": {"doc_hash": "384c98e97473eca62cfc14517740d8af294dbfceb4d137e72429361237e5b967", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "d140e15a-374a-4ab2-b715-785cbc0d9ff0": {"doc_hash": "17dc64118c7cf916ac24023c54bf4a8cc99a87131877808714a5d3a63580d524", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "4ffea2b7-c0ce-4ea1-9130-62932e17d028": {"doc_hash": "70cc54fa39f1e77537977e94913e67738e2bdff04fcbb10e98935a1446b3bca6", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "7e19ddc6-4ac2-4195-97c0-fdc587b464d6": {"doc_hash": "d76d4a016b7a33b727431492b6c11fe17e4bf41b17f321bcd57aed14f31c0316", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "395d81a8-55f0-4a10-9533-2ba7fc234f25": {"doc_hash": "e1621b63424b2e5ada5c56c0685a836a75ae82985249a17f0df87e81db0b52bf", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "4928f669-3824-4413-8eeb-165c3998f740": {"doc_hash": "3574257b8ed65367ce647702b939421237d09c17266bcdc6d11716bd8f966277", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "0aa839f8-7e29-4d6f-b523-39f386b16f20": {"doc_hash": "7df31f84156701ffc33d7a70c657b5c0ba3877f72b4d5e0a710d38334d0e8607", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "dbddeb51-4d56-4ebe-964a-724fcb239ada": {"doc_hash": "0be2e9b268b3faee733585d0ec46936905a1520b67cd38b488a364a16beafd8a", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "56a0ca6d-8fbe-4bf2-9fc4-1f49a4b85d4e": {"doc_hash": "76bb644d14cd7cb7e0c31ab362ee8745eb7b47d7e96e2a9705d483d3c63f91b5", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "ca4a7261-4efc-45d6-b876-a4cc76025959": {"doc_hash": "7cb60e071cab71deebd396da544eff0d8670f1987ae5c7850484c3c5d718ac87", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "bcf840d6-b1c0-4908-b507-39761d494d4b": {"doc_hash": "65074631d9115c2404b1888067606186b908fd3b0bce15e3f9e078a7c285f5b8", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "702c4a2f-a561-4983-8f49-d6a402d1fb51": {"doc_hash": "9c645d3eba1c31c65a700c440ec49699dc8fa578b326b14e6bd0b2cfb2b27994", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "8ce35227-1ba2-4563-90d4-79d4aaf1e010": {"doc_hash": "9633ab647db2827a8d3d0cbceae80bda3402dd643fe4658fde66e5e6024a3e3f", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "e9b51701-9342-4601-b3f0-7b7be34c17d0": {"doc_hash": "d939256bdd68f42506acd8c25215798b1230003590d64c26f669a61717808c83", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "e0451e4b-0da5-48cb-83f4-ac659828760f": {"doc_hash": "94e095760a8b54807ee5cce049a36b1721b8346d6acb2532b23a50bcd82d5f91", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "9e15d76e-a96c-434a-b368-f5ee094bc09c": {"doc_hash": "28c56203b6b69373a61964894a05bfc26e00bcc9579adf45c08e48122e8b4d1b", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "03a9d7c5-37e1-4893-90e3-bb8f34a9d9b0": {"doc_hash": "3ea901651544ce28c744fdbd5e0d425530b4620f87c4851e28e178517272ef7d", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "8a2fc72f-3569-4da4-b5b0-faf3e833bfab": {"doc_hash": "1308e33edee45e9f9b409849eb6437901d91e33b0b68fc01d4777ff45159c832", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "8c371fd8-a786-42e1-822b-dd622babd975": {"doc_hash": "248bacb6117f3c6ac390581ba14005edcfc08d04a4b38eaa491e1e5ecc8d0ceb", "ref_doc_id": "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb"}, "86b5f846-937b-4a81-8167-177111e34949": {"doc_hash": "ee6fe40ad43922638741d8cf2160bd4bed85a628fbd607c490aa5873c17ead49", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "38fdaae7-7f9c-4f1b-a91b-e0d8527a2b30": {"doc_hash": "2d73ff5132e6467396d931d7e0fccfde8b87dbd27896ea92af5d4947ac663bd1", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "979ccb41-6528-4d5b-8ef2-3413c768573e": {"doc_hash": "cbb185d0b205aeecd8cb392b625391c61ce01d4a7ef4d618bf7f3a417fe26424", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "58c2f43d-3a80-4557-85e6-e57b58347874": {"doc_hash": "3788ae21f14c3ba4153873758c087872084a72896862c6ed58c8e18d6204e4c7", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "9e680722-6e67-4407-8b01-2c940b747d13": {"doc_hash": "1e4bdf0080b5dabfbd56d242460d8c5a102e6e5ad35667456b1046bdfd7d3e40", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "7acae5d9-06e7-4d86-8488-bc188b45e465": {"doc_hash": "c0f3e63cbbc1f6ccc4483f4c18e16339f97b04704f21d31d45d40e0a607c414a", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "a28369d9-4927-4138-9c7c-3f455ae837cd": {"doc_hash": "ef57427bcd385232ee8d221d038e19fc4c8cbd6779cab0ddf39aa9bb9500e22a", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "cb92e3aa-e60d-4328-b0a7-f08a2209205b": {"doc_hash": "9d7bb0bde1712e071e1fd37eb1948f8abed6e4859d8c13b069f2b2b28f6b4e27", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "7ba55358-713c-4e33-a65c-376f5883287d": {"doc_hash": "6f3fc0904ee8dd4de86a291d24650484a70985bb272d69bc27e0971bf3fde797", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "697a1893-9e42-44de-a797-73b2a48cf833": {"doc_hash": "2272b97fd8f90bd1437834e8a40e905496f5fc20e71ddca915845d2579fc65a7", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "36044bbe-415c-4009-bf74-294f5f04c1e5": {"doc_hash": "72ca9978770b9ab3706aa8345a4b63738085b1f70c0916916dc2572847e05008", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "137adcdb-8ed0-4c11-a98e-c162c6f30cf0": {"doc_hash": "c2ac14dda4c5f9df4245054a7c41b994d83f5984bd968536373baa0f1c617bd2", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "169b0a24-5cc4-4e69-b490-5cb0f38cc82e": {"doc_hash": "79ab99949e6facc4b81c45554ec03f45a36e6ce15cc9ff5d23f71e2927c11870", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "17e672e4-edd7-4104-b03f-6da53bea4d84": {"doc_hash": "ffebb50b2d8ac5f19d3063f44461d47e24b0e5f3fecdee0d683d290c0dbe9eff", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "63d4033a-2f42-4fde-aa93-beb4a1183b21": {"doc_hash": "0728820ce902e55ff5a357a7bf4eeb7b295adda7e7c1e5a51d916fa9af879fd1", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "7045885d-156e-4cfc-98be-cedcae7216ee": {"doc_hash": "bede2e15a2ec29f87a0c6d110b14022dd27f31d2fa7881aa48cd3169a5cd7472", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "07f6b04c-a772-4fa3-af30-553e1fdf1ede": {"doc_hash": "1d37f409ca3c781894ddfbf111796877b5f42d34f55dd7f83d0c97bd360ec6f5", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "fc161c00-834d-4e30-a0be-fed8aa982cfa": {"doc_hash": "1e7eaed0900f04fff89d26958069b80a920e2120f862268c180c290bcd84eff8", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "e35e2b97-ec56-4041-b857-32919d865d82": {"doc_hash": "6db2513a22097ef16e1d2178bb7658c7d37c7c9f7da0dc086abb9433cc91de08", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "311b7cd8-aaee-49de-b5ed-6f9fff0c48ba": {"doc_hash": "2f77e5df763e8f244395e46736eaf5fa783220ed52275d63cefb940df40366f6", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "c823b97d-69d9-44df-9668-8c8773008581": {"doc_hash": "9abf9a958cc1bfe5c2521e905aa6164f351e92a3b3fa776bce297b476783a9a3", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "e15f9dd6-d800-4150-bafe-482ba13f6421": {"doc_hash": "8a0c9dd74f8d6cf6d35d65fbf2f84b4fa02da770c631f624687c9a68636f2084", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "5561ced5-18ae-42c5-88fc-4fd8352399b3": {"doc_hash": "08cb4c38a954ab104c0ce04f54e7f2496da5a0f5609d2e72453f5659e08aecc9", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "936c9b8f-42f8-4e5f-a1f9-7f409a0cc96b": {"doc_hash": "df0fc3be93a70bed87f3919be95d33d676999af0034a9068bdf5ead06384f547", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "b27d3e43-2783-4a3b-83ed-23ee19742efb": {"doc_hash": "c09456357f51b61e5f9cf082dcb2b3bd3616d17adbdf486164d7446e7066d9d6", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "bda0a599-4626-49c8-9edd-cfb12594164b": {"doc_hash": "6ec85ecd3b5ec70b652113393884d5b46e359addc3a578f4816987da1b61e9b4", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "c42d0bf4-29ee-44bc-b6a4-58fbddca4b13": {"doc_hash": "b1e52949a1850d1a014b7dfa88530805626f6c3f10b5d1ff56bbc44f45113587", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "1a660a6b-1396-4264-ba5b-a58e3ef76e1c": {"doc_hash": "4919ab59631cf4b56c5737434045625864e93a0fed291c9bfd48323d872e4a82", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "810a8229-7eb8-4d39-bbe2-e6e30ac3aff0": {"doc_hash": "7836e10699686528ac78c275043027d9297a113749937985ee29ce2c0867cd8f", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "fd56bc6c-5197-4c88-96f7-d9c6027af72c": {"doc_hash": "2d552783d8b340372dd110fba8c4460a3bf95762d1f18663730046661efb9e71", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "7073da2f-923d-455b-bf4e-bdc4aa6583ec": {"doc_hash": "7f45d06cad0407843dc6729232ef94b007f3b7e04f2dbab29df069a4a18a91d1", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "56f3d31a-a3f5-449f-806a-34e31c0203fc": {"doc_hash": "c0eb0d6eaf6fc63d39f77f0f304c2316151f4fb928f3c1f6e0d14bde47c166b3", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "e7e325d8-4a6a-43bd-9d4c-e493da39de6a": {"doc_hash": "5a8b5aab8fa2358305e9726415a1d6efc6b876bd900b9cc0e96c7cbda04a9e37", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "cf6a680a-4448-40b4-b8c4-d7ab7017ad1d": {"doc_hash": "930b493d57efa8d82f6d46acb394cf88786f6da118dd9c713861fd6f33095c75", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "9c235363-2a27-4595-8e37-7e6a8292e7a1": {"doc_hash": "541c33f3722cc8c72016b493d054ef1003eb4724b09dab1c16318d8b3ea5c4df", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "f288c12c-123d-4782-92e4-a91885896603": {"doc_hash": "645d3b5bc39113f40412df631a9677bbe60410ed09452c9521c6a616bc6b317a", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "52b28768-fb86-42af-883d-fd604f22a4a3": {"doc_hash": "79b70e2b2e5711045e4e7db3e998d64035aaed18751362ef4da230abfe19e210", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "7e9ecc9e-8b2d-4d2e-9fe8-9edce61f36b8": {"doc_hash": "40d1cd2021fde877650ce08db7959e79e90629437814b6ce02194346d47c2a60", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "26dc5bbc-1884-4635-8aa6-301fc8e78d97": {"doc_hash": "513b58b450b307c9390353e4c75db07fab658bb584dac5340ee616634e3b7e80", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "76b654fa-360e-4ef2-81ca-45f4971fbd15": {"doc_hash": "45a3becce012a1879e967070deff725d3fdd8449d598057383c590680d939ed0", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "ffb464b0-6ebb-42e1-be48-e9eee33747c9": {"doc_hash": "fa52fd6b39ae85a05fedd0edf4e8286de33f9785bb8625817b1385148f7c7dd5", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "6c3b6125-cbad-4c29-ba3f-fd3b2d9ffe6c": {"doc_hash": "db2509422eea4a89a02983595058a09be0aba745e0a70fb8e7845627a1b96134", "ref_doc_id": "eb78cca2-9143-477b-9ec3-de5e991d0773"}, "4bb21e63-061b-4c0d-bed7-597fb48e4faa": {"doc_hash": "3f7624f95877cd028b862521c10893f1a2d9dfaeb610a9bdce02086777121b34", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "a94e2a2a-dff1-4803-b873-df1ff48557dd": {"doc_hash": "86272b4c9d7c5e25464d0415dd1f211a75915ea617b43cf61464284014c3add0", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "b0adaa64-8805-4987-b00d-19b2efca2d5c": {"doc_hash": "9c4c6191dd1201558106b465f0cff431e51a2e5070d5707afbf6a7aaeccc9483", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "fb2ad34c-5afa-4ffe-ac8d-872779990f73": {"doc_hash": "8b3157aa6e7b172d95d3a9088a2c5fb6039279a4397c8f6df533d0201a2af17d", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "784a0c91-6929-43c0-98ed-7ed31ac9c363": {"doc_hash": "678342edfd1749366b13cb1b9dcb979250f78fe61af3baf22948a5e54304acaf", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "b113e33b-0afc-4330-bd3d-355a5f5c5442": {"doc_hash": "5ae55cdb07db803d1a4401b04defb60607edd5332a46980bef72639e5f3a4042", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "f41fe671-c2c3-4361-b8b5-d81ed3bbf433": {"doc_hash": "48b7f8a8fa0a11c3c6d82aff4bf3716434e94d35481ea52bd23d7627048280ab", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "a39d3b5f-47ad-4d10-82cd-150145562870": {"doc_hash": "035465b2302507388668b8ab73cfcaf7d522408caaa20b933634613d61de9eab", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "2e76c33b-35e6-4522-9c1f-8f0f96eb37f8": {"doc_hash": "a7bb0f18808574c2fae117b873fd7cd6cdee310903c0c0c5d711698e99da15ab", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "aa829da8-6124-4c8f-abfd-6bcd3bd03784": {"doc_hash": "c7c1e272129d52c12ecf14be2e43cd404c258c394780c997c7cb4e6e5a7f4114", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "1339128d-e9d2-4f42-9647-7c553af0cde7": {"doc_hash": "91452de921bc9352db8b35b208a7fae0984be3eb490521c69978441339164b3b", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "be5b6881-e430-4cfd-b008-8fd2a5a1b3c5": {"doc_hash": "d1129edebf7290e92c67fd9c270709c49e8f68ff7259db7ac7adfc528dcb9450", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "6584a356-e918-41cf-91e1-bd2f53527a14": {"doc_hash": "7c4684e2f6fbe88e92bb226b4156514c825f9d81382bbfa3d0b3aff77169ba0a", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "040edf54-e66d-4488-9a49-02c5836a71c7": {"doc_hash": "f94da78d5596a0156c62e8ec2cabf4fc9703271bd697b5543292fe8902271a20", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "b1aad11b-cdaf-4a47-bf91-24b00941a3a9": {"doc_hash": "ca3cb93035922e7733e72cf01c49cfdf4aa77251da3789c8ac8d1b5dabbea580", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "f0b99814-865c-466f-9157-02a392c0be4a": {"doc_hash": "39a6c7ff404a8f83cdc01cdec331e57a57f7f2270c7f14e153f35bee8740e3f1", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "bc8ae448-92b0-45d0-bd41-c04d2c12b23d": {"doc_hash": "ac0b7d6e573aea61b208fb97d3c2ac42ed8a8f023f5caf6f0355d6777a63a286", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "b8a5e74a-cad2-4e76-b557-5f965e9099ce": {"doc_hash": "f397fbdef95b96e37898aef8b42d547efcd7d1a74b3eae93086a3155522ceb97", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "e953a471-d32d-4b37-b0b1-4a6de39c199e": {"doc_hash": "128335a2663fbf5d33651293428d5fcf21460cabce469fff0f5a626fc8f19de8", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "84ffbd29-fd3e-486b-b168-26d1614a4089": {"doc_hash": "ffac247ad8f2393e69c6989772a29f171c7863d842972491426b1fda1eced3be", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "d496ceae-1033-4a2a-95c4-b11ae836ab77": {"doc_hash": "a5cef8c8877c77f3c9fb9bd7f90a631b56192fe79c44b52aec95f08ba96e9134", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "d2a5fe8d-bb3b-4213-91fa-7151dcf32bf9": {"doc_hash": "865a4339d98f649e89764a9f2c9b164eb41c71ad7104736bbbb43f17b40fa6cd", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "7a979e3c-889d-4027-9824-a1443a994b4a": {"doc_hash": "1561cbdfe0aded324585c1bbb7321fdc256d834a97ada3c1319f6a1b1452aab4", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "11fa7371-442b-4605-b7f0-ab863f26b602": {"doc_hash": "63c3cdec110372b502ade7a34af8f15f2f5a6a7a33b9ed9db2b1975a888b2e6b", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "40863518-9a5c-41e2-b479-597667e70d1d": {"doc_hash": "7569a342c72f87db4c059dd69c1357fbca26df482c37be47b6dffa2ebcdc1080", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "943ee088-4c32-422e-8e47-4febff37375e": {"doc_hash": "602da23d101d45238ec17d1984bccf7614cb35335ae89754be3692027d6afdc8", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "3fc160c1-6a37-44cd-b380-3956b514092e": {"doc_hash": "1317e46fad2de780f47bd4fdddeaf2f909739199cffa167ddc76062350362e8f", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "870fad3e-f1cc-41db-a70a-d12a7a575a54": {"doc_hash": "940c9f7de88daf05bc9ffcd2bddeaba4ae3695ba671fbfd395a7b397c7039f2d", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "c86c1ae7-49ca-4ae7-9462-78c33ff87b93": {"doc_hash": "18578fc0a7a9b3ccedd150d787f27d9c8e8452ccfd714195c59c239e49bebae6", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "124d58e9-15e1-4d7d-9fcd-1c131eac9201": {"doc_hash": "493c38c0f817695acf4c9ed10539d7a54b714fd023fff67d990ecf5262f1b4e3", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "0214d6a5-43ff-4195-814e-434b911d6f40": {"doc_hash": "a765a7fe1579122c0583edf8e08cbefd8e98e3cbe0a6615cd87bb0ac08923e59", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "849a9679-84fb-4a5e-9266-2c783f07e1fd": {"doc_hash": "05c4c22e7ab880ccd8e769077072dfa4c6f5e0f7dfce2ad37a78e7b76a3356bc", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "c0ec8ddc-1a42-4d08-a857-320de96d7b92": {"doc_hash": "10008fcf9e16811953204b5f312f2f2dd78ea8e8796daca2ffe8f7b6082a60fb", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "bf9844f7-71da-438b-bb63-8357ae0d8898": {"doc_hash": "4c1fd1ff57f876eb1572bce672da083adf61ca3f1ee001f4f3b3db544485a654", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "a3a0dc9c-4769-42e3-b07f-36ec5195963d": {"doc_hash": "a8a2a7ac20dfaecc6b133dfdfa1e30815882e77253840dbc7ab1e601b89cf5be", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "9a2c2406-5e85-426b-b897-79060c9a7c59": {"doc_hash": "9bc86486660321f240208e477f89cd22021b3ce9b8b8114410e8945b64ac3183", "ref_doc_id": "270bb366-14e3-4684-8f2b-c987d802abeb"}, "6c5b9fea-9c9f-4dd1-9df8-0b9980de94f0": {"doc_hash": "81c0957e8c7a98039bea2a3c8143b50aaed3a924f06544d4131dc6f2a99a2044", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "4a60fbaf-cd37-4ba8-a0c6-37e737626fce": {"doc_hash": "0a6b68be66b2b1fc38cb0a36d9275bfd230581b2a995eda3098a75fe6dc3dfe6", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "648e04a1-be0d-4619-a1ea-ceaf0544b2aa": {"doc_hash": "18ff05f877efed660bc03b3fbe0a8e47704a8391c7e9e9055bac2687855c4a62", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "18b05b00-b814-4121-8f40-1f8e675024bd": {"doc_hash": "6f131c2d6e264261d9bc444af21a9662cea8d5630159a4631ded1e9ccd98c3d3", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "5bf4f2a5-c44b-4ebc-9149-8160fa2bbbe2": {"doc_hash": "5c292ada2a16b49be981419700023a68428070637d7e8286ae3bf8ddc18ad342", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "6d69bb8f-967d-4a84-b8f5-178ebd78ead4": {"doc_hash": "7ce913bc7f08f4ef194b2c46f2e9b9ae0343bce11631687b526945b197fca722", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "8ac957de-32de-40d2-abfb-c22cff5fca45": {"doc_hash": "8802316f898b91bfe475e97324e780353fb3f06f60fa3e73fa7cd2277a4b9054", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "305def90-32af-4ee6-b0a2-f4d6783f78bc": {"doc_hash": "6022987203228f5c97c8309abdee4f1a33a31b655c2394fe4e9faf8061e821d0", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "7c7a74e8-d3c1-4093-a6c6-81a29ba4aae8": {"doc_hash": "ba071eaae9b7ad86b7b39c57eafa6551ca82a7f4c30ae6958611ca3953dac915", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "27ce9137-4d65-439a-b3fd-f5e9958d399e": {"doc_hash": "425776d55c272c15ae01dca5b18ed574b85b3d26b7c2dc241c1fafa9602eafe6", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "653d842d-3cd4-4771-b119-76308ebb8290": {"doc_hash": "f08963f281104a370ef9f02142ebb2149c6c4cf061019cfcd9ed47defde64274", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "bf97c747-a546-42ec-9bb1-d9ab12e0d29e": {"doc_hash": "4564d0db3d0008b911150579dace719b488f01c9a54f72e36fe69f59e3d72d6b", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "19b6c15a-75f5-43e4-960c-292d7af4e07e": {"doc_hash": "9c2f08271d07cce4181c40bb540618ebc1aee5d49447b714460a128dfa8f0a98", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "a60571b1-1968-4b83-acda-1bed4e9cb0b7": {"doc_hash": "93fc36905e5603f8aeb715d28cc010ca2a82a719def200a481f23f95009b3805", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "80de4d9d-fdb6-4479-8fdf-e8829c707d32": {"doc_hash": "00b057f16f8c9fffa8aa263272681bc6c41da9e59df11135b8a1aa4b96fc980c", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "be792133-4b0b-4ebe-a8de-1d7407420fb3": {"doc_hash": "f5f981a62f9d44c85fbadd173bc0d00d80cddd974b76c8b9826b6c0a9c86f858", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "f445f5ec-a8cc-4de5-95eb-7e142a320c14": {"doc_hash": "42b5bed98319e176c9667ba3db02b94f904e018cf6ef018ff74a39c435bd03bd", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "88f6a298-e000-45f7-8e5a-bc5a70707530": {"doc_hash": "0ff19dde6ac68a3f0998259153ac1992b877b131a7b19e0be71686641a0bb628", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "5d0e8c25-7dfc-401a-8b79-769d9ed60d7b": {"doc_hash": "db92959e9f3717aae7124b13019595f1c7981ab92ac2c3c2944d8544f96ce338", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "df28fadd-33d9-469f-8773-0c2b416a5d3b": {"doc_hash": "b038f458688e84ee46aa8e15b815d4dcc9b807507d88b23818381edf7baf9c19", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "c56d208a-b23e-42d4-ba93-7a4d78ad116e": {"doc_hash": "20cbc5aed6cb3482b128f5b082251ab73cc73830a964602405f0d7a0458f51d9", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "69305aec-f8b7-44c1-933f-a7649d080082": {"doc_hash": "821198546da1e1087e06e35b09e710785626f6cb5c20aaaa55fa186d18591c0e", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "3cb9f30a-cf27-4654-9c40-5494b47a7cff": {"doc_hash": "795b41801e9f2a9d5e74a25d5a4afcaaccd89e8698728394c1c7398fb64e0762", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "7bd22a89-e0c2-4f26-b5ea-66e346acae5a": {"doc_hash": "bfa9f503d7aaa218f7ddfd6eb04b9c3330a154644363b257995ec282362a1cec", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "86e33590-37f7-4118-8791-ad17fc40f919": {"doc_hash": "1e8e7cb67f536f38376f63e7b19c801fb5d2eb66ab6c8d2b00696695aa94ca73", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "444aadaf-8457-4fe2-9743-845fe7bb2801": {"doc_hash": "6945c24995f8a9ec27ebc63089ea65cee5c38572e6c90f234a17f0ae8729ab88", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "9b18c8bb-363b-4f51-83e4-09c7ca61de0f": {"doc_hash": "0043dc7e3dff6adb3ef2c711322657c142532d4981b04ceacc1a315533591500", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "b2a58c01-b247-4927-bd99-05eff7266a77": {"doc_hash": "d7be206ac26af51925584edaccdf937a3ffb5c93e50320aac9567f432d263114", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "02aa3147-ba3b-4b62-9ff7-8a90a1a68cbd": {"doc_hash": "8d7323bee98c94e5a4aed1aa061c17c93435eb8497342ce691fe04f44f187565", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "faf3b0af-982a-4824-b29a-e95d2915dd46": {"doc_hash": "dcd83c04fcad740b9bf409aa4cd6bf7fc5683fba90cac7d031575ebb238ab248", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "2f8dad45-d057-4f5d-9999-e2c211dca105": {"doc_hash": "a00c5c6736ab05dff881cb66c7beddb30f8b6aba3f7ffbf1732021ff330becba", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "069b33b6-386d-4737-b0c5-0e2c10fa6af4": {"doc_hash": "98debf3563fcd06cc776c8f4beaa4716e9601c36dd32fafb72f75b735c262daf", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "69f7b407-53ba-46c1-8b20-2241ad3dd9e8": {"doc_hash": "fbc4549fa4a1b0387e97f8847dcae264405fb98ddbd654ed24c3be01f08ea773", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "3e2781d4-56af-4a29-80dc-b99c493980e7": {"doc_hash": "467f26fdecb94a0b49309cd0229df7189127acd736beaf9ada47b466521104b3", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "820c0dcc-80d8-4039-8015-c9e327a70b5a": {"doc_hash": "ced59a3088c3eec091d644e16dc8f43350c858e3c2421e8f6516c185dc9f943c", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "9fb629f1-6a62-4cb9-a3b2-c8a2b7ef5629": {"doc_hash": "0594f6aacabb0a624f45d5b86cd018a2a72f2c86ef1fadbd4347ad6a8c963d62", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "b2328d53-ef28-4dfa-a82b-d01a6dd53c75": {"doc_hash": "29954e5996422bcbcd5c965653b1101774dd0146b618ec2cc89a1224373e14ad", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "eb46c93a-0e09-467a-9e70-8119fd91b437": {"doc_hash": "3b9d6729b48c6eb0fd9589d5b252e43d670e95b24bbd2d01eb72289bf889b0fc", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "4194458b-549e-4cec-8092-5f9ffe3127bc": {"doc_hash": "519bc9c4cbac41c98fe0d067f6ae5d68e27265394f42d43261851a952f45d3f0", "ref_doc_id": "26808593-a6ae-4d2a-967e-b90d1987aa1f"}, "162941fd-7b8b-4ca3-9d3d-8c191fe48e03": {"doc_hash": "f943f04981e636af5aa73e1d1864f37ea0e2d9ecc736d15dc4c26b71c1e9d998", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "0f324ac8-596e-4f25-9da1-8a55ad5e4df4": {"doc_hash": "20149f97ee1499953171437a0ebaa09911f84575b3572bcf50f6835de69176a3", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "6a0e19ff-d746-4543-9a32-de438868459a": {"doc_hash": "fafaa9171c9430cd28a5b70a01201a943f264dbc9601ddba03d01709aed62e8d", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "182fe6e8-52d8-4dae-aa09-6f707397c5f1": {"doc_hash": "50be183415e27fb1df77ba758a0105eaae80bdaf1e2e0fd6c376452d3d39de2f", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "60f9d5f7-b119-459d-a477-a000545ce4ab": {"doc_hash": "7cc7f1e32ee8ae0977ec40658b1df85651df09eb9e4ad6f80046a949ae7c4da3", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "10930c63-f714-4d19-8566-36222be27a77": {"doc_hash": "a7b0ce2e95f40999cdb5a6791cecda08856e632a49c3adf7e3e1d0af3bcc5ef5", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "a01eafd9-c3cb-41cc-ba23-b679570f7b76": {"doc_hash": "04dd59e64e0692eaf72333ecc06d574e3dde88af0d5bbfe731a3141560cc07ab", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "cd2c6e86-f976-4d20-9847-6932030e0ebc": {"doc_hash": "00761043e59f6699037b3a1507939aa43ecddf0a11b2ec664a8c1d03e2edc5a3", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "b9d2a32c-1402-46d4-9be2-165c3c08e09f": {"doc_hash": "0e9bb45252a2ca8372f5c6f73918157f798a800f5fae7c0be5aec6cc7f7b115d", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "0612f3f3-80f0-40a8-9b68-5e9dbe7ff4e2": {"doc_hash": "35c7a3f4eb32ef1974323c9db78970aef34fe05c06091439d42d0b3cf0280c6f", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "7d6767aa-f5cf-4714-99d1-6c6c9334ee7b": {"doc_hash": "f359642823f945261fc5d9bab2bf35b0fad927ddd0518adc9b366b60821f98b6", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "e8666932-62d8-44f2-aac2-61a4ffcd8a68": {"doc_hash": "9657cdc7fa3f2f04d5d5f750a2e7cb058ab5dd67c37c87bf9d8c85b755b7e43e", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "03975480-279c-4420-887c-1716df50644b": {"doc_hash": "22fe5c3afc947a6aa3a98617ec2f14c77c35dd8d0cd7bac77a0f513b2ce3caa7", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "ef5d0ed3-2083-4b4f-b6c3-98f81eeb813d": {"doc_hash": "72946082110e9b328849ddb80aee154aa72c4ac4154861fd06bcf5d4ff4e4ef4", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "d0bfc667-7481-4601-8542-8353f74f6c27": {"doc_hash": "00b6a150af7f2ae50c692d2cf7343319376584a222bc6e579886760826a5f421", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "48d7a1dd-6e1c-4b18-9110-54d38dfe7ee7": {"doc_hash": "fe762c57b4aa47b90f78d03a3efdde6281593b63f024131caed246fdcbfb944c", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "3c44c15e-dd2f-4298-8f98-4bcf57b4cb2a": {"doc_hash": "bf768ed6760710194baacdb10f4bce96f10c377585d4d9f1873f1f584382aaa7", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "53b62fda-b9c4-4cb6-aee4-70fe74a5e955": {"doc_hash": "11b707930f061ba7f5bcf6dd37690592af848afe118b7e5920f72553637f5d33", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "b058630d-8c85-47ed-a8bd-e8364ca07464": {"doc_hash": "af9d6055589ddf06a1eed56b3dfa16c81df156b0398f56614fc4a59d7bb5b21e", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "e0d09e52-ebac-4679-8aa8-57ddd7890091": {"doc_hash": "17ef58fae0468ab1228e9215eb38dd52502e8939c125c6e8d87f4097fe9dfdf8", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "50f5d8be-2377-4bbd-9947-7c22deb5dc0e": {"doc_hash": "fb589238852f88981c72765703dcc2932879d2cbde48a083f9a5c9d0047414ce", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "0824d247-faa4-4c04-983e-295fa9a7f0c0": {"doc_hash": "48522b54b08d34cd9c89c3ab50aa47f5e9461117cabf7dfdf781eaee3a1c540e", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "48ff3e55-35ee-4226-aa01-c51e21402a3b": {"doc_hash": "834350c00fba226ea5a9934681b79bb8760ac9c238385af38e37d14a964e3082", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "f2683d19-236d-48c5-8001-22269599561f": {"doc_hash": "7c0113889957df3c81e73b367a6959dd05e7df5c9617ed0570188f1638e52733", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "4f99840a-c2c7-458d-8db7-5c85474962c0": {"doc_hash": "555c91f0effe77154fbff90eaef33de0a69afaea3a47103b9629421a0b0e0cc3", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "a36fae0e-04c7-4559-b1e8-5549e1af468b": {"doc_hash": "ff69c67b25bc6322027d7592deaeae5f8a347c79b1ab6597d170c82d06b2a2df", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "5ac0c755-4f47-492b-a088-4bcb502402d1": {"doc_hash": "a1b3584e593aed463279f5498ae540085415c9596ddd1f1b7589c569bed351b6", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "ddfc8364-38e5-4754-a81f-b668d8d279ee": {"doc_hash": "32286fe39e50da09d7271f0dfbd83645dff0cc3a0f544951f67eca9bd3acade3", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "b21dba85-0b75-489c-8e9d-9c1f7c5d405e": {"doc_hash": "5c0d06a6b77be506a6f2c652a7fb95d9fb2bf31a14c884b845550f9cf789d6b4", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "8b8eeb6f-db4c-4274-94eb-a1f1bdbdff04": {"doc_hash": "051edd4208267304fd47bcc078a026c7a60589d327741eb144f57042ac3c0bbc", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "9b1ddd2f-dcbc-4f39-858d-d0c7c553aeec": {"doc_hash": "bb2b418824bcd994bc32f490311ff93686d566623109f617d6d36cd9d4dfda9f", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "7e9b238e-3f38-4039-a934-138e7a7c72c0": {"doc_hash": "ba7a94519f96ff4d8e94178676b7d3e22af569efa5a9c61bb2b198cfcd14c727", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "3c5496aa-b14a-450c-959e-c602451968fe": {"doc_hash": "1127f431104e668b505f2dd88ebd599cfef57b749f6b9ac599893d7a5f18b487", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}, "ddad80b3-f780-48fd-a2be-68efb5416689": {"doc_hash": "031e31ac63468cba496bafd50755b98a065078e7359a686101c8ec90ecb3c79a", "ref_doc_id": "4f381e66-390b-485e-8876-9a33c7c20d11"}}, "docstore/ref_doc_info": {"f43cc1d0-0218-4941-a2a2-4b921ef536d8": {"node_ids": ["4972ee75-c737-4c62-adc6-975003ebb7d2", "fd0e9e2e-5fb9-40c2-adbe-54c6853b322b"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.   (MCK ) \nQ2 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n01-Nov-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6a16dced-c81a-4c27-b101-6755155f7b96": {"node_ids": ["c03e914f-f60c-4e7f-aa8f-b29dd6e865d8", "9698887a-5846-49bf-b947-5f85bd0d096f", "f438986e-ed83-4a47-9861-e24f7e799d83", "bfb49db0-67d7-45b9-8ab4-117b853430a0", "77677100-623b-4db3-9022-1b26e28830e7", "5fdb68c1-027d-4a01-a262-6eddb01bb8b2", "1653a396-7214-4f45-8ffe-efb60e19fee0", "8faf3715-f1dd-488f-93fa-2f9ff63fc449", "03890988-ea69-4f7a-815a-ddbf3631867d", "8719cd4c-754a-418f-99e6-b4e380ae59f4", "7294be3f-2c4b-4c17-8bc1-f7840a1d25e0", "f81b5f3d-df62-4633-93f1-c0954b0f3cd3", "1d277702-4ea3-4c50-ba12-02899cfcb02d", "19ee4baf-1c35-4491-b34c-ea993670210c", "90676184-35fa-46f6-826f-6334d51adc5a", "05cf3aea-0273-429d-b6e6-59dda3ce6212", "91745cef-186d-4347-9f12-aaf8b08cc44d", "386ecae3-bd0c-49fd-9c57-6c65b14f9c9e", "1a76bc05-343f-4f56-8972-c8008458898a", "dcc3b48a-ab1d-4bbf-a5a2-c705cfa29d96", "ace85974-01eb-4186-a6e6-7b8684524612", "05085222-e830-462b-9baa-f700c0475121", "0f89ca5a-7484-4d43-b424-ae05308686a3", "c0b5ed14-cb7d-4294-b0a5-67a489b8276f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nPublic Relations Contact -Investors, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9bffb322-0dc4-43ec-a89b-103c20c10ef1": {"node_ids": ["34a304f7-d91e-4536-8ddd-f3cc6e2b6c74", "d35235ab-9c1e-4111-afea-8365b511e7a7", "45dc345e-9d05-4ba1-88fe-cc25ef3d158a", "a1fab1de-4322-40a5-b6cf-7c65ee04a996", "c4a98fcd-a082-4d17-9962-65d001ccdc92", "86a1ec01-4c90-4e4e-bc6d-761bbc8426cf", "0cfc8f6c-4ec9-4c02-bb0f-0cd91cca5186", "ddba9857-0301-4b02-9dee-07348904aebb", "dfe20a8e-80ca-45bf-b1f7-475b19ef3a90", "6fdc5ac4-f23d-4391-b6e7-016649d4ffcb", "28ca8238-c13a-46c4-bc62-8594df734550", "8dc4af81-13d0-4945-9672-15324fc2a1c5", "759ca668-b276-45dd-a551-a356f04f4add", "8dce0e43-0058-45fa-a356-0456e6209d68", "fe15e061-c9d4-45ad-a0a7-b8d9f3e0533d", "9716f33f-eca4-413e-80e9-34037095cb4b", "11e0890f-261b-468e-8c27-c2e612f3fac5", "e3b5f654-ebdd-4d14-a143-8a3a59a60e16", "fdaf1edc-00df-472c-aa19-292a9feb015c", "99b51cae-eac2-4f7a-9b6d-61362092aa7a", "be0aed15-29b5-4b33-b82f-7eabbcf05600", "5d94f93b-552f-47b0-b015-19b0503d4570", "e9050348-8720-4ea8-b78a-ba2604a77d98", "be9ec31e-5326-4717-ab59-c9eeeb953e51", "408350a7-0960-4395-9b54-0e470131bf56", "e41fc4e2-8e86-40d3-8ccf-25832310a5ab", "3d463d52-7e93-47c6-8e63-9891e3381c17", "6a62fa0f-c731-4a15-854d-0ba670913d70", "5ee20a0e-5f18-4e5a-95b2-16a63e40ee1f", "eb2b5651-1c00-4849-bdce-69512600964c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everyone.  Thank you for joining us on our second quarter call today. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9ab4e218-d905-45a2-b786-9c74cebc28f2": {"node_ids": ["4761bf74-8559-4b55-9b99-5459610a6bd9", "816be645-f31f-4f1b-8628-ec3e050e6baa", "2f6a59cb-481e-4680-b482-54413aad6a48", "81653593-7634-4284-b844-1771f1ac6b6c", "38173c01-8fcd-466d-b375-d14568b53900", "21a66825-0a99-41c5-86d9-67192e06fad0", "fed2f864-8456-4446-8fa3-28de33a17456", "667067c6-a91f-4f54-8ff7-c5376f129b8b", "ea308ee1-d756-4e0e-bbbe-84bc3ae780ac", "55a06f22-c320-4273-9ba1-04fec8db0bde", "76f68b29-596a-4c4a-ba46-3f903cf8a9ca", "a0918f91-e83d-4eca-a27a-615767f1329e", "6c99776e-0eb7-47ed-9f1d-6bb7654102fb", "f00e5e36-bc0d-4266-a586-7d2cc93e4aa5", "2050ef4d-d9d5-487b-b83b-28ddaf0ec0d4", "d2e452cd-cdfb-42aa-b859-fa514ffc9888", "4179669b-dc20-48a3-adf2-6f02936d0ebe", "4e7db23e-4a92-486a-9f5c-07b6e5772b40", "f97ffe18-3a54-4e76-b799-4231335188f1", "19fab122-5c53-489e-bb1a-62601c60f5d6", "c3097d65-a296-4f76-a187-b3b3ef300e54", "3159a24f-25e7-45c0-aad0-0023f5a8dac0", "d1ec5762-0224-4517-9b05-cf43c46ee4b4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n2,000 independent pharmacies prioritize education and networking, which we believe will shape the future of \ncommunity pharmac y and strengthen the independent business for the better.  \n \n In Canada, we've been the leader in healthcare related logistics and distribution for 100 years, and we support \nhospitals, community and retail pharmacies to ensure that medication is always availa ble.  We're a leader in \nmedical distribution to alternate site markets, and our footprint in the US healthcare is underpinned by our strong \nsourcing and supply chain capabilities. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "54941f87-b696-42fe-b719-ddf222a3bf03": {"node_ids": ["1b5e6dd4-e7a9-43db-b311-8e1c0d70c3ae", "48ddf2ae-b7db-4571-b411-a91c22b72739", "5c91c3fa-43be-4fc6-8529-d9ed31f3cd63", "a8180407-fa32-46e2-a182-5d62cc9743fb", "cbeb1214-53db-4c3f-a9ed-989c2eeac47b", "b20a446c-a639-4374-8472-24843ec119d7", "ec4ab925-28a4-443f-b8cf-091faf765a30", "9c525ebd-e59d-4b7f-86a6-6bf1cc568516", "dae4129c-b121-4efe-805a-a0cc00a249ff", "a17f6c9d-72aa-49b5-9fed-2bbeb8195a9f", "e183fb6f-6416-4e14-8aab-dfb1f90be615", "6362c647-3296-4d01-af20-a85406979720", "f29e39b3-4b96-491c-be24-4a9c8106df29", "bb55197d-adbe-4d8b-b3b8-d0a6a2012c4e", "e54576d6-4eeb-4ad1-ad9a-7d7402c831c0", "c6d14a09-d91f-4889-b09d-7ec6e843e08b", "54e9552e-a613-4060-8402-95a909543f05", "a1045f4a-c4b1-45aa-94e8-e55fc9a79fad", "e937c734-40be-4fac-bc9d-c070eaddfd3a", "006ff6a7-f48b-4945-8787-07db49735a73", "640382c3-307a-4538-9feb-f75e8d5cd909", "4578289b-774d-4860-965a-894454c1c4cb", "db0ed7b4-863e-4bab-ae88-14bf365e731b", "3ba5d83c-f41c-470a-9c70-bf1bc6025d92", "f2607f03-ec67-4701-979a-c6dc3de98f89", "e570ae5b-5833-4baf-9adc-b915f740a55e", "3b551c54-9f86-4c7b-99b3-f0ab8c433fb6", "f56cf395-bde0-4a0e-91df-0061fc11e176", "43756234-b8ae-46d2-9713-5668919e560c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRxCrossroads.  It allows us to connect providers, payers and patients together to focus on access, adherence and \naffordability solutions.  \n \n Our two strategic pillars of oncology and biopharma services  are not just businesses or products, but \nfundamentally a suite of solutions that solve long -standing problems in ways that bring more speed, impact, and \nefficiency. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c51dad55-d9fd-45a3-9396-240a2bfdce5b": {"node_ids": ["f04e1ea7-114b-451a-aeca-ebda1a43cae9", "f1b08697-f73b-4213-94c7-9bb42e0e4725", "c7741f89-0c3a-4fb7-9511-652023a7b072", "b9364745-9987-4132-bd11-8460daa6a7ad", "c93f4a12-5f2e-4691-afcd-55aa44f80c81", "e0e8b8ff-cc50-4112-978a-5ceee1a2771a", "bc3db8b5-665e-49a1-8e0d-af5bcdbcc2b0", "6a08d0d2-9bc5-45a6-aff5-b046e008a4b4", "190b4988-d2bc-430c-9d93-c641a55ed89b", "7acb295a-23d4-4685-805c-d1767645f086", "df731444-ac1c-413c-a43e-ab8ca0306d24", "696874bb-c18d-43b5-a653-328295a098a6", "ca34b33f-f66e-4f78-a92e-c4c45f2ce263", "4a28f04a-eb47-48a1-8ed4-da47866e5dd5", "75cb6151-ab7e-40bc-8e46-2ae6bd673dfe", "1b536aa8-b5a4-4bbb-8972-12d5ebee2c7c", "73df242d-7750-428e-98c6-dfb31eda065a", "d437dce9-f9e4-48da-97ce-b90896c84805", "e1c2a1ef-5474-4467-9dfd-009a19cf9e81", "4b3196f6-78c7-4ad3-b918-3ef366f46ba3", "b0698ac6-7cda-4562-a9de-3ab802bb7bdd", "d4645d28-f102-4ea1-a5cb-48c0ab361bab", "a3b9c012-562b-4051-b019-b4a97851c4b0", "702dd0b2-b802-4d5d-914b-1538a22ad145", "e67b1856-8196-48d2-bcd9-6360b887953a", "e8d94c48-57bd-4e2e-a5b7-c64a8af8ae35", "00a36027-2045-40ca-b18b-70e4b6ac9059", "f7d48126-42ab-4845-9f85-0ef54daacfc8", "9b5163d3-28b9-4e31-9142-c83b9dfe31fb", "e02f7078-3bdf-4f47-af63-75030f04dbe6", "f615acc2-7089-4860-81e0-6feea9f2f591", "33c67cec-d842-4989-8d3a-564bb6a2da79"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nlocal governments to distribute and administer COVID -19 vaccines.  And through September, we've distributed \nover 58 million vaccines to administration sites in select markets across our international geographies.  \n \n As a reminder, excluding our planned divestitures in Europe, we have businesses in Norway, Austria, Denmark \nand Canada in our International segment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9d8c3317-db52-4fa8-8aa5-dec9ebab7c35": {"node_ids": ["3ae9a421-4389-4ed3-ab23-3e580a9dedb7", "66981b51-07b6-4250-b274-c38ba2655b14", "247ca319-2a9e-434c-b808-b2d64f7192bd", "d1f61059-c08d-4f0f-8e84-7cde9144ce9e", "3914ccf1-15ab-4fb7-86c5-6a2731febc7f", "bb257384-d078-433b-b271-89ffbf8ca6ee", "2a4a71ac-fa5d-43f0-becb-bed7601a3c55", "c39ffa58-444d-4364-97b4-8dc557756bf0", "c95b6270-63d6-4b19-b7df-824b86730d13", "1b6bc8a4-ea7b-454c-ad9d-7acd628e7431", "872fff90-26b0-4f87-ad74-fcbac058bd31", "d099e347-6402-4346-9151-2a810f43c1da", "07cd82b7-6d58-46df-a679-f7eb38781b95", "d15266d6-3b21-4c9a-bcba-e77e7a3dd795", "6f2a3782-fc19-421d-bd9d-5a5181716c65", "de8937de-c087-40cc-be25-dd6144df57f7", "9d76a053-cff3-4051-923b-3ef00646c6ee", "c497d2e4-f57e-4c3a-a4f9-b4056f822ca1", "2be07b2a-92e6-49a4-9a7b-0b86d1634d1e", "24eed68b-b64a-4bb9-8c81-0a1bcf0f5848", "f88a1afe-40f9-4ae9-bcd7-a03f1485717c", "6b92650f-a360-4932-865d-9e2fd803589d", "78a0c186-253c-4c81-81e3-ffeb7c957ecc", "7f429c90-7422-4d80-a354-acd058666400", "3aebb428-0fd1-4d10-9caa-8cd6bb870605"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ntransaction provides us the focus to pursue the growth strategies of oncology and biopharmaceutical services in \nNorth America.  And as Brian mentioned, we remain committed to a full exit of our European businesses, which \nincludes announ ced transactions to the PHOENIX Group and Aurelius, as well as our remaining operations in \nNorway, Austria, and Denmark.  \n \n Let me now turn to our second quarter results. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5d0e2ab0-b08d-4faf-8b59-2946d2b3ecff": {"node_ids": ["23ec26b0-7baf-463f-86bd-95e4b12b4479", "5d761151-2212-409a-a679-f5014ff9ba3a", "e09ea273-f233-4e98-9d60-8c13ab0572f1", "77ce9666-e03c-4034-ba1e-9196730afb58", "8caa337a-8405-4b23-bbbe-168fe5a686e8", "e0851e4a-5782-47f5-9c62-ab0895ae3967", "d9eed8f9-a3e4-4d9a-9d07-77f0a80905b8", "5ded3b79-6cdb-48a5-aecd-30afe95f76f0", "be9db5f2-8eb7-4116-b1bc-e8b464712c39", "4e285a6d-a1b4-4681-89c5-899f5a860150", "063b2b36-6ac4-4310-9f55-69d321b6465c", "291397ab-808f-4a18-930c-ad5fd063cf8a", "37825d74-83ea-4b3b-8bb1-92855d64c092", "e5493218-35cd-48c6-b949-3fb11cebeecb", "7c69ea80-0c61-4b93-a253-375d9a1dc51c", "865c378a-e8d9-4be1-97fb-5d1b82da3008", "3a149578-af6c-42b1-bbf7-a31b4b10c279", "3f12507c-eb3f-477e-bcc5-e352baed018b", "44bcd7e1-151c-4654-98b9-38e8e4973361", "0b5d926a-5deb-4706-9ee5-215eea9e4471", "2fb5121b-529b-4354-9f6b-764aa855bb08", "da459ec2-c506-4f1b-91c6-895d61e57160", "1305a02d-300b-4bf7-8225-d42c80bf319e", "edf1554f-eecf-4d99-965e-453d583f3422", "9a7f32ea-c863-451d-a94b-26fc50472136", "9edc12e3-1936-49b8-95ff-d01c00506ff2", "0b2ae835-a4a4-4256-9f4e-55b25fbd9775", "009204e6-6970-4fed-8148-e20adedc164e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit increased 12% to $735 million, driven by growth in the distribution of specialty products \nto providers and health systems and the contribution from COVID -19 vaccine distribution.  The con tribution from \nour contract with the US government related to the distribution of COVID -19 provided a benefit of approximately \n$0.28 per share in the quarter, which was above our original expectations.  \n \n In the Prescription Technology Solutions segment, rev enues were $932 million, an increase of 40%, driven by \nhigher biopharma service offerings, including third -party logistics services and increased technology service \nrevenue, partially resulting from the growth of prescription volumes. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "12dde7bb-e1b9-4067-9dc8-557030e1fc41": {"node_ids": ["d7d7eead-7bab-429a-84c5-c6dca66b8362", "584380b9-474d-48c2-8417-185fe2e4fd84", "96cc169e-4fe8-4644-ac42-34069426591d", "33642ae0-4fde-4fe3-a581-270b427c44be", "b0d99f51-cfa5-4626-a7ff-a6e0eb9bc092", "03a9b762-29f5-45c5-9f29-3d461367c9f6", "52f732db-7bc2-4cef-92c9-353168e50d07", "75858345-16fd-491a-8ddf-6a00422791d9", "1c3b29c7-3102-4bf3-ab3c-d259dee692bb", "27d38ccf-9c25-44e0-9fcb-0fba4a479f28", "658f14e3-5134-4ca9-be98-b2fe4fdb5146", "674837f0-b4d5-4265-b800-03a232b60835", "92d5f7f4-dd6e-442b-aa44-ea32c7c57bf3", "0552b3a8-d0cb-4a3d-879f-7c7381cd3d07", "8d090e98-2a51-401f-be5c-4c2b9558a137", "3737e843-3641-4773-950f-8848823633c1", "e52ebe43-1c44-499b-a485-0055be50a818", "31ab3d2b-9875-4583-b299-70f11cf488ab", "da5b9c00-6060-40bd-b406-ef2b4b77d158", "062116e6-4114-46a9-8c02-8defc02c6899", "035bd5e9-12b4-4e7d-bceb-e0e1033b64b2", "a770ceb3-8a17-4730-99cc-10e4bc7a8844", "6ac3bbbf-11b4-4752-b8e7-ce7bf08e1c55", "c638c24f-9663-4d26-aa0e-8679461b8cb3", "c5cc9a9c-91c7-4bc6-a742-45c55d219e2a", "371298cc-a828-4b97-a846-6d8ee0ddcded"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn August, we completed a cash -funded upsized tender offer, which resulted in the redemption of $922 million \nprincipal outstanding debt.  And final ly, we completed a public offering of a note in the principal amount of $500 \nmillion at 1.3%.  These actions align with our previously stated intent to modestly delever and to further strengthen \nour balance sheet and financial position.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1cc9bbfd-bb1c-47f4-ab34-d7023c07aeb2": {"node_ids": ["1d54c29d-9bee-45a2-8638-af37430828f3", "2c598bfe-3e26-4076-90ee-7cc2c96158b5", "a5eb6743-3447-4c36-8b10-4171b8480645", "13399cfe-ea54-4cd4-9d72-eae08c3cd1f2", "31e39d7d-314c-4422-b5a2-5556e09b5259", "92a52618-c21f-4690-8b57-3811a2671f33", "9b0f7166-2d2e-495a-aefa-229d497ea422", "5cc43cc6-46e2-474f-b8e1-0567e580fef2", "645a88c8-da8d-46ac-95a8-14a94f293e4d", "b1fbe1bf-3d86-40df-a5f1-6bd5b2b4f61a", "fbfaa442-5917-4e45-95da-d569b8bcd01b", "17318181-cbb0-4025-b2d2-5ea08d4e2c17", "22af26f2-cdd4-49f0-a54e-e55e50e3ee21", "83bdd5e1-6f76-4105-bf1a-9195afb4c0f0", "f2a1a370-f4f1-44cb-8893-86e8585dbfb4", "23363178-3960-412f-8d28-7ee70be8f8ae", "9631e2cc-4393-4707-b44d-3f1b5e4380e2", "272c9897-5ffa-4979-8481-aa010ebc8f67", "c2ed3620-07a8-4198-9ec0-c58ec196114c", "876b96ef-c365-4991-9bc1-b0f93bbfcd3f", "cc50696f-bca1-456d-a625-b843576c5b56", "9dcc3df1-b8b6-43c6-b15e-fffdfac7de48", "810096df-9872-48c9-8953-4d9b1ed934be", "194800c1-b233-47e0-82a1-bc51f8b9a121", "863b7cd5-b84a-48ab-b839-1d0b8de8c86d", "0f944d22-e9bb-4963-b21b-5584779d2c17", "90637c96-c397-49b2-95df-3b5c1dc31fdd"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn our Prescription Technology Solutions segment, we see revenue growth of 31% to 37%, and adjusted \noperating profit growth of 23% to 29%.  This growth reflects the strong service and transaction momentum in the \nbusiness.  \n \n Now transit ioning to Medical -Surgical. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2146536e-10ce-4a7f-892f-b5a4655aaf77": {"node_ids": ["7587010d-8ab2-41c8-9199-48dedada6f44", "870acf29-4570-408a-9eaa-74710b49e96a", "6ac46ef1-d7c4-452a-a282-0c2f10e26149", "99482e58-cb0e-41ca-a434-061dbcf9d104", "a9c26dba-0f77-4fff-bc00-f732f5d9c327", "dc219016-7ff3-4af8-a3e8-cbaf5f90b5c2", "0e22f8cb-8dcc-46f2-80c0-70eda22a6959", "bb4e5f64-9d84-4558-afbf-3b08c95986d7", "44762c8b-00d4-4213-823b-7f0275ffac70", "ae876694-832e-40b8-84f3-07c6c82eda8e", "d19cfa6e-7ede-458c-9689-e5cb9ab2ebe9", "7e83f386-df4e-49e6-835f-0f655238a284", "623ed1fb-db78-41b0-be76-ef296b537dd1", "4a5f3cb2-5b20-4bdd-885c-030800aea8b9", "91139d65-c0a0-4810-bfc3-eb26c7739645", "ba43d4b5-e316-47c6-ae95-0c701e4d03c2", "39c36584-880b-4885-85f4-076ca2163bd2", "46f882c4-12d6-4d37-9f8e-a612262975ca", "e1168737-d670-42b1-b431-cd7efb1e7bbc", "80e2049e-5f0d-4f0e-a2b4-3ec839b4815f", "d3b920ef-48c3-4983-9270-cafc28eaa7ec", "cfa71ed7-899a-41f5-8c1d-1c6bbd79f3a3", "a49c12de-ef07-457d-a6ce-05de07060a66", "dd8a44f5-0de2-419f-b962-fe46e0a27d82", "902fd331-313d-454e-b648-191086da350a", "42be638c-cf75-46a0-a9ea-ed0ff48ea134", "82714da5-e7f9-40ab-9443-3d65b759ac36", "9b6cda48-72fb-4233-8594-46e9bc9857c7", "40a1c9c5-b10c-4fbb-9457-982e8ba36320", "7aac1d1b-d620-4e0b-a1c4-48ef5c63fb3e", "350f6ceb-d78b-45ab-ad9d-d7602755bf69", "2129128c-e4dd-4777-a5fb-a8e921c37078"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIn closing, we are encouraged by our strong performance in the  first half of our fiscal year.  The momentum across \nthe business, including our partnership with the US government, positions us to deliver the updated fiscal 2022 \noutlook provided here today.  \n \n Finally, we're looking forward to providing additional details  on our strategies and the strength of our businesses \nat our upcoming Investor Day on December 8. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "73d644b9-ab65-40f0-a3eb-32ca012da062": {"node_ids": ["ce64e808-9f9f-4855-a5e4-173131876e1e", "befd9623-a933-44c4-afb5-25b26618ed4e", "1ef4cf66-f29f-40dd-83ce-a5d318d380e8", "3c5b7d6d-ce43-441f-8f7a-444282a8b7e6", "e5890d9a-5872-486a-aef3-0357d35e6488", "06d67dfb-232e-4ff6-acf5-b05cac10db4d", "2e479f1c-2d7a-4385-a62d-2c94bbed49b9", "5bd7758e-c79d-4327-93b2-c3cddcd35b2a", "9bb4b6fd-c12c-4575-b578-fdc5de04d404", "a827da38-f43b-4ea1-9b70-97681c71c14a", "5357fcbd-417a-427d-8ae6-1af705956ecf", "3547ee16-6280-4de1-9e4c-ad7e255d1e38", "c0c7e112-344b-44b4-8169-c9434b44b451", "14b7114a-8a60-494a-a863-301ad2d560fd", "15904a43-a154-4689-93b5-4e7aed277ab7", "bbcec476-023a-4c4c-8f7d-01fe344560b0", "d90a6038-d1af-4b55-9f05-b67d578736a8", "8354447e-fb36-45c7-878f-81dbd5b507f6", "ff57b910-6996-444e-a3a5-6bc63b17de75", "f6fe5db1-da58-4446-9ec4-14a2eff0e1ff", "cbab295e-7026-4626-945f-81d894b27b84", "941ad6c4-c790-4cc1-81ed-f6345a9021ff", "57c72aa6-c431-4fee-a936-811ace44c272", "bc52265c-d898-4c2e-a2eb-3a170a858ce3", "eb0f99dd-d15e-4e58-879d-6f51a039cb58", "5b1b575c-2ea4-41d4-aa7c-55827417ac04", "88a527da-f3a8-451d-9a94-8169a8899258", "fdcdd3f9-aef8-4e2e-8199-704754ee0f36", "4c31a1fa-e80e-4a77-9ca0-6d3aa6cf5d89", "c318ab98-2199-4a52-a3d2-4668f8efbaa0", "18f85ee5-ed99-4b9e-a371-cf3ef504226f", "c1ad15be-b8fa-4b5a-9572-a44988f523be", "dd53171e-dd58-46ae-ac00-0366b2b83f8f", "c54b2e3e-2f0b-47af-9dce-52d0d7297433"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGood afternoon.  Thanks for taking the question.  First of all, the call cut off, so I don't know if you've got the \nchance to finish Lisa's question on freight. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c0e2e448-9843-40c6-9444-18e505a2516c": {"node_ids": ["e7b22f6a-549f-4e81-b972-a2f0b05a3b53", "4ade4db9-fa61-47bd-99f5-b74e7872b40f", "c156ffaa-0604-4a9f-b3e7-e9aad995c0dc", "ebe13713-13d7-4d89-9f98-8f8f30837df3", "4267b03b-1710-41ef-8c44-0aaff4270ada", "66c679c9-97de-45c5-966f-9ce52aad61ef", "c376c9c4-377f-4f69-a3c8-ecdd488f49e7", "9db5bc63-c5bd-46fc-a486-f9d057583043", "1169e45a-5534-484a-a82e-e7e3c009820f", "0014ac81-1a7e-4abc-999d-402f8489780e", "74754e23-5613-42ea-b6c6-e9057138a62c", "f36a3f80-8b73-4ff8-9465-8fa8f7b3d6c1", "c4e5a7be-947e-4b3a-bcd0-32e23919d9ed", "5e56e160-2839-4ad2-9632-1c6c6122c7fe", "ec9850dd-3f4a-4f16-a73d-44e83bcac825", "4328413d-b581-43fd-84cc-3cca48892fda", "6e25fba5-9220-4b7e-bc69-f9858c07c916", "44bdf80f-88db-4e8d-b01b-6f74ce9f25a4", "cd7ee590-160e-4ce2-969b-c6ffbcc73aba", "1a2600d5-3198-4183-a23c-c6250be92254", "45cea5c3-46b6-4c17-94b7-9ae6451a71af", "02c45896-dd82-4bee-936b-00fcda9aa2c1", "1671da03-5e9c-4eb9-96a2-7bf41a701708", "f1331b53-6bfc-4430-9feb-5290f44c65e5", "a0eb2f52-d934-4f01-aa56-7730fe244f3e", "010147e2-5fa8-471d-9c45-df2ac371fa71", "bde223f6-d6ec-455d-b01d-e722be4df210", "82920ffe-39e9-4744-be50-33af84fc9831", "f4d5696a-35fa-4d8f-a37b-572a50a7f34b", "b23fc13a-2aa0-48df-b098-afec98581e39", "915991c5-266b-453d-9354-a5d990b7e828", "f3e550a9-bc75-4fef-a2ed-264e388dbef2", "1109a807-48fc-42c1-aba0-08d375980876", "852449ff-104b-42dc-b751-4949f1ffe1cb", "8a70d03f-03a7-4e43-91c9-3bcb7b8b4da0", "0cca8f2b-ee36-465a-bd1e-bf8714b24373", "44aaa3b0-6e61-442e-8047-7478174a901b", "a6a6e2e7-757c-440f-b533-e1372e47f108", "e3c7c1fc-0a6f-4496-a240-ad6e398e031c", "7b710299-d879-43fe-a0b6-5ea809d42fd7", "5207d818-56c9-4db6-aaea-92fc40e8d30f", "da6dab38-8cab-4716-a554-0a948077bc6c", "a48c6ed9-3d41-4adc-9ba4-9b0d6d656cb2"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nYeah.  Thanks for taking the question.  Wanted to ask a little bit about Prescription Technology Solutions. \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ce16b010-d6c5-49fe-b30e-e3f4e1e59ccb": {"node_ids": ["b6d2400d-2379-41cb-a3e6-2b7b85066cab", "9c2a316c-8c35-4b7d-8c2b-e4bb10ec415f", "fc028ad8-9fd3-4cc3-a003-41bece537121", "a21b02a4-ef94-42c9-8ea5-eb50cb606e38", "1cb07ea0-9417-475c-a8ed-b3faff72bd17", "70d4d3ee-065b-4b7a-9eb0-321b34784dcb", "e2acf0f6-d791-4a10-9b1a-300804e039e4", "1d5a0114-15c4-42a7-ac21-c9ce7e0e3757", "409be16d-a4b8-497f-8a73-a903afcc3736", "36ac1dd7-ded7-4401-bbd3-c6b8474195a6", "2faa0771-3c50-4b89-a6c0-66c7150aa5e2", "1f2d2a74-5a16-4095-a2c5-f242e3d09c06", "ad32f58b-706a-461a-9853-34a86030ea4d", "9c9436c4-39fa-4039-9e1c-1055270f09ba", "d140e15a-374a-4ab2-b715-785cbc0d9ff0", "4ffea2b7-c0ce-4ea1-9130-62932e17d028", "7e19ddc6-4ac2-4195-97c0-fdc587b464d6", "395d81a8-55f0-4a10-9533-2ba7fc234f25", "4928f669-3824-4413-8eeb-165c3998f740", "0aa839f8-7e29-4d6f-b523-39f386b16f20", "dbddeb51-4d56-4ebe-964a-724fcb239ada", "56a0ca6d-8fbe-4bf2-9fc4-1f49a4b85d4e", "ca4a7261-4efc-45d6-b876-a4cc76025959", "bcf840d6-b1c0-4908-b507-39761d494d4b", "702c4a2f-a561-4983-8f49-d6a402d1fb51", "8ce35227-1ba2-4563-90d4-79d4aaf1e010", "e9b51701-9342-4601-b3f0-7b7be34c17d0", "e0451e4b-0da5-48cb-83f4-ac659828760f", "9e15d76e-a96c-434a-b368-f5ee094bc09c", "03a9d7c5-37e1-4893-90e3-bb8f34a9d9b0", "8a2fc72f-3569-4da4-b5b0-faf3e833bfab", "8c371fd8-a786-42e1-822b-dd622babd975"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nbusiness, but we're pleased with the performance of our primary care business and the core business underneath \nour medical business in addition to labor investment that I called out.  So, both businesses continue to have good \nmomentum.  \n \n In the case of ou r US Pharmaceutical business, continuing to invest in oncology as well as the labor investment in \nour medical business, really continuing to leverage the strength of the lab business and the investments we made \nthere, and we're seeing good performance in o ur primary care business.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "eb78cca2-9143-477b-9ec3-de5e991d0773": {"node_ids": ["86b5f846-937b-4a81-8167-177111e34949", "38fdaae7-7f9c-4f1b-a91b-e0d8527a2b30", "979ccb41-6528-4d5b-8ef2-3413c768573e", "58c2f43d-3a80-4557-85e6-e57b58347874", "9e680722-6e67-4407-8b01-2c940b747d13", "7acae5d9-06e7-4d86-8488-bc188b45e465", "a28369d9-4927-4138-9c7c-3f455ae837cd", "cb92e3aa-e60d-4328-b0a7-f08a2209205b", "7ba55358-713c-4e33-a65c-376f5883287d", "697a1893-9e42-44de-a797-73b2a48cf833", "36044bbe-415c-4009-bf74-294f5f04c1e5", "137adcdb-8ed0-4c11-a98e-c162c6f30cf0", "169b0a24-5cc4-4e69-b490-5cb0f38cc82e", "17e672e4-edd7-4104-b03f-6da53bea4d84", "63d4033a-2f42-4fde-aa93-beb4a1183b21", "7045885d-156e-4cfc-98be-cedcae7216ee", "07f6b04c-a772-4fa3-af30-553e1fdf1ede", "fc161c00-834d-4e30-a0be-fed8aa982cfa", "e35e2b97-ec56-4041-b857-32919d865d82", "311b7cd8-aaee-49de-b5ed-6f9fff0c48ba", "c823b97d-69d9-44df-9668-8c8773008581", "e15f9dd6-d800-4150-bafe-482ba13f6421", "5561ced5-18ae-42c5-88fc-4fd8352399b3", "936c9b8f-42f8-4e5f-a1f9-7f409a0cc96b", "b27d3e43-2783-4a3b-83ed-23ee19742efb", "bda0a599-4626-49c8-9edd-cfb12594164b", "c42d0bf4-29ee-44bc-b6a4-58fbddca4b13", "1a660a6b-1396-4264-ba5b-a58e3ef76e1c", "810a8229-7eb8-4d39-bbe2-e6e30ac3aff0", "fd56bc6c-5197-4c88-96f7-d9c6027af72c", "7073da2f-923d-455b-bf4e-bdc4aa6583ec", "56f3d31a-a3f5-449f-806a-34e31c0203fc", "e7e325d8-4a6a-43bd-9d4c-e493da39de6a", "cf6a680a-4448-40b4-b8c4-d7ab7017ad1d", "9c235363-2a27-4595-8e37-7e6a8292e7a1", "f288c12c-123d-4782-92e4-a91885896603", "52b28768-fb86-42af-883d-fd604f22a4a3", "7e9ecc9e-8b2d-4d2e-9fe8-9edce61f36b8", "26dc5bbc-1884-4635-8aa6-301fc8e78d97", "76b654fa-360e-4ef2-81ca-45f4971fbd15", "ffb464b0-6ebb-42e1-be48-e9eee33747c9", "6c3b6125-cbad-4c29-ba3f-fd3b2d9ffe6c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsubstantial benefit to CMS.  So I think the mix is \u2013 it's really \u2013 it's not exactly clear where this will go.  I think we \nhave a lot of assets. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "270bb366-14e3-4684-8f2b-c987d802abeb": {"node_ids": ["4bb21e63-061b-4c0d-bed7-597fb48e4faa", "a94e2a2a-dff1-4803-b873-df1ff48557dd", "b0adaa64-8805-4987-b00d-19b2efca2d5c", "fb2ad34c-5afa-4ffe-ac8d-872779990f73", "784a0c91-6929-43c0-98ed-7ed31ac9c363", "b113e33b-0afc-4330-bd3d-355a5f5c5442", "f41fe671-c2c3-4361-b8b5-d81ed3bbf433", "a39d3b5f-47ad-4d10-82cd-150145562870", "2e76c33b-35e6-4522-9c1f-8f0f96eb37f8", "aa829da8-6124-4c8f-abfd-6bcd3bd03784", "1339128d-e9d2-4f42-9647-7c553af0cde7", "be5b6881-e430-4cfd-b008-8fd2a5a1b3c5", "6584a356-e918-41cf-91e1-bd2f53527a14", "040edf54-e66d-4488-9a49-02c5836a71c7", "b1aad11b-cdaf-4a47-bf91-24b00941a3a9", "f0b99814-865c-466f-9157-02a392c0be4a", "bc8ae448-92b0-45d0-bd41-c04d2c12b23d", "b8a5e74a-cad2-4e76-b557-5f965e9099ce", "e953a471-d32d-4b37-b0b1-4a6de39c199e", "84ffbd29-fd3e-486b-b168-26d1614a4089", "d496ceae-1033-4a2a-95c4-b11ae836ab77", "d2a5fe8d-bb3b-4213-91fa-7151dcf32bf9", "7a979e3c-889d-4027-9824-a1443a994b4a", "11fa7371-442b-4605-b7f0-ab863f26b602", "40863518-9a5c-41e2-b479-597667e70d1d", "943ee088-4c32-422e-8e47-4febff37375e", "3fc160c1-6a37-44cd-b380-3956b514092e", "870fad3e-f1cc-41db-a70a-d12a7a575a54", "c86c1ae7-49ca-4ae7-9462-78c33ff87b93", "124d58e9-15e1-4d7d-9fcd-1c131eac9201", "0214d6a5-43ff-4195-814e-434b911d6f40", "849a9679-84fb-4a5e-9266-2c783f07e1fd", "c0ec8ddc-1a42-4d08-a857-320de96d7b92", "bf9844f7-71da-438b-bb63-8357ae0d8898", "a3a0dc9c-4769-42e3-b07f-36ec5195963d", "9a2c2406-5e85-426b-b897-79060c9a7c59"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd I think what you're seeing here by our actions is a focus on return on invested capital, really making sure that \n\u2013 where we all ocate capital that finds the highest returns in the company.  And our actions thus far that you've \nheard us talk about the last couple of quarters have been focused on divesting and moving capital away from \nlower -returning assets to higher returning assets and to Brian's point, are right on strategy.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "26808593-a6ae-4d2a-967e-b90d1987aa1f": {"node_ids": ["6c5b9fea-9c9f-4dd1-9df8-0b9980de94f0", "4a60fbaf-cd37-4ba8-a0c6-37e737626fce", "648e04a1-be0d-4619-a1ea-ceaf0544b2aa", "18b05b00-b814-4121-8f40-1f8e675024bd", "5bf4f2a5-c44b-4ebc-9149-8160fa2bbbe2", "6d69bb8f-967d-4a84-b8f5-178ebd78ead4", "8ac957de-32de-40d2-abfb-c22cff5fca45", "305def90-32af-4ee6-b0a2-f4d6783f78bc", "7c7a74e8-d3c1-4093-a6c6-81a29ba4aae8", "27ce9137-4d65-439a-b3fd-f5e9958d399e", "653d842d-3cd4-4771-b119-76308ebb8290", "bf97c747-a546-42ec-9bb1-d9ab12e0d29e", "19b6c15a-75f5-43e4-960c-292d7af4e07e", "a60571b1-1968-4b83-acda-1bed4e9cb0b7", "80de4d9d-fdb6-4479-8fdf-e8829c707d32", "be792133-4b0b-4ebe-a8de-1d7407420fb3", "f445f5ec-a8cc-4de5-95eb-7e142a320c14", "88f6a298-e000-45f7-8e5a-bc5a70707530", "5d0e8c25-7dfc-401a-8b79-769d9ed60d7b", "df28fadd-33d9-469f-8773-0c2b416a5d3b", "c56d208a-b23e-42d4-ba93-7a4d78ad116e", "69305aec-f8b7-44c1-933f-a7649d080082", "3cb9f30a-cf27-4654-9c40-5494b47a7cff", "7bd22a89-e0c2-4f26-b5ea-66e346acae5a", "86e33590-37f7-4118-8791-ad17fc40f919", "444aadaf-8457-4fe2-9743-845fe7bb2801", "9b18c8bb-363b-4f51-83e4-09c7ca61de0f", "b2a58c01-b247-4927-bd99-05eff7266a77", "02aa3147-ba3b-4b62-9ff7-8a90a1a68cbd", "faf3b0af-982a-4824-b29a-e95d2915dd46", "2f8dad45-d057-4f5d-9999-e2c211dca105", "069b33b6-386d-4737-b0c5-0e2c10fa6af4", "69f7b407-53ba-46c1-8b20-2241ad3dd9e8", "3e2781d4-56af-4a29-80dc-b99c493980e7", "820c0dcc-80d8-4039-8015-c9e327a70b5a", "9fb629f1-6a62-4cb9-a3b2-c8a2b7ef5629", "b2328d53-ef28-4dfa-a82b-d01a6dd53c75", "eb46c93a-0e09-467a-9e70-8119fd91b437", "4194458b-549e-4cec-8092-5f9ffe3127bc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi, there.  So a quick follow -up on your last comment. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4f381e66-390b-485e-8876-9a33c7c20d11": {"node_ids": ["162941fd-7b8b-4ca3-9d3d-8c191fe48e03", "0f324ac8-596e-4f25-9da1-8a55ad5e4df4", "6a0e19ff-d746-4543-9a32-de438868459a", "182fe6e8-52d8-4dae-aa09-6f707397c5f1", "60f9d5f7-b119-459d-a477-a000545ce4ab", "10930c63-f714-4d19-8566-36222be27a77", "a01eafd9-c3cb-41cc-ba23-b679570f7b76", "cd2c6e86-f976-4d20-9847-6932030e0ebc", "b9d2a32c-1402-46d4-9be2-165c3c08e09f", "0612f3f3-80f0-40a8-9b68-5e9dbe7ff4e2", "7d6767aa-f5cf-4714-99d1-6c6c9334ee7b", "e8666932-62d8-44f2-aac2-61a4ffcd8a68", "03975480-279c-4420-887c-1716df50644b", "ef5d0ed3-2083-4b4f-b6c3-98f81eeb813d", "d0bfc667-7481-4601-8542-8353f74f6c27", "48d7a1dd-6e1c-4b18-9110-54d38dfe7ee7", "3c44c15e-dd2f-4298-8f98-4bcf57b4cb2a", "53b62fda-b9c4-4cb6-aee4-70fe74a5e955", "b058630d-8c85-47ed-a8bd-e8364ca07464", "e0d09e52-ebac-4679-8aa8-57ddd7890091", "50f5d8be-2377-4bbd-9947-7c22deb5dc0e", "0824d247-faa4-4c04-983e-295fa9a7f0c0", "48ff3e55-35ee-4226-aa01-c51e21402a3b", "f2683d19-236d-48c5-8001-22269599561f", "4f99840a-c2c7-458d-8db7-5c85474962c0", "a36fae0e-04c7-4559-b1e8-5549e1af468b", "5ac0c755-4f47-492b-a088-4bcb502402d1", "ddfc8364-38e5-4754-a81f-b668d8d279ee", "b21dba85-0b75-489c-8e9d-9c1f7c5d405e", "8b8eeb6f-db4c-4274-94eb-a1f1bdbdff04", "9b1ddd2f-dcbc-4f39-858d-d0c7c553aeec", "7e9b238e-3f38-4039-a934-138e7a7c72c0", "3c5496aa-b14a-450c-959e-c602451968fe", "ddad80b3-f780-48fd-a2be-68efb5416689"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2022 Earnings Call  Corrected Transcript  \n01-Nov-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo your first part of the question, I think, answered your question.  We are not including \u2013 we have provided \nguidance based on what the CDC has provided to us. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 367899, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}